aspirin has been researched along with Coronary Disease in 1502 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All participants had a documented history of coronary heart disease or high cardiovascular risk at screening and received aspirin (acetylsalicylic acid) 100 mg daily throughout the trial." | 9.51 | Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi ( Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022) |
| "This study was to study the efficacy of rosuvastatin, amlodipine, and aspirin in the treatment of hypertension with coronary heart disease and its effect on platelet aggregation." | 9.51 | The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. ( Fu, J; Li, B; Wang, T; Zhao, N, 2022) |
| "To investigate the feasibility of periodontal mechanical therapy for chronic periodontitis and coronary heart disease patients with low dose of aspirin." | 9.24 | [Bleeding control of periodontal mechanical therapy for patients taking aspirin]. ( Ding, F; Duan, XQ; Han, X; Liu, DY; Lyu, YL; Xuan, W, 2017) |
| "To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients." | 9.19 | Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014) |
| "In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA." | 9.17 | Aspirin increases nitric oxide formation in chronic stable coronary disease. ( Borzak, S; DeMets, D; Hennekens, CH; Hetzel, S; Schneider, R; Schneider, W; Schröder, H; Serebruany, V, 2013) |
| "The goal of this study was to investigate the antiplatelet efficacy and tolerability of clopidogrel resinate in patients with coronary heart disease (CHD) or CHD-equivalent risks." | 9.15 | Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial ( Choi, YJ; Gwak, CH; Hong, SJ; Joo, SJ; Kim, HS; Kim, KS; Kim, SH; Park, TH; Seung, KB; Suh, JW; Tahk, SJ, 2011) |
| "Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function." | 9.14 | Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "Inadequate platelet response to aspirin is associated with increased incidence of peri-procedural myonecrosis." | 9.13 | The effect of high-dose aspirin pre-treatment on the incidence of myonecrosis following elective coronary stenting. ( Duzen, V; Erol, C; Gulec, S; Ozdemir, AO; Ozdol, C; Ozturk, S; Selcuk, T; Temizhan, A; Turhan, S; Vurgun, K, 2008) |
| "As the mainstay treatment for coronary heart disease (CHD), aspirin alone is reported to be less effective than in combination when treating CHD." | 9.12 | Clinical efficacy of aspirin combination treatment in the treatment of coronary heart disease and its effect on inflammatory factors: a systematic review and meta-analysis. ( Liu, X; Mao, P; Tang, L; Tang, Y; Weng, Y, 2021) |
| "Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required." | 9.12 | Aspirin, warfarin and a thienopyridine for acute coronary syndromes. ( Behar, S; Gottlieb, S; Hammerman, H; Hasdai, D; Hod, H; Iakobishvili, Z; Konstantino, Y; Porter, A; Sandach, A; Zahger, D, 2006) |
| "Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel." | 9.12 | No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. ( Arnesen, H; Pettersen, AA; Seljeflot, I; Solheim, S, 2006) |
| "The antiplatelet effect of aspirin was studied prospectively in 54 consecutive patients with stable coronary heart disease." | 9.12 | Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. ( Cheng, G; Liu, P; Lu, X; Shan, J; Xu, G; Zhou, Y; Zhu, Y, 2007) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 9.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| " We assessed the possible 'synergy' of statins and aspirin (ASA) in reducing vascular events in patients with coronary heart disease, in a post hoc analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study." | 9.11 | Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. ( Athyros, VG; Bouloukos, VI; Daskalopoulou, SS; Elisaf, M; Kakafika, AI; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN, 2005) |
| "To investigate the occurrence of aspirin resistance in coronary heart disease (CHD) patients and its influence on myonecrosis among patients undergoing non-emergent percutaneous coronary intervention (PCI)." | 9.11 | [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention]. ( Dong, L; Liang, J; Yuan, H; Zhang, Y; Zhang, YZ; Zhou, YJ, 2005) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 9.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 9.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "The Thrombosis Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of coronary heart disease (CHD) with warfarin and/or aspirin." | 9.10 | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. ( Ashby, D; Brennan, P; Meade, T; Rudnicka, AR, 2003) |
| "Whether thienopyridines (ticlopidine or clopidogrel) produce similar effects on fibrinolysis in patients with non ST elevation acute coronary syndrome (NSTEACS) was not well elucidated." | 9.10 | [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel]. ( Averkov, OV; Dobrovol'skiĭ, AB; Gratsianskiĭ, NA; Slavina, NN, 2003) |
| "We investigated intolerance and bleeding while on aspirin and aspirin discontinuation using 5337 post-acute coronary syndrome patients considered appropriate for chronic antiplatelet therapy who were randomly assigned to aspirin in SYMPHONY and 2nd SYMPHONY and followed for 94 (64,157) days." | 9.10 | Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. ( Armstrong, PW; Bhapkar, MV; Califf, RM; Kandzari, DE; Kramer, JM; LaPointe, NM; Moliterno, DJ; Newby, LK; Verheugt, FW; White, HD, 2003) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 9.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "Aspirin and statins are beneficial in coronary heart disease across a broad range of cholesterol levels." | 9.09 | Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. ( Brozek, J; Musiał, J; Szczeklik, A; Undas, A; Undas, R, 2001) |
| "We compared the efficacy of oral administration of pentoxifylline (PTX) and intravenous infusions of gamma globulin (IVGG) combination therapy with that of IVGG in reducing the frequency of coronary-artery lesions (CAL) in children with Kawasaki disease (KD), in a randomized trial." | 9.07 | Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. ( Furukawa, S; Ino, T; Matsubara, T; Motohashi, T; Umezawa, Y; Yabuta, K, 1994) |
| "This study was undertaken to determine if a standard dose of aspirin interacts relevantly with the circulatory effects of enalapril in severe heart failure." | 9.07 | Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. ( Hall, D; Rudolph, W; Zeitler, H, 1992) |
| "Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1." | 9.07 | Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. ( Brennan, PJ; Kelleher, CC; Meade, TW; Roderick, PJ; Wilkes, HC, 1992) |
| "Patients admitted for suspected acute myocardial infarction within 6 hours (mean 3 hours 42 minutes) after onset of symptoms were randomised to double-blind treatment with low-dose oral aspirin or placebo." | 9.07 | Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction. ( Følling, M; Pedersen, D; Rodt, SA; Rønnevik, PK; von der Lippe, G, 1991) |
| "Data from six randomized, placebo-controlled clinical trials of aspirin, involving a total of 10,703 postmyocardial infarction (MI) patients, are compared and combined." | 9.05 | Aspirin in coronary heart disease. Comparison of six clinical trials. ( Canner, PL, 1983) |
| "Three randomized controlled trials of aspirin and secondary mortality have been conducted in patients who had had a myocardial infarction." | 9.05 | Aspirin and secondary mortality after myocardial infarction. ( Elwood, PC; Sweetnam, PM, 1980) |
| "The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study." | 9.05 | Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985) |
| "Both the Coronary Drug Project (CDP) and the Aspirin Myocardial Infarction Study (AMIS) were successfully able to recruit adequate members of postmyocardial infarction patients to long-term multicenter clinical trials in the secondary prevention of coronary heart disease." | 9.04 | Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study. ( Schoenberger, JA, 1979) |
| "Tobacco smoking results in increased platelet aggregability, which suggests that low-dose aspirin used in common clinical practice may not effectively inhibit platelet activity in smokers with coronary heart disease (CHD)." | 8.87 | Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease. ( DU, X; Li, WJ; Ma, CS; Miao, CL; Shi, JH; Tang, RB; Zhang, HY, 2011) |
| "Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing." | 8.86 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010) |
| "After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established." | 8.84 | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. ( Agostoni, P; Andreotti, F; Crea, F; Porto, I; Testa, L; Trotta, G; Zoccai, GB, 2007) |
| "The TIMI Risk Score recognizes prior aspirin use as an independent risk factor for adverse outcomes in subjects presenting with an acute coronary syndrome." | 8.84 | The role of aspirin resistance in the treatment of acute coronary syndromes. ( Jain, H; Lancaster, GI; Zarich, SW, 2008) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 8.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding." | 8.82 | Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. ( Celestin, C; Cook, JR; Fiore, LD; Lawler, E; Rothberg, MB, 2005) |
| "According to meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease." | 8.82 | [Primary prevention of coronary heart disease with aspirin]. ( Darius, H; Kübler, W, 2005) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 8.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| "The incidence of death or myocardial infarction after acute coronary syndrome (ACS) is still high despite the widespread use of aspirin." | 8.81 | [Oral anticoagulants combined with aspirin in the prolonged treatment after acute coronary syndrome]. ( Biancoli, S; Cerè, E; Di Pasquale, G; Parlangeli, R, 2002) |
| "Although there is firm consensus that aspirin reduces the incidences (and severity) of reinfarction if given to patients after a myocardial infarction or in patients with unstable angina, there is disagreement about the optimum dose that should be used." | 8.79 | The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? ( Förster, W; Parratt, JR, 1997) |
| "This study aims to explore the clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and the effects on N terminal pro B type natriuretic peptide (NT-ProBNP) and creatine kinase-MB (CK-MB) levels." | 7.96 | Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. ( Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020) |
| "To investigate the correlation of tumor necrosis factor α (TNF-α) polymorphisms with upper gastrointestinal bleeding (UGIB) induced by enteric-coated aspirin in coronary heart disease (CHD) patients." | 7.91 | Association between TNF-α polymorphisms and the risk of upper gastrointestinal bleeding induced by aspirin in patients with coronary heart disease. ( Wang, TP, 2019) |
| "To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia." | 7.83 | Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016) |
| "In patients with both stable coronary disease and atrial fibrillation, a baseline treatment of aspirin and an oral anticoagulant is often prescribed due to the proven benefits of each therapy on cardiovascular and thromboembolic events and mortality." | 7.81 | [Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?]. ( Lister, K; Louis Simonet, M, 2015) |
| "We recruited 162 coronary heart disease patients treated with aspirin and clopidogrel, and we genotyped them for the CES1A2 A(-816)C, CYP2C19 *2/*3, PON1 Q192R, and ABCB1 C3435T polymorphisms." | 7.80 | The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. ( Ding, X; Gao, J; Hang, Y; Jiang, B; Miao, L; Wang, H; Xie, C; Zhang, H; Zhang, J, 2014) |
| "Aspirin for the primary prevention of coronary heart disease (CHD) is only recommended for individuals at high risk for CHD although the majority of CHD events occur in individuals who are at low to intermediate risk." | 7.80 | Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. ( Blaha, MJ; Blankstein, R; Budoff, MJ; Duprez, DA; Folsom, AR; Greenland, P; Miedema, MD; Misialek, JR; Nasir, K; Silverman, MG, 2014) |
| "This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease." | 7.78 | [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012) |
| "To evaluate the risk of myocardial infarction and death from coronary heart disease after discontinuation of low dose aspirin in primary care patients with a history of cardiovascular events." | 7.77 | Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. ( Cea-Soriano, L; Johansson, S; Martín-Merino, E; Rodríguez, LA, 2011) |
| "Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but not mortality." | 7.76 | Prior aspirin use and outcomes in acute coronary syndromes. ( Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Qin, J; Rich, JD, 2010) |
| "Insufficient platelet inhibition by low-dose aspirin is associated with poor prognosis in patients with coronary heart disease (CHD)." | 7.76 | Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. ( Bierend, A; Böger, RH; Kom, GD; Maas, R; Schwedhelm, E; Trinks, R; Tsikas, D, 2010) |
| "Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS)." | 7.75 | The prevalence of aspirin resistance in patients with metabolic syndrome. ( Aras, D; Cağirci, G; Cay, S; Geyik, B; Ozdemir, O; Oztürk, S; Topaloğlu, S, 2009) |
| "Aspirin use may reduce the risk of stroke and coronary heart disease." | 7.74 | Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? ( Cushman, M; Glasser, SP; Howard, G; Howard, VJ; Kleindorfer, D; Prince, V; Prineas, R; You, Z, 2008) |
| "This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy." | 7.74 | Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008) |
| "Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding." | 7.74 | Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. ( Botz, G; Champion, JC; Durand, JB; Hirch-Ginsburg, C; Lakkis, N; Lenihan, DJ; Sarkiss, MG; Shaw, AD; Swafford, J; Warneke, CL; Yusuf, SW, 2007) |
| "To identify the risk factors for myocardial ischemia in patients undergoing aspirin therapy for coronary artery disease (CAD) presenting with upper gastrointestinal hemorrhage and to ascertain the impacts on mortality and length of hospital stay." | 7.74 | Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| "Aspirin reduces mortality for men and women with coronary heart disease (CHD)." | 7.74 | Gender differences in aspirin use among adults with coronary heart disease in the United States. ( Cannon, CP; McWilliams, JM; Opotowsky, AR, 2007) |
| "To determine the patterns of aspirin use for the primary prevention of coronary heart disease (CHD)." | 7.74 | Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. ( Butler, J; Cornuz, J; Hayoz, D; Marques-Vidal, P; Paccaud, F; Pécoud, A; Rodondi, N; Vollenweider, P; Waeber, G, 2008) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 7.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "A 58-year-old Caucasian male with a history of coronary heart disease and hypercholesterolemia, under treatment with acetyl-salicylate for 6 years and simvastatin for 2 months, presented to the Emergency Department of our hospital with epigastric pain and vomiting of 24-hour duration." | 7.73 | A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. ( Antonopoulos, S; Filioti, K; Giannoulis, G; Karamanolis, D; Kokkoris, S; Mikros, S; Protopsaltis, J, 2005) |
| "Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke." | 7.73 | Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. ( Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005) |
| "Aspirin for the primary prevention of coronary heart disease (has a more favorable risk/benefit profile among adults with high coronary heart disease risk than among low-risk adults, but there is little information on the current patterns of aspirin use for primary prevention." | 7.73 | Aspirin use for the primary prevention of coronary heart disease in older adults. ( Bauer, DC; Butler, J; Cornuz, J; Ding, J; Harris, TB; Hulley, SB; Newman, AB; Rodondi, N; Satterfield, S; Vittinghoff, E, 2005) |
| "Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied." | 7.73 | Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. ( Earnshaw, S; Pignone, M; Pletcher, MJ; Tice, JA, 2006) |
| "The safety of aspirin in heart failure (HF) has been called into question, particularly in those patients (1) without coronary disease, (2) with renal dysfunction, or (3) treated with low-dose angiotensin-converting enzyme (ACE) inhibitors and high-dose aspirin." | 7.73 | Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. ( Armstrong, PW; Fang, J; Ghali, WA; Gong, Y; McAlister, FA; Tu, JV, 2006) |
| "Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS)." | 7.73 | A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. ( Chan, WK; Lee, KK; Lee, VW, 2006) |
| "According to the meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease." | 7.72 | [Primary prevention of coronary heart disease with aspirin]. ( Kübler, W, 2004) |
| "To evaluate the effect of treatment without aspirin in the acute phase of Kawasaki disease (KD) and to determine whether it is necessary to expose children to high- or medium-dose aspirin." | 7.72 | Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. ( Hsieh, KS; Huang, SM; Huang, TC; Lee, CL; Lin, CC; Weng, KP, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 7.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| "We sought (1) to determine how often aspirin is prescribed as a discharge medication among patients 65 years or older and hospitalized with both heart failure and coronary artery disease; (2) to identify patient characteristics associated with the decision to prescribe aspirin; and (3) to evaluate the association between aspirin prescription at discharge and 1-year survival." | 7.71 | Aspirin and the treatment of heart failure in the elderly. ( Chen, YT; Krumholz, HM; Radford, MJ, 2001) |
| " The effect of the nitro-derivative of aspirin, NCX4016, was assessed on ischaemic ventricular arrhythmias and myocardial infarct size in anaesthetized pigs in comparison to native aspirin." | 7.71 | NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. ( Del Soldato, P; Miller, AM; Wainwright, CL; Work, LM, 2002) |
| "Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease." | 7.71 | Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. ( Coxson, PG; Gaspoz, JM; Goldman, L; Goldman, PA; Hunink, MG; Kuntz, KM; Williams, LW, 2002) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 7.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "A 64-year-old man presented with worsening dyspnea on exertion and hemothorax of the left chest 7 days after discharge from the hospital on ticlopidine and aspirin after coronary stent placement to his left circumflex artery." | 7.70 | Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. ( Dillard, TA; Quinn, MW, 1999) |
| "Platelet-related events being associated with the increment of infarct size at reperfusion in the presence of a residual stenosis, we tested in dogs whether intravenous aspirin (ASA) could limit infarct size." | 7.70 | Intravenous aspirin at reperfusion does not reduce infarct size in the dog with a residual critical stenosis. ( Laperrière, L; Latour, JG; Libersan, D; Merhi, Y; Quan, E; Uzan, A, 1999) |
| "To evaluate the effects of resuscitation with a 10% diaspirin-crosslinked hemoglobin (DCLHb) solution on global hemodynamic variables, systemic and myocardial oxygen transport and tissue oxygenation, and contractile function of the left ventricle in an experimental model of severe hemorrhagic shock and critical stenosis of the left anterior descending coronary artery (LAD)." | 7.70 | Diaspirin-crosslinked hemoglobin reduces mortality of severe hemorrhagic shock in pigs with critical coronary stenosis. ( Habler, O; Kemming, G; Kleen, M; Meisner, F; Messmer, K; Pape, A, 2000) |
| "The aim of this study was to determine changes in treatment of myocardial infarction between 1986 and 1989 in the Haute-Garonne region and, in particular, to assess the role of aspirin and antiaggregant therapy." | 7.69 | [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Richard, JL; Ruidavets, JB, 1995) |
| "Serum salicylate concentrations were measured in 60 patients with acute phase Kawasaki disease (KD), who were treated with intravenous aspirin (IVASP), to evaluate its anti-inflammatory effect in the treatment of KD." | 7.68 | Treatment of Kawasaki disease using the intravenous aspirin anti-inflammatory effect of salicylate. ( Matsuo, N; Saji, T; Umezawa, T, 1992) |
| "Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily." | 7.67 | Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989) |
| "The effects of arginine aspirin (AAs) on the effective refractory period (ERP) and ventricular fibrillation threshold (VFT) of ischemic ventricular muscle were observed in 24 anesthetized open-chest rabbits." | 7.67 | [Effects of arginine aspirin on changes in effective refractory period and ventricular fibrillation threshold of ischemic myocardium in rabbit]. ( Wu, BW; Zang, YM; Zhao, RR; Zhao, ZQ; Zhou, YY; Zhu, MZ, 1989) |
| "Between 1950 and 1975, 473 Rochester patients had the diagnosis of rheumatoid arthritis and received aspirin treatment." | 7.66 | Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. ( Fuster, V; Kurland, LT; Linos, A; O'Fallon, W; Whisnant, JP; Worthington, JW, 1978) |
| "Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications." | 6.87 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. ( Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY, 2018) |
| "Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days." | 6.77 | Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012) |
| "Aspirin has been shown to decrease cardiovascular (CV) events by ∼25%." | 6.76 | Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. ( Auer, J; Berent, R; Franklin, B; Schmid, P; von Duvillard, SP, 2011) |
| "Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy." | 6.74 | Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009) |
| "We examined the prevalence and medical treatment of hypertension among 15,904 ACS patients randomized in the SYMPHONY and 2nd SYMPHONY trials." | 6.71 | Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical ( Armstrong, PW; Aylward, PE; Bhapkar, MV; Frazier, CG; Klein, WW; Kristinsson, A; McGuire, DK; Newby, LK; Sadowski, Z; Shah, SH; Weaver, WD, 2005) |
| "Pretreatment with aspirin did not change the vasodilator responses in any group." | 6.69 | Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. ( Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999) |
| "Treatment with aspirin emerged as an independent predictor of reduced cardiovascular (RR = 0." | 6.68 | Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group. ( Behar, S; Benderly, M; Goldbourt, U; Harpaz, D; Kishon, Y, 1996) |
| " The dosage of aspirin was 30 mg/kg orally during the acute febrile stage and 5-10 mg/kg orally after lysis of fever." | 6.67 | Histopathologic and coronary angiographic assessment of effectiveness of aspirin or aspirin-and-gammaglobulin in Kawasaki disease. ( Haneda, N; Mori, C, 1993) |
| " Administration of DPY alone at a higher dosage increased the exercise duration and had a similar effect on platelet survival." | 6.65 | Effect of platelet suppressant treatment with dipyridamole and aspirin on exercise performance and platelet survival time in coronary disease. ( Rainwater, J; Steele, P; Vogel, R, 1981) |
| "Aspirin has proven benefits in primary and secondary prevention of coronary artery disease." | 6.42 | Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. ( Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003) |
| "In patients requiring treatment for heart failure, if possible, aspirin should be avoided and the integrity of prostaglandin metabolism respected; the severer the heart failure the more compelling." | 6.41 | Controversies in heart failure. Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure? ( Hall, D, 2001) |
| "In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent." | 6.38 | Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990) |
| " This study evaluated the safety and efficacy of treatment with glycoprotein IIb/IIIa inhibition in addition to aspirin, low molecular-weight heparin and its influence on coagulation and inflammation." | 6.21 | Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. ( James, S, 2004) |
| " All participants had a documented history of coronary heart disease or high cardiovascular risk at screening and received aspirin (acetylsalicylic acid) 100 mg daily throughout the trial." | 5.51 | Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi ( Gao, B; Gao, W; Ji, Q; Wan, H; Xu, F; Zhang, X; Zhou, R, 2022) |
| "This study was to study the efficacy of rosuvastatin, amlodipine, and aspirin in the treatment of hypertension with coronary heart disease and its effect on platelet aggregation." | 5.51 | The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. ( Fu, J; Li, B; Wang, T; Zhao, N, 2022) |
| "Findings from this MR analysis suggest a genetic protective effect of aspirin use on AD, possibly influenced by coronary heart disease, blood pressure, and lipid levels." | 5.41 | Aspirin Use and Risk of Alzheimer's Disease: A 2-Sample Mendelian Randomization Study. ( Ding, P; Gorenflo, MP; Xu, R; Zhu, X, 2023) |
| "In this, randomized, parallel-grouped, single-center clinical trial, 18 patients with coronary heart disease were randomly allocated into three groups: aspirin (AP) group, salvianolate (SV) group, and combination (A + S) group." | 5.41 | Drug-drug interactions between salvianolate injection and aspirin based on their metabolic enzymes. ( Cao, W; Gao, R; Guo, Z; Li, R; Wang, S; Wu, Y; Xu, Y; Yang, Q; Zhang, W; Zhao, Y, 2021) |
| "Incident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068)." | 5.41 | Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. ( Aboyans, V; Berkowitz, SD; Bhatt, DL; Bosch, JJ; Connolly, SJ; Dagenais, GR; Dyal, L; Eikelboom, JW; Fox, KAA; Leong, DP; Muehlhofer, E; Probstfield, JL; Widimsky, P; Winkelmann, BR; Yusuf, S, 2021) |
| "Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy." | 5.35 | Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). ( Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008) |
| " Dosing was individualized for each patient but followed this general sequence (in milligrams): 0." | 5.31 | Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. ( Bloch, KJ; Krinzman, SJ; Maclean, JA; Nagy, CS; Wong, JT, 2000) |
| "In a multicenter, open-label trial conducted in Japan, we randomly assigned 2236 patients with atrial fibrillation who had undergone percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) more than 1 year earlier or who had angiographically confirmed coronary artery disease not requiring revascularization to receive monotherapy with rivaroxaban (a non-vitamin K antagonist oral anticoagulant) or combination therapy with rivaroxaban plus a single antiplatelet agent." | 5.30 | Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. ( Akao, M; Ako, J; Hagiwara, N; Hirayama, A; Kaikita, K; Kimura, K; Matoba, T; Matsui, K; Miyauchi, K; Nakamura, M; Ogawa, H; Yasuda, S, 2019) |
| "In a double-blind trial, we examined the effect of ticagrelor alone as compared with ticagrelor plus aspirin with regard to clinically relevant bleeding among patients who were at high risk for bleeding or an ischemic event and had undergone PCI." | 5.30 | Ticagrelor with or without Aspirin in High-Risk Patients after PCI. ( Angiolillo, DJ; Baber, U; Briguori, C; Cha, JY; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Džavík, V; Escaned, J; Gibson, CM; Gil, R; Gurbel, P; Hamm, CW; Han, YL; Henry, T; Huber, K; Kastrati, A; Kaul, U; Kornowski, R; Krucoff, M; Kunadian, V; Marx, SO; Mehran, R; Mehta, SR; Moliterno, D; Ohman, EM; Oldroyd, K; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Steg, PG; Weisz, G; Witzenbichler, B, 2019) |
| " The dosage of aspirin decreased from 500 mg or more per day in 1986 to a daily dose of approximately 250 mg in 1989." | 5.29 | [Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Ruidavets, JB, 1994) |
| "Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 to 100 mg per day appears to be beneficial for patients with a history of unstable angina, myocardial infarction, transient ischaemic attacks and stroke." | 5.28 | Aspirin and coronary heart disease. Clinical applications. ( Koutts, J, 1990) |
| "To investigate the feasibility of periodontal mechanical therapy for chronic periodontitis and coronary heart disease patients with low dose of aspirin." | 5.24 | [Bleeding control of periodontal mechanical therapy for patients taking aspirin]. ( Ding, F; Duan, XQ; Han, X; Liu, DY; Lyu, YL; Xuan, W, 2017) |
| "To compare the therapeutic warfarin and aspirin efficacies for treatments of atrial fibrillation (AF) complicated with stable coronary heart disease particularly in older Chinese patients." | 5.19 | Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications. ( Cao, G; Feng, L; Huang, H; Li, Y; Liu, X; Xu, Q; Yu, J; Zhang, S; Zhou, M, 2014) |
| "In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA." | 5.17 | Aspirin increases nitric oxide formation in chronic stable coronary disease. ( Borzak, S; DeMets, D; Hennekens, CH; Hetzel, S; Schneider, R; Schneider, W; Schröder, H; Serebruany, V, 2013) |
| "Noninvasive stress testing might guide the use of aspirin and statins for primary prevention of coronary heart disease, but it is unclear if such a strategy would be cost effective." | 5.16 | Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis. ( Coxson, PG; Galper, BZ; Goldman, L; Heidenreich, P; Lazar, LD; Moran, A; Pletcher, MJ; Rodondi, N; Wang, YC, 2012) |
| "The goal of this study was to investigate the antiplatelet efficacy and tolerability of clopidogrel resinate in patients with coronary heart disease (CHD) or CHD-equivalent risks." | 5.15 | Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial ( Choi, YJ; Gwak, CH; Hong, SJ; Joo, SJ; Kim, HS; Kim, KS; Kim, SH; Park, TH; Seung, KB; Suh, JW; Tahk, SJ, 2011) |
| "This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications." | 5.14 | The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "Despite the use of anti-platelet agents such as acetylsalicylic acid (ASA) and clopidogrel in coronary heart disease, some patients continue to suffer from atherothrombosis." | 5.14 | Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. ( Eriksson, AC; Hedbäck, B; Jonasson, L; Lindahl, TL; Whiss, PA, 2009) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function." | 5.14 | Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "To investigate the effect of Tongxinluo Capsule (TXLC) on platelet aggregation in patients of coronary heart disease (CHD) with aspirin resistance (AR)." | 5.14 | [Effect of tongxinluo capsule on platelet aggregation function in patients with aspirin resistance]. ( Bi, DP; Du, M; Yin, CH, 2010) |
| "The blood levels of P-selectin (P), thrombin B2 (TXB2), and platelet aggregation (PAG) induced by arachidonic acid (AA) and adenosine diphosphate (ADP) were determined in 145 patients with cardio-cerebrovascular diseases (diabetes mellitus, hypertension, coronary heart disease and cerebral infarction), after they were medicated with aspirin 100 mg per day for 7 days." | 5.13 | [Intervening effect of naoxintong on anti-platelet treatment with aspirin]. ( Chen, DK; Zhang, HQ; Zhang, JH, 2008) |
| "Inadequate platelet response to aspirin is associated with increased incidence of peri-procedural myonecrosis." | 5.13 | The effect of high-dose aspirin pre-treatment on the incidence of myonecrosis following elective coronary stenting. ( Duzen, V; Erol, C; Gulec, S; Ozdemir, AO; Ozdol, C; Ozturk, S; Selcuk, T; Temizhan, A; Turhan, S; Vurgun, K, 2008) |
| "To assess the prevalence of a lacking aspirin effect on cyclooxygenase-1 (COX-1) ("aspirin resistance") in patients with symptomatic, stable coronary heart disease (CHD) using test methods directly reflecting inhibition of COX-1." | 5.13 | No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. ( Ameln, W; Bjørnsen, S; Brosstad, F; Erikssen, G; Gjertsen, E; Khiabani, H; Lauritsen, ME; Meen, O; Ng, EC; Pedersen, TM; Schjelderup, NM; Siddique, SP; Wettergreen, M, 2008) |
| "As the mainstay treatment for coronary heart disease (CHD), aspirin alone is reported to be less effective than in combination when treating CHD." | 5.12 | Clinical efficacy of aspirin combination treatment in the treatment of coronary heart disease and its effect on inflammatory factors: a systematic review and meta-analysis. ( Liu, X; Mao, P; Tang, L; Tang, Y; Weng, Y, 2021) |
| "Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required." | 5.12 | Aspirin, warfarin and a thienopyridine for acute coronary syndromes. ( Behar, S; Gottlieb, S; Hammerman, H; Hasdai, D; Hod, H; Iakobishvili, Z; Konstantino, Y; Porter, A; Sandach, A; Zahger, D, 2006) |
| "120 in-hospital coronary heart disease patients with coronary stenting were randomized to two groups receiving either triple antiplatelet drugs of aspirin and clopidogrel combined with cilostazol or dual antiplatelet drugs of aspirin and clopidogrel." | 5.12 | [The effects of post coronary stenting triple antiplatelet therapies on platelet functions]. ( Han, YL; Kang, J; Li, Y; Su, QF; Wang, SL; Yan, CH, 2006) |
| "Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel." | 5.12 | No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. ( Arnesen, H; Pettersen, AA; Seljeflot, I; Solheim, S, 2006) |
| "The antiplatelet effect of aspirin was studied prospectively in 54 consecutive patients with stable coronary heart disease." | 5.12 | Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease. ( Cheng, G; Liu, P; Lu, X; Shan, J; Xu, G; Zhou, Y; Zhu, Y, 2007) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 5.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel)." | 5.11 | [Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. ( Kapilevich, NA; Kisteneva, IV; Markov, VA; Novitskiĭ, VV; Poponina, TM, 2004) |
| "Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate." | 5.11 | Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005) |
| " We assessed the possible 'synergy' of statins and aspirin (ASA) in reducing vascular events in patients with coronary heart disease, in a post hoc analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study." | 5.11 | Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. ( Athyros, VG; Bouloukos, VI; Daskalopoulou, SS; Elisaf, M; Kakafika, AI; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN, 2005) |
| "To investigate the occurrence of aspirin resistance in coronary heart disease (CHD) patients and its influence on myonecrosis among patients undergoing non-emergent percutaneous coronary intervention (PCI)." | 5.11 | [Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention]. ( Dong, L; Liang, J; Yuan, H; Zhang, Y; Zhang, YZ; Zhou, YJ, 2005) |
| "At coronary angiography <48 hours after fibrinolytic therapy, 308 patients receiving aspirin and intravenous heparin had a patent infarct-related artery (Thrombolysis In Myocardial Infarction [TIMI] grade 3 flow)." | 5.10 | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. ( Aengevaeren, WR; Brouwer, MA; Hertzberger, DP; Luijten, HE; Uijen, GJ; van Boven, AJ; van den Bergh, PJ; Veen, G; Verheugt, FW; Vromans, RP, 2002) |
| "Our objective was to provide estimates of the frequency of bleeding complications, as defined by means of the Thrombolysis In Myocardial Infarction(TIMI) group, and collect data on clinical efficacy of the combination of tirofiban with enoxaparin plus ASA." | 5.10 | Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and ( Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD, 2002) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 5.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "The Thrombosis Prevention Trial was a primary prevention factorial trial that reported a reduction in the risk of coronary heart disease (CHD) with warfarin and/or aspirin." | 5.10 | Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect. ( Ashby, D; Brennan, P; Meade, T; Rudnicka, AR, 2003) |
| " Although the dose of aspirin was not randomly assigned, the finding of increased bleeding with doses >162 mg/d is noteworthy." | 5.10 | Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. ( Amarenco, P; Califf, RM; Davis, S; Diener, HC; Easton, D; Ferguson, J; Fitzgerald, D; Graffagnino, C; Granett, J; Harrington, RA; Koudstaal, PJ; Pieper, K; Shuaib, A; Sigmon, K; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F; Willerson, JT, 2003) |
| "We studied stent thrombosis in 4,607 patients with acute coronary syndromes who received a coronary stent as part of routine care during 2 trials of aspirin versus sibrafiban for secondary prevention." | 5.10 | Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). ( Berger, PB; Bhapkar, MV; Califf, RM; Harrington, RA; Moliterno, DJ; Newby, LK; Ohman, EM; Tolleson, TR; Topol, EJ; Van de Werf, F; Verheugt, FW; White, HD, 2003) |
| "Whether thienopyridines (ticlopidine or clopidogrel) produce similar effects on fibrinolysis in patients with non ST elevation acute coronary syndrome (NSTEACS) was not well elucidated." | 5.10 | [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel]. ( Averkov, OV; Dobrovol'skiĭ, AB; Gratsianskiĭ, NA; Slavina, NN, 2003) |
| "We investigated intolerance and bleeding while on aspirin and aspirin discontinuation using 5337 post-acute coronary syndrome patients considered appropriate for chronic antiplatelet therapy who were randomly assigned to aspirin in SYMPHONY and 2nd SYMPHONY and followed for 94 (64,157) days." | 5.10 | Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation. ( Armstrong, PW; Bhapkar, MV; Califf, RM; Kandzari, DE; Kramer, JM; LaPointe, NM; Moliterno, DJ; Newby, LK; Verheugt, FW; White, HD, 2003) |
| "5 and 75 mg of aspirin per day each reduced the incidence of coronary heart disease (CHD)." | 5.10 | Antithrombotic treatment and the incidence of angina pectoris. ( Brennan, PJ; Knottenbelt, C; Meade, TW, 2002) |
| "Despite the use of heparin, aspirin, and other antiplatelet agents, acute coronary syndrome patients without ST-segment elevation remain at risk of cardiovascular thrombotic events." | 5.10 | Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. ( Altman, R; Berman, SG; Del Rio, F; Gonzalez, C; Lopez, R; Luciardi, HL; Muntaner, J, 2002) |
| "High-dose intravenous gamma-globulin (IVGG) plus aspirin (ASA) treatment is effective in preventing coronary artery complications in acute Kawasaki disease (KD)." | 5.09 | Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness. ( Akagi, T; Eto, G; Hashino, K; Iemura, M; Ishii, M; Kato, H; Sato, N; Sugimura, T; Yamakawa, R, 1999) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "Several provocative reports have recently suggested that aspirin is unsafe in patients with heart failure and has negative interaction with ACE inhibitors that might attenuate their beneficial effects upon survival." | 5.09 | Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. ( Battler, A; Behar, S; Boyko, V; Goldbourt, U; Gottlieb, S; Leor, J; Reicher-Reiss, H, 1999) |
| " From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan." | 5.09 | Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. ( Michiels, JJ, 1999) |
| "0001) after adjustment for age, aspirin use, smoking, physical activity, body mass index, and history of angina, hypertension, and high cholesterol." | 5.09 | Alcohol consumption and risk of coronary heart disease by diabetes status. ( Ajani, UA; Buring, JE; Gaziano, JM; Hennekens, CH; Liu, S; Lotufo, PA; Manson, JE, 2000) |
| " Because it is desirable to know possible benefits for different indications so that optimal therapy can be administered in as wide a range of conditions as possible, we analyzed data from the Thrombosis Prevention Trial, a factorial trial that compared treatment with low-intensity, dose-adjusted warfarin and low-dose aspirin separately and together, to determine the minimum effective intensity of oral anticoagulation in the primary prevention of coronary heart disease." | 5.09 | Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease. ( Brennan, PJ; MacCallum, PK; Meade, TW, 2000) |
| "Aspirin and statins are beneficial in coronary heart disease across a broad range of cholesterol levels." | 5.09 | Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. ( Brozek, J; Musiał, J; Szczeklik, A; Undas, A; Undas, R, 2001) |
| "Combining aspirin with LDS did not improve outcomes after acute coronary syndromes and caused more bleeding compared with aspirin alone." | 5.09 | Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. ( , 2001) |
| " At 5 hospitals, 39 patients with unstable angina or non-Q wave myocardial infarction, who were receiving aspirin and heparin, were administered intravenous AR-C69931MX with stepped dose increments over 3 h to a plateau of either 2 microg/kg/min for 21 h (Part 1; n = 12) or up to 69 h (Part 2; n = 13) or 4 microg/kg/min for up to 69 h (Part 3: n = 14)." | 5.09 | Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. ( Oldroyd, KG; Storey, RF; Wilcox, RG, 2001) |
| "In a double-blind randomized trial, 135 patients with unstable angina or non-ST-segment elevation myocardial infarction, with prior CABG, and who were poor candidates for a revascularization procedure received therapy with aspirin and placebo+warfarin, warfarin and placebo+aspirin, or aspirin and warfarin for 12 months." | 5.09 | Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. ( Bogaty, P; Huynh, T; Nasmith, J; Solymoss, S; Théroux, P, 2001) |
| "Twelve habitual smokers with stable coronary disease, on aspirin 325 mg/d, were studied immediately before and 5 minutes after smoking two cigarettes each." | 5.08 | Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. ( Hung, J; Lacoste, L; Lam, JY; Letchacovski, G, 1995) |
| "This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction." | 5.08 | Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. ( Brown, MA; Cross, DB; French, JK; Hamer, AW; Ormiston, JA; White, HD; Williams, BF, 1995) |
| "1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
| "One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)." | 5.08 | Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997) |
| "Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present." | 5.08 | Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. ( Albiero, R; Blengino, S; Colombo, A; Ferraro, M; Hall, P; Itoh, A; Martini, G; Nakamura, S, 1997) |
| "As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone." | 5.08 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998) |
| "We compared the efficacy of oral administration of pentoxifylline (PTX) and intravenous infusions of gamma globulin (IVGG) combination therapy with that of IVGG in reducing the frequency of coronary-artery lesions (CAL) in children with Kawasaki disease (KD), in a randomized trial." | 5.07 | Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. ( Furukawa, S; Ino, T; Matsubara, T; Motohashi, T; Umezawa, Y; Yabuta, K, 1994) |
| "This study was undertaken to determine if a standard dose of aspirin interacts relevantly with the circulatory effects of enalapril in severe heart failure." | 5.07 | Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. ( Hall, D; Rudolph, W; Zeitler, H, 1992) |
| "Data from the early stages of the thrombosis prevention trial (TPT) have been used to establish and quantify the risk of extracranial bleeding due to low dose aspirin (75 mg) and low intensity oral anticoagulation with warfarin (international normalised ratio, INR, 1." | 5.07 | Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. ( Brennan, PJ; Kelleher, CC; Meade, TW; Roderick, PJ; Wilkes, HC, 1992) |
| "Patients admitted for suspected acute myocardial infarction within 6 hours (mean 3 hours 42 minutes) after onset of symptoms were randomised to double-blind treatment with low-dose oral aspirin or placebo." | 5.07 | Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction. ( Følling, M; Pedersen, D; Rodt, SA; Rønnevik, PK; von der Lippe, G, 1991) |
| "To evaluate the effectiveness of gammaglobulin in decreasing the incidence of coronary artery lesions in Kawasaki disease, a randomized controlled study in 136 patients was conducted using high doses of gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d (gammaglobulin group) and aspirin alone at the same dosage (aspirin group)." | 5.06 | High-dose gammaglobulin therapy for Kawasaki disease. ( Matsuoka, H; Matsushima, M; Nagashima, M; Ogawa, A; Okumura, N, 1987) |
| "The ability of high-dose intravenous gammaglobulin (IVGG) to prevent the coronary artery lesion of Kawasaki disease has been studied in a multicentre controlled trial of IVGG plus aspirin versus aspirin alone, aspirin being the conventional treatment for Kawasaki disease." | 5.05 | High-dose intravenous gammaglobulin for Kawasaki disease. ( Furusho, K; Hayashidera, T; Hirose, O; Kamiya, T; Kiyosawa, N; Manabe, Y; Nakano, H; Shinomiya, K; Tamura, T; Yokoyama, T, 1984) |
| "Data from six randomized, placebo-controlled clinical trials of aspirin, involving a total of 10,703 postmyocardial infarction (MI) patients, are compared and combined." | 5.05 | Aspirin in coronary heart disease. Comparison of six clinical trials. ( Canner, PL, 1983) |
| " Critical study of trials of long-term secondary prevention of myocardial infarction carried out between 1967 and 1982 have failed to yield any definitive conclusion as to the value of oral anticoagulants, aspirin, sulfinpyrazone or dipyridamole." | 5.05 | [Long-term antithrombotic treatment in coronary disease]. ( Hodara, M; Samama, M, 1983) |
| "The efficacy and safety of a combination of Persantine and aspirin, of aspirin alone and of a placebo as a regimen for preventing reinfarction were compared in 2026 patients who had recovered from a documented acute myocardial infarction (MI) that had occurred 8 weeks to 5 years previously." | 5.05 | The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group. ( , 1980) |
| " These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins." | 5.05 | Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981) |
| "The Persantine-Aspirin Reinfarction Study (PARIS) was a randomized, controlled, double-blind study of dipyridamole (Persantine) and aspirin in secondary prevention of coronary heart disease." | 5.05 | Persantine-aspirin reinfarction study. Design, methods and baseline results. By the persantine-aspirin reinfarction study research group. ( , 1980) |
| "Three randomized controlled trials of aspirin and secondary mortality have been conducted in patients who had had a myocardial infarction." | 5.05 | Aspirin and secondary mortality after myocardial infarction. ( Elwood, PC; Sweetnam, PM, 1980) |
| "The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study." | 5.05 | Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985) |
| "Both the Coronary Drug Project (CDP) and the Aspirin Myocardial Infarction Study (AMIS) were successfully able to recruit adequate members of postmyocardial infarction patients to long-term multicenter clinical trials in the secondary prevention of coronary heart disease." | 5.04 | Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study. ( Schoenberger, JA, 1979) |
| " Data from RCTs show that aspirin is an effective antithrombotic at doses below 75 mg daily, and that direct oral anticoagulants reduce the risk of stroke in patients with coronary disease at doses 1/4 of those recommended in atrial fibrillation." | 5.01 | Antithrombotic dose: Some observations from published clinical trials. ( Dimmitt, SB; Ferner, RE; Floyd, CN, 2019) |
| "Tobacco smoking results in increased platelet aggregability, which suggests that low-dose aspirin used in common clinical practice may not effectively inhibit platelet activity in smokers with coronary heart disease (CHD)." | 4.87 | Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease. ( DU, X; Li, WJ; Ma, CS; Miao, CL; Shi, JH; Tang, RB; Zhang, HY, 2011) |
| "Niacin is the most effective lipid-modifying agent for raising high-density lipoprotein cholesterol levels, but it also causes cutaneous vasodilation with flushing." | 4.86 | A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. ( Jacobson, TA, 2010) |
| " The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel in decreasing the risk of adverse events in coronary heart disease patients has been well established in the past 20 years." | 4.85 | Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working ( Arnesen, H; Budaj, A; De Caterina, R; Filipiak, K; Golanski, J; Gorski, J; Huber, K; Kristensen, SD; Kuliczkowski, W; Opolski, G; Polonski, L; Pregowski, J; Sitkiewicz, D; Watala, C; Witkowski, A; Zembala, M, 2009) |
| " The clinical benefits of combined pravastatin-acetylsalicylic acid in the management of coronary patients have been demonstrated by a meta-analysis of five randomized clinical trials for secondary prevention; compared with pravastatin alone, the pravastatin-acetylsalicylic acid combination reduced the risk of fatal or non fatal myocardial infarction by 26%, the risk of ischemic stroke by 31%, and the risk of cardiovascular events at 5 years by 13%." | 4.84 | [Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes]. ( Hennekens, C, 2007) |
| "After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established." | 4.84 | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. ( Agostoni, P; Andreotti, F; Crea, F; Porto, I; Testa, L; Trotta, G; Zoccai, GB, 2007) |
| "The TIMI Risk Score recognizes prior aspirin use as an independent risk factor for adverse outcomes in subjects presenting with an acute coronary syndrome." | 4.84 | The role of aspirin resistance in the treatment of acute coronary syndromes. ( Jain, H; Lancaster, GI; Zarich, SW, 2008) |
| ", statins), and aspirin therapy for the primary prevention of coronary heart disease (CHD) in an elderly patient population (age >or=65 y)." | 4.82 | Primary prevention of coronary heart disease in the elderly. ( Dornbrook-Lavender, KA; Pieper, JA; Roth, MT, 2003) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 4.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "After the acute coronary syndrome, adding warfarin to standard aspirin therapy decreases myocardial infarction and stroke but increases major bleeding." | 4.82 | Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. ( Celestin, C; Cook, JR; Fiore, LD; Lawler, E; Rothberg, MB, 2005) |
| "According to meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease." | 4.82 | [Primary prevention of coronary heart disease with aspirin]. ( Darius, H; Kübler, W, 2005) |
| " In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel." | 4.81 | Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002) |
| "To determine the cardiovascular and coronary risk thresholds at which aspirin for primary prevention of coronary heart disease is safe and worthwhile." | 4.81 | Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. ( Ghahramani, P; Jackson, PR; Ramsay, LE; Sanmuganathan, PS; Wallis, EJ, 2001) |
| " Patients receiving anti-GP IIb-IIIa therapy have a lower risk of death or myocardial infarction than those receiving the classic anti-agregant, aspirin, alone." | 4.81 | [GPIIb-IIIa inhibitors]. ( Nurden, P, 2001) |
| "1) Randomized trials at least 1 year in duration that examined aspirin chemoprevention in patients without previously known cardiovascular disease and 2) systematic reviews, recent trials, and observational studies that examined rates of hemorrhagic strokes and gastrointestinal bleeding secondary to aspirin use." | 4.81 | Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. ( Hayden, M; Mulrow, C; Phillips, C; Pignone, M, 2002) |
| "The incidence of death or myocardial infarction after acute coronary syndrome (ACS) is still high despite the widespread use of aspirin." | 4.81 | [Oral anticoagulants combined with aspirin in the prolonged treatment after acute coronary syndrome]. ( Biancoli, S; Cerè, E; Di Pasquale, G; Parlangeli, R, 2002) |
| "Antithrombotic and antiplatelet agents, particularly unfractionated heparin and aspirin, are longstanding therapeutic mainstays for acute coronary syndromes such as unstable angina and non-Q-wave myocardial infarction (MI)." | 4.80 | Anticoagulants in acute coronary syndromes. ( Turpie, AG, 1999) |
| " Randomized trials have found that in specific patient subgroups, tamoxifen and raloxifene decreased the occurrence of breast cancer, and lovastatin and aspirin decreased the frequency of CAD events." | 4.80 | Preventing heart disease and cancer. What randomized, primary-prevention studies show. ( Lush, DT, 1999) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| " For primary prevention, aspirin showed no effect in a British study, but reduced the incidence of myocardial infarction by 44% per year in an American trial concerning men and by 32% concerning women." | 4.79 | [Blood thinning in heart patients]. ( Meier, B, 1995) |
| " (1) Proven: one or more TIAs in the past 6 months and carotid stenosis > or = 70% or mild stroke within 6 months and a carotid stenosis > or = 70%; (2) acceptable but not proven: TIAs within the past 6 months and a stenosis 50% to 69%, progressive stroke and a stenosis > or = 70%, mild or moderate stroke in the past 6 months and a stenosis 50% to 69%, or carotid endarterectomy ipsilateral to TIAs and a stenosis > or = 70% combined with required coronary artery bypass grafting; (3) uncertain: TIAs with a stenosis < 50%, mild stroke and stenosis < 50%, TIAs with a stenosis < 70% combined with coronary artery bypass grafting, or symptomatic, acute carotid thrombosis; (4) proven inappropriate: moderate stroke with stenosis < 50%, not on aspirin; single TIA, < 50% stenosis, not on aspirin; high-risk patient with multiple TIAs, not on aspirin, stenosis < 50%; high-risk patient, mild or moderate stroke, stenosis < 50%, not on aspirin; global ischemic symptoms with stenosis < 50%; acute dissection, asymptomatic on heparin." | 4.79 | Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. ( Barnett, HJ; Beebe, HG; Bernstein, EF; Brener, BJ; Brott, T; Caplan, LR; Day, A; Goldstone, J; Hobson, RW; Moore, WS, 1995) |
| "A vast consensus exists in defining a narrow range of recommended daily doses of aspirin, ie, 75 to 160 mg, for the prevention of myocardial infarction, stroke, and vascular death in patients with different manifestations of coronary hearth disease." | 4.79 | Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? ( Patrono, C; Roth, GJ, 1996) |
| "Although there is firm consensus that aspirin reduces the incidences (and severity) of reinfarction if given to patients after a myocardial infarction or in patients with unstable angina, there is disagreement about the optimum dose that should be used." | 4.79 | The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low? ( Förster, W; Parratt, JR, 1997) |
| "A wide array of clinical trials over the past two decades has established that aspirin is indicated to prevent myocardial infarction in patients with clinically evident coronary artery disease, and to prevent stroke in patients with a history of stroke or TIAs." | 4.78 | Prophylactic aspirin and the elderly population. ( Dalen, JE; Goldberg, RJ, 1992) |
| " Aspirin in doses of approximately 300 mg/day may be recommended for the primary prevention of myocardial infarction (MI), but only in those patients with a moderate to high risk of cardiovascular disease." | 4.78 | Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases. ( Verstraete, M, 1991) |
| " Lush reviews positive and negative aspects of recent trends and summarizes the results of studies on the prophylactic potential of maintenance of normal body weight, exercise, aspirin, fish oils, estrogens, and antioxidants." | 4.78 | Coronary artery disease. The latest on prevention. ( Lush, DT, 1992) |
| "We have reviewed some of the voluminous literature on the effects of aspirin combined with dipyridamole on coronary thrombosis." | 4.78 | Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease. ( Folts, JD; Rowe, GG, 1990) |
| " These studies, in conjunction with recent histopathologic studies demonstrating plaque defects and overlying thrombosis in patients with unstable ischemia and sudden death, suggest a common mechanism for unstable angina and myocardial infarction and strongly support the rationale for antithrombotic therapy with heparin and with aspirin in the management of patients with unstable angina." | 4.77 | Thrombosis in unstable angina: angiographic aspects. ( Cowley, MJ; DiSciascio, G; Rehr, RB, 1987) |
| "In parallel with experimental research into methods for salvage of ischemic myocardium after acute myocardial infarction (AMI) over the last decade, there has been a growing interest in prostaglandins (PG) and their inhibition by aspirin-like drugs or nonsteroidal anti-inflammatory drugs (NSAID)." | 4.76 | Prostaglandin inhibition and myocardial infarct size. ( Becker, LC; Jugdutt, BI, 1981) |
| "There were no significant differences in age, sex, alcohol consumption, smoking habits, history of diabetes, hypertension, and dyslipidemia, and aspirin intake between the eradication and non-eradication groups (3783 vs." | 4.31 | Preventive effect of Helicobacter pylori eradication on the coronary heart diseases depending on age and sex with a median follow-up of 51 months. ( Ahn, S; Choi, Y; Hwang, IC; Kim, N; Kim, SB; Lee, DH; Lim, SH; Park, J; Park, YS; Shin, CM; Song, DH; Yoon, H, 2023) |
| "To examine the association between CAC, bleeding, and ASCVD and explore the net estimated effect of aspirin at different CAC thresholds." | 4.02 | Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease. ( Ajufo, E; Ayers, CR; de Lemos, JA; Joshi, PH; Khera, A; Rohatgi, A; Vigen, R, 2021) |
| "This study aims to explore the clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and the effects on N terminal pro B type natriuretic peptide (NT-ProBNP) and creatine kinase-MB (CK-MB) levels." | 3.96 | Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels. ( Chen, LL; Lu, WL; Tang, DD; Wang, JP; Wang, W; Yan, SR; Zhao, LH, 2020) |
| "To investigate the correlation of tumor necrosis factor α (TNF-α) polymorphisms with upper gastrointestinal bleeding (UGIB) induced by enteric-coated aspirin in coronary heart disease (CHD) patients." | 3.91 | Association between TNF-α polymorphisms and the risk of upper gastrointestinal bleeding induced by aspirin in patients with coronary heart disease. ( Wang, TP, 2019) |
| " Recommendations address diagnosis and treatment of cardiovascular risk factors (hypertension and dyslipidemia), aspirin use, screening for and treatment of coronary heart disease, and lifestyle interventions." | 3.88 | Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. ( Chamberlain, JJ; Johnson, EL; Leal, S; Peterson, L; Rhinehart, AS; Shubrook, JH, 2018) |
| "The patient has been treated with statin, ezetimibe, aspirin, and traditional heart failure (HF) medications." | 3.88 | Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report. ( Kuang, H; Li, L; Lu, T; Shou, W; Yi, Q; Zhou, X, 2018) |
| "Dialysis did not affect the antiplatelet effects of aspirin and clopidogrel in uremic patients with coronary heart disease." | 3.85 | Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease. ( Fu, DL; Gao, YX; Li, XL; Liu, XF; Lu, HK; Peng, WH; Wang, Q; Wang, Y; Yang, P; Zhang, H; Zhao, TT; Zheng, JG, 2017) |
| "The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR." | 3.85 | Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017) |
| "To evaluate the efficacy and safety of aspirin usage for coronary heart disease (CHD) primary prevention in patients with dyslipidemia." | 3.83 | Effects of low-dose aspirin in subjects with dyslipidemia. ( Chen, J; Lou, G; Xia, Y, 2016) |
| "CYP2C19 genotype and the residual platelet reactivity (RPR) were measured in 361 coronary heart disease patients (male, mean age 69yrs), and the risk of cardiovascular events over a 3-month follow-up was assessed to evaluate the impact of co-administration of esomeprazole during dual antiplatelet therapy with aspirin and clopidogrel." | 3.81 | Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. ( Akasaka, T; Arima, Y; Hokimoto, S; Kaikita, K; Kumagae, N; Morita, K; Nakagawa, K; Ogawa, H; Oniki, K; Sakamoto, K; Tabata, N; Tsujita, K; Yamamoto, E, 2015) |
| "Aspirin prevention of thrombosis and death in patients undergoing HD might require consideration of the anti-PF4/H antibody status." | 3.81 | Effectiveness of and risk associated with aspirin therapy in hemodialysis patients with a background of antiplatelet factor 4/heparin complex antibody detection. ( Chen, G; Jin, L; Kong, D; Li, C; Ma, L; Qi, K; Song, M; Wang, C; Wang, Y; Yang, Y, 2015) |
| "In patients with both stable coronary disease and atrial fibrillation, a baseline treatment of aspirin and an oral anticoagulant is often prescribed due to the proven benefits of each therapy on cardiovascular and thromboembolic events and mortality." | 3.81 | [Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?]. ( Lister, K; Louis Simonet, M, 2015) |
| "Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding." | 3.81 | Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015) |
| " Optimal use of 4 oral drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors) in all eligible patients with AMI or unfractionated heparin in non-ST-segment-elevation myocardial infarction was a highly cost-effective strategy (incremental cost-effectiveness ratios approximately US $3100 or less)." | 3.80 | Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. ( Coxson, PG; Goldman, L; Gu, D; He, J; Heidenreich, PA; Liu, J; Moran, AE; Wang, M; Zhao, D, 2014) |
| "We recruited 162 coronary heart disease patients treated with aspirin and clopidogrel, and we genotyped them for the CES1A2 A(-816)C, CYP2C19 *2/*3, PON1 Q192R, and ABCB1 C3435T polymorphisms." | 3.80 | The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. ( Ding, X; Gao, J; Hang, Y; Jiang, B; Miao, L; Wang, H; Xie, C; Zhang, H; Zhang, J, 2014) |
| "Aspirin for the primary prevention of coronary heart disease (CHD) is only recommended for individuals at high risk for CHD although the majority of CHD events occur in individuals who are at low to intermediate risk." | 3.80 | Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. ( Blaha, MJ; Blankstein, R; Budoff, MJ; Duprez, DA; Folsom, AR; Greenland, P; Miedema, MD; Misialek, JR; Nasir, K; Silverman, MG, 2014) |
| " We aim to document the prevalence of aspirin and clopidogrel resistance in Saudi patients with coronary heart disease (CHD) and to probe the possible responsible mechanism[s]." | 3.80 | Evaluation of resistance to anti-platelet therapy in patients with coronary heart disease in a developing country. ( Abdel Gader, AM; Al Shamiri, MQ; Bayoumy, NM, 2014) |
| "These were post hoc analyses of datasets from the Aspirin Myocardial Infarction Study, a 1:1 randomized, double-blind clinical trial, conducted from 1975 to 1979, that examined mortality rates following daily aspirin administration over three years in individuals with documented MI." | 3.78 | Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. ( Dabbous, O; Hariri, A; Krishnan, E; Lingala, B; Pandya, BJ, 2012) |
| "This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease." | 3.78 | [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012) |
| "The proper use of statins and aspirin decrease the risk of coronary heart disease (CHD) among patients with diabetes (DM) and hyperlipidemia." | 3.78 | Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006. ( Chen, YJ; Hwu, CM; Li, CY; Lin, YC; Peng, WC; Yang, CC, 2012) |
| "Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding." | 3.77 | Cost-utility of aspirin and proton pump inhibitors for primary prevention. ( Earnshaw, SR; Fendrick, AM; McDade, C; Pignone, M; Scheiman, J, 2011) |
| "To evaluate the risk of myocardial infarction and death from coronary heart disease after discontinuation of low dose aspirin in primary care patients with a history of cardiovascular events." | 3.77 | Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. ( Cea-Soriano, L; Johansson, S; Martín-Merino, E; Rodríguez, LA, 2011) |
| " Oklahoma Behavioral Risk Factor Surveillance System (BRFSS) data were used to determine past history of CHD, risk factors for CHD and stroke, and aspirin use among persons 45 years and older." | 3.76 | Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma. ( Cline, TL; Daniels, CG; Mallonee, S; Mold, JW, 2010) |
| "Prior aspirin use was associated with more comorbidities and coronary disease and a higher risk of recurrent MI, but not mortality." | 3.76 | Prior aspirin use and outcomes in acute coronary syndromes. ( Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Qin, J; Rich, JD, 2010) |
| "Insufficient platelet inhibition by low-dose aspirin is associated with poor prognosis in patients with coronary heart disease (CHD)." | 3.76 | Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. ( Bierend, A; Böger, RH; Kom, GD; Maas, R; Schwedhelm, E; Trinks, R; Tsikas, D, 2010) |
| "To determine the frequency of use of pharmacotherapy with aspirin, beta blocker, statin, and angiotensin-converting enzyme (ACE) inhibitor in patients with stable coronary heart disease (CHD) among physicians at different levels of health care in Rajasthan state, India." | 3.75 | Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. ( Agrawal, A; Bana, A; Deedwania, PC; Gupta, R; Kasliwal, A; Roy, S; Sharma, KK; Tongia, RK, 2009) |
| "To examine the current status of the use of aspirin among outpatients with established coronary heart disease (CHD) in China." | 3.75 | [The present status of the use of aspirin for secondary prevention of coronary artery disease]. ( Liu, J; Smith, SC; Sun, JY; Zhao, D, 2009) |
| "Aspirin is recommended for primary prevention in patients with metabolic syndrome (MetS)." | 3.75 | The prevalence of aspirin resistance in patients with metabolic syndrome. ( Aras, D; Cağirci, G; Cay, S; Geyik, B; Ozdemir, O; Oztürk, S; Topaloğlu, S, 2009) |
| "Aspirin has been shown to reduce the number of transient ischemic attacks (TIA), stroke and death in patients with multiple TIA." | 3.75 | Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells. ( Turpie, AG, 1982) |
| "Aspirin use may reduce the risk of stroke and coronary heart disease." | 3.74 | Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? ( Cushman, M; Glasser, SP; Howard, G; Howard, VJ; Kleindorfer, D; Prince, V; Prineas, R; You, Z, 2008) |
| "Patients with coronary heart disease (CHD) require long-term therapy with low-dose aspirin (ASA)." | 3.74 | Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention. ( Fendrick, AM; Saini, SD; Scheiman, J; Schoenfeld, P, 2008) |
| "Rate of resistance to aspirin and clopidogrel was assessed in 44 patients with non ST elevation acute coronary syndrome." | 3.74 | [Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome]. ( Aĭnetdinova, DKh; Sulimov, VA; Udovichenko, AE, 2008) |
| "This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy." | 3.74 | Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008) |
| "Patients with cancer who have thrombocytopenia may experience acute coronary syndromes (ACS), and the use of aspirin (ASA) poses an increased risk of bleeding." | 3.74 | Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. ( Botz, G; Champion, JC; Durand, JB; Hirch-Ginsburg, C; Lakkis, N; Lenihan, DJ; Sarkiss, MG; Shaw, AD; Swafford, J; Warneke, CL; Yusuf, SW, 2007) |
| "To identify the risk factors for myocardial ischemia in patients undergoing aspirin therapy for coronary artery disease (CAD) presenting with upper gastrointestinal hemorrhage and to ascertain the impacts on mortality and length of hospital stay." | 3.74 | Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| "Aspirin reduces mortality for men and women with coronary heart disease (CHD)." | 3.74 | Gender differences in aspirin use among adults with coronary heart disease in the United States. ( Cannon, CP; McWilliams, JM; Opotowsky, AR, 2007) |
| "To identify an interaction between hormone therapy (HT) and COX inhibition, we measured a priori the association between concomitant nonsteroidal anti-inflammatory drugs (NSAIDs), excluding aspirin, in peri- and postmenopausal women on HT and the incidence of myocardial infarction (MI) in a population-based epidemiological study." | 3.74 | Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction? ( Egan, K; FitzGerald, GA; García Rodríguez, LA, 2007) |
| "To determine the patterns of aspirin use for the primary prevention of coronary heart disease (CHD)." | 3.74 | Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. ( Butler, J; Cornuz, J; Hayoz, D; Marques-Vidal, P; Paccaud, F; Pécoud, A; Rodondi, N; Vollenweider, P; Waeber, G, 2008) |
| "Aspirin is the standard therapy applied after coronary intervention, and statins are also prescribed to prevent secondary coronary heart disease." | 3.74 | Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. ( Akimoto, Y; Hiroyuki, D; Kajimoto, K; Kasai, T; Ken, Y; Kojima, T; Kubota, N; Miyauchi, K; Njaman, W; Takeshi, K, 2008) |
| " We sought to estimate the incremental cost-effectiveness of providing full coverage for aspirin, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins (combination pharmacotherapy) to individuals enrolled in the Medicare drug benefit program after acute myocardial infarction." | 3.74 | Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries. ( Antman, EM; Avorn, J; Choudhry, NK; Patrick, AR; Shrank, WH, 2008) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 3.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "A 58-year-old Caucasian male with a history of coronary heart disease and hypercholesterolemia, under treatment with acetyl-salicylate for 6 years and simvastatin for 2 months, presented to the Emergency Department of our hospital with epigastric pain and vomiting of 24-hour duration." | 3.73 | A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. ( Antonopoulos, S; Filioti, K; Giannoulis, G; Karamanolis, D; Kokkoris, S; Mikros, S; Protopsaltis, J, 2005) |
| " Independent predictors of coronary artery disease were: typical chest pain, aspirin use, diabetes, and age >64 years." | 3.73 | [A new risk score for patients with a normal or non-diagnostic ECG admitted to a chest pain unit]. ( Andueza, J; Bueno, H; de Miguel, J; Estévez, A; Martínez-Sellés, M; Ortiz, J, 2005) |
| "Regular aspirin use was associated with increasing age, male gender, lower educational attainment, hypertension, diabetes, overweight, and histories of myocardial infarction, coronary heart disease, and stroke." | 3.73 | Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke. ( Brown, DW; Croft, JB; Giles, WH; Greenlund, KJ; Shepard, D, 2005) |
| "Aspirin for the primary prevention of coronary heart disease (has a more favorable risk/benefit profile among adults with high coronary heart disease risk than among low-risk adults, but there is little information on the current patterns of aspirin use for primary prevention." | 3.73 | Aspirin use for the primary prevention of coronary heart disease in older adults. ( Bauer, DC; Butler, J; Cornuz, J; Ding, J; Harris, TB; Hulley, SB; Newman, AB; Rodondi, N; Satterfield, S; Vittinghoff, E, 2005) |
| "During the past 2 decades, randomized trials have proved the efficacy of several treatments for non-ST-elevation acute coronary syndromes (NSTE-ACSs), including aspirin, beta blockers, and coronary revascularization." | 3.73 | Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities. ( Coresh, J; Folsom, AR; Powe, N; Rosamond, W; Thiemann, D; Watkins, S, 2005) |
| "Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs." | 3.73 | [Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005) |
| "Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied." | 3.73 | Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. ( Earnshaw, S; Pignone, M; Pletcher, MJ; Tice, JA, 2006) |
| "The safety of aspirin in heart failure (HF) has been called into question, particularly in those patients (1) without coronary disease, (2) with renal dysfunction, or (3) treated with low-dose angiotensin-converting enzyme (ACE) inhibitors and high-dose aspirin." | 3.73 | Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. ( Armstrong, PW; Fang, J; Ghali, WA; Gong, Y; McAlister, FA; Tu, JV, 2006) |
| "To assess bleeding complications among patients undergoing percutaneous coronary intervention (PCI) and receiving triple therapy of warfarin, aspirin, and a thienopyridine." | 3.73 | Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. ( Battler, A; Hasdai, D; Iakobishvili, Z; Konstantino, Y; Porter, A; Shachar, L, 2006) |
| "Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS)." | 3.73 | A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. ( Chan, WK; Lee, KK; Lee, VW, 2006) |
| "Depression severity in hospital was associated with nonadherence in a gradient fashion: 15% of non-depressed patients (BDI score 0 to 4), 29% of mildly depressed patients (BDI score 10 to 16), and 37% of patients with moderately-to-severely depressive symptoms (BDI score >16) took aspirin less than 80% of the time (p = 0." | 3.73 | Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study. ( Burg, MM; Chaplin, WF; Davidson, KW; Gerin, W; Kong, G; Kronish, IM; Lespérance, F; Rieckmann, N, 2006) |
| "Aspirin provides benefit in nearly all groups of patients with clinical manifestations of coronary heart disease." | 3.72 | Aspirin for cardiovascular disease prevention. ( Hung, J, 2003) |
| "We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
| " Patients and providers can then examine the effect of introducing one or more risk-reducing interventions (aspirin, lipid-lowering drug therapy, antihypertensive medication, or smoking cessation) on the patient's CHD risk." | 3.72 | Heart to Heart: a computerized decision aid for assessment of coronary heart disease risk and the impact of risk-reduction interventions for primary prevention. ( Kuo, J; Lee, YZ; Mulrow, C; Phillips, C; Pignone, M; Sheridan, SL; Zeiger, R, 2004) |
| "According to the meta-analysis and the results of the two studies with the highest power, aspirin is effective in primary prevention of coronary heart disease." | 3.72 | [Primary prevention of coronary heart disease with aspirin]. ( Kübler, W, 2004) |
| "In this nonrandomized, prospective, multinational, multicenter study, adherence to aspirin, beta-blockers, statins, or angiotensin-converting enzyme (ACE) inhibitors 6 months after discharge for myocardial infarction or unstable angina was assessed in 21,408 patients aged 18 years or older." | 3.72 | Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. ( Avezum, A; Eagle, KA; Erickson, S; Flather, MD; Goodman, SG; Granger, CB; Gurfinkel, EP; Kline-Rogers, E; Steg, PG; White, K, 2004) |
| "To evaluate the effect of treatment without aspirin in the acute phase of Kawasaki disease (KD) and to determine whether it is necessary to expose children to high- or medium-dose aspirin." | 3.72 | Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. ( Hsieh, KS; Huang, SM; Huang, TC; Lee, CL; Lin, CC; Weng, KP, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "We evaluated both the effect of aspirin treatment (81 mg/day) on serum Lp(a) concentrations and the correlation between the degree of reduction in serum Lp(a) and the type of apo(a) isoform in 70 patients with coronary artery disease or cerebral infarction." | 3.71 | Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. ( Aihara, K; Akaike, M; Azuma, H; Hayashi, I; Iuchi, T; Kagawa, A; Kanagawa, Y; Matsumoto, K; Matsumoto, T; Nishiuchi, T; Takamori, N; Tamura, K; Yoshida, T, 2002) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 3.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| "We sought (1) to determine how often aspirin is prescribed as a discharge medication among patients 65 years or older and hospitalized with both heart failure and coronary artery disease; (2) to identify patient characteristics associated with the decision to prescribe aspirin; and (3) to evaluate the association between aspirin prescription at discharge and 1-year survival." | 3.71 | Aspirin and the treatment of heart failure in the elderly. ( Chen, YT; Krumholz, HM; Radford, MJ, 2001) |
| "To determine whether aspirin is associated with a mortality benefit in stable patients with known or suspected coronary disease and to identify patient characteristics that predict the maximum absolute mortality benefit from aspirin." | 3.71 | Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. ( Blackstone, EH; Gum, PA; Lauer, MS; Thamilarasan, M; Watanabe, J, 2001) |
| "Non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs) have complex effects that could either prevent or promote coronary heart disease." | 3.71 | Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. ( Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM, 2002) |
| " The effect of the nitro-derivative of aspirin, NCX4016, was assessed on ischaemic ventricular arrhythmias and myocardial infarct size in anaesthetized pigs in comparison to native aspirin." | 3.71 | NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. ( Del Soldato, P; Miller, AM; Wainwright, CL; Work, LM, 2002) |
| "Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease." | 3.71 | Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. ( Coxson, PG; Gaspoz, JM; Goldman, L; Goldman, PA; Hunink, MG; Kuntz, KM; Williams, LW, 2002) |
| ", age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with beta-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin." | 3.70 | Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival. ( Gibbs, NM; Mahon, BD; Newman, MA; Sheminant, MR; Weightman, WM; Whitford, EG, 1999) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 3.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "A 64-year-old man presented with worsening dyspnea on exertion and hemothorax of the left chest 7 days after discharge from the hospital on ticlopidine and aspirin after coronary stent placement to his left circumflex artery." | 3.70 | Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. ( Dillard, TA; Quinn, MW, 1999) |
| "Platelet-related events being associated with the increment of infarct size at reperfusion in the presence of a residual stenosis, we tested in dogs whether intravenous aspirin (ASA) could limit infarct size." | 3.70 | Intravenous aspirin at reperfusion does not reduce infarct size in the dog with a residual critical stenosis. ( Laperrière, L; Latour, JG; Libersan, D; Merhi, Y; Quan, E; Uzan, A, 1999) |
| "Combination antiplatelet therapy using aspirin and ticlopidine has been the standard of care for prevention of subacute thrombosis following coronary stent implantation." | 3.70 | Combination therapy with clopidogrel and aspirin after coronary stenting. ( Curran, SC; Herrmann, HC; Hirshfeld, JW; Klugherz, BD; Kolansky, DM; Magness, K; Wilensky, RL, 2000) |
| "To evaluate the effects of resuscitation with a 10% diaspirin-crosslinked hemoglobin (DCLHb) solution on global hemodynamic variables, systemic and myocardial oxygen transport and tissue oxygenation, and contractile function of the left ventricle in an experimental model of severe hemorrhagic shock and critical stenosis of the left anterior descending coronary artery (LAD)." | 3.70 | Diaspirin-crosslinked hemoglobin reduces mortality of severe hemorrhagic shock in pigs with critical coronary stenosis. ( Habler, O; Kemming, G; Kleen, M; Meisner, F; Messmer, K; Pape, A, 2000) |
| "Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established." | 3.70 | Nonplatelet effects of aspirin during acute coronary occlusion: electrophysiologic and cation alterations in ischemic myocardium. ( Arena, J; Moschos, CB; Regan, TJ; Shehadeh, AA, 2000) |
| "The aim of this study was to determine changes in treatment of myocardial infarction between 1986 and 1989 in the Haute-Garonne region and, in particular, to assess the role of aspirin and antiaggregant therapy." | 3.69 | [Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Richard, JL; Ruidavets, JB, 1995) |
| " All patients were prescribed a twice-per-day regimen of low dose aspirin to reduce their risk for myocardial infarction." | 3.69 | Major depression and medication adherence in elderly patients with coronary artery disease. ( Carney, RM; Eisen, SA; Freedland, KE; Jaffe, AS; Rich, MW, 1995) |
| " Those with acute myocardial infarction, radiolucent defects in coronary arteries suggestive of thrombus, and results that were not optimal after stent implantation were anticoagulated with warfarin and not Included in the study." | 3.69 | Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin. ( Aroney, CN; Bett, JH; McEniery, PT; Sankardas, MA, 1996) |
| "We sought to assess the role of aspirin in a precisely defined cohort with coronary disease receiving current therapy." | 3.69 | Marked reduction in long-term cardiac deaths with aspirin after a coronary event. Multicenter Myocardial Ischemia Research Group. ( Andrews, M; Goldstein, RE; Hall, WJ; Moss, AJ, 1996) |
| " There were 12 independent significant predictors for readmission: clinical history (a previous history of either congestive heart failure or myocardial infarction, or CABG); acute operation; postoperative complications (time in intensive care unit greater than two days, neurological complications); clinical findings four to seven days after the operation (arrhythmia, systolic murmur equivalent to mitral regurgitation); medication four to seven days after the operation (antidiabetics, diuretics for heart failure, other antiarrhythmics (other than beta blockers, calcium antagonists, and digitalis), and lack of treatment with aspirin)." | 3.69 | Predictors of hospital readmission two years after coronary artery bypass grafting. ( Albertsson, P; Brandrup-Wognsen, G; Emanuelsson, H; Haglid, M; Hartford, M; Herlitz, J; Hjalmarson, A; Karlson, BW; Karlsson, T; Sandén, W, 1997) |
| "Serum salicylate concentrations were measured in 60 patients with acute phase Kawasaki disease (KD), who were treated with intravenous aspirin (IVASP), to evaluate its anti-inflammatory effect in the treatment of KD." | 3.68 | Treatment of Kawasaki disease using the intravenous aspirin anti-inflammatory effect of salicylate. ( Matsuo, N; Saji, T; Umezawa, T, 1992) |
| "Low-dose aspirin is widely used in patients operated on for coronary disease as secondary prevention of coronary artery occlusion." | 3.68 | Gastric changes in coronary-operated patients with low-dose aspirin. ( Kivilaakso, E; Leivonen, M; Sipponen, P, 1992) |
| "The difference in the effectiveness of aspirin for the prevention of stroke and secondary prevention of myocardial infarction was discussed on the basis of inhibition of platelet aggregation." | 3.67 | Experimental basis of platelet aggregation inhibition by acetylsalicylic acid. ( Begent, NA; Born, GV; Görög, P, 1984) |
| "The effects on platelet function of a four-week administration of aspirin at a low dosage (100 mg daily) were compared in two groups, 14 healthy young volunteers and 14 patients with coronary heart disease." | 3.67 | [Effects of low-dose acetylsalicylic acid on thrombocytes in health subjects and in patients with coronary heart disease]. ( Bleifeld, W; Kupper, W; Schuster, O; Terres, W, 1989) |
| "Incidences of cardiovascular diseases, cancers, gastrointestinal bleeding, ulcers, and cataracts were compared in participants who did and did not take aspirin daily." | 3.67 | Aspirin use and chronic diseases: a cohort study of the elderly. ( Chao, A; Henderson, BE; Paganini-Hill, A; Ross, RK, 1989) |
| "The effects of arginine aspirin (AAs) on the effective refractory period (ERP) and ventricular fibrillation threshold (VFT) of ischemic ventricular muscle were observed in 24 anesthetized open-chest rabbits." | 3.67 | [Effects of arginine aspirin on changes in effective refractory period and ventricular fibrillation threshold of ischemic myocardium in rabbit]. ( Wu, BW; Zang, YM; Zhao, RR; Zhao, ZQ; Zhou, YY; Zhu, MZ, 1989) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "Prostacyclin (PGI2) release by human aortic tissue obtained at surgery was assessed in patients (n = 23) with ischaemic heart disease undergoing coronary artery bypass grafting (group 1) patients (n = 14) undergoing surgery for aortic stenosis (group 2), patients (n = 4) undergoing surgery for aortic regurgitation (group 3), and patients (n = 8) with ischaemic heart disease taking aspirin (group 4)." | 3.67 | Release of prostacyclin from the human aorta. ( Dandona, P; Jeremy, JY; Mikhailidis, DP; Tsang, V; Walesby, RK; Wright, JC, 1988) |
| "A relationship between the emergence of ventricular arrhythmias and other signs of myocardial ischemia was assessed in 96 coronary patients on the basis of comparative results of the physical and psychoemotional stressful tests, and the nitroglycerin and aspirin tests." | 3.67 | [Detection of latent disorders of coronary circulation and heart rhythm in ischemic heart disease patients by using psychoemotional loading]. ( Gaprindashvili, TG; Kvantaliani, TG; Mamaladze, GT, 1987) |
| "Arrhythmias were produced by ouabain (2." | 3.67 | Prostaglandin involvement in hypersensitivity of ischemic hearts to arrhythmogenic influence of ouabain. ( Ferrier, GR; Karmazyn, M; Moffat, MP, 1985) |
| "The effects of aspirin on coronary hemodynamics and transcardiac concentrations of thromboxane B2 (the stable metabolite of thromboxane A2) were determined at rest and during pacing-induced myocardial ischemia in 11 patients with coronary disease." | 3.67 | Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia. ( Addonizio, VP; Fisher, CA; Harken, AH; Hirshfeld, JW; Laskey, WK; Martin, JL; Untereker, WJ, 1985) |
| "Baseline white blood cell count (WCC) and haematocrit were examined in relation to recurrent coronary events and to all-cause mortality in 2026 persons enrolled in the first Persantin-Aspirin Reinfarction Study (PARIS-1) 2-60 months after myocardial infarction." | 3.67 | White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. ( Barton, BA; Forbes, CD; Krol, WF; Lowe, GD; Machado, SG, 1985) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| "Thromboxane A2 (TxA2), released by aggregating platelets, has been proposed as a potential mediator of coronary vasospasm." | 3.66 | Failure of thromboxane A2 blockade to prevent attacks of vasospastic angina. ( Chierchia, S; Crea, F; de Caterina, R; Maseri, A; Patrono, C, 1982) |
| " Pretreatment with carbenicillin, which markedly inhibited platelet aggregation or estradiol cypionate, which induced severe thrombocytopenia, significantly reduced the incidence of sudden death to 9% and zero, respectively." | 3.66 | Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death. ( Franciosa, J; Heckel, R; Johnson, GJ; Leis, LA, 1981) |
| "Ninety-two patients with Kawasaki disease were treated with five different types of drug therapy: a steroid preparation (prednisolone), aspirin, an antibiotic, a combination of steroid plus aspirin, and a combination of steroid plus warfarin." | 3.66 | Kawasaki disease: effect of treatment on coronary artery involvement. ( Kato, H; Koike, S; Yokoyama, T, 1979) |
| "Between 1950 and 1975, 473 Rochester patients had the diagnosis of rheumatoid arthritis and received aspirin treatment." | 3.66 | Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. ( Fuster, V; Kurland, LT; Linos, A; O'Fallon, W; Whisnant, JP; Worthington, JW, 1978) |
| "Patients with type 2 diabetes mellitus (T2DM) are at higher risk of thrombotic complications." | 2.87 | Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease. ( Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY, 2018) |
| " Salvianolate can significantly inhibit the aggregation and activation of platelets in patients with CHD; however, its optimum combination with western medicine is not established or supported by clinical trial results." | 2.87 | Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial. ( Cao, W; Gao, R; Li, R; Wang, S; Zhang, W; Zhu, B, 2018) |
| "Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days." | 2.77 | Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012) |
| " Using the PFA-100 system, reassessment of platelet function following oral administration of daily aspirin dosage significantly reduces the number of stable coronary disease patients considered to be non-responders to such treatment." | 2.76 | Can resistance to aspirin be reversed after an additional dose? ( Angiolillo, DJ; Azcona, L; Bernardo, E; Fernández-Ortiz, A; García-Rubira, JC; González-Ferrer, JJ; Macaya, C; Núñez-Gil, I; Vivas, D, 2011) |
| "Aspirin has been shown to decrease cardiovascular (CV) events by ∼25%." | 2.76 | Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. ( Auer, J; Berent, R; Franklin, B; Schmid, P; von Duvillard, SP, 2011) |
| "Aspirin (ASA) is an effective antiplatelet drug that reduces the risk of myocardial infarction, stroke, or death by approximately 25% in patients who are at increased risk of cardiovascular events." | 2.75 | Factors responsible for "aspirin resistance" - can we identify them? ( Filipiak, KJ; Huczek, Z; Kosior, D; Opolski, G; Postuła, M; Serafin, A; Tarchalska-Kryńska, B, 2010) |
| "Major bleeding was less frequent in the <2-h group (1." | 2.74 | Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. ( Aymong, E; Buller, CE; Carere, RG; Densem, C; Fox, RS; Fung, AY; Hamburger, JN; Humphries, KH; Jokhi, P; Ricci, DR; Saw, J; Starovoytov, A; Walsh, SJ; Webb, JG, 2009) |
| " We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel." | 2.74 | Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. ( Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ, 2009) |
| "Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy." | 2.74 | Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009) |
| "Treatment with citalopram was associated with greater increase in tNO over 12 weeks compared to placebo (P = 0." | 2.74 | Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. ( Atar, D; Frasure-Smith, N; Laliberté, MA; Lespérance, F; Malinin, AI; Serebruany, VL; van Zyl, LT, 2009) |
| "We prospectively studied the effect of aspirin dosing on platelet function in 125 stable outpatients with coronary artery disease randomized in a double-blind, double-crossover investigation (81, 162, and 325 mg/d for 4 weeks each over a 12-week period)." | 2.73 | Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. ( Bliden, KP; Chaganti, SK; DiChiara, J; Etherington, A; Gesheff, T; Gurbel, PA; Neerchal, NK; Newcomer, J; Tantry, US; Weng, W, 2007) |
| "Several studies have shown that treatment of coronary heart disease (CHD) does not meet the goals set in recommendations." | 2.73 | Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting. ( Kähönen, M; Kallio, J; Kööbi, T; Lehtimäki, T; Lehtinen, R; Michou, SM; Niemelä, K; Nieminen, T; Nikus, K; Turjanmaa, V; Viik, J, 2007) |
| "Aspirin resistance was higher at the 81-mg dose in diabetic versus nondiabetic patients using collagen-induced LTA (27 vs." | 2.73 | The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. ( Antonino, MJ; Bailon, O; Bliden, KP; DiChiara, J; Gurbel, PA; Hamed, MS; Singla, A; Suarez, TA; Tantry, US, 2007) |
| "Minor bleeding was more frequent in the enoxaparin group (30." | 2.71 | Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003) |
| "Although pharmacologic treatment for hyperlipidemia had the greatest favorable impact on the ratio over time, our data also show that maintaining an ideal weight and exercise have beneficial effects." | 2.71 | Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men. ( Buring, JE; Gaziano, JM; Levenson, JW; Scranton, R; Sesso, HD; Stampfer, MJ, 2004) |
| "Aspirin 100 mg/d was administrated concomitantly with cilostazol or ticlopidine." | 2.71 | [Effects of cilostazol on long-term clinical outcomes after coronary stenting]. ( Deng, J; Ge, JB; Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, SL; Yang, GT; Yu, HB, 2005) |
| "We examined the prevalence and medical treatment of hypertension among 15,904 ACS patients randomized in the SYMPHONY and 2nd SYMPHONY trials." | 2.71 | Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical ( Armstrong, PW; Aylward, PE; Bhapkar, MV; Frazier, CG; Klein, WW; Kristinsson, A; McGuire, DK; Newby, LK; Sadowski, Z; Shah, SH; Weaver, WD, 2005) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.70 | Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002) |
| "Aspirin therapy was associated with a 48 percent reduction in the incidence of myocardial infarction (2." | 2.70 | Aspirin and mortality from coronary bypass surgery. ( Mangano, DT, 2002) |
| " Monotherapy with ticlopidine is as safe and effective as a combined regimen of ticlopidine plus aspirin after coronary artery stenting in an unselected patient population." | 2.70 | Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. ( Barmeyer, J; Bojara, W; Deneke, T; Germing, A; Grewe, P; Jaeger, D; Lawo, T; Lemke, B; Lindstaedt, M; Machraoui, A; von Dryander, S, 2001) |
| " In patients with stable CAD, platelet aggregation was dose dependently inhibited by RPR 109891, and the dose-response relation was shifted to the right by the concomitant administration of aspirin (p = 0." | 2.70 | Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. ( Catella-Lawson, F; Combe, S; Cucchiara, AJ; De Marco, S; FitzGerald, GA; Kapoor, S; Moretti, D; Ramsey, KE; Rocca, B; Theroux, P; Vigilante, GJ, 2001) |
| "Ticlopidine reduces stent thrombosis and other adverse events among patients receiving coronary stents." | 2.70 | Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). ( Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001) |
| " Significant predictors of pharmacokinetic response included infusion dose and weight." | 2.70 | First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. ( Armstrong, PW; Becker, RC; Bovill, EG; Dyke, CK; Dzavik, V; Gardner, LH; Gerstenblith, G; Harrington, RA; Hasselblad, V; Hochman, JS; Kleiman, NS; Kunitada, S; Lincoff, AM; Robertson, TL; Shimoto, Y; Zillman, LA, 2002) |
| "Study of the tolerance and pharmacodynamic and pharmacokinetic characteristics of ascolong, a new buccal dosage form of aspirin containing a very low dose of acetylsalicylic acid (ASA): 12." | 2.69 | [Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant]. ( Belolipetskaia, VG; Bochkareva, EV; Davydo, AB; Deev, AD; Demina, EG; Gorin, NN; Ionova, VG; Khromov, GL; Kokurina, EV; Kucheriaeva, NG; Metelitsa, VI; Rumiantsev, DO; Suslina, ZA; Tanashian, MM; Zidra, SI, 1998) |
| "In a prospective randomized trial in 42 patients undergoing coronary artery bypass surgery, we analyzed the long term platelet inhibiting effects of 50 mg acetylsalicylic acid (ASA) by itself and in combination with dipyridamole (2 x 200 mg), in comparison with phenprocoumon." | 2.69 | [Long term effects of 50 mg acetylsalicylic acid alone and in combination with dipyridamole on platelet function after coronary bypass surgery]. ( Hoffmann, MW; Rauhöft, C; Terres, W, 1998) |
| "Pretreatment with aspirin did not change the vasodilator responses in any group." | 2.69 | Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction. ( Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Montagne, O; Sediame, S, 1999) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| "Aspirin alone at the low dose of 100 mg administered or the combination of coumadin and aspirin after high-pressure coronary stenting does not prevent adverse clinical events when ultrasound guidance is not used." | 2.69 | Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study. ( Barmeyer, J; Germing, A; Jäger, D; Lange, S; Lemke, B; Machraoui, A; von Dryander, S, 1999) |
| " No in-hospital adverse cardiac events occurred." | 2.69 | beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. ( Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999) |
| "Dipyridamole was administered in 550 PTCA procedures (455 interventions in men, mean (SD) age 59." | 2.69 | Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 2000) |
| "Major or severe bleeding (but not intracranial hemorrhage) was higher with orbofiban; it occurred in 2." | 2.69 | Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. ( Alexander, JC; Anders, RJ; Berink, P; Braunwald, E; Cannon, CP; Caspi, A; Charlesworth, A; Langer, A; Lopez-Sendon, J; McCabe, CH; Skene, A; Toman, J; Wilcox, RG, 2000) |
| "Cilostazol is a potent antiplatelet agent with antiproliferative properties." | 2.69 | Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000) |
| " Patients were randomized to placebo (n = 19) or to 1 of 4 integrelin dosing regimens (total n = 54) that were studied sequentially." | 2.68 | Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. ( Harrington, RA; Joseph, D; Kleiman, NS; Kottke-Marchant, K; Lincoff, AM; Rios, G; Rose, D; Sigmon, KN; Tcheng, JE; Trainor, K, 1995) |
| " These results suggest that while waiting for the technological advancements of stents, postprocedural treatment that includes a low dosage of ticlopidine, aspirin, and low-molecular-weight heparin is a very effective alternative to conventional poststenting therapy." | 2.68 | Intracoronary stenting without coumadin: one month results of a French multicenter study. ( Benveniste, E; Biron, Y; Bourdonnec, C; Faivre, R; Fajadet, J; Gaspard, P; Glatt, B; Joly, P; Morice, MC; Zemour, G, 1995) |
| "Tirofiban was associated with a dose-dependent inhibition of ex vivo ADP-mediated platelet aggregation that was sustained during intravenous infusion and resolved rapidly after drug cessation." | 2.68 | Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. ( Ambrose, J; Cohen, M; Fitzpatrick, V; Herrmann, HC; Kereiakes, DJ; Kleiman, NS; McKee, DB; Palabrica, T; Rodriguez, S; Sax, FL; Sutton, JM; Weaver, WD, 1996) |
| "Treatment with aspirin emerged as an independent predictor of reduced cardiovascular (RR = 0." | 2.68 | Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group. ( Behar, S; Benderly, M; Goldbourt, U; Harpaz, D; Kishon, Y, 1996) |
| "Eptifibatide treatment did not increase rates of major bleeding or transfusion." | 2.68 | Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. ( , 1997) |
| "Dipyridamole was applied in 550 interventions (455 interventions in men, 95 interventions in women, age = 59." | 2.68 | [Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study]. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 1997) |
| " The dosage of aspirin was 30 mg/kg orally during the acute febrile stage and 5-10 mg/kg orally after lysis of fever." | 2.67 | Histopathologic and coronary angiographic assessment of effectiveness of aspirin or aspirin-and-gammaglobulin in Kawasaki disease. ( Haneda, N; Mori, C, 1993) |
| " Microscopic hematuria was the most frequent (20%) adverse clinical event, but was unrelated to the INR." | 2.67 | Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. ( Comp, PC; Durica, SS; Goodman, SG; Gray, RJ; Hall, JH; Hua, TA; Kelley, RP; Langer, A; Lee, RJ; Raskob, GE, 1994) |
| "Aspirin has an established benefit in reducing the incidence of coronary events and vein graft occlusion." | 2.67 | Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. ( Bevan, DH; Cowans, D; Kallis, P; Talbot, S; Tooze, JA; Treasure, T, 1994) |
| "Patients with carotid stenosis have a high frequency of asymptomatic coronary artery disease (CAD)." | 2.67 | Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167. ( Chimowitz, MI; Cohen, SL; Hobson, RW; Starling, MR; Weiss, DG, 1994) |
| " Further studies are underway to develop alternative heparin dosing strategies in an effort to reduce the occurrence of bleeding complications associated with c7E3 Fab administration and to assess the benefit of c7E3 Fab-mediated platelet inhibition in lower risk patient subgroups." | 2.67 | Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results. ( Popma, JJ; Satler, LF, 1994) |
| "Aspirin-treated lesions (n = 163) had lost 16 +/- 22% (mean +/- standard deviation) of lumen and placebo-treated lesions 22 +/- 25% of lumen (n = 134) at angiography (p less than 0." | 2.67 | Effects of low-dose aspirin on restenosis after coronary angioplasty. ( Cope, GD; Cumpston, GN; Gibbons, FA; Luke, P; Mews, GC; Taylor, RR, 1991) |
| "Restenosis was assessed by percent area stenosis as determined by quantitative angiographic techniques before, immediately and 1 year after angioplasty." | 2.67 | Effects of diltiazem on complications and restenosis after coronary angioplasty. ( Giorgi, LV; Good, TH; Hartzler, GO; Ligon, RW; McCallister, BD; O'Keefe, JH; Webb, DL, 1991) |
| " These results demonstrate that high aspirin dosage does not reduce the restenosis rate more than low dosage." | 2.67 | [Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty]. ( Grimme, M; Kochsiek, K; Schanzenbächer, P; Walter, U, 1991) |
| "This review presents prevalence of type 2 diabetes mellitus (DM) in patients with ischemic heart disease (IHD), risk factors in common, and a considerable worsening of prognosis in their combination." | 2.66 | [Choosing Antithrombotic Therapy in Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus: How to Reduce the Risk of Death]. ( Karavaev, PG; Koziolova, NA; Veklich, AS, 2020) |
| "No child had sequelae of Kawasaki disease at a follow-up of 2 to 31 months." | 2.66 | Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Preliminary report. ( Bussel, JB; Engle, MA; Fatica, NS; Lesser, ML; O'Loughlin, JE; Snyder, MS, 1989) |
| " Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued." | 2.66 | Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. ( Aldridge, HE; Bonan, R; Bourassa, MG; David, PR; Henderson, M; Kazim, F; Lespérance, J; Salvatori, VA; Schwartz, L, 1988) |
| "Treatment with sulfinpyrazone or aspirin/dipyridamole did not produce changes in platelet survival time or plasma beta TG concentration that were significantly different from the values during the placebo phase." | 2.65 | Platelet tests and antiplatelet drugs in coronary artery disease. ( Butt, R; de Boer, AC; Gent, M; Genton, E; Han, P; Turpie, AG, 1983) |
| "Many such trials in coronary heart disease have terminated inconclusively or in controversy." | 2.65 | Are clinical trials in coronary heart disease oversold or undersold? ( Detre, KM; Mantel, N; Ware, J, 1981) |
| " Administration of DPY alone at a higher dosage increased the exercise duration and had a similar effect on platelet survival." | 2.65 | Effect of platelet suppressant treatment with dipyridamole and aspirin on exercise performance and platelet survival time in coronary disease. ( Rainwater, J; Steele, P; Vogel, R, 1981) |
| " Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie." | 2.49 | [Thrombocyte aggregation inhibitors: what are the risks?]. ( Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013) |
| "Aspirin's ability to suppress platelet function varies widely among individuals and lesser suppression of platelet function is associated with increased risk of myocardial infarction, stroke and cardiovascular death." | 2.44 | Pharmacogenomics of platelet responsiveness to aspirin. ( Becker, DM; Becker, LC; Faraday, N, 2007) |
| "Thrombosis has a proinflammatory component whereby biologically active substances are synthesized by different cell types that could not individually synthesize the metabolite(s)." | 2.43 | Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. ( Broekman, MJ; Drosopoulos, JH; Islam, N; Levi, R; Marcus, AJ; Olson, KE; Pinsky, DJ, 2005) |
| " As well, we highlight current research around optimal dosage and other issues related to aspirin administration." | 2.43 | What every emergency nurse needs to know about aspirin. ( Smith, S; Turris, SA, 2005) |
| " Furthermore, (i) the optimal dosage of aspirin for complete inhibition of platelet aggregation by physiological agonists (i." | 2.43 | Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. ( Christiaens, L; Macchi, L; Sorel, N, 2006) |
| " Data indicate that eptifibatide, at the current recommended dosing schedule, achieves the highest level of consistent platelet inhibition compared with current doses of abciximab and tirofiban." | 2.43 | Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. ( Jennings, LK, 2005) |
| "Diabetes mellitus is a well-recognized risk-factor for coronary artery disease." | 2.43 | [Coronary heart disease in patients with diabetes mellitus]. ( Nakayama, M; Ogawa, H, 2006) |
| "Conservative treatment of coronary heart disease is the therapeutic mainstay and includes various measures aimed at achieving a general reduction of risks." | 2.43 | [Conservative treatment of coronary heart disease--current options]. ( Desch, S; Niebauer, J; Schuler, G, 2005) |
| "Aspirin has proven benefits in primary and secondary prevention of coronary artery disease." | 2.42 | Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. ( Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003) |
| " Intravenous glycoprotein IIb/IIIa inhibitors effectively prevent periprocedural thrombotic complications, but their short duration of action and parenteral dosing don't allow for long-term protection." | 2.42 | What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? ( Berger, P; Steinhubl, S, 2003) |
| "Coronary heart disease is the leading cause of death in women older than 50." | 2.42 | Modifiable risk factors for the primary prevention of heart disease in women. ( Alt, S; Friedman, J; Hong, S, 2003) |
| "Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience." | 2.42 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004) |
| "To review systematically the clinical effectiveness and the cost-effectiveness of clopidogrel used in combination with standard therapy including aspirin, compared with standard therapy alone for the treatment of non-ST-segment elevation acute coronary syndromes (ACS)." | 2.42 | Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. ( Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004) |
| "Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia." | 2.41 | Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002) |
| "She developed aplastic anemia seven weeks after initiation of ticlopidine." | 2.41 | Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review. ( Ammash, Z; Dabajah, B; Mourad, FH; Nasrallah, A; Taher, A, 2000) |
| "In aspirin-treated patients with acute coronary syndrome without ST elevation, short-term unfractionated heparin or LMWH halves the risk of myocardial infarction or death." | 2.41 | Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. ( Anand, SS; Eikelboom, JW; Ginsberg, JS; Malmberg, K; Weitz, JI; Yusuf, S, 2000) |
| "Kawasaki disease is the leading cause of acquired heart disease in childhood." | 2.41 | Long-term cardiac sequelae of Kawasaki disease. ( Fulton, DR; Newburger, JW, 2000) |
| "Kawasaki disease is an acute self-limited vasculitis of infancy and early hildhood that is now the leading cause of acquired heart disease in children in the United States and Japan." | 2.41 | Kawasaki disease. ( Burns, JC, 2001) |
| "Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors." | 2.41 | Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001) |
| "In patients requiring treatment for heart failure, if possible, aspirin should be avoided and the integrity of prostaglandin metabolism respected; the severer the heart failure the more compelling." | 2.41 | Controversies in heart failure. Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure? ( Hall, D, 2001) |
| "The phenomenal growth in the rate of type 2 diabetes presents an enormous burden to society." | 2.41 | Glycemic control and beyond: the ABCs of standards of care for type 2 diabetes and cardiovascular disease. ( Cunningham, M; Kernan-Schroeder, D, 2002) |
| "This may reflect a reduction in restenosis, although this remains to be proven." | 2.40 | Pharmacologic prevention of acute ischemic complications of coronary angioplasty. ( Cumberland, D; Wheeldon, N, 1997) |
| "Diabetes mellitus is another CHD risk factor which is stronger in women than in men, and CHD death rates are 3-7 times greater among diabetic than nondiabetic women." | 2.40 | Risk factors for coronary heart disease in women. ( Hennekens, CH, 1998) |
| "Coronary artery ectasia is the abnormal enlargement of the coronary artery." | 2.40 | Current knowledge and significance of coronary artery ectasia: a chronologic review of the literature, recommendations for treatment, possible etiologies, and future considerations. ( Bove, AA; Davis, MJ; Sorrell, VL, 1998) |
| "The well-documented disadvantages of unfractionated heparin in the management of coronary syndromes, such as unpredictable bioavailability and maintenance of therapeutic range, has prompted several studies into the benefits of low-molecular-weight heparins (LMWHs)." | 2.40 | Rationale for the management of coronary syndromes with low-molecular-weight heparins. ( Antman, E; Cohen, M; Fareed, J; Gurfinkel, E; Mautner, B, 1998) |
| "Aspirin has a role in secondary prevention of coronary artery disease; among patients who are allergic to or intolerant of aspirin, ticlopidine has a role in patients with unstable angina and clopidogrel has a potential role in patients with ischemic heart or vascular disease." | 2.40 | Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. ( Tisdale, JE, 1998) |
| "The final common pathway to the coronary thrombosis underlying ACS involves the aggregation of platelets mediated by the binding of soluble fibrinogen to the platelet receptor glycoprotein (GP) IIb-IIIa." | 2.40 | Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. ( Harrington, RA, 1999) |
| "Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects." | 2.40 | The thienopyridines in coronary artery disease. ( Berger, PB, 1999) |
| "Kawasaki disease is now the leading cause of acquired heart disease in children in most developed countries." | 2.39 | Kawasaki disease. ( De Inocencio, J; Hirsch, R; Shulman, ST, 1995) |
| "Current recommendations for the treatment of hypercholesterolemia include drug therapy for persons at sufficiently elevated risk for coronary heart disease." | 2.39 | Lowering risk without lowering cholesterol: implications for national cholesterol policy. ( Avins, AL; Browner, WS, 1996) |
| " A metaanalysis of ten trials has shown a 25% decrease in vascular events in the long-term, irrespective of age, gender, blood pressure blood glucose level, and dosage whether low (75 to 160 mg) or moderate (160 to 325 mg/day)." | 2.39 | [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents]. ( Aumont, MC; Seknadji, P, 1996) |
| " The dosage of ticlopidine is 2 tablets per day; that of aspirin is not well established (100 to 330 mg per day in a single dose)." | 2.39 | [Antiplatelet agents (inhibitors of platelet function) orally administered. Bases for their practical use in coronary artery disease]. ( de Maistre, E; Lecompte, T, 1996) |
| "Total prevention of mural thrombus in deeply injured arteries is impossible with aspirin or conventional antithrombotic therapy, which can reduce occlusive thrombus." | 2.38 | Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. ( Badimon, JJ; Badimon, L; Chesebro, JH; Roche, PC; Webster, MW; Zoldhelyi, P, 1992) |
| "Kawasaki disease is an immunologically mediated diffuse vasculitis of childhood of unknown etiology." | 2.38 | Kawasaki disease. Epidemiology, late prognosis, and therapy. ( Barron, KS, 1991) |
| "In secondary-prevention trials to treat unstable angina, which were performed in USA and Canada, the number of non-fatal myocardial infarctions was reduced by about 50 per cent." | 2.38 | Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. ( Born, GV, 1990) |
| "When nifedipine was compared with isosorbide dinitrate in a randomized crossover, double-blind trial in patients with coronary artery spasm, both drugs were shown to be efficacious and neither was superior." | 2.37 | Large vessel coronary vasospasm: diagnosis, natural history and treatment. ( Conti, CR, 1985) |
| " The majority of patients were given aspirin 1300 mg daily, but the optimum dosage was not properly evaluated." | 2.37 | The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs. ( Goodman, DS, 1987) |
| "Aspirin has significantly reduced both the occurrence of myocardial infarction and mortality rate in patients with unstable angina and/or previous myocardial infarction; it has also proved beneficial in cerebrovascular disease." | 2.37 | Current issues in thrombosis prevention with antiplatelet drugs. ( Cerletti, C; de Gaetano, G; Dejana, E; Vermylen, J, 1986) |
| "Dipyridamole can inhibit both platelet adhesion and aggregation by raising the platelet cyclic AMP level through phosphodiesterase inhibition." | 2.37 | Aspirin and other platelet-aggregation inhibiting drugs. ( Gallus, AS, 1985) |
| "Diagnosis of Kawasaki Disease (KD) can be challenging due to lack of a diagnostic test, and some children present with 'incomplete' KD when not all diagnostic criteria are met." | 1.48 | Kawasaki Disease - A Review of Treatment and Outcomes in an Irish Paediatric Cohort 2010-14. ( Butler, KM; Flinn, AM; Gavin, PJ; McMahon, CJ; Oslizok, P, 2018) |
| "Aspirin was the most common used western medicine (51 132 patients, 67." | 1.40 | [Preliminary study on integration of traditional Chinese medicine and western medicine in patients with coronary heart disease in real world]. ( Ai, QH; Jiang, HY; Li, GH; Xie, YM; Zhao, W, 2014) |
| " Treatment courses were from 3 to7 days, at a dosage of 60 mL." | 1.39 | [Outcome study on parenterally administered shenfu in treatment of coronary heart disease]. ( Li, L; Shen, H; Xie, YM; Yang, J; Zhuang, Y, 2013) |
| "In order to understand the treatment of coronary heart disease with parenterally administered Shenmai and the efficacy of combination therapies, the study selected 18 hospitals for analysis." | 1.39 | [Real-world study in analysis of effects on concomitant medications with parenterally administered shenmai for coronary heart disease]. ( Jiang, JJ; Tang, H; Xie, YM; Yang, H; Zhuang, Y, 2013) |
| "Aspirin-sensitivity was indicated by the absence of either of these criteria; aspirinsensitivity was indicated as both criteria being met." | 1.38 | [Prevalence of laboratory aspirin resistance in 431 old patients]. ( Cao, J; Fan, L; Hu, G; Hu, Y; Li, X; Liu, L; Wang, Q; Wang, Y; Wu, R, 2012) |
| "Aspirin treatment did not prevent either CD62P or CD40L expression." | 1.36 | Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. ( Chandler, AB; Earhart, AD; Hansen, J; Jennings, LK; Kueter, TJ; Speich, HE; White, MM, 2010) |
| "Women with CHD also had a higher rate of cerebral ischemia than did men (27." | 1.36 | Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010) |
| "Despite aspirin's established role in the treatment of atherosclerotic vascular disease, considerable controversy exists regarding its most effective dosing strategy." | 1.35 | Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). ( Amarenco, P; Aronow, HD; Califf, RM; Davis, S; Diener, HC; Easton, JD; Ferguson, J; Fitzgerald, DJ; Graffagnino, C; Harrington, RA; Koudstaal, PJ; Shuaib, A; Theroux, P; Topol, EJ; Vallee, M; Van de Werf, F, 2008) |
| "A sample of 208 from 463 patients with type 2 diabetes aged 20-75 years with or without a history of ischaemic heart disease (IHD)." | 1.35 | Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus. ( Hudson, SA; Johnson, BJ; Kamyar, M; Lemmens-Gruber, R; McAnaw, JJ, 2008) |
| "Aspirin plays a key role in the secondary prevention of atherothrombotic events and thrombotic complications after stent implantation." | 1.35 | Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. ( Angiolillo, DJ; Bass, TA; Gavazzi, A; Invernizzi, P; Mihalcsik, L; Musumeci, G; Rossini, R; Scuri, P, 2008) |
| "Aspirin was used in 64% of patients with CAD and in 28." | 1.35 | Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive. ( Garg, P; Jeevanantham, V; Khan, A; Nautiyal, A; Reddy, PC; Shrivastava, R, 2008) |
| "Aspirin resistance was significantly associated with genetic variation in the platelet surface adenosine 5-diphosphate receptor gene P2Y1." | 1.33 | Aspirin resistance and a single gene. ( Foster, JH; Ginsburg, G; Jefferson, BK; Kottke-Marchant, K; McCarthy, JJ; Parker, A; Topol, EJ, 2005) |
| "Aspirin resistance was noted in 128 (27." | 1.33 | Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. ( Chen, WH; Cheng, X; Kwok, JY; Lau, CP; Lee, PY; Ng, W; Tse, HF, 2005) |
| "ticlopidine) treatment remained the sole predictor of TSO (OR: 5." | 1.33 | Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. ( Amit, G; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2005) |
| "Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded." | 1.33 | Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "Women with coronary disease are at high risk for myocardial infarction or death from coronary heart disease even in the absence of other risk factors, and their risk increases up to sixfold when many risk factors are present." | 1.32 | Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. ( Barrett-Connor, E; Blumenthal, R; Furberg, CD; Hulley, S; Ireland, CC; Khan, SS; Shlipak, MG; Varosy, PD; Vittinghoff, E, 2003) |
| "The average postoperative blood loss (845 mL versus 775 mL; p = 0." | 1.32 | Effect of preoperative aspirin use in off-pump coronary artery bypass operations. ( Dihmis, WC; Fabri, BM; Grayson, AD; Pullan, DM; Srinivasan, AK, 2003) |
| "Naproxen was associated with an OR of 0." | 1.32 | Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. ( García Rodríguez, LA; González-Pérez, A; Maguire, A; Varas-Lorenzo, C, 2004) |
| "Thrombosis was the main cause of death." | 1.32 | A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). ( Finazzi, G, 2004) |
| "Stroke is a devastating complication in patients with prosthetic valves, but characterization of its late occurrence from a large cohort is lacking." | 1.32 | Late incidence and determinants of stroke after aortic and mitral valve replacement. ( Bédard, PJ; Goldstein, WG; Hendry, PJ; Masters, RG; Mesana, TG; Pipe, AL; Rubens, FD; Ruel, M, 2004) |
| "Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB." | 1.31 | Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. ( de Andres, R; Farré, J; García-Méndez, A; Gómez, J; López-Farré, A; Mateos-Cáreres, PJ; Rico, L; Romero, J; Sánchez de Miguel, L, 2002) |
| " Dosing was individualized for each patient but followed this general sequence (in milligrams): 0." | 1.31 | Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. ( Bloch, KJ; Krinzman, SJ; Maclean, JA; Nagy, CS; Wong, JT, 2000) |
| " Interindividual variability is observed in the level of platelet inhibition achieved with use of the current abciximab dosing regimen (0." | 1.31 | Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. ( Berkowitz, SD; Christie, DJ; Glazer, S; Jennings, LK; Madan, M; Sigmon, KN; Smit, AC; Tcheng, JE, 2001) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis." | 1.30 | Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. ( Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| "Treatment with aspirin, beta blockers, and angiotensin converting enzyme inhibitors." | 1.30 | Secondary prevention in coronary heart disease: baseline survey of provision in general practice. ( Campbell, NC; Deans, HG; Rawles, JM; Ritchie, LD; Thain, J, 1998) |
| "015), and chronic intake of nitrates (P<0." | 1.30 | Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. ( Beckmann, R; Binder, BR; Geppert, A; Graf, S; Hornykewycz, S; Huber, K; Schuster, E, 1998) |
| "Aspirin use was protective for colorectal cancer (odds ratio, 0." | 1.30 | Association between coronary heart disease and cancers of the breast, prostate, and colon. ( Ahsan, H; Chen, L; Hagan, M; Jacobson, JS; Khan, ZR; Neugut, AI; Pablos-Mendez, A; Rahman, MI; Rosenberg, DJ; Shea, S; Wahid, N, 1998) |
| "Treatment with aspirin was associated with a significant reduction in cardiac and total mortality among non-insulin-dependent diabetic patients with coronary artery disease." | 1.30 | Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. ( Behar, S; Boyko, V; Gottlieb, S; Graff, E; Harpaz, D; Kishon, Y, 1998) |
| " The investigations were performed with different amounts of 4 different inducers (ADP, arachidonic acid, epinephrine and collagen) taking dose-response curves." | 1.30 | [The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis]. ( Barczi, V; Blaskó, G; Dinnyés, J; Hamvas, J; Jáger, R; Kinczel, A; Pál, A; Poór, F; Salamon, A; Tarján, J, 1999) |
| "Aspirin was being taken by 56% of patients." | 1.30 | Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. ( Armitage, M; Cox, P; Davies, J; Flanagan, DE; Paine, D, 1999) |
| "Left ventricular dysfunction was attributed to idiopathic dilated cardiomyopathy in 18 and coronary artery disease in 19 patients." | 1.30 | Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. ( Atar, D; Gurbel, PA; Lowry, DR; Murugesan, SR; O'Connor, CM; Pothula, A; Serebruany, VL, 1999) |
| "Since then, Kawasaki disease has been described worldwide in children of all racial groups and has been recognized as a leading cause of acquired heart disease among children in the United States (Figure 1)." | 1.29 | Kawasaki disease and its cardiac sequelae. ( Newburger, JW; Sundel, RP, 1993) |
| " The dosage of aspirin decreased from 500 mg or more per day in 1986 to a daily dose of approximately 250 mg in 1989." | 1.29 | [Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne]. ( Branchu, MP; Cambou, JP; Ferrières, J; Lablache-Combier, B; Marques-Vidal, P; Ruidavets, JB, 1994) |
| "Patients admitted to the coronary care unit who received both intravenous nitroglycerin and heparin were studied to evaluate heparin dosage requirements." | 1.29 | Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. ( Berk, SI; Bodenheimer, MM; Grunwald, A; Pal, S, 1993) |
| "For every 100 patients with Kawasaki syndrome, the cost was reduced by $323,400 when aspirin therapy alone was changed to IVIG-HD therapy and 14 cases of coronary artery dilation were thereby prevented." | 1.29 | Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. ( Gafni, A; Klassen, TP; Rowe, PC, 1993) |
| " A dose-response relation was found between level of anger and overall CHD risk (P for trend, ." | 1.29 | A prospective study of anger and coronary heart disease. The Normative Aging Study. ( Kawachi, I; Sparrow, D; Spiro, A; Vokonas, P; Weiss, ST, 1996) |
| "Hypertension is a known risk factor in the genesis of coronary artery disease." | 1.28 | Influence of mild to moderate treated hypertension on 9-11 year mortality in patients with pre-existing coronary heart disease. ( Gupta, KD; Gupta, R; Kasliwal, P, 1992) |
| "Aspirin was used in most patients often in conjunction with dipyridamole and from 1986 intravenous immunoglobulin was given routinely to those patients seen early in the illness." | 1.28 | Clinical aspects of 100 patients with Kawasaki disease. ( Dillon, MJ; Levin, M; Suzuki, A; Tizard, EJ, 1991) |
| "Treatment with aspirin and a residual stenosis of 25-49% immediately after successful PTCA were the only variables associated with restenosis (P less than 0." | 1.28 | Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. ( Emanuelsson, H; Hjalmarson, A; Johansson, SR; Karlsson, T; Wiklund, O, 1991) |
| " There were significantly lower thromboxane B2 and 6-keto-PFG1a levels in the stenosed left arterior descending (LAD) segments with increasing dosage of aspirin-208 +/- 36, 24 +/- 31, 50 +/- 6 ng/g (P less than 0." | 1.28 | Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. ( Benedict, CR; Buja, LM; Campbell, WB; Falinska, B; McNatt, J; Rosolowsky, M; Willerson, JT; Yao, SK, 1991) |
| "Aspirin has been successfully used in the secondary prophylaxis of myocardial infarction, cerebral vascular events and peripheral arterial disease." | 1.28 | [Aspirin against aging? For whom and how much?]. ( Meier, PJ; Oelz, O, 1990) |
| "The overall restenosis rate was 40%." | 1.28 | Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group. ( Bass, T; Cowley, M; Goldberg, SH; Henderson, MA; Hirshfeld, JW; Macdonald, RG; Margolis, JR; Taussig, A; Vetrovec, G; Whitworth, H, 1990) |
| "Aspirin, which is an effective anti-platelet agent, given in the low dosage of 60 to 100 mg per day appears to be beneficial for patients with a history of unstable angina, myocardial infarction, transient ischaemic attacks and stroke." | 1.28 | Aspirin and coronary heart disease. Clinical applications. ( Koutts, J, 1990) |
| "Patients with transient ischemic attacks (TIA) were previously shown to have high plasma values of thiobarbituric acid-reactive substances (TBA-RS)." | 1.28 | Blood lipid peroxides in TIA: relation to platelet function and metabolic profile. ( Alessandri, C; Balsano, F; Caliendo, C; Censi, C; Germani, M; Ghiselli, A; Servi, M; Violi, F, 1989) |
| "The reported recurrence rate is lower than comparable figures in published reports." | 1.27 | [Incidence of recurrence after successful transluminal coronary angioplasty]. ( Kaltenbach, M; Kober, G; Scherer, D; Schmidt-Moritz, A, 1983) |
| "The mean degree of stenosis was reduced from 77 +/- 12% to 29 +/- 15% and the mean systolic pressure gradient from 78 +/- 18 to 25 +/- 9 mmHg." | 1.27 | Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy. ( Brücke, P; Herbinger, W; Leisch, F, 1984) |
| "Twenty-six patients suffering from Kawasaki Disease (24 from the U." | 1.27 | Kawasaki disease: a report of 26 patients. ( Gray, JA; Welsby, PD, 1984) |
| "Patients with Kawasaki disease are mostly in Japan, however, an increasing number of patients have recently been published in the foreign literatures, and this entity has become an important cause of heart disease in children." | 1.27 | [Kawasaki disease: new and important problems in cardiology]. ( Ichinose, E; Kato, H, 1983) |
| " Dose-response platelet aggregometry detected no differences between groups in the sensitivity of platelets to adenosine diphosphate (ADP), collagen, and epinephrine." | 1.27 | Etiologic factors for recurrent carotid artery stenosis. ( Clagett, GP; Hutton, JE; McDonald, PT; Olson, DW; Rich, NM; Salander, JM; Youkey, JR, 1983) |
| "A higher recurrence rate after angioplasty is seen in the presence of a wall thrombus." | 1.27 | [Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis]. ( Lorenz, RL; Schramm, W; Theisen, K; Weber, MA, 1986) |
| "This is a reangiography rate of 94%." | 1.27 | The Frankfurt experience in restenosis after coronary angioplasty. ( Bussmann, WD; Kaltenbach, M; Kober, G; Vallbracht, C, 1987) |
| "Ibuprofen was the most effective, producing an average recovery of 70% (P less than 0." | 1.27 | Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts. ( Karmazyn, M, 1986) |
| "The observed restenosis rate is less than 50% of that reported by the PTCA registry of the NHLBI." | 1.27 | Recurrence rate after successful coronary angioplasty. ( Kaltenbach, M; Kober, G; Scherer, D; Vallbracht, C, 1985) |
| "Pretreatment with aspirin (6 mg/kg i." | 1.27 | Cardiac sympathetic nerve activity and progressive vasoconstriction distal to coronary stenoses: feed-back aggravation of myocardial ischemia. ( Deussen, A; Heusch, G; Thämer, V, 1985) |
| "In 67 dogs with a 60-80% coronary stenosis produced by an external constricting plastic ring, blood flow measured with an electromagnetic flowmeter showed cyclical flow reductions of varying magnitude and duration, and then an abrupt return to control flow." | 1.26 | Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? ( Folts, JD; Gallagher, K; Rowe, GG, 1982) |
| "Aspirin-treated dogs did not differ from control dogs in percent ventricle at risk (mean +/- standard error 37 +/- 2 versus 40 +/- 2), percent infarct weight/left ventricle (29 +/- 3 versus 31 +/- 2) or percent infarct weight/weight of ventricle at risk (78 +/- 4 versus 77 +/- 3)." | 1.26 | Lack of effect of aspirin on myocardial infarct size in the dog. ( Bonow, RO; Capurro, NL; Epstein, SE; Goldstein, RE; Isner, JM; Lipson, LC; Roberts, WC; Sheehan, FH, 1981) |
| "Sulfinpyrazone treatment of patients with myocardial infarction (Killip--classification I and II), starting 25--35 days after the acute myocardial infarction, reduces cardiac mortality and incidence of sudden death for a period of two years." | 1.26 | [Action mechanism and clinical indications for thrombocyte aggregation inhibitors]. ( Oelz, O, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 368 (24.50) | 18.7374 |
| 1990's | 411 (27.36) | 18.2507 |
| 2000's | 544 (36.22) | 29.6817 |
| 2010's | 158 (10.52) | 24.3611 |
| 2020's | 21 (1.40) | 2.80 |
| Authors | Studies |
|---|---|
| Mao, P | 1 |
| Liu, X | 2 |
| Weng, Y | 1 |
| Tang, L | 1 |
| Tang, Y | 1 |
| Lv, WH | 1 |
| Dong, JZ | 1 |
| Du, X | 2 |
| Hu, R | 1 |
| He, L | 1 |
| Long, DY | 1 |
| Sang, CH | 1 |
| Jia, CQ | 1 |
| Feng, L | 2 |
| Li, X | 3 |
| Ning, M | 1 |
| Chen, X | 1 |
| Cui, YK | 1 |
| Tang, RB | 2 |
| Ma, CS | 2 |
| Neumann, JT | 1 |
| Riaz, M | 1 |
| Bakshi, A | 1 |
| Polekhina, G | 1 |
| Thao, LTP | 1 |
| Nelson, MR | 1 |
| Woods, RL | 1 |
| Abraham, G | 1 |
| Inouye, M | 1 |
| Reid, CM | 1 |
| Tonkin, AM | 2 |
| McNeil, J | 1 |
| Lacaze, P | 1 |
| Gao, B | 1 |
| Gao, W | 1 |
| Wan, H | 1 |
| Xu, F | 1 |
| Zhou, R | 1 |
| Zhang, X | 3 |
| Ji, Q | 1 |
| Wang, X | 2 |
| Han, L | 1 |
| Yang, J | 2 |
| Fu, J | 1 |
| Wang, T | 1 |
| Li, B | 1 |
| Zhao, N | 1 |
| Chang, R | 1 |
| Zhou, W | 1 |
| Ye, Y | 1 |
| Liu, Y | 1 |
| Wu, J | 1 |
| Ding, P | 1 |
| Gorenflo, MP | 1 |
| Zhu, X | 1 |
| Xu, R | 1 |
| Kim, SB | 1 |
| Kim, N | 1 |
| Park, J | 1 |
| Hwang, IC | 1 |
| Lim, SH | 1 |
| Song, DH | 1 |
| Choi, Y | 1 |
| Yoon, H | 1 |
| Shin, CM | 1 |
| Park, YS | 1 |
| Lee, DH | 2 |
| Ahn, S | 1 |
| Yasuda, S | 1 |
| Kaikita, K | 3 |
| Akao, M | 1 |
| Ako, J | 3 |
| Matoba, T | 1 |
| Nakamura, M | 1 |
| Miyauchi, K | 3 |
| Hagiwara, N | 2 |
| Kimura, K | 1 |
| Hirayama, A | 1 |
| Matsui, K | 2 |
| Ogawa, H | 7 |
| Mehran, R | 4 |
| Baber, U | 1 |
| Sharma, SK | 2 |
| Cohen, DJ | 2 |
| Angiolillo, DJ | 11 |
| Briguori, C | 1 |
| Cha, JY | 1 |
| Collier, T | 1 |
| Dangas, G | 4 |
| Dudek, D | 1 |
| Džavík, V | 3 |
| Escaned, J | 4 |
| Gil, R | 2 |
| Gurbel, P | 1 |
| Hamm, CW | 6 |
| Henry, T | 1 |
| Huber, K | 4 |
| Kastrati, A | 9 |
| Kaul, U | 2 |
| Kornowski, R | 1 |
| Krucoff, M | 1 |
| Kunadian, V | 1 |
| Marx, SO | 1 |
| Mehta, SR | 3 |
| Moliterno, D | 1 |
| Ohman, EM | 4 |
| Oldroyd, K | 1 |
| Sardella, G | 1 |
| Sartori, S | 1 |
| Shlofmitz, R | 1 |
| Steg, PG | 6 |
| Weisz, G | 3 |
| Witzenbichler, B | 3 |
| Han, YL | 4 |
| Pocock, S | 1 |
| Gibson, CM | 2 |
| Orgeron, GM | 1 |
| Havistin, R | 1 |
| Hahn, LS | 1 |
| Wang, J | 1 |
| Crichlow, C | 1 |
| Mugmon, M | 1 |
| Mahajan, A | 1 |
| Jourdan, A | 1 |
| Sekhsaria, S | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 7 |
| De Caterina, R | 7 |
| Condorelli, G | 2 |
| Ferrante, G | 2 |
| Stefanini, GG | 1 |
| Koziolova, NA | 1 |
| Karavaev, PG | 1 |
| Veklich, AS | 1 |
| Sun, LX | 1 |
| Li, YY | 1 |
| Xie, YM | 5 |
| Wang, H | 2 |
| Zhuang, Y | 4 |
| Zhao, LH | 1 |
| Tang, DD | 1 |
| Lu, WL | 1 |
| Yan, SR | 1 |
| Wang, JP | 1 |
| Wang, W | 1 |
| Chen, LL | 1 |
| Krasińska, B | 1 |
| Paluszkiewicz, L | 1 |
| Miciak-Ławicka, E | 1 |
| Krasinski, M | 1 |
| Rzymski, P | 1 |
| Tykarski, A | 1 |
| Krasiński, Z | 1 |
| Ajufo, E | 1 |
| Ayers, CR | 1 |
| Vigen, R | 1 |
| Joshi, PH | 1 |
| Rohatgi, A | 1 |
| de Lemos, JA | 3 |
| Khera, A | 1 |
| Cao, W | 2 |
| Yang, Q | 1 |
| Zhang, W | 3 |
| Xu, Y | 1 |
| Wang, S | 2 |
| Wu, Y | 1 |
| Zhao, Y | 1 |
| Guo, Z | 1 |
| Li, R | 2 |
| Gao, R | 3 |
| Cherqaoui, B | 1 |
| Koné-Paut, I | 1 |
| Yager, H | 1 |
| Bourgeois, FL | 1 |
| Piram, M | 1 |
| Darmon, A | 1 |
| Ducrocq, G | 1 |
| Dagenais, GR | 1 |
| Dyal, L | 1 |
| Bosch, JJ | 1 |
| Leong, DP | 1 |
| Aboyans, V | 1 |
| Berkowitz, SD | 2 |
| Bhatt, DL | 9 |
| Connolly, SJ | 1 |
| Fox, KAA | 1 |
| Muehlhofer, E | 1 |
| Probstfield, JL | 2 |
| Widimsky, P | 1 |
| Winkelmann, BR | 1 |
| Yusuf, S | 8 |
| Eikelboom, JW | 4 |
| Liu, Z | 2 |
| Li, G | 1 |
| Ma, Y | 1 |
| Lin, L | 1 |
| Pagnotta, P | 2 |
| Dallaire, F | 1 |
| Fortier-Morissette, Z | 1 |
| Blais, S | 1 |
| Dhanrajani, A | 1 |
| Basodan, D | 1 |
| Renaud, C | 1 |
| Mathew, M | 1 |
| De Souza, AM | 1 |
| Dionne, A | 1 |
| Blanchard, J | 1 |
| Saulnier, H | 1 |
| Kaspy, K | 1 |
| Rached-d'Astous, S | 1 |
| Dahdah, N | 1 |
| McCrindle, BW | 1 |
| Human, DG | 1 |
| Scuccimarri, R | 1 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| van Capelleveen, JC | 1 |
| Bochem, AE | 1 |
| Boekholdt, SM | 1 |
| Mora, S | 1 |
| Hoogeveen, RC | 1 |
| Ballantyne, CM | 2 |
| Ridker, PM | 4 |
| Sun, W | 1 |
| Barter, PJ | 1 |
| Tall, AR | 1 |
| Zwinderman, AH | 1 |
| Kastelein, JJP | 1 |
| Wareham, NJ | 1 |
| Khaw, KT | 1 |
| Hovingh, GK | 1 |
| Fu, DL | 1 |
| Zhao, TT | 1 |
| Peng, WH | 1 |
| Yang, P | 1 |
| Liu, XF | 1 |
| Zhang, H | 2 |
| Li, XL | 1 |
| Wang, Y | 5 |
| Zheng, JG | 1 |
| Gao, YX | 1 |
| Lu, HK | 1 |
| Wang, Q | 2 |
| Harada, Y | 2 |
| Michel, J | 1 |
| Lohaus, R | 1 |
| Mayer, K | 2 |
| Emmer, R | 1 |
| Lahmann, AL | 1 |
| Colleran, R | 1 |
| Giacoppo, D | 1 |
| Wolk, A | 1 |
| Ten Berg, JM | 2 |
| Neumann, FJ | 12 |
| Han, Y | 1 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 2 |
| Maeng, M | 1 |
| Zrenner, B | 1 |
| Jacobshagen, C | 1 |
| Wöhrle, J | 2 |
| Kufner, S | 1 |
| Morath, T | 1 |
| Ibrahim, T | 1 |
| Bernlochner, I | 2 |
| Fischer, M | 1 |
| Schunkert, H | 1 |
| Laugwitz, KL | 1 |
| Mehilli, J | 3 |
| Byrne, RA | 2 |
| Schulz-Schüpke, S | 1 |
| He, RX | 1 |
| Zhang, L | 2 |
| Zhou, TN | 1 |
| Yuan, WJ | 1 |
| Liu, YJ | 1 |
| Fu, WX | 1 |
| Jing, QM | 3 |
| Liu, HW | 1 |
| Wang, XZ | 2 |
| Montero-Balosa, MC | 1 |
| Fernández-Urrusuno, R | 1 |
| Vilches-Arenas, A | 1 |
| Shang, LL | 1 |
| Guo, DD | 1 |
| Zhao, HY | 1 |
| Quan, AJ | 1 |
| Cao, PG | 1 |
| Stähli, BE | 1 |
| Landmesser, U | 1 |
| Ebrahimi, R | 1 |
| Gupta, S | 1 |
| Carr, BM | 1 |
| Bishawi, M | 1 |
| Bakaeen, FG | 1 |
| Almassi, GH | 1 |
| Collins, J | 1 |
| Grover, FL | 1 |
| Quin, JA | 1 |
| Wagner, TH | 1 |
| Shroyer, ALW | 1 |
| Hattler, B | 1 |
| Hu, W | 1 |
| Tong, J | 1 |
| Kuang, X | 1 |
| Chen, W | 1 |
| Chamberlain, JJ | 1 |
| Johnson, EL | 1 |
| Leal, S | 1 |
| Rhinehart, AS | 1 |
| Shubrook, JH | 1 |
| Peterson, L | 1 |
| Flinn, AM | 1 |
| Gavin, PJ | 1 |
| McMahon, CJ | 2 |
| Oslizok, P | 1 |
| Butler, KM | 1 |
| Zhu, B | 1 |
| Kuang, H | 1 |
| Zhou, X | 1 |
| Li, L | 2 |
| Yi, Q | 1 |
| Shou, W | 1 |
| Lu, T | 1 |
| Wang, TP | 1 |
| Chan, NC | 1 |
| Weitz, JI | 3 |
| Wessels, F | 1 |
| Kriegmair, MC | 1 |
| Oehme, A | 1 |
| Rassweiler-Seyfried, MC | 1 |
| Erben, P | 1 |
| Oberneder, R | 1 |
| Kriegmair, M | 1 |
| Ritter, M | 1 |
| Michel, MS | 1 |
| Honeck, P | 1 |
| Yang, H | 2 |
| Luo, C | 1 |
| Shen, C | 1 |
| Ding, H | 1 |
| Wu, B | 1 |
| Cai, X | 2 |
| Dimmitt, SB | 2 |
| Floyd, CN | 1 |
| Ferner, RE | 2 |
| Chow, CK | 1 |
| Meng, Q | 1 |
| Stevenson, JC | 1 |
| Hetzel, S | 1 |
| DeMets, D | 1 |
| Schneider, R | 1 |
| Borzak, S | 2 |
| Schneider, W | 2 |
| Serebruany, V | 1 |
| Schröder, H | 1 |
| Hennekens, CH | 7 |
| Puchin'ian, NF | 1 |
| Furman, NV | 1 |
| Dovgalevskiĭ, IaP | 1 |
| Korzh, AN | 1 |
| Krasnokutskiĭ, SV | 1 |
| Maĭboroda, OF | 1 |
| Stone, GW | 3 |
| Rinaldi, MJ | 2 |
| Metzger, DC | 2 |
| Henry, TD | 2 |
| Cox, DA | 3 |
| Duffy, PL | 2 |
| Mazzaferri, E | 1 |
| Gurbel, PA | 11 |
| Xu, K | 2 |
| Parise, H | 1 |
| Kirtane, AJ | 2 |
| Brodie, BR | 2 |
| Stuckey, TD | 2 |
| Thornley, SJ | 1 |
| Barzi, F | 1 |
| Curkovic, I | 1 |
| Egbring, M | 1 |
| Kullak-Ublick, GA | 1 |
| Leyh-Bannurah, SR | 1 |
| Hansen, J | 2 |
| Isbarn, H | 1 |
| Steuber, T | 1 |
| Tennstedt, P | 1 |
| Michl, U | 1 |
| Schlomm, T | 1 |
| Haese, A | 1 |
| Heinzer, H | 1 |
| Huland, H | 1 |
| Graefen, M | 1 |
| Budäus, L | 1 |
| Gong, XX | 1 |
| Zhu, TT | 1 |
| Li, CJ | 1 |
| Yang, ZJ | 1 |
| Wang, M | 2 |
| Moran, AE | 1 |
| Liu, J | 5 |
| Coxson, PG | 3 |
| Heidenreich, PA | 1 |
| Gu, D | 1 |
| He, J | 1 |
| Goldman, L | 3 |
| Zhao, D | 3 |
| Mensah, GA | 1 |
| Sampson, UK | 1 |
| Shen, H | 1 |
| Jiang, JJ | 2 |
| Tang, H | 1 |
| Martínez-Quintana, E | 1 |
| Medina-Gil, JM | 1 |
| Rodríguez-González, F | 1 |
| Garay-Sánchez, P | 1 |
| Limiñana, JM | 1 |
| Saavedra, P | 1 |
| Tugores, A | 1 |
| Xie, C | 1 |
| Ding, X | 1 |
| Gao, J | 1 |
| Hang, Y | 1 |
| Zhang, J | 1 |
| Jiang, B | 1 |
| Miao, L | 1 |
| Goldenberg, EM | 1 |
| Huang, H | 1 |
| Yu, J | 1 |
| Cao, G | 1 |
| Xu, Q | 1 |
| Zhang, S | 1 |
| Zhou, M | 1 |
| Li, Y | 6 |
| Camargo, LM | 1 |
| França, CN | 1 |
| Izar, MC | 1 |
| Bianco, HT | 1 |
| Lins, LS | 1 |
| Barbosa, SP | 1 |
| Pinheiro, LF | 1 |
| Fonseca, FA | 1 |
| Miedema, MD | 1 |
| Duprez, DA | 1 |
| Misialek, JR | 1 |
| Blaha, MJ | 1 |
| Nasir, K | 1 |
| Silverman, MG | 1 |
| Blankstein, R | 1 |
| Budoff, MJ | 1 |
| Greenland, P | 2 |
| Folsom, AR | 3 |
| Tsurko, VV | 1 |
| Eliseeva, ME | 1 |
| Vorob'ev, PA | 1 |
| Cho, EH | 1 |
| Ligh, C | 1 |
| Hodulik, KL | 1 |
| Hollenbeck, ST | 1 |
| Sood, A | 1 |
| Trinh, QD | 1 |
| Schreiber, P | 1 |
| Fauchère, I | 1 |
| Wyss, C | 1 |
| Kounis, NG | 1 |
| Davlouros, P | 1 |
| Al Shamiri, MQ | 1 |
| Abdel Gader, AM | 1 |
| Bayoumy, NM | 1 |
| Garratt, KN | 2 |
| Weaver, WD | 4 |
| Jenkins, RG | 2 |
| Pow, TK | 2 |
| Mauri, L | 2 |
| Kereiakes, DJ | 7 |
| Winters, KJ | 4 |
| Christen, T | 2 |
| Allocco, DJ | 2 |
| Lee, DP | 3 |
| Collet, JP | 3 |
| Silvain, J | 2 |
| Montalescot, G | 5 |
| Jaben, EA | 1 |
| Mulay, SB | 1 |
| Stubbs, JR | 1 |
| Li, GH | 2 |
| Jiang, HY | 2 |
| Yang, W | 1 |
| Zhao, W | 2 |
| Wang, YY | 1 |
| Ai, QH | 1 |
| Cheng, Y | 1 |
| Lin, J | 1 |
| Yan, W | 1 |
| Zhang, M | 1 |
| Jim, MH | 1 |
| Wong, KL | 1 |
| Yiu, KH | 1 |
| Soleman, J | 1 |
| Baumgarten, P | 1 |
| Perrig, WN | 1 |
| Fandino, J | 1 |
| Fathi, AR | 1 |
| Hokimoto, S | 2 |
| Akasaka, T | 1 |
| Tabata, N | 1 |
| Arima, Y | 1 |
| Tsujita, K | 1 |
| Sakamoto, K | 1 |
| Morita, K | 1 |
| Kumagae, N | 1 |
| Yamamoto, E | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Yang, Y | 1 |
| Wang, C | 1 |
| Jin, L | 1 |
| Chen, G | 1 |
| Li, C | 1 |
| Qi, K | 1 |
| Kong, D | 1 |
| Song, M | 1 |
| Ma, L | 1 |
| Capodanno, D | 1 |
| Musumeci, G | 2 |
| Lettieri, C | 1 |
| Limbruno, U | 1 |
| Senni, M | 1 |
| Guagliumi, G | 2 |
| Valsecchi, O | 1 |
| Rossini, R | 2 |
| Capranzano, P | 1 |
| Castiglioni, B | 1 |
| Siasos, G | 1 |
| Oikonomou, E | 1 |
| Zaromitidou, M | 1 |
| Kioufis, S | 1 |
| Kokkou, E | 1 |
| Mourouzis, K | 1 |
| Vlasis, K | 1 |
| Vavuranakis, M | 1 |
| Stone, PH | 1 |
| Papavassiliou, AG | 1 |
| Tousoulis, D | 2 |
| Friberg, L | 1 |
| Rosenqvist, M | 1 |
| Zheng, XT | 1 |
| Chen, KY | 1 |
| Liu, T | 1 |
| Xu, LX | 1 |
| Che, JJ | 1 |
| Rha, SW | 3 |
| Li, GP | 1 |
| Shah, AH | 1 |
| Buch, AN | 1 |
| Jeger, RV | 1 |
| Pfisterer, ME | 1 |
| Suwita, BM | 1 |
| Laksmi, PW | 1 |
| Wijaya, IP | 1 |
| Lister, K | 1 |
| Louis Simonet, M | 1 |
| Parikh, PB | 1 |
| Mazzaferri, EL | 1 |
| Parvataneni, R | 1 |
| Maehara, A | 1 |
| Généreux, P | 1 |
| Einecke, D | 2 |
| Yao, Y | 1 |
| Tang, XF | 1 |
| Zhang, JH | 2 |
| He, C | 1 |
| Ma, YL | 1 |
| Xu, JJ | 1 |
| Song, Y | 1 |
| Liu, R | 1 |
| Meng, XM | 1 |
| Song, L | 1 |
| Chen, J | 3 |
| Xu, B | 2 |
| Gao, RL | 2 |
| Yuan, JQ | 2 |
| Smilowitz, NR | 1 |
| Berger, JS | 1 |
| Stiefelhagen, P | 3 |
| Elajami, TK | 1 |
| Colas, RA | 1 |
| Dalli, J | 1 |
| Chiang, N | 1 |
| Serhan, CN | 2 |
| Welty, FK | 1 |
| Bockeria, OL | 1 |
| Kudzoeva, ZF | 1 |
| Shvarts, VA | 1 |
| Koasari, AK | 1 |
| Donakanyan, SA | 1 |
| Lou, G | 1 |
| Xia, Y | 1 |
| Timmis, A | 2 |
| Rapsomaniki, E | 1 |
| Chung, SC | 1 |
| Pujades-Rodriguez, M | 1 |
| Moayyeri, A | 1 |
| Stogiannis, D | 1 |
| Shah, AD | 1 |
| Pasea, L | 1 |
| Denaxas, S | 1 |
| Emmas, C | 1 |
| Hemingway, H | 1 |
| Hashimoto, T | 1 |
| Nilsson, S | 1 |
| Järemo, P | 1 |
| Pérez-Cuadrado-Robles, E | 1 |
| Quesada-Vázquez, N | 1 |
| Martínez-Andrés, B | 1 |
| Sánchez-Melgarejo, JF | 1 |
| Rubio-Mateos, JM | 1 |
| López-Higueras, A | 1 |
| Pérez-Cuadrado-Martínez, E | 1 |
| Cubero, JL | 1 |
| Simó Sánchez, B | 1 |
| Millán, P | 1 |
| Colás, C | 1 |
| Ding, F | 1 |
| Lyu, YL | 1 |
| Xuan, W | 1 |
| Liu, DY | 1 |
| Duan, XQ | 1 |
| Han, X | 1 |
| Ng, FH | 2 |
| Lam, KF | 2 |
| Wong, SY | 2 |
| Chang, CM | 1 |
| Lau, YK | 2 |
| Yuen, WC | 1 |
| Chu, WM | 1 |
| Wong, BC | 2 |
| Glasser, SP | 1 |
| Cushman, M | 2 |
| Prineas, R | 1 |
| Kleindorfer, D | 1 |
| Prince, V | 1 |
| You, Z | 1 |
| Howard, VJ | 1 |
| Howard, G | 1 |
| O'Kane, PD | 1 |
| Reebye, V | 1 |
| Ji, Y | 1 |
| Stratton, P | 1 |
| Jackson, G | 1 |
| Ferro, A | 1 |
| Guzman, LA | 2 |
| Bass, TA | 7 |
| Bates, ER | 2 |
| Saini, SD | 1 |
| Schoenfeld, P | 1 |
| Fendrick, AM | 2 |
| Scheiman, J | 2 |
| Weintraub, WS | 2 |
| Spertus, JA | 1 |
| Kolm, P | 1 |
| Maron, DJ | 1 |
| Zhang, Z | 1 |
| Jurkovitz, C | 1 |
| Hartigan, PM | 1 |
| Lewis, C | 1 |
| Veledar, E | 1 |
| Bowen, J | 1 |
| Dunbar, SB | 1 |
| Deaton, C | 1 |
| Kaufman, S | 1 |
| O'Rourke, RA | 1 |
| Goeree, R | 1 |
| Barnett, PG | 1 |
| Teo, KK | 1 |
| Boden, WE | 1 |
| Mancini, GB | 1 |
| Alberts, MJ | 2 |
| Aĭnetdinova, DKh | 1 |
| Udovichenko, AE | 1 |
| Sulimov, VA | 1 |
| Asano, T | 1 |
| Kobayashi, Y | 2 |
| Fukushima, K | 1 |
| Iwata, Y | 1 |
| Kitahara, H | 1 |
| Ishio, N | 1 |
| Kuroda, N | 1 |
| Komuro, I | 1 |
| Zimmermann, N | 2 |
| Hohlfeld, T | 2 |
| Engberding, N | 1 |
| Wenger, NK | 2 |
| Chan, P | 1 |
| Kwanching, CP | 1 |
| Loo, CK | 1 |
| Cheung, TK | 1 |
| Kng, C | 1 |
| Ng, KM | 1 |
| Lai, ST | 1 |
| Koton, S | 1 |
| Howard, SC | 1 |
| Warlow, CP | 1 |
| Murphy, MF | 1 |
| Rothwell, PM | 1 |
| Maegdefessel, L | 1 |
| Schlitt, A | 1 |
| Faerber, J | 1 |
| Bond, SP | 1 |
| Messow, CM | 1 |
| Buerke, M | 1 |
| Raaz, U | 1 |
| Werdan, K | 1 |
| Muenzel, T | 1 |
| Weiss, C | 2 |
| Aronow, HD | 1 |
| Califf, RM | 12 |
| Harrington, RA | 8 |
| Vallee, M | 2 |
| Graffagnino, C | 2 |
| Shuaib, A | 2 |
| Fitzgerald, DJ | 3 |
| Easton, JD | 1 |
| Van de Werf, F | 7 |
| Diener, HC | 2 |
| Ferguson, J | 2 |
| Koudstaal, PJ | 3 |
| Amarenco, P | 2 |
| Theroux, P | 8 |
| Davis, S | 2 |
| Topol, EJ | 16 |
| Chen, DK | 1 |
| Zhang, HQ | 1 |
| Scharf, RE | 1 |
| Kuliczkowski, W | 1 |
| Witkowski, A | 2 |
| Polonski, L | 2 |
| Watala, C | 1 |
| Filipiak, K | 1 |
| Budaj, A | 3 |
| Golanski, J | 1 |
| Sitkiewicz, D | 1 |
| Pregowski, J | 1 |
| Gorski, J | 1 |
| Zembala, M | 1 |
| Opolski, G | 3 |
| Arnesen, H | 4 |
| Kristensen, SD | 2 |
| Mak, KH | 4 |
| Shao, M | 1 |
| Haffner, SM | 1 |
| Hankey, GJ | 2 |
| Johnston, SC | 1 |
| Steinhubl, SR | 10 |
| Fox, KA | 6 |
| Fung, AY | 1 |
| Saw, J | 2 |
| Starovoytov, A | 1 |
| Densem, C | 1 |
| Jokhi, P | 1 |
| Walsh, SJ | 1 |
| Fox, RS | 1 |
| Humphries, KH | 1 |
| Aymong, E | 1 |
| Ricci, DR | 3 |
| Webb, JG | 1 |
| Hamburger, JN | 1 |
| Carere, RG | 1 |
| Buller, CE | 4 |
| Berger, PB | 10 |
| Briasoulis, A | 1 |
| Dhamrait, SS | 1 |
| Antoniades, C | 1 |
| Stefanadis, C | 2 |
| Varenhorst, C | 1 |
| James, S | 2 |
| Erlinge, D | 1 |
| Brandt, JT | 1 |
| Braun, OO | 1 |
| Man, M | 1 |
| Siegbahn, A | 2 |
| Walker, J | 1 |
| Wallentin, L | 8 |
| Close, SL | 1 |
| Pecot, CV | 1 |
| Fuller, M | 1 |
| Muldowney, JA | 1 |
| Misra, S | 1 |
| Chandler, AB | 1 |
| Earhart, AD | 1 |
| Speich, HE | 1 |
| Kueter, TJ | 1 |
| White, MM | 1 |
| Jennings, LK | 3 |
| Eriksson, AC | 1 |
| Jonasson, L | 1 |
| Lindahl, TL | 1 |
| Hedbäck, B | 1 |
| Whiss, PA | 1 |
| Harjai, KJ | 1 |
| Shenoy, C | 1 |
| Orshaw, P | 1 |
| Boura, J | 1 |
| Shiffman, D | 2 |
| Chasman, DI | 1 |
| Nambi, V | 1 |
| Devlin, JJ | 2 |
| Boerwinkle, E | 1 |
| Koscielny, J | 1 |
| Skowasch, D | 3 |
| Tuleta, I | 1 |
| Viktor, A | 1 |
| Bauriedel, G | 3 |
| Nickenig, G | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 2 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Guyer, KE | 1 |
| Tetik, S | 1 |
| Ak, K | 1 |
| Isbir, S | 1 |
| Eksioglu-Demiralp, E | 1 |
| Arsan, S | 1 |
| Iqbal, O | 1 |
| Yardimci, T | 1 |
| Yasuda, H | 1 |
| Yamada, M | 1 |
| Sawada, S | 1 |
| Endo, Y | 1 |
| Inoue, K | 1 |
| Asano, F | 1 |
| Takeyama, Y | 1 |
| Yoshiba, M | 1 |
| Hennekens, C | 1 |
| Chatterjee, T | 1 |
| Akin, I | 1 |
| Rehders, TC | 1 |
| Chatterjee, A | 1 |
| Schüpfer, C | 1 |
| Nienaber, CA | 1 |
| Ince, H | 1 |
| Sharma, KK | 1 |
| Gupta, R | 2 |
| Agrawal, A | 1 |
| Roy, S | 1 |
| Kasliwal, A | 1 |
| Bana, A | 1 |
| Tongia, RK | 1 |
| Deedwania, PC | 1 |
| Sun, JY | 1 |
| Smith, SC | 3 |
| Cağirci, G | 1 |
| Ozdemir, O | 1 |
| Geyik, B | 1 |
| Cay, S | 1 |
| Oztürk, S | 2 |
| Aras, D | 1 |
| Topaloğlu, S | 1 |
| Persell, SD | 1 |
| Zei, C | 1 |
| Cameron, KA | 1 |
| Zielinski, M | 1 |
| Lloyd-Jones, DM | 1 |
| Park, SJ | 6 |
| Park, DW | 1 |
| Kim, YH | 2 |
| Kang, SJ | 1 |
| Lee, SW | 2 |
| Lee, CW | 5 |
| Han, KH | 2 |
| Park, SW | 6 |
| Yun, SC | 1 |
| Lee, SG | 1 |
| Seong, IW | 1 |
| Jeong, MH | 2 |
| Hur, SH | 3 |
| Lee, NH | 3 |
| Yoon, J | 1 |
| Yang, JY | 1 |
| Lee, BK | 2 |
| Choi, YJ | 3 |
| Chung, WS | 1 |
| Lim, DS | 2 |
| Cheong, SS | 1 |
| Kim, KS | 3 |
| Chae, JK | 1 |
| Nah, DY | 2 |
| Jeon, DS | 1 |
| Seung, KB | 2 |
| Jang, JS | 2 |
| Park, HS | 1 |
| Lee, K | 1 |
| Uchida, Y | 2 |
| Mori, F | 1 |
| Takagi, A | 1 |
| Jacobson, TA | 1 |
| Tresukosol, D | 1 |
| Sudjaritruk, S | 1 |
| Pornratanarangsi, S | 1 |
| Chotinaiwattarakul, C | 2 |
| Phankingthongkum, R | 1 |
| Tungsubutra, W | 1 |
| Wongpraparat, N | 1 |
| Lerdwilai, T | 1 |
| Panchavinnin, P | 1 |
| Postuła, M | 1 |
| Tarchalska-Kryńska, B | 1 |
| Filipiak, KJ | 2 |
| Kosior, D | 1 |
| Serafin, A | 1 |
| Huczek, Z | 2 |
| Eckel, RH | 1 |
| Shen, WF | 1 |
| Chen, JL | 1 |
| Gao, LJ | 1 |
| Yang, YJ | 1 |
| Li, JJ | 2 |
| Qiao, SB | 1 |
| Huang, JH | 1 |
| Yao, M | 1 |
| Qin, XW | 1 |
| Liu, HB | 1 |
| Wu, YJ | 1 |
| You, SJ | 1 |
| Dai, J | 1 |
| Pignone, M | 7 |
| Colwell, JA | 3 |
| Inzucchi, SE | 1 |
| Mukherjee, D | 1 |
| Rosenson, RS | 1 |
| Williams, CD | 1 |
| Wilson, PW | 1 |
| Kirkman, MS | 1 |
| Storey, RF | 2 |
| Bliden, KP | 5 |
| Patil, SB | 1 |
| Karunakaran, A | 1 |
| Ecob, R | 1 |
| Butler, K | 1 |
| Teng, R | 1 |
| Wei, C | 1 |
| Tantry, US | 5 |
| Duvernoy, CS | 1 |
| Yeo, AA | 1 |
| Wong, M | 2 |
| Kim, HM | 1 |
| Okura, H | 1 |
| Yin, CH | 1 |
| Bi, DP | 1 |
| Du, M | 1 |
| Mallonee, S | 1 |
| Daniels, CG | 1 |
| Mold, JW | 1 |
| Cline, TL | 1 |
| Memtsoudis, SG | 1 |
| Sharrock, NE | 1 |
| Rennings, AJ | 1 |
| Schouwenberg, BJ | 1 |
| van Onzenoort, HA | 1 |
| Knosalla, C | 1 |
| Dandel, M | 1 |
| Hetzer, R | 1 |
| Rich, JD | 1 |
| Cannon, CP | 7 |
| Murphy, SA | 3 |
| Qin, J | 2 |
| Giugliano, RP | 2 |
| Braunwald, E | 6 |
| Schwedhelm, E | 1 |
| Bierend, A | 1 |
| Maas, R | 1 |
| Trinks, R | 1 |
| Kom, GD | 1 |
| Tsikas, D | 1 |
| Böger, RH | 1 |
| Cai, J | 1 |
| Wu, Q | 1 |
| Fan, L | 2 |
| Liu, CF | 1 |
| Wang, ZG | 1 |
| Sun, J | 1 |
| Menown, IB | 1 |
| Armstrong, C | 1 |
| Kautzky-Willer, A | 1 |
| Kamyar, MR | 1 |
| Gerhat, D | 1 |
| Handisurya, A | 1 |
| Stemer, G | 1 |
| Hudson, S | 1 |
| Luger, A | 1 |
| Lemmens-Gruber, R | 2 |
| Suh, JW | 2 |
| Lee, SP | 1 |
| Park, KW | 2 |
| Lee, HY | 1 |
| Kang, HJ | 2 |
| Koo, BK | 2 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Chae, IH | 2 |
| Choi, DJ | 1 |
| Bae, JH | 1 |
| Kwon, TG | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kim, HS | 5 |
| Martin-Yuste, V | 1 |
| Brugaletta, S | 1 |
| Ferreira-González, I | 1 |
| Cola, C | 1 |
| Alvarez-Contreras, L | 1 |
| de Antonio, M | 1 |
| Martí, V | 1 |
| García-Picart, J | 1 |
| Sabaté, M | 5 |
| Rassaf, T | 1 |
| Earnshaw, SR | 1 |
| McDade, C | 1 |
| Schattner, P | 1 |
| Saunders, M | 1 |
| Stanger, L | 1 |
| Speak, M | 1 |
| Russo, K | 1 |
| Sharma, JC | 1 |
| Sharma, N | 1 |
| Sibbing, D | 1 |
| Koch, W | 2 |
| Massberg, S | 2 |
| Schulz, S | 1 |
| Schömig, A | 15 |
| Vivas, D | 1 |
| Bernardo, E | 5 |
| García-Rubira, JC | 1 |
| Azcona, L | 3 |
| Núñez-Gil, I | 1 |
| González-Ferrer, JJ | 1 |
| Macaya, C | 7 |
| Fernández-Ortiz, A | 5 |
| Berent, R | 1 |
| Auer, J | 1 |
| Franklin, B | 1 |
| Schmid, P | 1 |
| von Duvillard, SP | 1 |
| Tremmel, JA | 1 |
| Ng, MK | 1 |
| Ikeno, F | 1 |
| Hunt, SA | 1 |
| Yeung, AC | 3 |
| Fearon, WF | 2 |
| Yokoi, H | 2 |
| Komaroff, AL | 1 |
| Yang, TH | 1 |
| Kim, DI | 1 |
| Kim, DK | 2 |
| Kim, U | 1 |
| Seol, SH | 1 |
| Hong, GR | 1 |
| Park, JS | 1 |
| Shin, DG | 1 |
| Kim, YJ | 1 |
| Cho, YK | 1 |
| Nam, CW | 1 |
| Kim, KB | 3 |
| Kim, DS | 1 |
| Li, WJ | 1 |
| Zhang, HY | 1 |
| Miao, CL | 1 |
| Shi, JH | 1 |
| Gaglia, MA | 1 |
| Torguson, R | 1 |
| Pakala, R | 1 |
| Xue, Z | 1 |
| Sardi, G | 1 |
| Mahmoudi, M | 1 |
| Suddath, WO | 1 |
| Kent, KM | 3 |
| Satler, LF | 3 |
| Pichard, AD | 2 |
| Waksman, R | 2 |
| Rodríguez, LA | 1 |
| Cea-Soriano, L | 1 |
| Martín-Merino, E | 1 |
| Johansson, S | 1 |
| Medeiros, FB | 1 |
| de Andrade, AC | 1 |
| Angelis, GA | 1 |
| Conrado, VC | 1 |
| Timerman, L | 1 |
| Farsky, P | 1 |
| Dib, LL | 1 |
| Gwak, CH | 1 |
| Hong, SJ | 1 |
| Park, TH | 1 |
| Kim, SH | 1 |
| Joo, SJ | 1 |
| Tahk, SJ | 1 |
| Kim, HJ | 1 |
| Lee, JM | 1 |
| Seo, JH | 1 |
| Kim, JH | 1 |
| Hong, DM | 1 |
| Bahk, JH | 1 |
| Jeon, Y | 1 |
| Luke, MM | 1 |
| Chitose, T | 1 |
| Oshima, S | 1 |
| Nakao, K | 1 |
| Fujimoto, K | 1 |
| Miyao, Y | 1 |
| Shimomura, H | 1 |
| Tsunoda, R | 1 |
| Maruyama, H | 1 |
| Hirose, T | 1 |
| Yamamoto, K | 1 |
| Mizobe, M | 1 |
| Nakamura, S | 4 |
| DiNicolantonio, JJ | 1 |
| Galper, BZ | 1 |
| Moran, A | 1 |
| Pletcher, MJ | 2 |
| Heidenreich, P | 1 |
| Lazar, LD | 1 |
| Rodondi, N | 3 |
| Wang, YC | 1 |
| Pfisterer, M | 2 |
| Kaiser, C | 1 |
| Jeger, R | 1 |
| Gwon, HC | 1 |
| Hahn, JY | 1 |
| Song, YB | 1 |
| Han, KR | 1 |
| Choi, JH | 1 |
| Choi, SH | 1 |
| Ahn, T | 1 |
| Yoon, JH | 1 |
| Hong, TJ | 1 |
| Chung, WY | 1 |
| Kwon, HM | 1 |
| Jeon, DW | 1 |
| Kim, BO | 1 |
| Park, SH | 1 |
| Jeon, HK | 1 |
| Jang, Y | 4 |
| Krishnan, E | 1 |
| Pandya, BJ | 1 |
| Lingala, B | 1 |
| Hariri, A | 1 |
| Dabbous, O | 1 |
| Jia, XQ | 1 |
| Dong, CM | 1 |
| Kent, DM | 1 |
| Shah, ND | 1 |
| Soejima, H | 2 |
| Kishikawa, H | 1 |
| Cao, J | 1 |
| Liu, L | 1 |
| Hu, G | 1 |
| Hu, Y | 1 |
| Wu, R | 1 |
| López Farré, AJ | 1 |
| Jiménez Mateos-Cáceres, P | 1 |
| Segura, A | 1 |
| Rodríguez, P | 1 |
| Modrego, J | 1 |
| Zamorano-León, JJ | 1 |
| Harrasser, N | 1 |
| Harnoss, T | 1 |
| Brettner, F | 1 |
| Liska, F | 1 |
| Pauschinger, M | 1 |
| Price, MJ | 1 |
| Walder, JS | 1 |
| Baker, BA | 1 |
| Heiselman, DE | 1 |
| Jakubowski, JA | 1 |
| Logan, DK | 1 |
| Li, W | 1 |
| Campo, G | 1 |
| Marchesini, J | 1 |
| Bristot, L | 1 |
| Monti, M | 2 |
| Gambetti, S | 1 |
| Pavasini, R | 1 |
| Pollina, A | 1 |
| Ferrari, R | 1 |
| De Bruyne, B | 1 |
| Pijls, NH | 1 |
| Kalesan, B | 1 |
| Barbato, E | 2 |
| Tonino, PA | 1 |
| Piroth, Z | 1 |
| Jagic, N | 1 |
| Möbius-Winkler, S | 1 |
| Mobius-Winckler, S | 1 |
| Rioufol, G | 1 |
| Witt, N | 1 |
| Kala, P | 1 |
| MacCarthy, P | 1 |
| Engström, T | 1 |
| Oldroyd, KG | 2 |
| Mavromatis, K | 1 |
| Manoharan, G | 1 |
| Verlee, P | 1 |
| Frobert, O | 1 |
| Curzen, N | 1 |
| Johnson, JB | 1 |
| Jüni, P | 1 |
| Dodson, T | 1 |
| Matsumoto, C | 1 |
| Matthan, NR | 1 |
| Wilk, JB | 1 |
| Lichtenstein, AH | 1 |
| Michael Gaziano, J | 1 |
| Djoussé, L | 1 |
| Cuisset, T | 2 |
| Rangé, G | 1 |
| Cayla, G | 1 |
| Elhadad, S | 1 |
| Pouillot, C | 1 |
| Henry, P | 1 |
| Motreff, P | 1 |
| Carrié, D | 1 |
| Boueri, Z | 1 |
| Belle, L | 1 |
| Van Belle, E | 3 |
| Rousseau, H | 1 |
| Aubry, P | 2 |
| Monségu, J | 1 |
| Sabouret, P | 1 |
| O'Connor, SA | 1 |
| Abtan, J | 1 |
| Kerneis, M | 1 |
| Saint-Etienne, C | 1 |
| Barthélémy, O | 1 |
| Beygui, F | 1 |
| Vicaut, E | 1 |
| Bobbert, P | 1 |
| Stellbaum, C | 1 |
| Steffens, D | 1 |
| Schütte, C | 1 |
| Bobbert, T | 1 |
| Schultheiss, HP | 1 |
| Rauch, U | 1 |
| Schneider, AR | 1 |
| Armbruster, S | 1 |
| Mann, J | 1 |
| von Römer, W | 1 |
| Schuster, T | 1 |
| Schepp, W | 1 |
| Lin, YC | 1 |
| Yang, CC | 1 |
| Chen, YJ | 1 |
| Peng, WC | 1 |
| Li, CY | 1 |
| Hwu, CM | 1 |
| Solomon, DH | 1 |
| Glynn, RJ | 1 |
| Avorn, J | 2 |
| Brouwer, MA | 2 |
| van den Bergh, PJ | 1 |
| Aengevaeren, WR | 1 |
| Veen, G | 1 |
| Luijten, HE | 1 |
| Hertzberger, DP | 1 |
| van Boven, AJ | 1 |
| Vromans, RP | 1 |
| Uijen, GJ | 1 |
| Verheugt, FW | 10 |
| Kamishirado, H | 1 |
| Inoue, T | 2 |
| Mizoguchi, K | 1 |
| Uchida, T | 1 |
| Nakata, T | 1 |
| Sakuma, M | 1 |
| Takayanagi, K | 1 |
| Morooka, S | 1 |
| Macchi, L | 2 |
| Brizard, A | 1 |
| Christiaens, L | 2 |
| Herpin, D | 1 |
| Akaike, M | 1 |
| Azuma, H | 1 |
| Kagawa, A | 1 |
| Matsumoto, K | 1 |
| Hayashi, I | 1 |
| Tamura, K | 1 |
| Nishiuchi, T | 1 |
| Iuchi, T | 1 |
| Takamori, N | 1 |
| Aihara, K | 1 |
| Yoshida, T | 1 |
| Kanagawa, Y | 1 |
| Matsumoto, T | 1 |
| Bonz, AW | 1 |
| Lengenfelder, B | 1 |
| Strotmann, J | 1 |
| Held, S | 1 |
| Turschner, O | 1 |
| Harre, K | 1 |
| Wacker, C | 1 |
| Waller, C | 1 |
| Kochsiek, N | 1 |
| Meesmann, M | 1 |
| Neyses, L | 1 |
| Schanzenbächer, P | 4 |
| Ertl, G | 1 |
| Voelker, W | 2 |
| Cohen, M | 6 |
| Frey, MJ | 1 |
| White, HD | 10 |
| Van Mieghem, W | 1 |
| Senatore, F | 1 |
| Lis, J | 1 |
| Mukherjee, R | 1 |
| Harris, K | 1 |
| Bigonzi, F | 1 |
| Kong, DF | 1 |
| Hasselblad, V | 4 |
| Kandzari, DE | 2 |
| Newby, LK | 9 |
| Shah, PB | 1 |
| Lilly, CM | 1 |
| Turpie, AG | 7 |
| Mehta, JL | 4 |
| Mascitelli, L | 1 |
| Pezzetta, F | 1 |
| Tognoni, G | 1 |
| Zhao, F | 3 |
| Chrolavicius, S | 2 |
| Hunt, D | 1 |
| Keltai, M | 1 |
| Franzosi, MG | 1 |
| SoRelle, R | 2 |
| Mehta, P | 5 |
| Brotons, C | 1 |
| Moral, I | 1 |
| Ribera, A | 1 |
| Cascant, P | 1 |
| Iglesias, M | 1 |
| Permanyer-Miralda, G | 1 |
| Ferreira González, I | 1 |
| Soler-Soler, J | 1 |
| Bartorelli, AL | 3 |
| Trabattoni, D | 3 |
| Mangano, DT | 1 |
| Yikona, JI | 1 |
| Wallis, EJ | 2 |
| Ramsay, LE | 3 |
| Jackson, PR | 2 |
| Barbash, I | 1 |
| Freimark, D | 1 |
| Gottlieb, S | 4 |
| Hod, H | 2 |
| Hasin, Y | 1 |
| Battler, A | 3 |
| Crystal, E | 1 |
| Matetzky, S | 1 |
| Boyko, V | 3 |
| Mandelzweig, L | 1 |
| Behar, S | 5 |
| Leor, J | 2 |
| Woodworth, S | 1 |
| Nayak, D | 1 |
| Aronow, WS | 1 |
| Pucillo, AL | 1 |
| Koneru, S | 1 |
| McRedmond, J | 1 |
| Fitzgerald, D | 2 |
| Copland, I | 2 |
| Maciejewski, P | 1 |
| Johnston, M | 1 |
| Rollins, G | 2 |
| Ouali, S | 1 |
| Anselme, F | 1 |
| Savouré, A | 1 |
| Cribier, A | 1 |
| Ishikawa, K | 2 |
| Nakai, S | 1 |
| Otterstad, JE | 1 |
| Friend, M | 1 |
| Vucenik, I | 1 |
| Miller, M | 1 |
| Vittinghoff, E | 3 |
| Shlipak, MG | 1 |
| Varosy, PD | 1 |
| Furberg, CD | 2 |
| Ireland, CC | 1 |
| Khan, SS | 1 |
| Blumenthal, R | 2 |
| Barrett-Connor, E | 1 |
| Hulley, S | 2 |
| Amit, G | 2 |
| Ilia, R | 3 |
| Zahger, D | 3 |
| Mateos-Cáreres, PJ | 1 |
| García-Méndez, A | 1 |
| Farré, J | 2 |
| Sánchez de Miguel, L | 2 |
| Gómez, J | 2 |
| de Andres, R | 1 |
| Rico, L | 2 |
| Romero, J | 2 |
| López-Farré, A | 3 |
| Goodman, SG | 3 |
| Fitchett, D | 1 |
| Armstrong, PW | 8 |
| Tan, M | 1 |
| Langer, A | 3 |
| Riley, SJ | 1 |
| Stouffer, GA | 2 |
| Pollack, CV | 2 |
| Grand, A | 1 |
| Moustapha, A | 1 |
| Anderson, HV | 2 |
| Akinlade, BK | 1 |
| McGuire, DK | 3 |
| Armstrong, EC | 1 |
| Ramsey, SD | 1 |
| Yaes, RJ | 1 |
| Hézard, N | 2 |
| Metz, D | 2 |
| Nazeyrollas, P | 1 |
| Droullé, C | 2 |
| Potron, G | 2 |
| Nguyen, P | 2 |
| Joost, HG | 1 |
| Almagor, M | 1 |
| Keren, A | 1 |
| Banai, S | 1 |
| Schneider, M | 1 |
| Andrié, R | 2 |
| Jabs, A | 2 |
| Lüderitz, B | 1 |
| Bloom, JM | 2 |
| Zeidler, H | 1 |
| Bolten, WW | 1 |
| Ersöz, G | 1 |
| Tikiz, H | 1 |
| Yakaryilmaz, A | 1 |
| Tezcan, K | 1 |
| Genç, Y | 1 |
| Korkmaz, S | 1 |
| Toutouzas, K | 1 |
| Di Mario, C | 6 |
| Falotico, R | 1 |
| Takagi, T | 1 |
| Stankovic, G | 1 |
| Albiero, R | 2 |
| Corvaja, N | 1 |
| Colombo, A | 12 |
| Gharbi, M | 1 |
| Barakett, N | 1 |
| Lahidheb, DH | 1 |
| Smiri, Z | 1 |
| Fehri, W | 1 |
| Azzouzi, F | 1 |
| Rahal, N | 1 |
| Mhenni, H | 1 |
| Haouala, H | 1 |
| Guediche, M | 1 |
| Dardas, PS | 1 |
| Tsikaderis, DD | 1 |
| Mezilis, NE | 1 |
| Styliadis, G | 1 |
| Gerschutz, GP | 1 |
| Cotter, G | 1 |
| McCabe, CH | 3 |
| Michowitz, Y | 1 |
| Kaluski, E | 1 |
| Charlesworth, A | 2 |
| Milo, O | 1 |
| Bentley, J | 1 |
| Blatt, A | 1 |
| Krakover, R | 1 |
| Zimlichman, R | 1 |
| Reisin, L | 1 |
| Marmor, A | 1 |
| Lewis, B | 1 |
| Vered, Z | 1 |
| Caspi, A | 2 |
| Iturbe, T | 2 |
| Recaséns, Mdel V | 1 |
| Moreno, JA | 2 |
| Romero, MS | 1 |
| Lecompte, T | 3 |
| Shim, WH | 3 |
| Ho, DS | 1 |
| Raizner, AE | 2 |
| Hong, MK | 5 |
| Choi, D | 2 |
| Lam, R | 1 |
| Weissman, NJ | 1 |
| Mintz, GS | 1 |
| Danchin, N | 2 |
| Hanania, G | 1 |
| Grenier, O | 1 |
| Vaur, L | 1 |
| Amelineau, E | 1 |
| Guéret, P | 1 |
| Blanchard, D | 1 |
| Ferrières, J | 3 |
| Genès, N | 1 |
| Lablanche, JM | 2 |
| Cantet, C | 1 |
| Cambou, JP | 3 |
| Maurin, T | 1 |
| Zeller, M | 1 |
| Cottin, Y | 1 |
| Touzery, C | 1 |
| Beer, JC | 1 |
| L'Huillier, I | 1 |
| Fraison, M | 1 |
| Buffet, P | 2 |
| Louis, P | 1 |
| Wolf, JE | 1 |
| Lauten, WB | 1 |
| Khan, QA | 1 |
| Rajagopalan, S | 1 |
| Lerakis, S | 1 |
| Rahman, ST | 1 |
| Parthasarathy, S | 1 |
| Khan, BV | 1 |
| Strandberg, TE | 1 |
| Weinbrenner, T | 1 |
| Cladellas, M | 1 |
| Isabel Covas, M | 1 |
| Fitó, M | 1 |
| Tomás, M | 1 |
| Sentí, M | 1 |
| Bruguera, J | 1 |
| Marrugat, J | 2 |
| Jneid, H | 1 |
| Corti, R | 1 |
| Badimon, JJ | 6 |
| Fuster, V | 16 |
| Francis, GS | 1 |
| Sellmayer, A | 1 |
| Limmert, T | 1 |
| Hoffmann, U | 1 |
| Anand, SS | 3 |
| Pogue, J | 1 |
| Ginsberg, JS | 2 |
| Hirsh, J | 12 |
| Steinhubl, S | 2 |
| Berger, P | 1 |
| Rudnicka, AR | 1 |
| Ashby, D | 1 |
| Brennan, P | 1 |
| Meade, T | 1 |
| Srinivasan, AK | 1 |
| Grayson, AD | 1 |
| Pullan, DM | 1 |
| Fabri, BM | 1 |
| Dihmis, WC | 1 |
| Serebruany, VL | 5 |
| Malinin, AI | 3 |
| O'connor, CM | 2 |
| Joss, K | 1 |
| Lindsay, G | 1 |
| Easton, D | 1 |
| Granett, J | 1 |
| Sigmon, K | 1 |
| Pieper, K | 1 |
| Willerson, JT | 8 |
| Wilson, SH | 2 |
| Fasseas, P | 2 |
| Orford, JL | 2 |
| Lennon, RJ | 1 |
| Horlocker, T | 1 |
| Charnoff, NE | 1 |
| Melby, S | 3 |
| Demiroglu, H | 1 |
| Moliterno, DJ | 4 |
| Genoni, M | 1 |
| Tavakoli, R | 1 |
| Hofer, C | 1 |
| Bertel, O | 2 |
| Turina, M | 1 |
| Hung, J | 2 |
| Tolleson, TR | 1 |
| Bhapkar, MV | 4 |
| Ruygrok, PN | 1 |
| Sim, KH | 2 |
| Chan, C | 1 |
| Rachman, OJ | 1 |
| Adipranoto, JD | 1 |
| Trisnohadi, HB | 1 |
| Stewart, JT | 1 |
| Ahmad, N | 1 |
| Yusak, M | 1 |
| Boestan, I | 1 |
| Santoso, T | 1 |
| Suryapranata, H | 2 |
| Slavina, NN | 1 |
| Averkov, OV | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Gratsianskiĭ, NA | 4 |
| Gulba, DC | 2 |
| Lankes, W | 1 |
| Malhotra, S | 1 |
| Sharma, YP | 1 |
| Grover, A | 1 |
| Majumdar, S | 1 |
| Hanif, SM | 1 |
| Bhargava, VK | 1 |
| Bhatnagar, A | 1 |
| Pandhi, P | 1 |
| Talbert, RL | 1 |
| Pieper, JA | 3 |
| Ito, MK | 1 |
| Eisenberg, MJ | 2 |
| Okrainec, K | 1 |
| Lefkovits, J | 1 |
| Goudreau, E | 1 |
| Deligonul, U | 1 |
| Duerr, R | 1 |
| Tsang, J | 1 |
| Huynh, T | 2 |
| Sedlis, S | 1 |
| Brown, DL | 1 |
| Brieger, D | 1 |
| Pilote, L | 1 |
| Sánchez-Delgado, E | 1 |
| Pekdemir, H | 1 |
| Cin, VG | 1 |
| Camsari, A | 1 |
| Cicek, D | 1 |
| Akkus, MN | 1 |
| Doven, O | 1 |
| Parmaksiz, T | 1 |
| Fernandez, JS | 1 |
| Sadaniantz, BT | 1 |
| Sadaniantz, A | 1 |
| Knight, CJ | 1 |
| CRAVEN, LL | 1 |
| ALEXANDER, WD | 1 |
| MACDOUGALL, AI | 1 |
| OLIVER, MF | 2 |
| BOYD, GS | 1 |
| Wodlinger, AM | 1 |
| Dornbrook-Lavender, KA | 1 |
| Roth, MT | 1 |
| Pourati, I | 1 |
| Kimmelstiel, C | 1 |
| Rand, W | 1 |
| Karas, RH | 1 |
| Mueller, I | 1 |
| Besta, F | 1 |
| Thomas, P | 1 |
| Gawaz, M | 7 |
| Drown, DJ | 1 |
| Coletta, AP | 1 |
| Cleland, JG | 2 |
| Freemantle, N | 1 |
| Loh, H | 1 |
| Memon, A | 1 |
| Clark, AL | 1 |
| Tan, KT | 1 |
| Lip, GY | 3 |
| Werner, GS | 1 |
| Emig, U | 1 |
| Mutschke, O | 1 |
| Schwarz, G | 1 |
| Bahrmann, P | 1 |
| Figulla, HR | 1 |
| Senior, K | 1 |
| Hong, S | 1 |
| Friedman, J | 1 |
| Alt, S | 1 |
| Lim, E | 1 |
| Ali, Z | 1 |
| Ali, A | 1 |
| Routledge, T | 1 |
| Edmonds, L | 1 |
| Altman, DG | 1 |
| Large, S | 1 |
| Bélanger, P | 1 |
| Palisaitis, DA | 1 |
| Diodati, JG | 1 |
| Pharand, C | 1 |
| Lauer, MS | 4 |
| Gitt, AK | 3 |
| Schiele, R | 2 |
| Wienbergen, H | 3 |
| Zeymer, U | 1 |
| Schneider, S | 1 |
| Gottwik, MG | 1 |
| Senges, J | 3 |
| Lange, RA | 2 |
| Hillis, LD | 5 |
| Xu, CB | 1 |
| Welt, FG | 1 |
| Rogers, SD | 1 |
| Ehlers, R | 1 |
| Chen, Z | 1 |
| Nannizzi-Alaimo, L | 1 |
| Phillips, DR | 1 |
| Simon, DI | 2 |
| Sabatine, MS | 1 |
| Morrow, DA | 1 |
| Demopoulos, LA | 1 |
| DiBattiste, PM | 1 |
| Antman, EM | 3 |
| Howard, PA | 1 |
| Delafontaine, P | 1 |
| Montgomery, AA | 1 |
| Fahey, T | 1 |
| Brindle, P | 1 |
| Davey Smith, G | 1 |
| Ebrahim, S | 3 |
| Spencer, FA | 1 |
| Becker, RC | 4 |
| Burger, K | 1 |
| Holmes, DR | 5 |
| Song, SH | 1 |
| Brown, PM | 1 |
| Sheridan, SL | 1 |
| Lee, YZ | 1 |
| Kuo, J | 1 |
| Phillips, C | 2 |
| Mulrow, C | 4 |
| Zeiger, R | 1 |
| Ho, WK | 1 |
| Kübler, W | 4 |
| Lepäntalo, A | 1 |
| Virtanen, KS | 1 |
| Heikkilä, J | 1 |
| Wartiovaara, U | 1 |
| Lassila, R | 1 |
| Tonstad, S | 1 |
| Rosvold, EO | 1 |
| Furu, K | 1 |
| Skurtveit, S | 1 |
| LaPointe, NM | 1 |
| Kramer, JM | 1 |
| Vik-Mo, H | 3 |
| Hegbom, K | 1 |
| Helø, OH | 1 |
| Madsen, JK | 1 |
| Kastrup, J | 1 |
| Juenger, C | 1 |
| Heer, T | 1 |
| Vogel, C | 1 |
| Gottwik, M | 1 |
| García Rodríguez, LA | 2 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| González-Pérez, A | 1 |
| Scranton, R | 1 |
| Sesso, HD | 1 |
| Stampfer, MJ | 2 |
| Levenson, JW | 1 |
| Buring, JE | 5 |
| Gaziano, JM | 3 |
| Giral, A | 1 |
| Ozdogan, O | 1 |
| Celikel, CA | 1 |
| Tozun, N | 1 |
| Ulusoy, NB | 1 |
| Kalayci, C | 1 |
| Finazzi, G | 1 |
| Ruel, M | 1 |
| Masters, RG | 1 |
| Rubens, FD | 1 |
| Bédard, PJ | 1 |
| Pipe, AL | 1 |
| Goldstein, WG | 1 |
| Hendry, PJ | 1 |
| Mesana, TG | 1 |
| Wiviott, SD | 3 |
| Genest, M | 1 |
| Pochmalicki, G | 1 |
| Eagle, KA | 2 |
| Kline-Rogers, E | 1 |
| Gurfinkel, EP | 1 |
| Avezum, A | 1 |
| Flather, MD | 1 |
| Granger, CB | 4 |
| Erickson, S | 1 |
| White, K | 1 |
| Henkin, Y | 2 |
| Abuful, A | 2 |
| Yosefi, C | 1 |
| Elis, A | 1 |
| Gidron, Y | 2 |
| von Beckerath, N | 2 |
| Joost, A | 1 |
| Pogatsa-Murray, G | 3 |
| Gorchakova, O | 1 |
| Locker, C | 1 |
| Mohr, R | 1 |
| Lev-Ran, O | 1 |
| Uretzky, G | 1 |
| Frimerman, A | 1 |
| Shaham, Y | 1 |
| Shapira, I | 1 |
| Raffel, OC | 1 |
| Mansfield, M | 1 |
| Okazaki, S | 1 |
| Yokoyama, T | 4 |
| Shimada, K | 1 |
| Kurata, T | 1 |
| Sato, H | 1 |
| Daida, H | 1 |
| Critchley, J | 2 |
| Wei, W | 1 |
| Capewell, S | 3 |
| Kerr, JL | 1 |
| Oppelt, TF | 1 |
| Rowen, RC | 1 |
| Lama, A | 1 |
| Vega, J | 1 |
| Stein, PD | 1 |
| Schünemann, HJ | 1 |
| Dalen, JE | 4 |
| Gutterman, D | 1 |
| Blazing, MA | 1 |
| Brady, WE | 1 |
| Palmisano, J | 1 |
| Ramsey, KE | 2 |
| Bilheimer, DW | 1 |
| Lewis, EF | 1 |
| Pfeffer, M | 1 |
| Main, C | 1 |
| Palmer, S | 1 |
| Griffin, S | 1 |
| Jones, L | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Henderson, R | 1 |
| Sudlow, C | 2 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Poponina, TM | 1 |
| Kapilevich, NA | 1 |
| Kisteneva, IV | 1 |
| Markov, VA | 1 |
| Novitskiĭ, VV | 1 |
| Gage, BF | 1 |
| van Walraven, C | 1 |
| Pearce, L | 1 |
| Hart, RG | 2 |
| Boode, BS | 1 |
| Petersen, P | 1 |
| Kojda, G | 1 |
| Boonstra, PW | 1 |
| van Oeveren, W | 1 |
| Fang, CH | 1 |
| Hui, RT | 1 |
| Hsieh, KS | 2 |
| Weng, KP | 1 |
| Lin, CC | 1 |
| Huang, TC | 1 |
| Lee, CL | 1 |
| Huang, SM | 1 |
| Lee, KL | 1 |
| Simes, RJ | 2 |
| Claeys, MJ | 1 |
| Van der Planken, MG | 1 |
| Bosmans, JM | 1 |
| Michiels, JJ | 3 |
| Vertessen, F | 1 |
| Van Der Goten, P | 1 |
| Wuyts, FL | 1 |
| Vrints, CJ | 1 |
| Rajagopal, V | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Tcheng, JE | 6 |
| Parsons, E | 1 |
| Alexander, KP | 2 |
| Shah, SH | 2 |
| Bushnell, CD | 1 |
| Miser, WF | 1 |
| Campbell, CL | 1 |
| Bulpitt, CJ | 3 |
| Hölschermann, H | 1 |
| Sambola, A | 1 |
| Heras, M | 1 |
| Escolar, G | 1 |
| Lozano, M | 1 |
| Pino, M | 1 |
| Martorell, T | 1 |
| Torra, M | 1 |
| Sanz, G | 1 |
| Jefferson, BK | 1 |
| Foster, JH | 1 |
| McCarthy, JJ | 1 |
| Ginsburg, G | 1 |
| Parker, A | 1 |
| Kottke-Marchant, K | 3 |
| Gurevich, MA | 1 |
| Lindgren, P | 1 |
| Stenestrand, U | 1 |
| Malmberg, K | 4 |
| Jönsson, B | 1 |
| Emberson, JR | 1 |
| Whincup, PH | 2 |
| Lawlor, DA | 1 |
| Montaner, D | 1 |
| von Beckerath, O | 1 |
| Eichinger, M | 1 |
| Pettersen, AA | 2 |
| Seljeflot, I | 3 |
| Abdelnoor, M | 1 |
| Zimarino, M | 2 |
| Renda, G | 2 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 2 |
| Papageorgiou, AA | 1 |
| Bouloukos, VI | 1 |
| Pehlivanidis, AN | 1 |
| Symeonidis, AN | 1 |
| Kakafika, AI | 1 |
| Daskalopoulou, SS | 1 |
| Elisaf, M | 1 |
| Shanks, M | 1 |
| Holmes, DT | 1 |
| Cermakova, L | 1 |
| Frohlich, J | 1 |
| Marcus, AJ | 1 |
| Broekman, MJ | 1 |
| Drosopoulos, JH | 1 |
| Olson, KE | 1 |
| Islam, N | 1 |
| Pinsky, DJ | 1 |
| Levi, R | 2 |
| Lu, SZ | 1 |
| Ning, SQ | 1 |
| Turris, SA | 1 |
| Smith, S | 1 |
| Biondi-Zoccai, GG | 3 |
| Abbate, A | 1 |
| Agostoni, P | 4 |
| Testa, L | 2 |
| Burzotta, F | 1 |
| Lotrionte, M | 2 |
| Trani, C | 1 |
| Biasucci, LM | 1 |
| Curtiss, FR | 1 |
| Antonopoulos, S | 1 |
| Mikros, S | 1 |
| Kokkoris, S | 1 |
| Protopsaltis, J | 1 |
| Filioti, K | 1 |
| Karamanolis, D | 1 |
| Giannoulis, G | 1 |
| Ikonomidis, I | 1 |
| Lekakis, J | 1 |
| Vamvakou, G | 1 |
| Andreotti, F | 3 |
| Nihoyannopoulos, P | 1 |
| Graham, JJ | 1 |
| Cooper, J | 1 |
| Ramdany, S | 1 |
| Deaner, A | 1 |
| Ranjadayalan, K | 1 |
| Knight, C | 1 |
| Miller, MG | 1 |
| Lucas, BD | 1 |
| Papademetriou, V | 1 |
| Elhabyan, AK | 1 |
| Ajzenberg, N | 1 |
| Huisse, MG | 1 |
| Cachier, A | 1 |
| El Amara, W | 1 |
| Feldman, LJ | 2 |
| Himbert, D | 1 |
| Baruch, D | 1 |
| Guillin, MC | 1 |
| Fox, DJ | 1 |
| Kibiro, M | 1 |
| Eichhöfer, J | 1 |
| Curzen, NP | 1 |
| Elsässer, A | 1 |
| Nef, H | 1 |
| Möllmann, H | 1 |
| Guthikonda, S | 1 |
| Lev, EI | 1 |
| Kleiman, NS | 9 |
| Schwartz, DJ | 1 |
| Lee, PY | 2 |
| Chen, WH | 2 |
| Ng, W | 2 |
| Cheng, X | 1 |
| Kwok, JY | 1 |
| Tse, HF | 2 |
| Lau, CP | 2 |
| James, SK | 1 |
| Oldgren, J | 1 |
| Lindbäck, J | 1 |
| Johnston, N | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Thiele, H | 1 |
| Niebauer, J | 4 |
| Busch, I | 1 |
| Schuler, G | 3 |
| Ripa, RS | 1 |
| Holmvang, L | 1 |
| Maynard, C | 1 |
| Sejersten, M | 1 |
| Clemmensen, P | 1 |
| Grande, P | 1 |
| Lindahl, B | 1 |
| Lagerqvist, B | 1 |
| Wagner, GS | 1 |
| Martínez-Sellés, M | 1 |
| Ortiz, J | 1 |
| Estévez, A | 1 |
| Andueza, J | 1 |
| de Miguel, J | 1 |
| Bueno, H | 1 |
| Almsherqi, Z | 1 |
| McLachlan, C | 1 |
| Mossop, PJ | 1 |
| Deng, Y | 1 |
| Ramírez, C | 3 |
| Jimenez-Quevedo, P | 3 |
| Hernández, R | 3 |
| Moreno, R | 3 |
| Alfonso, F | 3 |
| Bañuelos, C | 3 |
| Costa, MA | 3 |
| Kriszbacher, I | 1 |
| Koppán, M | 1 |
| Bódis, J | 1 |
| Wolak, A | 1 |
| Cafri, C | 1 |
| Gilutz, H | 1 |
| Sun, JC | 1 |
| Crowther, MA | 1 |
| Warkentin, TE | 1 |
| Lamy, A | 1 |
| Teoh, KH | 1 |
| Rothberg, MB | 1 |
| Celestin, C | 1 |
| Fiore, LD | 1 |
| Lawler, E | 1 |
| Cook, JR | 1 |
| Jaumdally, R | 1 |
| Varma, C | 1 |
| Hacke, W | 1 |
| Pamukcu, B | 2 |
| Oflaz, H | 2 |
| Acar, RD | 1 |
| Umman, S | 1 |
| Koylan, N | 1 |
| Umman, B | 1 |
| Nisanci, Y | 2 |
| Rzeczuch, K | 1 |
| Szajn, G | 1 |
| Jankowska, E | 1 |
| Kaczmarek, A | 1 |
| Derkacz, A | 1 |
| Porada, A | 1 |
| Telichowski, A | 1 |
| Banasiak, W | 1 |
| Ponikowski, P | 1 |
| Bybee, KA | 1 |
| Powell, BD | 1 |
| Valeti, U | 1 |
| Rosales, AG | 1 |
| Kopecky, SL | 1 |
| Mullany, C | 1 |
| Wright, RS | 1 |
| Zhang, Y | 1 |
| Liang, J | 1 |
| Yuan, H | 1 |
| Zhang, YZ | 1 |
| Dong, L | 1 |
| Sud, A | 1 |
| Kline-Rogers, EM | 1 |
| Fang, J | 2 |
| Armstrong, DF | 1 |
| Rangarajan, K | 1 |
| Otten, RF | 1 |
| Stafkey-Mailey, DR | 1 |
| Taylor, SD | 1 |
| Erickson, SR | 1 |
| Leung, SK | 1 |
| Tan, HC | 1 |
| Leung, AW | 1 |
| Lee, MK | 1 |
| Li, SK | 1 |
| Cavallari, U | 1 |
| Trabetti, E | 1 |
| Pignatti, PF | 1 |
| Tang, E | 1 |
| Wong, CK | 1 |
| Wilkins, G | 1 |
| Herbison, P | 1 |
| Williams, M | 1 |
| Kay, P | 1 |
| Restieaux, N | 1 |
| Marx, N | 1 |
| Nusser, T | 1 |
| Walcher, D | 1 |
| Rinker, A | 1 |
| Hombach, V | 1 |
| Koenig, W | 1 |
| Höher, M | 1 |
| Darius, H | 3 |
| Brown, DW | 1 |
| Shepard, D | 1 |
| Giles, WH | 1 |
| Greenlund, KJ | 1 |
| Croft, JB | 1 |
| Soiza, RL | 1 |
| Leslie, SJ | 1 |
| Charpentier, G | 1 |
| Puel, J | 1 |
| Cornuz, J | 2 |
| Butler, J | 2 |
| Ding, J | 1 |
| Satterfield, S | 1 |
| Newman, AB | 1 |
| Harris, TB | 1 |
| Hulley, SB | 1 |
| Bauer, DC | 1 |
| Watkins, S | 1 |
| Thiemann, D | 1 |
| Coresh, J | 1 |
| Powe, N | 1 |
| Rosamond, W | 1 |
| Su, JT | 1 |
| Taylor, MD | 1 |
| Krishnamurthy, R | 1 |
| Muthupillai, R | 1 |
| Kovalchin, JP | 1 |
| Chung, T | 1 |
| Vick, GW | 1 |
| Arutiunov, GP | 1 |
| Kartseva, TP | 1 |
| Voevodina, NIu | 1 |
| Daĭter, II | 1 |
| Malanichev, RV | 1 |
| Marfunina, AA | 1 |
| Nakhaev, VI | 1 |
| Rozanov, AV | 1 |
| Rylova, AK | 1 |
| Stepanova, LV | 1 |
| Song, JM | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Kim, JJ | 4 |
| Konstantino, Y | 2 |
| Iakobishvili, Z | 2 |
| Porter, A | 2 |
| Sandach, A | 1 |
| Hammerman, H | 1 |
| Hasdai, D | 2 |
| Addad, F | 1 |
| Hassine, M | 1 |
| Ben Farhat, M | 1 |
| Abderrazak, F | 1 |
| Chakroun, T | 1 |
| Gamra, H | 1 |
| Hamdi, S | 1 |
| Betbout, F | 1 |
| Samama, M | 3 |
| Elalamy, I | 1 |
| Krantz, MJ | 1 |
| Coronel, SM | 1 |
| Hiatt, WR | 1 |
| Wang, SL | 3 |
| Ma, YY | 2 |
| Deng, J | 1 |
| Yang, GT | 1 |
| Yu, HB | 1 |
| Ge, JB | 1 |
| Marissal, JP | 1 |
| Sailly, JC | 1 |
| Crainich, D | 1 |
| Lebrun, T | 1 |
| Frazier, CG | 1 |
| Sadowski, Z | 2 |
| Kristinsson, A | 1 |
| Aylward, PE | 1 |
| Klein, WW | 1 |
| Giverhaug, T | 1 |
| Bruland, C | 1 |
| Trovik, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Barbou, F | 1 |
| Morange, PE | 1 |
| Hovasse, T | 1 |
| Bonnet, JL | 1 |
| Alessi, MC | 1 |
| Brogan, GX | 1 |
| Peterson, ED | 2 |
| Mulgund, J | 1 |
| Gibler, WB | 1 |
| Farkouh, ME | 1 |
| Roe, MT | 2 |
| Gurbuz, AT | 1 |
| Zia, AA | 1 |
| Vuran, AC | 1 |
| Cui, H | 1 |
| Aytac, A | 1 |
| Wepner, U | 1 |
| Klaus, T | 1 |
| Ahrens, I | 1 |
| Bode, C | 2 |
| Jennings, DL | 1 |
| Petricca, JC | 1 |
| Yageman, LA | 1 |
| O'Dell, K | 1 |
| Kalus, JS | 1 |
| Sorel, N | 1 |
| Fisher, M | 1 |
| Knappertz, V | 1 |
| Ziegelstein, RC | 2 |
| Piepoli, MF | 1 |
| Sangiorgi, GM | 1 |
| Iakovou, I | 1 |
| Antoniucci, D | 1 |
| Grube, E | 1 |
| Tamburino, C | 4 |
| Michev, I | 1 |
| Goktekin, O | 1 |
| Airoldi, F | 1 |
| Chieffo, A | 1 |
| Cosgrave, J | 1 |
| Tassanawiwat, W | 1 |
| Earnshaw, S | 1 |
| Tice, JA | 1 |
| Kurşaklioğlu, H | 1 |
| Köz, C | 1 |
| Iyisoy, A | 1 |
| Ide, T | 1 |
| Yildirim, V | 1 |
| Töre, HF | 1 |
| Işik, E | 1 |
| Demirtaş, E | 1 |
| Urban, P | 2 |
| Gershlick, AH | 5 |
| Guyon, P | 1 |
| Lotan, C | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Wijns, W | 2 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Tsuda, E | 1 |
| Kawamata, K | 1 |
| Neki, R | 1 |
| Echigo, S | 1 |
| Chiba, Y | 1 |
| Byrne, M | 2 |
| Murphy, AW | 1 |
| Walsh, JC | 1 |
| Shryane, E | 1 |
| McGroarty, M | 1 |
| Kelleher, CC | 2 |
| Bavry, AA | 1 |
| Lincoff, AM | 9 |
| Atar, S | 1 |
| Rosanio, S | 3 |
| Uretsky, BF | 1 |
| Birnbaum, Y | 1 |
| Silverman, ME | 1 |
| McAlister, FA | 2 |
| Ghali, WA | 2 |
| Gong, Y | 1 |
| Tu, JV | 1 |
| Shachar, L | 1 |
| Su, QF | 2 |
| Wang, ZL | 1 |
| Wang, DM | 1 |
| Luan, B | 1 |
| Violi, F | 3 |
| Pignatelli, P | 1 |
| Lyseng-Williamson, KA | 1 |
| Plosker, GL | 1 |
| Patel, TN | 1 |
| Kreindel, M | 1 |
| Soares, PR | 1 |
| Hueb, WA | 1 |
| Lemos, PA | 1 |
| Lopes, N | 1 |
| Martinez, EE | 1 |
| Cesar, LA | 1 |
| Oliveira, SA | 1 |
| Ramires, JA | 1 |
| Ali, MJ | 1 |
| Davidoff, R | 1 |
| Davì, G | 2 |
| Santilli, F | 1 |
| Batić-Mujanović, O | 1 |
| Zildzić, M | 1 |
| Beganlić, A | 1 |
| Chelmowski, MK | 1 |
| Sciulli, MG | 1 |
| Capone, ML | 1 |
| Tacconelli, S | 1 |
| Ricciotti, E | 1 |
| Manarini, S | 1 |
| Evangelista, V | 1 |
| Rebuzzi, A | 1 |
| Patrignani, P | 1 |
| Gilard, M | 1 |
| Arnaud, B | 1 |
| Le Gal, G | 1 |
| Abgrall, JF | 1 |
| Boschat, J | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Fuchs, I | 1 |
| Frossard, M | 1 |
| Spiel, A | 1 |
| Riedmüller, E | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Boos, CJ | 1 |
| Cooke, GE | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Smith, C | 1 |
| Damås, JK | 1 |
| Otterdal, K | 1 |
| Øie, E | 1 |
| Sandberg, WJ | 1 |
| Yndestad, A | 1 |
| Waehre, T | 1 |
| Scholz, H | 1 |
| Endresen, K | 1 |
| Olofsson, PS | 1 |
| Halvorsen, B | 1 |
| Gullestad, L | 1 |
| Frøland, SS | 1 |
| Hansson, GK | 1 |
| Aukrust, P | 1 |
| Kang, J | 1 |
| Yan, CH | 1 |
| Solheim, S | 1 |
| Nakayama, M | 1 |
| Lee, VW | 1 |
| Chan, WK | 1 |
| Lee, KK | 1 |
| Brinster, DR | 1 |
| Rogers, CD | 1 |
| Baim, DS | 6 |
| Couper, GS | 1 |
| Cohn, LH | 1 |
| Fernandes, JL | 1 |
| Serrano, CV | 1 |
| Blotta, MH | 1 |
| Coelho, OR | 1 |
| Nicolau, JC | 1 |
| Avila, LF | 1 |
| Rochitte, CE | 1 |
| Parga Filho, JR | 1 |
| Miller, SD | 1 |
| Rieckmann, N | 2 |
| Gerin, W | 1 |
| Kronish, IM | 2 |
| Burg, MM | 1 |
| Chaplin, WF | 1 |
| Kong, G | 1 |
| Lespérance, F | 2 |
| Davidson, KW | 2 |
| Sarkiss, MG | 1 |
| Yusuf, SW | 1 |
| Warneke, CL | 1 |
| Botz, G | 1 |
| Lakkis, N | 1 |
| Hirch-Ginsburg, C | 1 |
| Champion, JC | 1 |
| Swafford, J | 1 |
| Shaw, AD | 1 |
| Lenihan, DJ | 1 |
| Durand, JB | 1 |
| Junnila, JL | 1 |
| Runkle, GP | 1 |
| Dieker, HJ | 1 |
| French, JK | 2 |
| Joziasse, IC | 1 |
| Elliott, J | 1 |
| West, TM | 1 |
| Webber, BJ | 1 |
| Kraiem, S | 1 |
| Abassi, C | 1 |
| Annabi, N | 1 |
| Smaali, I | 1 |
| Issaa, I | 1 |
| Wali, M | 1 |
| Malou, M | 1 |
| Hannachi, S | 1 |
| Longo, S | 1 |
| Battikh, K | 1 |
| Slimane, ML | 1 |
| Chen, CC | 1 |
| Chong, CF | 1 |
| Kuo, CD | 1 |
| Wang, TL | 1 |
| Vilahur, G | 1 |
| Choi, BG | 1 |
| Zafar, MU | 1 |
| Viles-Gonzalez, JF | 1 |
| Vorchheimer, DA | 1 |
| Shimbo, D | 1 |
| Chin, SP | 1 |
| Liew, CK | 1 |
| Tay, SP | 1 |
| Rapaee, A | 1 |
| Liew, HB | 1 |
| Ang, CK | 1 |
| Fong, YY | 1 |
| Ong, TK | 1 |
| Gudum, HR | 1 |
| Berry, C | 1 |
| Tardif, JC | 1 |
| Bourassa, MG | 4 |
| Małek, ŁA | 1 |
| Spiewak, M | 1 |
| Grabowski, M | 1 |
| Szpotańska, M | 1 |
| Rosiak, M | 1 |
| Główczyńska, R | 1 |
| Imiela, T | 1 |
| Opotowsky, AR | 1 |
| McWilliams, JM | 1 |
| Hamdalla, H | 1 |
| Choudhury, A | 1 |
| Chung, I | 1 |
| Blann, AD | 1 |
| Lip, GYH | 1 |
| Ambrosi, P | 1 |
| Villani, P | 1 |
| Bouvenot, G | 1 |
| Liao, JK | 1 |
| Hsu, J | 1 |
| Pack, Q | 1 |
| Feldstein, DA | 1 |
| Gulec, S | 1 |
| Ozdol, C | 1 |
| Vurgun, K | 1 |
| Selcuk, T | 1 |
| Turhan, S | 1 |
| Duzen, V | 1 |
| Temizhan, A | 1 |
| Ozdemir, AO | 1 |
| Erol, C | 1 |
| Galassi, A | 1 |
| Serdoz, R | 1 |
| Sheiban, I | 4 |
| Piovaccari, G | 1 |
| Benassi, A | 1 |
| Sangiorgio, P | 1 |
| Chierchia, S | 3 |
| Fidan, D | 1 |
| Unal, B | 1 |
| Faraday, N | 2 |
| Yanek, LR | 1 |
| Mathias, R | 1 |
| Herrera-Galeano, JE | 1 |
| Vaidya, D | 1 |
| Moy, TF | 1 |
| Fallin, MD | 1 |
| Wilson, AF | 1 |
| Bray, PF | 1 |
| Becker, LC | 3 |
| Becker, DM | 2 |
| Grines, CL | 2 |
| Bonow, RO | 2 |
| Casey, DE | 1 |
| Gardner, TJ | 1 |
| Lockhart, PB | 1 |
| O'Gara, P | 1 |
| Whitlow, P | 1 |
| Cheng, G | 1 |
| Shan, J | 1 |
| Xu, G | 1 |
| Liu, P | 1 |
| Zhou, Y | 1 |
| Zhu, Y | 1 |
| Lu, X | 1 |
| Lee, CR | 1 |
| North, KE | 1 |
| Bray, MS | 1 |
| Couper, DJ | 1 |
| Heiss, G | 2 |
| Zeldin, DC | 1 |
| Krayenbuehl, PA | 1 |
| Wiesli, P | 1 |
| Schmid, M | 1 |
| Schmid, C | 1 |
| Ehses, JA | 1 |
| Hersberger, M | 1 |
| Vetter, W | 1 |
| Schulthess, G | 1 |
| Egan, K | 1 |
| FitzGerald, GA | 4 |
| Oreopoulos, A | 1 |
| Norris, CM | 1 |
| Graham, MM | 1 |
| Tsuyuki, RT | 1 |
| Knudtson, M | 1 |
| López-Farré, AJ | 1 |
| Mateos-Cáceres, PJ | 1 |
| Sacristán, D | 1 |
| de Prada, TP | 1 |
| Alonso-Orgaz, S | 1 |
| Fernández-Arquero, M | 1 |
| Zoccai, GB | 1 |
| Porto, I | 1 |
| Trotta, G | 1 |
| Crea, F | 2 |
| DiChiara, J | 2 |
| Newcomer, J | 1 |
| Weng, W | 1 |
| Neerchal, NK | 1 |
| Gesheff, T | 1 |
| Chaganti, SK | 1 |
| Etherington, A | 1 |
| Fabijanic, D | 1 |
| Banic, M | 1 |
| Kardum, D | 1 |
| Sutlic, Z | 1 |
| Radic, M | 1 |
| Rudez, I | 1 |
| Biocina, B | 1 |
| Rupprecht, HJ | 3 |
| Kamyar, M | 1 |
| Johnson, BJ | 1 |
| McAnaw, JJ | 1 |
| Hudson, SA | 1 |
| Lancaster, GI | 1 |
| Jain, H | 1 |
| Zarich, SW | 1 |
| Michou, SM | 1 |
| Kähönen, M | 1 |
| Lehtimäki, T | 1 |
| Nikus, K | 2 |
| Viik, J | 1 |
| Niemelä, K | 2 |
| Kallio, J | 1 |
| Lehtinen, R | 1 |
| Kööbi, T | 1 |
| Turjanmaa, V | 1 |
| Nieminen, T | 1 |
| Hamed, MS | 1 |
| Antonino, MJ | 1 |
| Suarez, TA | 1 |
| Bailon, O | 1 |
| Singla, A | 1 |
| Marques-Vidal, P | 3 |
| Hayoz, D | 1 |
| Pécoud, A | 1 |
| Paccaud, F | 1 |
| Waeber, G | 1 |
| Vollenweider, P | 1 |
| Tirnaksiz, E | 1 |
| Meen, O | 1 |
| Brosstad, F | 1 |
| Khiabani, H | 1 |
| Gjertsen, E | 1 |
| Lauritsen, ME | 1 |
| Pedersen, TM | 1 |
| Bjørnsen, S | 1 |
| Schjelderup, NM | 1 |
| Ameln, W | 1 |
| Ng, EC | 1 |
| Wettergreen, M | 1 |
| Siddique, SP | 1 |
| Erikssen, G | 1 |
| Fallen, E | 1 |
| Guyton, RA | 1 |
| Min, PK | 1 |
| Jung, JH | 1 |
| Ko, YG | 1 |
| Mann, KG | 1 |
| Michelson, AD | 2 |
| van Zyl, LT | 1 |
| Frasure-Smith, N | 1 |
| Atar, D | 2 |
| Laliberté, MA | 1 |
| Fares, RR | 1 |
| Lansing, LS | 1 |
| Gallati, CA | 1 |
| Mousa, SA | 1 |
| Sofi, F | 1 |
| Marcucci, R | 1 |
| Gori, AM | 1 |
| Abbate, R | 1 |
| Gensini, GF | 1 |
| Henriksen, PA | 1 |
| Palmer, K | 1 |
| Boon, NA | 1 |
| Kubota, N | 1 |
| Kasai, T | 1 |
| Njaman, W | 1 |
| Kajimoto, K | 1 |
| Akimoto, Y | 1 |
| Kojima, T | 1 |
| Ken, Y | 1 |
| Takeshi, K | 1 |
| Hiroyuki, D | 1 |
| Choudhry, NK | 1 |
| Patrick, AR | 1 |
| Shrank, WH | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Scuri, P | 1 |
| Invernizzi, P | 1 |
| Mihalcsik, L | 1 |
| Gavazzi, A | 1 |
| Gladding, P | 1 |
| Webster, M | 1 |
| Ormiston, J | 1 |
| Olsen, S | 1 |
| White, H | 1 |
| Mikkelsson, J | 1 |
| Eskola, M | 1 |
| Karhunen, PJ | 1 |
| Desch, S | 1 |
| Casterella, PJ | 1 |
| Klein, PS | 1 |
| Shrivastava, R | 1 |
| Khan, A | 1 |
| Jeevanantham, V | 1 |
| Nautiyal, A | 1 |
| Garg, P | 1 |
| Reddy, PC | 1 |
| Born, GV | 4 |
| Görög, P | 2 |
| Begent, NA | 2 |
| Boissel, JP | 1 |
| Leizorovicz, A | 1 |
| Faucomprez, C | 1 |
| McNicol, GP | 1 |
| Genton, E | 8 |
| Perrenoud, JJ | 1 |
| Marshall, AJ | 1 |
| Cheng, TO | 2 |
| Loew, D | 1 |
| Breddin, K | 2 |
| Uberla, K | 1 |
| Silke, B | 1 |
| Nelson, GI | 1 |
| Taylor, SH | 1 |
| Friedewald, WT | 2 |
| Schoenberger, JA | 3 |
| Omura, Y | 1 |
| Spann, JF | 1 |
| Kelton, JG | 1 |
| Chodorowski, Z | 1 |
| Kornitzer, M | 1 |
| Epstein, SE | 2 |
| Palmeri, ST | 1 |
| Caruzzo, C | 3 |
| Sechi, A | 1 |
| Monti, C | 1 |
| Campagna, G | 1 |
| Spinnler, MT | 1 |
| de Boer, AC | 2 |
| Webster, J | 2 |
| Swanson, KT | 1 |
| Vlietstra, RE | 1 |
| Smith, HC | 1 |
| Reeder, GS | 1 |
| Bresnahan, JF | 1 |
| Bove, AA | 4 |
| Furusho, K | 2 |
| Kamiya, T | 2 |
| Nakano, H | 2 |
| Kiyosawa, N | 2 |
| Shinomiya, K | 2 |
| Hayashidera, T | 2 |
| Tamura, T | 3 |
| Hirose, O | 2 |
| Manabe, Y | 2 |
| Neame, PB | 1 |
| Sherry, S | 2 |
| Han, P | 1 |
| Butt, R | 1 |
| Gent, M | 3 |
| Sanborn, TA | 2 |
| Faxon, DP | 2 |
| Kellett, MA | 1 |
| Ryan, TJ | 1 |
| Kaltenbach, M | 4 |
| Kober, G | 3 |
| Schmidt-Moritz, A | 1 |
| Scherer, D | 2 |
| Thaulow, E | 2 |
| Leisch, F | 1 |
| Herbinger, W | 1 |
| Brücke, P | 1 |
| Aiken, JW | 1 |
| Shebuski, RJ | 1 |
| Miller, OV | 1 |
| Gorman, RR | 1 |
| de Gaetano, G | 3 |
| Hayashi, H | 1 |
| Kisamori, K | 1 |
| Kaneko, M | 1 |
| Masumura, Y | 1 |
| Kamikawa, T | 1 |
| Kobayashi, A | 1 |
| Suzuki, Y | 1 |
| Yamazaki, N | 1 |
| Yamaguchi, T | 1 |
| Harris, R | 1 |
| Mehta, J | 6 |
| Stamler, J | 2 |
| Canner, PL | 2 |
| Sharma, GV | 1 |
| Khuri, SF | 1 |
| Josa, M | 2 |
| Folland, ED | 1 |
| Parisi, AF | 1 |
| Cheatham, JP | 1 |
| Kugler, JD | 1 |
| Pinsky, WW | 1 |
| Hofschire, PJ | 1 |
| Zoler, ML | 1 |
| Weber, M | 2 |
| von Schacky, C | 1 |
| Lorenz, R | 2 |
| Meister, W | 1 |
| Kotzur, J | 1 |
| Reichart, B | 1 |
| Theisen, K | 3 |
| Weber, PC | 1 |
| Markiewicz, M | 1 |
| Rymar, B | 1 |
| Florkiewicz, H | 1 |
| Wysokiński, A | 1 |
| Eichner, ER | 1 |
| Dyken, ML | 1 |
| Loeliger, EA | 2 |
| Podell, RN | 1 |
| Campbell, WB | 4 |
| Winniford, MD | 2 |
| Schmitz, J | 1 |
| Apprill, P | 1 |
| Firth, BG | 1 |
| Ashton, J | 1 |
| Smitherman, T | 1 |
| Bush, L | 1 |
| Buja, LM | 5 |
| Ordinas, A | 1 |
| Hodara, M | 1 |
| Lewy, RI | 1 |
| Gitler, B | 1 |
| Gitler, ES | 1 |
| Rehr, RB | 2 |
| Jackson, JA | 1 |
| Khalfen, ESh | 1 |
| Shvarts, IL | 1 |
| Ivanova, IA | 1 |
| Gray, JA | 1 |
| Welsby, PD | 1 |
| Crowley, DC | 1 |
| Dale, J | 1 |
| Myhre, E | 1 |
| Karmazyn, M | 4 |
| Bouchier-Hayes, D | 1 |
| Pagano, T | 1 |
| Nair, CK | 1 |
| Sketch, MH | 1 |
| Jahrmärker, H | 1 |
| Kato, H | 5 |
| Ichinose, E | 2 |
| Shirahata, A | 1 |
| Nakamura, T | 1 |
| Asakura, A | 1 |
| Zukel, WJ | 1 |
| Van Aken, WG | 1 |
| Fisher, LD | 1 |
| Kennedy, JW | 1 |
| Verstraete, M | 7 |
| Polli, EE | 1 |
| Cortellaro, M | 1 |
| Mann, GV | 1 |
| Valles, J | 1 |
| Aznar, J | 1 |
| Santos, MT | 1 |
| Fernandez, MA | 1 |
| Clagett, GP | 1 |
| Rich, NM | 1 |
| McDonald, PT | 1 |
| Salander, JM | 1 |
| Youkey, JR | 1 |
| Olson, DW | 1 |
| Hutton, JE | 1 |
| Black, CA | 1 |
| Bocchini, JA | 1 |
| Everist, J | 1 |
| Diamond, GA | 1 |
| Forrester, JS | 1 |
| Olszańska-Skorek, T | 2 |
| Mazurowa, A | 2 |
| Pełczyńska, I | 2 |
| Chojnowski, K | 2 |
| Hołub, A | 1 |
| Drzewoski, J | 1 |
| Mustard, JF | 2 |
| Packham, MA | 2 |
| Kinlough-Rathbone, RL | 2 |
| White, GL | 1 |
| Marouf, AA | 1 |
| Whisnant, JP | 2 |
| Passamani, ER | 1 |
| Weiss, HJ | 3 |
| May, GS | 1 |
| O'Grady, J | 1 |
| Bunting, S | 1 |
| Moncada, S | 2 |
| Lands, WE | 1 |
| Pitt, BW | 1 |
| Culp, BR | 1 |
| Chesebro, JH | 10 |
| Sirtori, CR | 1 |
| Tremoli, E | 1 |
| Paoletti, R | 1 |
| Jugdutt, BI | 1 |
| Newman, PE | 1 |
| Detre, KM | 1 |
| Ware, J | 1 |
| Mantel, N | 1 |
| Reimers, HJ | 1 |
| Misera, R | 1 |
| Loogen, F | 1 |
| Sloan, RW | 1 |
| Cristol, R | 1 |
| Martinez, TT | 1 |
| Crampton, JM | 1 |
| Castaldi, PA | 1 |
| Frishman, WH | 4 |
| Verdecchia, P | 1 |
| Harbold, NB | 1 |
| Addonizio, VP | 2 |
| Wetstein, L | 1 |
| Fisher, CA | 2 |
| Feldman, P | 1 |
| Strauss, JF | 1 |
| Harken, AH | 2 |
| Folts, JD | 8 |
| Gallagher, K | 1 |
| Rowe, GG | 5 |
| Almazov, VA | 1 |
| Vashkinel', VK | 1 |
| Safronnikov, LV | 1 |
| Lapotnikov, VA | 1 |
| Petrov, MN | 1 |
| Meade, TW | 7 |
| Thompson, SG | 1 |
| Patrono, C | 4 |
| Maseri, A | 3 |
| Pstruzinová, H | 1 |
| Goderová, Z | 1 |
| Kristan, M | 1 |
| Jain, A | 1 |
| Mehrotra, TN | 2 |
| Goel, VK | 1 |
| Mehrotra, ML | 1 |
| Raka, MS | 1 |
| Zabel-Langhennig, R | 1 |
| Ruttmann, B | 1 |
| Schiele, I | 1 |
| Schäfer, W | 1 |
| Aisch, W | 1 |
| Halawa, B | 1 |
| Mazurek, W | 1 |
| Skretkowicz, J | 1 |
| Szumejko, E | 1 |
| Eichelkraut, A | 1 |
| Zdichynec, B | 1 |
| Fritz, ME | 1 |
| Giambonini, S | 1 |
| Jenni, R | 1 |
| D'Apuzzo, V | 1 |
| Coker, SJ | 1 |
| Ledingham, IM | 1 |
| Parratt, JR | 2 |
| Zeitlin, IJ | 1 |
| Baluda, VP | 1 |
| Lakin, KM | 1 |
| Pabvlishchuk, SA | 1 |
| Deianov, I | 1 |
| Nedelkovskiĭ, I | 1 |
| Steele, P | 2 |
| Rainwater, J | 2 |
| Vogel, R | 1 |
| Johnson, GJ | 1 |
| Heckel, R | 1 |
| Leis, LA | 1 |
| Franciosa, J | 1 |
| Kumpuris, AG | 1 |
| Luchi, RJ | 1 |
| Waddell, CC | 1 |
| Miller, RR | 1 |
| Green, LH | 1 |
| Seroppian, E | 1 |
| Handin, RI | 1 |
| Pasternak, RC | 1 |
| Baughman, KL | 1 |
| Fallon, JT | 3 |
| Block, PC | 1 |
| Pepine, CJ | 3 |
| Conti, CR | 3 |
| Teixeira, OH | 1 |
| Martin, L | 1 |
| Carpenter, BF | 1 |
| Sellers, FJ | 1 |
| Ruf, W | 1 |
| McNamara, JJ | 1 |
| Suehiro, A | 1 |
| Suehiro, G | 1 |
| Wickline, SA | 1 |
| Elwood, PC | 2 |
| Sweetnam, PM | 1 |
| Moschos, CB | 5 |
| Haider, B | 2 |
| Escobinas, AJ | 1 |
| Gandhi, A | 1 |
| Regan, TJ | 5 |
| Frye, RL | 2 |
| Elveback, LR | 1 |
| Croveri, G | 1 |
| Lipson, LC | 1 |
| Sheehan, FH | 1 |
| Capurro, NL | 1 |
| Isner, JM | 1 |
| Roberts, WC | 1 |
| Goldstein, RE | 2 |
| Meier, B | 5 |
| Larsson, H | 2 |
| Areskog, M | 2 |
| Areskog, NH | 2 |
| Jonasson, T | 1 |
| Ringqvist, I | 1 |
| Fellenius, C | 1 |
| Sigmon, KN | 2 |
| Joseph, D | 1 |
| Rios, G | 1 |
| Trainor, K | 1 |
| Rose, D | 1 |
| Langford, EJ | 1 |
| Brown, AS | 1 |
| Wainwright, RJ | 1 |
| de Belder, AJ | 1 |
| Thomas, MR | 1 |
| Smith, RE | 1 |
| Radomski, MW | 1 |
| Martin, JF | 1 |
| Moor, E | 1 |
| Hamsten, A | 1 |
| Blombäck, M | 2 |
| Herzfeld, I | 1 |
| Wiman, B | 1 |
| Rydén, L | 1 |
| Falk, RH | 1 |
| Findlay, IN | 1 |
| Oakley, CM | 1 |
| Murray, G | 1 |
| Poole-Wilson, PA | 1 |
| Prentice, CR | 1 |
| Sutton, GC | 2 |
| Shulman, ST | 3 |
| De Inocencio, J | 1 |
| Hirsch, R | 1 |
| Savage, MP | 2 |
| Goldberg, S | 3 |
| Deutsch, E | 4 |
| Vetrovec, G | 3 |
| Macdonald, RG | 3 |
| Bass, T | 2 |
| Margolis, JR | 3 |
| Whitworth, HB | 2 |
| Taussig, A | 2 |
| Lam, JY | 1 |
| Lacoste, L | 1 |
| Letchacovski, G | 1 |
| Morice, MC | 4 |
| Zemour, G | 2 |
| Benveniste, E | 2 |
| Biron, Y | 2 |
| Bourdonnec, C | 1 |
| Faivre, R | 1 |
| Fajadet, J | 3 |
| Gaspard, P | 1 |
| Glatt, B | 2 |
| Joly, P | 1 |
| Mudra, H | 1 |
| Lablache-Combier, B | 2 |
| Ruidavets, JB | 2 |
| Branchu, MP | 2 |
| Richard, JL | 1 |
| Marshall, KG | 1 |
| Rees, MK | 1 |
| McFadden, EP | 2 |
| Bauters, C | 1 |
| Hamon, M | 1 |
| Bertrand, ME | 4 |
| Gould, KL | 1 |
| Casscells, SW | 1 |
| Goff, DC | 1 |
| Haneda, N | 1 |
| Mori, C | 1 |
| Sundel, RP | 1 |
| Newburger, JW | 4 |
| Carney, RM | 1 |
| Freedland, KE | 1 |
| Eisen, SA | 1 |
| Rich, MW | 1 |
| Jaffe, AS | 1 |
| Raskob, GE | 2 |
| Durica, SS | 2 |
| Morrissey, JH | 1 |
| Owen, WL | 1 |
| Comp, PC | 2 |
| Rich-Edwards, JW | 2 |
| Manson, JE | 3 |
| Mehan, VK | 2 |
| Salzmann, C | 1 |
| Kaufmann, U | 1 |
| Eritsland, J | 1 |
| Kierulf, P | 1 |
| Hamer, AW | 1 |
| Brown, MA | 1 |
| Williams, BF | 1 |
| Ormiston, JA | 1 |
| Cross, DB | 1 |
| Follath, F | 1 |
| Moore, WS | 1 |
| Barnett, HJ | 1 |
| Beebe, HG | 1 |
| Bernstein, EF | 1 |
| Brener, BJ | 1 |
| Brott, T | 1 |
| Caplan, LR | 1 |
| Day, A | 1 |
| Goldstone, J | 1 |
| Hobson, RW | 2 |
| Michalowski, AS | 1 |
| Turner, NA | 1 |
| Moake, JL | 1 |
| Kamat, SG | 2 |
| Schafer, AI | 3 |
| Jordan, R | 2 |
| McIntire, LV | 1 |
| Konstantopoulos, K | 1 |
| Bañez, EI | 1 |
| Hellums, JD | 1 |
| Hall, P | 3 |
| Almagor, Y | 1 |
| Maiello, L | 2 |
| Martini, G | 4 |
| Gaglione, A | 2 |
| Goldberg, SL | 1 |
| Tobis, JM | 1 |
| Motz, W | 1 |
| Buchanan, MR | 1 |
| Brister, SJ | 1 |
| Iruela, LM | 1 |
| Bonnier, JJ | 1 |
| Post, D | 1 |
| Gray, RJ | 1 |
| Hall, JH | 1 |
| Kelley, RP | 1 |
| Hua, TA | 1 |
| Lee, RJ | 1 |
| Brack, MJ | 1 |
| Hubner, PJ | 1 |
| Lanza, M | 1 |
| Manca, G | 1 |
| Strata, GB | 1 |
| Maffei, S | 1 |
| Salvatore, L | 1 |
| Furukawa, S | 1 |
| Matsubara, T | 1 |
| Umezawa, Y | 1 |
| Motohashi, T | 1 |
| Ino, T | 1 |
| Yabuta, K | 1 |
| Talley, JD | 2 |
| Kallis, P | 1 |
| Tooze, JA | 1 |
| Talbot, S | 1 |
| Cowans, D | 1 |
| Bevan, DH | 1 |
| Treasure, T | 1 |
| Mulder, BJ | 1 |
| van der Doef, RM | 1 |
| van der Wall, EE | 1 |
| Tijssen, JG | 2 |
| Piek, JJ | 1 |
| van der Meer, J | 1 |
| Dunning, AJ | 1 |
| Woods, SE | 1 |
| Michel, PL | 1 |
| Schweizer, J | 1 |
| Florek, HJ | 1 |
| Bunk, A | 1 |
| Voss, R | 1 |
| Geissler, BS | 1 |
| Tillmanns, H | 2 |
| Matthias, FR | 1 |
| Noble, MI | 1 |
| Drake-Holland, AJ | 1 |
| Hoberg, E | 2 |
| Dietz, R | 1 |
| Frees, U | 1 |
| Katus, HA | 1 |
| Rauch, B | 1 |
| Schwarz, F | 2 |
| Chimowitz, MI | 1 |
| Weiss, DG | 1 |
| Cohen, SL | 1 |
| Starling, MR | 1 |
| Asherson, RA | 1 |
| Cervera, R | 1 |
| Rosendaal, FR | 1 |
| Algra, A | 1 |
| Ranke, C | 2 |
| Creutzig, A | 2 |
| Alexander, K | 2 |
| Tanaka, T | 2 |
| Morishima, Y | 1 |
| Watanabe, K | 1 |
| Shibutani, T | 1 |
| Yasuoka, M | 1 |
| Shibano, T | 1 |
| Desmet, W | 1 |
| Vrolix, M | 2 |
| De Scheerder, I | 1 |
| Van Lierde, J | 1 |
| Willems, JL | 1 |
| Piessens, J | 1 |
| Dhillon, R | 1 |
| Newton, L | 1 |
| Rudd, PT | 1 |
| Hall, SM | 1 |
| Greilich, PE | 1 |
| Carr, ME | 1 |
| Zekert, SL | 1 |
| Dent, RM | 1 |
| Nyman, I | 2 |
| Swahn, E | 1 |
| Juillière, Y | 1 |
| Cherrier, F | 1 |
| Jauhari, J | 1 |
| Berk, SI | 1 |
| Grunwald, A | 1 |
| Pal, S | 1 |
| Bodenheimer, MM | 1 |
| Hebert, PR | 1 |
| Cook, NR | 1 |
| O'Connor, GT | 1 |
| Grabowski, EF | 3 |
| Rodriguez, M | 2 |
| McDonnell, SL | 2 |
| Roux, SP | 1 |
| Tschopp, TB | 1 |
| Kuhn, H | 1 |
| Steiner, B | 1 |
| Hadváry, P | 1 |
| Maraganore, JM | 1 |
| Loscalzo, J | 2 |
| McAllister, A | 1 |
| Eddings, K | 1 |
| George, D | 1 |
| Selwyn, AP | 1 |
| Adelman, B | 1 |
| Fox, I | 1 |
| Klassen, TP | 1 |
| Rowe, PC | 1 |
| Gafni, A | 1 |
| Prager, NA | 1 |
| Torr-Brown, SR | 1 |
| Sobel, BE | 4 |
| Abendschein, DR | 2 |
| Yudkin, JS | 1 |
| Kao, CH | 1 |
| Chen, YC | 1 |
| Wang, YL | 1 |
| Wang, SJ | 1 |
| Yeh, SH | 1 |
| Ott, I | 2 |
| May, A | 2 |
| Mössmer, G | 1 |
| Fernández-Avilés, F | 1 |
| Alonso, JJ | 1 |
| Durán, JM | 1 |
| Gimeno, F | 1 |
| Muñoz, JC | 1 |
| de la Fuente, L | 1 |
| San Román, JA | 1 |
| Serruys, PW | 4 |
| Emanuelsson, H | 3 |
| van der Giessen, W | 1 |
| Lunn, AC | 1 |
| Kiemeney, F | 1 |
| Rutsch, W | 2 |
| Heyndrickx, G | 1 |
| Legrand, V | 4 |
| Goy, JJ | 1 |
| Materne, P | 1 |
| Bonnier, H | 3 |
| Belardi, J | 1 |
| Garcia, E | 1 |
| Ruygrok, P | 1 |
| de Jaegere, P | 1 |
| Morel, MA | 1 |
| Beaughard, M | 1 |
| Brasset, M | 1 |
| John, G | 1 |
| Massingham, R | 1 |
| Schühlen, H | 4 |
| Blasini, R | 4 |
| Hadamitzky, M | 3 |
| Walter, H | 4 |
| Zitzmann-Roth, EM | 2 |
| Richardt, G | 2 |
| Alt, E | 2 |
| Schmitt, C | 3 |
| Ulm, K | 2 |
| Ambrose, J | 1 |
| Rodriguez, S | 1 |
| Palabrica, T | 1 |
| Herrmann, HC | 2 |
| Sutton, JM | 1 |
| McKee, DB | 1 |
| Fitzpatrick, V | 1 |
| Sax, FL | 1 |
| Carney, AJ | 1 |
| Carney, TA | 1 |
| Roth, GJ | 1 |
| Shahar, E | 1 |
| Romm, FJ | 1 |
| Bisgard, KM | 1 |
| Metcalf, PA | 1 |
| Crum, L | 1 |
| McGovern, PG | 1 |
| Hutchinson, RG | 1 |
| Jay, RH | 1 |
| Milani, RV | 1 |
| Lavie, CJ | 1 |
| Roy, PR | 1 |
| Lowe, HC | 1 |
| Walker, BW | 1 |
| Baron, DW | 1 |
| Gavaghan, TP | 1 |
| Morgan, JJ | 1 |
| Maalej, N | 1 |
| Drobinski, G | 1 |
| Thomas, D | 1 |
| Zampieri, P | 1 |
| Aggio, S | 1 |
| Roncon, L | 1 |
| Rinuncini, M | 1 |
| Canova, C | 1 |
| Zanazzi, G | 1 |
| Fiorencis, R | 1 |
| Zonzin, P | 1 |
| Elsman, P | 1 |
| Zijlstra, F | 2 |
| Bowker, TJ | 1 |
| Clayton, TC | 1 |
| Ingham, J | 1 |
| McLennan, NR | 1 |
| Hobson, HL | 1 |
| Pyke, SD | 1 |
| Schofield, B | 1 |
| Wood, DA | 1 |
| Sankardas, MA | 1 |
| McEniery, PT | 1 |
| Aroney, CN | 1 |
| Bett, JH | 1 |
| Lienhart, Y | 1 |
| Valeix, B | 1 |
| Louvard, Y | 1 |
| Lefevre, T | 1 |
| Guérin, Y | 1 |
| Saito, S | 1 |
| Hosokawa, FG | 1 |
| Kim, K | 1 |
| Tanaka, S | 1 |
| Miyake, S | 1 |
| Avins, AL | 1 |
| Browner, WS | 1 |
| Rüdiger, S | 2 |
| Boor, SE | 1 |
| Rodino, LJ | 1 |
| Jang, IK | 2 |
| Gold, H | 1 |
| Andrews, M | 1 |
| Hall, WJ | 1 |
| Moss, AJ | 1 |
| Breddin, HK | 2 |
| Vogel, RA | 1 |
| Stephens, NG | 1 |
| Ludman, PF | 1 |
| Petch, MC | 2 |
| Schofield, PM | 1 |
| Shapiro, LM | 1 |
| Reininger, A | 1 |
| Fatah, K | 1 |
| Beving, H | 1 |
| Albåge, A | 1 |
| Ivert, T | 1 |
| De Lorgeril, M | 2 |
| Salen, P | 2 |
| Martin, JL | 2 |
| Mamelle, N | 2 |
| Monjaud, I | 1 |
| Touboul, P | 1 |
| Delaye, J | 1 |
| Kawachi, I | 1 |
| Sparrow, D | 1 |
| Spiro, A | 1 |
| Vokonas, P | 1 |
| Weiss, ST | 1 |
| Goods, CM | 2 |
| al-Shaibi, KF | 2 |
| Liu, MW | 2 |
| Yadav, JS | 2 |
| Mathur, A | 2 |
| Jain, SP | 1 |
| Dean, LS | 2 |
| Iyer, SS | 2 |
| Parks, JM | 2 |
| Roubin, GS | 3 |
| Julian, DG | 1 |
| Markert, T | 1 |
| Bertsch, G | 1 |
| Langenfeld, H | 1 |
| Aumont, MC | 1 |
| Seknadji, P | 1 |
| Umemura, K | 1 |
| Nishiyama, H | 1 |
| Kikuchi, S | 1 |
| Kondo, K | 1 |
| Nakashima, M | 1 |
| Harpaz, D | 2 |
| Benderly, M | 1 |
| Goldbourt, U | 2 |
| Kishon, Y | 2 |
| Paloncy, R | 1 |
| Moussa, I | 5 |
| Akiyama, T | 1 |
| Tobis, J | 2 |
| Gregorini, L | 2 |
| Marco, J | 2 |
| Bernies, M | 1 |
| Cassagneau, B | 1 |
| Brunel, P | 1 |
| Bossi, IM | 1 |
| Mannucci, PM | 1 |
| Tiecco, F | 1 |
| Di Maggio, M | 1 |
| Dirschinger, J | 3 |
| Hausleiter, J | 1 |
| Mattioli, AV | 1 |
| Haushofer, A | 1 |
| Halbmayer, WM | 1 |
| Prachar, H | 1 |
| Caillat-Vallet, E | 1 |
| Hanauer, MT | 1 |
| Barthelemy, JC | 1 |
| Carrozza, JP | 2 |
| Itoh, A | 1 |
| Blengino, S | 1 |
| Ferraro, M | 2 |
| Galassi, AR | 2 |
| Grassi, R | 2 |
| Monaco, A | 2 |
| Russo, G | 2 |
| Ierna, SM | 1 |
| Calvi, V | 1 |
| Giuffrida, G | 2 |
| Bendet, M | 1 |
| Mahanonda, N | 1 |
| Kangkagate, C | 1 |
| Chaithiraphan, S | 1 |
| Fava, S | 1 |
| Azzopardi, J | 1 |
| Agius-Muscat, H | 1 |
| de Maistre, E | 1 |
| Barragan, P | 1 |
| Pietri, P | 1 |
| Villain, P | 1 |
| Silvestri, M | 1 |
| Roquebert, PO | 1 |
| Cohen, EA | 1 |
| Adelman, AG | 1 |
| Mark, DB | 1 |
| Cho, SY | 2 |
| Jang, YS | 1 |
| Oh, DJ | 1 |
| Oh, BH | 1 |
| Kang, JC | 1 |
| Förster, W | 1 |
| Bashour, TT | 1 |
| Espinosa, E | 1 |
| Blumenthal, J | 1 |
| Wong, T | 1 |
| Mason, DT | 1 |
| Zubaid, M | 1 |
| Penn, IM | 3 |
| Moscovich, MD | 2 |
| Chauhan, A | 2 |
| Hunziker, P | 1 |
| Brown, BG | 3 |
| Zhao, XQ | 1 |
| Bardsley, J | 1 |
| Albers, JJ | 1 |
| Dickfeld, T | 2 |
| Wehinger, A | 1 |
| Duval, N | 1 |
| Grosset, A | 1 |
| O'Connor, SE | 1 |
| Hobson, AG | 1 |
| Sowinski, KM | 1 |
| Herlitz, J | 2 |
| Albertsson, P | 1 |
| Brandrup-Wognsen, G | 1 |
| Haglid, M | 1 |
| Hartford, M | 1 |
| Hjalmarson, A | 2 |
| Karlson, BW | 1 |
| Karlsson, T | 2 |
| Sandén, W | 1 |
| Sinzinger, H | 1 |
| Karanikas, G | 1 |
| Kritz, H | 1 |
| Parmar, R | 1 |
| McCartney, P | 1 |
| Macdowall, W | 1 |
| Thorogood, M | 1 |
| Moses, J | 1 |
| Di Francesco, L | 1 |
| Kleiman, N | 1 |
| Ferguson, JJ | 2 |
| Runyon, JP | 2 |
| Broderick, TM | 1 |
| Higby, NA | 1 |
| Martin, LH | 1 |
| Hantsbarger, G | 1 |
| McDonald, S | 1 |
| Anders, RJ | 2 |
| Iuliano, L | 1 |
| Iullano, L | 1 |
| Kontny, F | 1 |
| Robinson, J | 1 |
| Steely, D | 1 |
| Wheeldon, N | 1 |
| Cumberland, D | 1 |
| Anzuini, A | 2 |
| Tocchi, M | 2 |
| Coppi, R | 2 |
| Marazzi, G | 1 |
| Vicedomini, G | 1 |
| Montorfano, M | 1 |
| Kulbertus, HE | 2 |
| Chierchia, SL | 2 |
| Matsuzaki, K | 1 |
| Okabe, H | 1 |
| Kajihara, N | 1 |
| Haraguchi, N | 1 |
| Nagano, I | 1 |
| Tatewaki, H | 1 |
| Reinhardt, R | 1 |
| Byrne, A | 1 |
| Moran, N | 1 |
| Maher, M | 1 |
| Walsh, N | 1 |
| Crean, P | 1 |
| Sánchez, C | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Sheridan, P | 1 |
| Savege, P | 1 |
| Silverman, S | 1 |
| Piazza, V | 1 |
| Rulli, F | 1 |
| Rutter, MK | 1 |
| Marshall, SM | 1 |
| McComb, JM | 1 |
| Heintzen, MP | 2 |
| Heidland, UE | 2 |
| Klimek, WJ | 2 |
| Michel, CJ | 2 |
| Kelm, M | 2 |
| Leschke, M | 2 |
| Schwartzkopff, B | 2 |
| Vester, EG | 2 |
| Strauer, BE | 2 |
| Machnig, T | 1 |
| Zahn, R | 1 |
| Rustige, J | 1 |
| Gödicke, J | 1 |
| Marsalek, P | 1 |
| Gulba, D | 1 |
| Vu, E | 1 |
| Monkman, S | 1 |
| Tsuchikane, E | 2 |
| Katoh, O | 1 |
| Sumitsuji, S | 1 |
| Fukuhara, A | 2 |
| Funamoto, M | 1 |
| Otsuji, S | 2 |
| Tateyama, H | 2 |
| Awata, N | 2 |
| Kobayashi, T | 3 |
| Velich, T | 1 |
| Hauer, K | 1 |
| Kälberer, B | 1 |
| Bärtsch, P | 1 |
| Bell, MR | 2 |
| Grill, DE | 1 |
| Borkowski, U | 1 |
| Voigtländer, T | 1 |
| Nowak, B | 1 |
| Genth, S | 1 |
| Meyer, J | 2 |
| Kokurina, EV | 1 |
| Suslina, ZA | 1 |
| Khromov, GL | 1 |
| Davydo, AB | 1 |
| Metelitsa, VI | 1 |
| Ionova, VG | 1 |
| Tanashian, MM | 1 |
| Demina, EG | 1 |
| Bochkareva, EV | 1 |
| Belolipetskaia, VG | 1 |
| Deev, AD | 1 |
| Kucheriaeva, NG | 1 |
| Zidra, SI | 1 |
| Gorin, NN | 1 |
| Rumiantsev, DO | 1 |
| Sorrell, VL | 1 |
| Davis, MJ | 1 |
| Rowley, AH | 2 |
| Stoupel, E | 1 |
| Campbell, NC | 2 |
| Thain, J | 2 |
| Deans, HG | 2 |
| Ritchie, LD | 2 |
| Rawles, JM | 2 |
| Casado, S | 1 |
| Oemrawsingh, PV | 1 |
| Tuinenburg, JC | 1 |
| Schalij, MJ | 1 |
| Jukema, JW | 1 |
| Reiber, JH | 1 |
| Bruschke, AV | 1 |
| Schneider, DJ | 2 |
| Tracy, PB | 1 |
| Miller, DP | 1 |
| Aguirre, FV | 1 |
| Anderson, KM | 1 |
| Weisman, HF | 1 |
| Levi, M | 1 |
| Peters, RJ | 2 |
| Büller, HR | 1 |
| Martínez Elbal, L | 1 |
| López Mínguez, JR | 1 |
| Alonso, M | 1 |
| Calvo, I | 1 |
| Insa, L | 1 |
| Lezaun, R | 1 |
| Colman, T | 1 |
| Esplugas, E | 1 |
| Vázquez, N | 1 |
| Picó, F | 1 |
| Amaro, A | 1 |
| Yamasaki, M | 1 |
| Hara, K | 2 |
| Ikari, Y | 2 |
| Kobayashi, N | 1 |
| Kozuma, K | 1 |
| Ohmoto, Y | 1 |
| Oh-Hashi, Y | 1 |
| Nakajima, H | 2 |
| Chiku, N | 1 |
| Saeki, F | 1 |
| Gurfinkel, E | 1 |
| Fareed, J | 1 |
| Antman, E | 1 |
| Mautner, B | 1 |
| Gajdos, M | 1 |
| Spustová, V | 1 |
| Sebeková, K | 1 |
| Krivosiková, Z | 1 |
| Dzúrik, R | 1 |
| Stüsser, R | 1 |
| Batista, J | 1 |
| Padrón, R | 1 |
| Sosa, F | 1 |
| Pereztol, O | 1 |
| Geppert, A | 1 |
| Graf, S | 1 |
| Beckmann, R | 1 |
| Hornykewycz, S | 2 |
| Schuster, E | 1 |
| Binder, BR | 1 |
| Boland, J | 1 |
| Fleck, E | 2 |
| Bonnier, J | 1 |
| Emmanuelson, H | 1 |
| Missault, L | 1 |
| Casaccia, M | 1 |
| Niccoli, L | 1 |
| Oto, A | 1 |
| White, C | 1 |
| Webb-Peploe, M | 1 |
| Madan, M | 2 |
| Marquis, JF | 1 |
| de May, MR | 1 |
| Laramee, LA | 1 |
| Leddy, D | 1 |
| O'Brien, E | 1 |
| Williams, WL | 1 |
| Higginson, LA | 1 |
| Jelley, J | 1 |
| Reid, F | 1 |
| Johansen, H | 1 |
| Labinaz, M | 1 |
| Capron, L | 1 |
| Tisdale, JE | 1 |
| Kendall, MJ | 1 |
| Toescu, V | 1 |
| Nobuyoshi, M | 1 |
| Nakagawa, Y | 1 |
| Kaitani, K | 1 |
| Neugut, AI | 1 |
| Rosenberg, DJ | 1 |
| Ahsan, H | 1 |
| Jacobson, JS | 1 |
| Wahid, N | 1 |
| Hagan, M | 1 |
| Rahman, MI | 1 |
| Khan, ZR | 1 |
| Chen, L | 1 |
| Pablos-Mendez, A | 1 |
| Shea, S | 1 |
| Faergeman, O | 1 |
| Kjekshus, J | 1 |
| Cook, T | 1 |
| Pyörälä, K | 1 |
| Wilhelmsen, L | 1 |
| Thorgeirsson, G | 1 |
| Pedersen, TR | 1 |
| Cairns, JA | 2 |
| Lewis, HD | 4 |
| Ezekowitz, M | 2 |
| Popma, JJ | 5 |
| Weitz, J | 1 |
| Bittl, JA | 1 |
| Kuntz, RE | 4 |
| Lansky, AJ | 3 |
| King, SB | 3 |
| Reifart, N | 1 |
| Störger, H | 1 |
| Rabe, A | 1 |
| Leon, MB | 3 |
| Gordon, PC | 1 |
| Cutlip, DE | 2 |
| Ho, KK | 2 |
| Giambartolomei, A | 1 |
| Diver, DJ | 2 |
| Lasorda, DM | 1 |
| Williams, DO | 1 |
| Pocock, SJ | 1 |
| Speir, E | 1 |
| Yu, ZX | 1 |
| Ferrans, VJ | 1 |
| Casas, AC | 1 |
| Guerci, A | 1 |
| Bahner, U | 1 |
| Heidland, A | 1 |
| McGurk, C | 1 |
| Harper, R | 1 |
| McCance, DR | 1 |
| Gianetti, J | 1 |
| Gensini, G | 1 |
| Ruf, A | 1 |
| Zohlnhöfer, D | 1 |
| Chiamvimonvat, V | 1 |
| Sternberg, L | 1 |
| Graff, E | 1 |
| Hoffmann, MW | 1 |
| Rauhöft, C | 1 |
| Terres, W | 4 |
| Reffelmann, T | 1 |
| vom Dahl, J | 1 |
| Hendriks, F | 1 |
| Klues, HG | 1 |
| Hanrath, P | 1 |
| Astrup, P | 1 |
| Gyntelberg, F | 1 |
| Riggs, PN | 1 |
| DeWeese, JA | 1 |
| Lehmann, KG | 1 |
| Gonzales, E | 1 |
| Tri, BD | 1 |
| Vaziri, ND | 1 |
| Squair, JL | 1 |
| Calver, AL | 2 |
| Dawkins, KD | 2 |
| Gray, HH | 2 |
| Haywood, GA | 1 |
| Morgan, JM | 1 |
| Simpson, IA | 2 |
| McDiarmid, TD | 1 |
| Hensel, WA | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Sheminant, MR | 1 |
| Whitford, EG | 1 |
| Mahon, BD | 1 |
| Newman, MA | 1 |
| Muller, JE | 1 |
| Andrieu, S | 1 |
| Lebret, M | 1 |
| Maclouf, J | 1 |
| Bévérelli, F | 1 |
| Giudicelli, JF | 1 |
| Berdeaux, A | 1 |
| Vuillemenot, A | 1 |
| Schiele, F | 2 |
| Meneveau, N | 1 |
| Claudel, S | 1 |
| Donat, F | 1 |
| Fontecave, S | 1 |
| Cariou, R | 1 |
| Samama, MM | 1 |
| Bassand, JP | 2 |
| Pan, CX | 1 |
| Boal, J | 1 |
| Kwan, T | 1 |
| Feit, A | 1 |
| Alam, M | 1 |
| Afflu, E | 1 |
| Clark, LT | 1 |
| Morrison, CE | 1 |
| McMurray, JJ | 1 |
| Maresta, A | 1 |
| Balducelli, M | 1 |
| Cantini, L | 1 |
| Casari, A | 1 |
| Chioin, R | 1 |
| Fontanelli, A | 1 |
| Monici Preti, PA | 1 |
| Repetto, S | 1 |
| Raffaghello, S | 1 |
| Coller, BS | 2 |
| Turner-Boutle, M | 1 |
| Sheldon, T | 1 |
| Smith, GD | 1 |
| Rihal, CS | 1 |
| Velianou, JL | 1 |
| Sato, N | 1 |
| Sugimura, T | 1 |
| Akagi, T | 1 |
| Yamakawa, R | 1 |
| Hashino, K | 1 |
| Eto, G | 1 |
| Iemura, M | 1 |
| Ishii, M | 1 |
| Ferrer, F | 1 |
| Moraleda, JM | 1 |
| Vicente, V | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| Moses, JW | 3 |
| Branzi, A | 1 |
| Melandri, G | 1 |
| Semprini, F | 1 |
| Descovich, B | 1 |
| Nanni, S | 1 |
| Cervi, V | 1 |
| Morrell, J | 1 |
| Dahlöf, B | 1 |
| Nicosia, A | 1 |
| Reicher-Reiss, H | 1 |
| McCullough, PA | 2 |
| Marks, KR | 1 |
| Moynihan, JL | 1 |
| Al-Mousa, EN | 1 |
| Campsey, M | 1 |
| Gandhi, R | 1 |
| Murphy, S | 1 |
| Mattson, S | 1 |
| Ryan, KA | 1 |
| Mesley, R | 1 |
| Swanson, J | 1 |
| Arshad, MN | 1 |
| Marble, SJ | 1 |
| Mazur, W | 1 |
| Kaluza, G | 1 |
| Marmur, JD | 1 |
| King, TE | 1 |
| De Leon, J | 1 |
| Vidhun, R | 1 |
| Feldman, D | 1 |
| Stoynov, MY | 1 |
| Ambrose, JA | 1 |
| Kirino, M | 1 |
| Yamasaki, K | 1 |
| Izumi, M | 1 |
| Sakurai, M | 1 |
| Holmes, MB | 1 |
| Howard, DB | 1 |
| Hébert, M | 1 |
| Quinn, MW | 1 |
| Dillard, TA | 1 |
| Avidan, MS | 1 |
| Hunt, BJ | 2 |
| Dobson, AJ | 1 |
| McElduff, P | 1 |
| Heller, R | 1 |
| Alexander, H | 1 |
| Colley, P | 1 |
| D'Este, K | 1 |
| Benacerraf, S | 2 |
| Carville, C | 2 |
| Adnot, S | 2 |
| Montagne, O | 1 |
| Sediame, S | 2 |
| Belhassen, L | 2 |
| Dubois-Randé, JL | 2 |
| Williams, B | 1 |
| Johnston, GD | 1 |
| MacGregor, GA | 1 |
| Poston, L | 1 |
| Potter, JF | 1 |
| Poulter, NR | 1 |
| Russell, G | 1 |
| Lee, HJ | 1 |
| Park, HK | 1 |
| Smith, NL | 1 |
| Reiber, GE | 1 |
| Psaty, BM | 1 |
| Heckbert, SR | 1 |
| Siscovick, DS | 1 |
| Ritchie, JL | 2 |
| Every, NR | 1 |
| Koepsell, TD | 1 |
| Jauhar, R | 1 |
| Bergman, G | 1 |
| Savino, S | 1 |
| Shaknovich, A | 1 |
| Parikh, M | 1 |
| Machraoui, A | 2 |
| Germing, A | 2 |
| von Dryander, S | 2 |
| Lange, S | 1 |
| Jäger, D | 1 |
| Lemke, B | 2 |
| Barmeyer, J | 2 |
| Juran, NB | 1 |
| Libersan, D | 1 |
| Quan, E | 1 |
| Merhi, Y | 1 |
| Uzan, A | 1 |
| Laperrière, L | 1 |
| Latour, JG | 1 |
| Quinn, MJ | 1 |
| Wardeh, AJ | 1 |
| Kay, IP | 1 |
| Coen, VL | 1 |
| Gijzel, AL | 1 |
| Ligthart, JM | 1 |
| den Boer, A | 1 |
| Levendag, PC | 1 |
| van Der Giessen, WJ | 3 |
| Tsai, SK | 1 |
| Huang, CH | 1 |
| Huang, SS | 1 |
| Hung, LM | 1 |
| Hong, CY | 1 |
| Tarján, J | 1 |
| Salamon, A | 1 |
| Jáger, R | 1 |
| Poór, F | 1 |
| Barczi, V | 1 |
| Dinnyés, J | 1 |
| Hamvas, J | 1 |
| Kinczel, A | 1 |
| Pál, A | 1 |
| Blaskó, G | 1 |
| Lush, DT | 2 |
| Wurzburger, BJ | 1 |
| Avner, JR | 1 |
| Brookes, CI | 1 |
| Sigwart, U | 3 |
| Fries, JF | 1 |
| Carson, JJ | 1 |
| Salomon, F | 1 |
| Feuring, M | 1 |
| Haseroth, K | 1 |
| Janson, CP | 1 |
| Falkenstein, E | 1 |
| Schmidt, BM | 1 |
| Wehling, M | 1 |
| Yoon, Y | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Jafri, SM | 1 |
| Jafary, FH | 1 |
| Kimmelstiel, CD | 1 |
| Robbins, MA | 1 |
| Marso, SP | 1 |
| Wolski, K | 1 |
| Peterson, J | 1 |
| Brener, S | 1 |
| Flanagan, DE | 1 |
| Cox, P | 1 |
| Paine, D | 1 |
| Davies, J | 1 |
| Armitage, M | 1 |
| Taher, A | 1 |
| Ammash, Z | 1 |
| Dabajah, B | 1 |
| Nasrallah, A | 1 |
| Mourad, FH | 1 |
| Brener, SJ | 1 |
| Fonarow, GC | 1 |
| Gawlinski, A | 1 |
| Stafford, RS | 1 |
| Maruyama, R | 1 |
| Smith, NC | 1 |
| Seyedi, N | 1 |
| Goldstein, MR | 1 |
| Powers, JB | 1 |
| Brooks, L | 1 |
| Kundu, S | 1 |
| Christie, DJ | 2 |
| Del Campo, C | 1 |
| Zelman, R | 1 |
| Bidstrup, BP | 1 |
| Sheikh, S | 1 |
| Parratt, RN | 1 |
| Bidstrup, JM | 1 |
| Sapsford, RN | 1 |
| Asplund, K | 1 |
| Foussas, S | 1 |
| Alexopoulos, D | 1 |
| Olympios, C | 1 |
| Voudris, V | 1 |
| Hatzimiltiadis, S | 1 |
| Sionis, D | 1 |
| Vavouranakis, E | 1 |
| Vrahatis, A | 1 |
| Fakiolas, C | 1 |
| Pissimisis, E | 1 |
| Stefanidis, A | 1 |
| Zairis, M | 1 |
| Pavlides, G | 1 |
| Vitakis, S | 1 |
| Louridas, G | 1 |
| Cokkinos, D | 3 |
| Toutouzas, P | 1 |
| Wong, JT | 1 |
| Nagy, CS | 1 |
| Krinzman, SJ | 1 |
| Maclean, JA | 1 |
| Bloch, KJ | 1 |
| Schenck, J | 1 |
| Müller, CH | 1 |
| Lübbers, H | 1 |
| Mahlke, R | 1 |
| Lehnick, D | 1 |
| Lankisch, PG | 1 |
| Ritzmann, P | 1 |
| Frey, R | 1 |
| Rüttimann, S | 1 |
| Nawarskas, JJ | 1 |
| Spinler, SA | 2 |
| Ezekowitz, MD | 1 |
| Kolansky, DM | 1 |
| Klugherz, BD | 1 |
| Curran, SC | 1 |
| Magness, K | 1 |
| Wilensky, RL | 1 |
| Hirshfeld, JW | 5 |
| Roberts, CS | 1 |
| Wilcox, RG | 2 |
| Berink, P | 1 |
| Lopez-Sendon, J | 1 |
| Toman, J | 1 |
| Alexander, JC | 1 |
| Skene, A | 1 |
| Habler, O | 1 |
| Kleen, M | 1 |
| Pape, A | 1 |
| Meisner, F | 1 |
| Kemming, G | 1 |
| Messmer, K | 1 |
| Kelder, JC | 1 |
| Suttorp, MJ | 2 |
| Mast, EG | 2 |
| Bal, E | 1 |
| Ernst, SM | 1 |
| Plokker, HW | 1 |
| Ajani, UA | 2 |
| Lotufo, PA | 1 |
| Liu, S | 1 |
| Fitzgerald, PJ | 2 |
| Oshima, A | 1 |
| Hayase, M | 1 |
| Metz, JA | 1 |
| Bailey, SR | 1 |
| Cleman, MW | 2 |
| Oesterle, SN | 2 |
| Overlie, PA | 1 |
| Safian, RD | 1 |
| Shani, J | 1 |
| Simonton, CA | 1 |
| Smalling, RW | 1 |
| Teirstein, PS | 2 |
| Zidar, JP | 2 |
| Yock, PG | 1 |
| Gottsauner-Wolf, M | 1 |
| Zasmeta, G | 1 |
| Nikfardjam, M | 1 |
| Stepan, E | 1 |
| Wexberg, P | 1 |
| Zorn, G | 1 |
| Glogar, D | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Ritchie, AJ | 1 |
| Hartshorn, S | 1 |
| Crosbie, AE | 1 |
| Callingham, BA | 1 |
| Latimer, RD | 1 |
| Vuylsteke, A | 1 |
| Ruzyłło, W | 1 |
| Górecka, B | 1 |
| Purzycki, Z | 1 |
| Kośmider, M | 1 |
| Lekston, A | 1 |
| Gasior, M | 1 |
| Zmudka, K | 1 |
| Pieniazek, P | 1 |
| Buszman, P | 1 |
| Drzewiecki, J | 1 |
| Ciećwierz, D | 1 |
| Murugesan, SR | 1 |
| Pothula, A | 1 |
| Lowry, DR | 2 |
| Chadow, HL | 1 |
| Hauptman, RE | 1 |
| VanAuker, M | 1 |
| Rafii, SE | 1 |
| Gunsburg, MY | 1 |
| Giarraffa, L | 1 |
| Strom, JA | 1 |
| Lim, YL | 1 |
| Vandertie, L | 1 |
| Chiu, JK | 1 |
| White, LR | 1 |
| Kaluza, GL | 1 |
| Ali, NM | 1 |
| Fichtlscherer, S | 1 |
| Rosenberger, G | 1 |
| Walter, DH | 1 |
| Breuer, S | 1 |
| Dimmeler, S | 1 |
| Zeiher, AM | 1 |
| Blows, LJ | 1 |
| Harmer, S | 1 |
| Morgan, JH | 1 |
| MacCallum, PK | 1 |
| Brennan, PJ | 4 |
| Albert, MA | 1 |
| Miyamoto, S | 1 |
| Takazoe, K | 1 |
| Kajiwara, I | 1 |
| Sakamoto, T | 1 |
| Yoshimura, M | 1 |
| Kugiyama, K | 1 |
| Yasue, H | 1 |
| Isles, CG | 1 |
| Paterson, JR | 1 |
| Barbour, MM | 1 |
| Peterson, JG | 1 |
| Sapp, SK | 1 |
| Young, JB | 1 |
| Lloyd-Mostyn, R | 1 |
| Shen, YT | 1 |
| Wiedmann, RT | 1 |
| Lynch, JJ | 1 |
| Gould, RJ | 1 |
| Malaviya, AN | 1 |
| Mourou, M | 1 |
| Andrioli, G | 1 |
| Minuz, P | 1 |
| Solero, P | 1 |
| Pincelli, S | 1 |
| Ortolani, R | 1 |
| Lussignoli, S | 1 |
| Bellavite, P | 1 |
| Fry, JA | 1 |
| Silber, S | 1 |
| Krischke, I | 1 |
| Prohaska, M | 1 |
| Dotzer, F | 1 |
| von Welser, N | 1 |
| Araujo, R | 1 |
| Agustí, A | 1 |
| Permanyer Miralda, G | 1 |
| Peter, K | 1 |
| Nordt, T | 1 |
| Müller, I | 1 |
| Wolf, B | 1 |
| Fulton, DR | 1 |
| Ascherio, A | 1 |
| Rimm, EB | 1 |
| Giovannucci, E | 1 |
| Willett, WC | 1 |
| Lanza, GA | 1 |
| Sciahbasi, A | 1 |
| Fischetti, D | 1 |
| Sestito, A | 1 |
| De Cristofaro, R | 1 |
| Cannan, CR | 1 |
| Garnotel, R | 1 |
| Shehadeh, AA | 1 |
| Arena, J | 1 |
| Shechter, M | 1 |
| Merz, CN | 1 |
| Paul-Labrador, M | 1 |
| Meisel, SR | 1 |
| Rude, RK | 1 |
| Molloy, MD | 1 |
| Dwyer, JH | 1 |
| Shah, PK | 1 |
| Kaul, S | 1 |
| Meade , TW | 1 |
| Baum, PK | 1 |
| Verhallen, P | 1 |
| Eisenberg, PR | 1 |
| Sullivan, ME | 1 |
| Light, DR | 1 |
| Yu, H | 1 |
| Rifai, N | 1 |
| Smit, AC | 1 |
| Glazer, S | 1 |
| Lowe, GD | 2 |
| Sanmuganathan, PS | 1 |
| Ghahramani, P | 1 |
| Pache, J | 1 |
| Abizaid, AS | 1 |
| Curry, BH | 1 |
| Paliou, M | 1 |
| Skerrett, PJ | 1 |
| Chew, DP | 1 |
| Sapp, S | 1 |
| Howell, TH | 1 |
| Christen, WG | 1 |
| Musiał, J | 2 |
| Undas, A | 1 |
| Undas, R | 1 |
| Brozek, J | 1 |
| Szczeklik, A | 2 |
| Vass, A | 1 |
| Leng, G | 1 |
| Papacosta, O | 1 |
| Walker, M | 1 |
| Lennon, L | 1 |
| Krumholz, HM | 1 |
| Chen, YT | 1 |
| Radford, MJ | 1 |
| Naber, CK | 1 |
| Kaiser, CA | 1 |
| Rahman, YA | 1 |
| Haude, M | 1 |
| Erbel, R | 2 |
| Baumgart, D | 1 |
| Madan, ZM | 1 |
| Sainani, GS | 1 |
| Cohen, JD | 1 |
| Chauhan, MS | 1 |
| Rodriguez, O | 1 |
| Kuroda, Y | 1 |
| Scheen, AJ | 1 |
| Allen, JK | 1 |
| Blumenthal, RS | 1 |
| Margolis, S | 1 |
| Young, DR | 1 |
| Tanabe, Y | 1 |
| Ito, E | 1 |
| Nakagawa, I | 1 |
| Suzuki, K | 1 |
| Lindstaedt, M | 1 |
| Bojara, W | 1 |
| Lawo, T | 1 |
| Jaeger, D | 1 |
| Grewe, P | 1 |
| Deneke, T | 1 |
| Young, JJ | 1 |
| Shimshak, TM | 1 |
| Nurden, P | 1 |
| Griffo, R | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Walenga, JM | 1 |
| Hoppensteadt, D | 1 |
| Pifarré, R | 1 |
| Fox, NL | 1 |
| Forman, S | 1 |
| Hunninghake, DB | 1 |
| Campeau, L | 1 |
| Herd, JA | 1 |
| Hoogwerf, BJ | 1 |
| Hickey, A | 1 |
| Terrin, ML | 1 |
| Callejas Rubio, JL | 1 |
| López-Haldón, J | 1 |
| Fernández-Moyano, A | 1 |
| García-Núñez, E | 1 |
| Bogaty, P | 1 |
| Nasmith, J | 1 |
| Solymoss, S | 1 |
| Lentini, S | 1 |
| Calvin, JE | 1 |
| Klein, LW | 1 |
| Crossen, K | 1 |
| Scott, RS | 1 |
| McGeoch, GR | 1 |
| George, PM | 1 |
| Catella-Lawson, F | 1 |
| Kapoor, S | 1 |
| Moretti, D | 1 |
| De Marco, S | 1 |
| Vigilante, GJ | 1 |
| Cucchiara, AJ | 1 |
| Combe, S | 1 |
| Rocca, B | 1 |
| Kitai, T | 1 |
| Nishikawa, M | 1 |
| Tanigawa, T | 1 |
| Okinaka, T | 1 |
| Wada, H | 1 |
| Shiku, H | 1 |
| Ikeda, Y | 1 |
| Ito, M | 1 |
| Isaka, N | 1 |
| Nakano, T | 1 |
| Fitzpatrick, MA | 1 |
| Burns, JC | 2 |
| George, BS | 1 |
| Sane, DC | 1 |
| Cines, DB | 1 |
| Jordan, RE | 1 |
| Mascelli, MA | 1 |
| Langrall, MA | 1 |
| Damaraju, L | 1 |
| Schantz, A | 1 |
| Effron, MB | 1 |
| Braden, GA | 1 |
| Liistro, F | 1 |
| Stables, RH | 1 |
| Lewis, BS | 1 |
| Natarajan, MK | 1 |
| Rupprecht, H | 1 |
| Frances, CD | 1 |
| Alperin, P | 1 |
| Adler, JS | 1 |
| Grady, D | 2 |
| Alvarez, JM | 1 |
| Jackson, LR | 1 |
| Chatwin, C | 1 |
| Smolich, JJ | 1 |
| Gum, PA | 1 |
| Thamilarasan, M | 1 |
| Watanabe, J | 1 |
| Blackstone, EH | 1 |
| El-Beyrouty, C | 1 |
| Cummings, CC | 1 |
| Grundy, SM | 1 |
| Piscione, F | 1 |
| Galasso, G | 1 |
| Chiariello, M | 1 |
| Catellier, D | 1 |
| George, PB | 1 |
| Tobin, KJ | 1 |
| Corpus, RA | 1 |
| Devlin, WH | 1 |
| O'Neill, WW | 1 |
| Gheeraert, PJ | 1 |
| Henriques, JP | 1 |
| De Buyzere, ML | 1 |
| De Pauw, M | 1 |
| Taeymans, Y | 1 |
| Batchelor, WB | 1 |
| Mahaffey, KW | 1 |
| Meier, S | 1 |
| Fry, ET | 1 |
| Ross, AM | 1 |
| Binanay, CA | 1 |
| Hall, D | 2 |
| Lanas A, A | 1 |
| Ferrández A, A | 1 |
| L'Allier, PL | 1 |
| Taniuchi, M | 1 |
| Lasala, JM | 1 |
| Ellis, SG | 3 |
| Zhang, D | 1 |
| Shen, W | 1 |
| Reilly, M | 1 |
| Hayden, M | 1 |
| Kernan-Schroeder, D | 1 |
| Cunningham, M | 1 |
| Ray, WA | 1 |
| Stein, CM | 1 |
| Hall, K | 1 |
| Daugherty, JR | 1 |
| Griffin, MR | 1 |
| Sigal, RJ | 1 |
| Montorsi, P | 1 |
| Fabbiocchi, F | 1 |
| Galli, S | 1 |
| Ravagnani, P | 1 |
| Grancini, L | 1 |
| Cozzi, S | 1 |
| Loaldi, A | 1 |
| Pueyo, G | 1 |
| Elosua, R | 1 |
| Donnelly, R | 1 |
| Yeung, JM | 1 |
| Doggrell, SA | 1 |
| Mattila, K | 1 |
| Ristola, M | 1 |
| Repo, H | 1 |
| Asikainen, S | 1 |
| Metsä-Ketelä, T | 1 |
| Dörr, G | 1 |
| Schmidt, G | 1 |
| Gräfe, M | 1 |
| Regitz-Zagrosek, V | 1 |
| Meune, C | 1 |
| Mourad, JJ | 1 |
| Poerner, TC | 1 |
| Kralev, S | 1 |
| Sueselbeck, T | 1 |
| Latsch, A | 1 |
| Pfleger, S | 1 |
| Schumacher, B | 1 |
| Borggrefe, M | 1 |
| Haase, KK | 1 |
| Goolsby, MJ | 1 |
| Maggioni, AP | 2 |
| Lapane, KL | 1 |
| Hughes, CM | 1 |
| Sandercock, P | 2 |
| Warlow, C | 3 |
| Taubes, G | 1 |
| Wainwright, CL | 1 |
| Miller, AM | 1 |
| Work, LM | 1 |
| Del Soldato, P | 1 |
| Knottenbelt, C | 1 |
| Weber, AA | 1 |
| Przytulski, B | 1 |
| Schumacher, M | 1 |
| Gams, E | 1 |
| Schrör, K | 1 |
| Dyke, CK | 1 |
| Hochman, JS | 1 |
| Bovill, EG | 1 |
| Gerstenblith, G | 1 |
| Gardner, LH | 1 |
| Zillman, LA | 1 |
| Shimoto, Y | 1 |
| Robertson, TL | 1 |
| Kunitada, S | 1 |
| Gaspoz, JM | 1 |
| Goldman, PA | 1 |
| Williams, LW | 1 |
| Kuntz, KM | 1 |
| Hunink, MG | 1 |
| Wood, AJ | 1 |
| Di Pasquale, G | 1 |
| Biancoli, S | 1 |
| Cerè, E | 1 |
| Parlangeli, R | 1 |
| Iung, B | 1 |
| Deckers, J | 1 |
| Keil, U | 1 |
| Herrington, D | 1 |
| Bittner, V | 1 |
| Davidson, M | 1 |
| Hlatky, M | 1 |
| Hsia, J | 1 |
| Herd, A | 1 |
| Khan, S | 1 |
| Waters, D | 2 |
| Wenger, N | 1 |
| Altman, R | 1 |
| Luciardi, HL | 1 |
| Muntaner, J | 1 |
| Del Rio, F | 1 |
| Berman, SG | 1 |
| Lopez, R | 1 |
| Gonzalez, C | 1 |
| Haft, JI | 1 |
| Belli, R | 2 |
| Biasci, R | 1 |
| Gaschino, G | 1 |
| Bruna, C | 1 |
| Douglas, AS | 3 |
| Chalmers, TC | 1 |
| Klimt, CR | 1 |
| Bokarev, IN | 3 |
| Ovcinnikova, LV | 1 |
| Aleksandrova, NA | 2 |
| Kabaeva, EV | 1 |
| Marcukova, EV | 1 |
| Kun, IS | 1 |
| Olbinskaja, LI | 1 |
| Atanasov, K | 1 |
| Yovkova, T | 1 |
| Tzvetkova, T | 1 |
| Pick, R | 1 |
| Chediak, J | 3 |
| Glick, G | 1 |
| Jobin, F | 1 |
| Hollander, W | 1 |
| Kirkpatrick, B | 1 |
| Paddock, J | 1 |
| Colombo, M | 1 |
| Nagraj, S | 1 |
| Prusty, S | 1 |
| Boss, GR | 1 |
| Seegmiller, JE | 1 |
| Avellone, G | 1 |
| Mandalà, V | 1 |
| Novo, S | 1 |
| Pinto, A | 1 |
| Riolo, FP | 1 |
| Metke, MP | 1 |
| Lie, JT | 1 |
| Kaye, MP | 1 |
| Didisheim, P | 2 |
| Komarov, FI | 2 |
| Liusov, VA | 2 |
| Jhawar, BK | 1 |
| Trivedi, HH | 1 |
| Bhargava, RK | 1 |
| Misra, NP | 1 |
| Keber, I | 1 |
| Jerse, M | 1 |
| Keber, D | 1 |
| Stegnar, M | 1 |
| Gryglik, J | 1 |
| De Mey, C | 1 |
| Wellens, D | 1 |
| Vanhoutte, PM | 1 |
| Dettori, AG | 1 |
| Pini, M | 1 |
| Quintavalla, R | 1 |
| Gantmacher, ML | 1 |
| Oelz, O | 2 |
| Koike, S | 1 |
| Gleichmann, U | 1 |
| Trieb, G | 1 |
| Oelert, H | 1 |
| Gryglewski, RJ | 1 |
| Grodzińska, L | 1 |
| Serwońska, M | 1 |
| Marcinkiewicz, E | 1 |
| Peto, R | 2 |
| Markvardt, F | 1 |
| Kleking, GP | 1 |
| Horrobin, DF | 1 |
| Oka, M | 1 |
| Manku, MS | 1 |
| Ally, AI | 1 |
| Karmali, RA | 1 |
| Morgan, RO | 1 |
| Cunnane, SC | 1 |
| Armitage, P | 1 |
| Stolarska, B | 1 |
| Skarzyńska, M | 1 |
| Mjøs, OD | 1 |
| Beasci, R | 1 |
| De La Cruz, C | 1 |
| Lyons, MM | 1 |
| Karlson, LK | 1 |
| Rosner, B | 1 |
| Evangelisti, GB | 1 |
| Faggioli, F | 1 |
| Garagnani, A | 1 |
| Lama, G | 1 |
| Linos, A | 1 |
| Worthington, JW | 1 |
| O'Fallon, W | 1 |
| Kurland, LT | 1 |
| Dejana, E | 2 |
| Bonaccorsi, A | 1 |
| Burger, C | 1 |
| Czaplicki, S | 1 |
| Gietka, J | 1 |
| Sułek, K | 1 |
| Harker, LA | 5 |
| Williams, WO | 1 |
| Christodoulou, J | 1 |
| Weksler, B | 1 |
| Smithen, C | 1 |
| Killip, T | 1 |
| Scheidt, S | 1 |
| Broustet, JP | 1 |
| Boisseau, M | 1 |
| Bouloumie, J | 1 |
| Emeriau, JP | 1 |
| Bricaud, H | 1 |
| Storstein, O | 1 |
| Nitter-Hauge, S | 1 |
| Enge, I | 1 |
| Ogletree, ML | 1 |
| Lefer, AM | 2 |
| Monson, RR | 1 |
| Hall, AP | 1 |
| Crowell, EB | 1 |
| Shaper, AG | 1 |
| Danilevicius, Z | 1 |
| Wu, KK | 1 |
| Hoak, JC | 1 |
| Michaels, L | 1 |
| Galbraith, PA | 1 |
| Ledwich, JR | 1 |
| Tzivoni, D | 1 |
| Licht, A | 1 |
| Eliakim, M | 1 |
| Ikematsu, S | 1 |
| Itoh, O | 2 |
| Samori, T | 1 |
| Hosokawa, T | 1 |
| Vaisrub, S | 1 |
| Kordenat, RK | 1 |
| Hornstra, G | 1 |
| ten Hoor, F | 1 |
| Umezawa, T | 1 |
| Matsuo, N | 1 |
| Saji, T | 1 |
| Willard, JE | 1 |
| Dabrowski, M | 1 |
| Trenkwalder, P | 1 |
| Lydtin, H | 1 |
| Weber, R | 1 |
| Manske, CL | 1 |
| Rector, T | 1 |
| Wilson, RF | 1 |
| White, CW | 1 |
| Gupta, KD | 1 |
| Kasliwal, P | 1 |
| Ruchelka, A | 2 |
| Weilepp, A | 2 |
| Kupper, W | 3 |
| Yli-Mäyry, S | 1 |
| Huikuri, HV | 1 |
| Korhonen, UR | 1 |
| Airaksinen, KE | 1 |
| Ikäheimo, MJ | 1 |
| Linnaluoto, MK | 1 |
| Takkunen, JT | 1 |
| Kloner, RA | 1 |
| Webster, MW | 1 |
| Zoldhelyi, P | 1 |
| Roche, PC | 1 |
| Badimon, L | 3 |
| Boldt, J | 1 |
| Knothe, C | 1 |
| Zickmann, B | 1 |
| Herold, C | 1 |
| Dapper, F | 1 |
| Hempelmann, G | 1 |
| Zeitler, H | 1 |
| Rudolph, W | 1 |
| Leivonen, M | 1 |
| Sipponen, P | 1 |
| Kivilaakso, E | 1 |
| Chong, BH | 1 |
| Roderick, PJ | 1 |
| Wilkes, HC | 1 |
| Ganes, S | 1 |
| Adlakha, A | 1 |
| Bechard, DL | 1 |
| Geer, MR | 1 |
| Cella, G | 1 |
| Luzzatto, G | 1 |
| Strauss, WE | 1 |
| Rezkalla, S | 1 |
| Reinhart, R | 1 |
| Goldberg, RJ | 1 |
| Utech, A | 1 |
| Szczepaniec, M | 1 |
| Bauer, U | 1 |
| Sievert, H | 1 |
| van Oppen, J | 1 |
| van Ommen, V | 1 |
| Bär, FW | 1 |
| de Swart, JB | 1 |
| van der Veen, FH | 1 |
| Wellens, HJ | 1 |
| Brezinski, DA | 1 |
| Nesto, RW | 1 |
| Koop, H | 1 |
| Kerins, DM | 1 |
| Gonzalez-Crussi, F | 1 |
| Pierach, CA | 1 |
| Katira, R | 1 |
| Bakhoviddinova, GSh | 1 |
| Rønnevik, PK | 1 |
| Følling, M | 1 |
| Pedersen, D | 1 |
| Rodt, SA | 1 |
| von der Lippe, G | 1 |
| Leblhuber, F | 1 |
| Költringer, P | 1 |
| Reisecker, F | 1 |
| Barron, KS | 2 |
| Norden, C | 2 |
| Reimann, H | 1 |
| Grunow, G | 1 |
| Misselwitz, F | 2 |
| Beisiegel, B | 1 |
| Hafner, G | 1 |
| Pop, T | 1 |
| Treese, N | 1 |
| Ferlito, S | 1 |
| Heyndrickx, GR | 1 |
| Rensing, BJ | 1 |
| Vos, J | 1 |
| Stibbe, J | 1 |
| Taussig, AS | 1 |
| Cowley, M | 2 |
| Lespérance, J | 3 |
| Eastwood, C | 2 |
| Schwartz, L | 3 |
| Côté, G | 1 |
| Kazim, F | 3 |
| Hudon, G | 1 |
| Scheffer, MG | 1 |
| Simoons, ML | 1 |
| Roelandt, JR | 1 |
| Ip, JH | 1 |
| Tizard, EJ | 1 |
| Suzuki, A | 1 |
| Levin, M | 1 |
| Dillon, MJ | 1 |
| Hancock, EW | 1 |
| Taylor, RR | 1 |
| Gibbons, FA | 1 |
| Cope, GD | 1 |
| Cumpston, GN | 1 |
| Mews, GC | 1 |
| Luke, P | 1 |
| Harding, JJ | 1 |
| Johansson, SR | 1 |
| Wiklund, O | 1 |
| Yao, SK | 2 |
| Benedict, CR | 2 |
| Rosolowsky, M | 2 |
| McNatt, J | 1 |
| Falinska, B | 1 |
| Huang, TF | 2 |
| Huang, LL | 1 |
| Force, T | 1 |
| Milani, R | 1 |
| Hibberd, P | 1 |
| Uedelhoven, W | 1 |
| Leaf, A | 1 |
| Weber, P | 1 |
| Vane, JR | 1 |
| Botting, RM | 1 |
| Quyyumi, AA | 1 |
| Held, P | 1 |
| Boudoulas, H | 1 |
| Schatz, RA | 1 |
| Leon, M | 1 |
| Cabin, HS | 1 |
| Walker, C | 1 |
| Stagg, J | 1 |
| O'Keefe, JH | 1 |
| Giorgi, LV | 1 |
| Hartzler, GO | 1 |
| Good, TH | 1 |
| Ligon, RW | 1 |
| Webb, DL | 1 |
| McCallister, BD | 1 |
| Grimme, M | 1 |
| Walter, U | 1 |
| Kochsiek, K | 1 |
| Silagy, CA | 1 |
| McNeil, JJ | 1 |
| Donnan, GA | 1 |
| Worsam, B | 1 |
| Khamidov, NKh | 1 |
| Dodobaeva, MS | 1 |
| Berglund, U | 1 |
| Zhao, X | 1 |
| Zhang, YH | 1 |
| Feng, HF | 1 |
| Knudtson, ML | 1 |
| Flintoft, VF | 1 |
| Roth, DL | 1 |
| Hansen, JL | 1 |
| Duff, HJ | 1 |
| Aoyama, T | 1 |
| Yui, Y | 1 |
| Hattori, R | 1 |
| Kawai, C | 1 |
| Yasuda, T | 2 |
| Gold, HK | 3 |
| Yaoita, H | 1 |
| Leinbach, RC | 2 |
| Guerrero, JL | 2 |
| Holt, R | 1 |
| Collen, D | 2 |
| Markov, KhM | 1 |
| Degré, SG | 1 |
| Fang, ZY | 1 |
| Sobolski, J | 1 |
| Abramowicz, M | 1 |
| Unger, P | 1 |
| Berkenboom, G | 1 |
| Campbell, FW | 1 |
| Tyson, GS | 1 |
| Gravlee, GP | 1 |
| Horrow, JC | 1 |
| Tuman, KJ | 1 |
| Golino, P | 1 |
| NcNatt, JM | 1 |
| De Clerck, F | 1 |
| Schmidt, T | 1 |
| Tebbe, U | 1 |
| Schrader, J | 1 |
| Brune, S | 1 |
| Kreuzer, H | 1 |
| Kretschmer, G | 1 |
| Pratschner, T | 1 |
| Prager, M | 1 |
| Wenzl, E | 1 |
| Polterauer, P | 1 |
| Schemper, M | 1 |
| Ehringer, H | 1 |
| Minar, E | 1 |
| De Meersman, RE | 1 |
| Vine, DL | 1 |
| Clyne, CA | 1 |
| Pirk, J | 1 |
| Rohn, V | 1 |
| Peregrin, J | 1 |
| Meier, PJ | 1 |
| Henderson, MA | 1 |
| Goldberg, SH | 1 |
| Whitworth, H | 1 |
| Cox, RA | 1 |
| Vallbracht, C | 3 |
| Penkov, N | 1 |
| Sirakova, V | 1 |
| Davis, JW | 4 |
| Kouvaras, G | 1 |
| Chronopoulos, G | 1 |
| Soufras, G | 1 |
| Sofronas, G | 1 |
| Solomos, D | 1 |
| Bakirtzis, A | 1 |
| Pissimissis, E | 1 |
| Tzonou, A | 1 |
| Koutts, J | 1 |
| Ricou, F | 1 |
| Nukta, E | 1 |
| Keller, JW | 1 |
| Klein, W | 1 |
| Luha, H | 1 |
| Eber, B | 1 |
| Dusleag, J | 1 |
| Brussee, H | 1 |
| Rotman, B | 1 |
| Taggart, DP | 1 |
| Siddiqui, A | 1 |
| Wheatley, DJ | 1 |
| Arafah, M | 1 |
| Ganassin, L | 1 |
| Miterev, IuG | 1 |
| Kubantseva, IV | 1 |
| Voronina, LN | 1 |
| Solov'eva, TI | 1 |
| Ivanova, AN | 1 |
| Takahashi, M | 2 |
| Beiser, AS | 1 |
| Chung, KJ | 1 |
| Duffy, CE | 1 |
| Glode, MP | 1 |
| Mason, WH | 1 |
| Reddy, V | 1 |
| Sanders, SP | 1 |
| Feigin, RD | 1 |
| Nagashima, M | 1 |
| Matsushima, M | 1 |
| Matsuoka, H | 1 |
| Ogawa, A | 1 |
| Okumura, N | 1 |
| Nieves-Rivera, F | 1 |
| Martin Pumarejo, M | 1 |
| Villavicencio, R | 1 |
| Cox, JL | 1 |
| Gotlieb, AI | 1 |
| Engle, MA | 1 |
| Fatica, NS | 1 |
| Bussel, JB | 1 |
| O'Loughlin, JE | 1 |
| Snyder, MS | 1 |
| Lesser, ML | 1 |
| Oates, JA | 2 |
| Schuster, O | 1 |
| Bleifeld, W | 1 |
| Ito, BR | 1 |
| Roth, DM | 1 |
| Chenoweth, DE | 1 |
| Engler, RL | 1 |
| Paganini-Hill, A | 1 |
| Chao, A | 1 |
| Ross, RK | 1 |
| Henderson, BE | 1 |
| Hartman, CR | 2 |
| Shelton, L | 3 |
| Ruttinger, HA | 2 |
| Burkart, F | 1 |
| Jockers, G | 1 |
| Meyer, B | 1 |
| Regenass, S | 1 |
| Burckhardt, D | 1 |
| Schmitt, HE | 1 |
| Müller-Brand, J | 1 |
| Skarvan, K | 1 |
| Stulz, P | 1 |
| Mahony, C | 1 |
| Al-Mondhiry, H | 1 |
| Pierce, WS | 1 |
| Pennock, JL | 1 |
| Zhao, ZQ | 1 |
| Zang, YM | 1 |
| Zhu, MZ | 1 |
| Zhou, YY | 1 |
| Wu, BW | 1 |
| Zhao, RR | 1 |
| Resnekov, L | 2 |
| Leor, Y | 1 |
| Feldman, S | 1 |
| Rabinowitz, B | 1 |
| Sarris, GE | 1 |
| Mitchell, RS | 1 |
| Billingham, ME | 1 |
| Glasson, JR | 1 |
| Cahill, PD | 1 |
| Miller, DC | 1 |
| Stein, B | 1 |
| Israel, DH | 1 |
| Shalaev, SV | 1 |
| Castaigne, A | 1 |
| Duval-Moulin, AM | 1 |
| Dutoit, C | 1 |
| Schlant, RC | 1 |
| Leung, DY | 1 |
| Heine, H | 1 |
| Gore, JM | 1 |
| Halperin, J | 1 |
| Yeager, RA | 1 |
| Moneta, GL | 1 |
| McConnell, DB | 1 |
| Neuwelt, EA | 1 |
| Taylor, LM | 1 |
| Porter, JM | 1 |
| Alessandri, C | 1 |
| Ghiselli, A | 1 |
| Germani, M | 1 |
| Caliendo, C | 1 |
| Censi, C | 1 |
| Servi, M | 1 |
| Balsano, F | 1 |
| Scudder, LE | 1 |
| Kanke, M | 1 |
| Shealy, D | 1 |
| Ross, MJ | 1 |
| Dehmer, GJ | 2 |
| van den Berg, EK | 2 |
| Eichhorn, EJ | 1 |
| Prewitt, JB | 1 |
| Jennings, L | 1 |
| Schmitz, JM | 2 |
| Borhani, NO | 2 |
| Khimenko, PL | 1 |
| Nikitin, AE | 1 |
| Bélanger, GL | 1 |
| Lavallée, JP | 1 |
| Lenis, J | 1 |
| Ouellet, CA | 1 |
| Tomov, I | 1 |
| Bamford, J | 1 |
| Starkey, I | 1 |
| Gelman, JS | 1 |
| Corbeel, L | 1 |
| Gewillig, M | 1 |
| Baeten, E | 1 |
| Casteels-Van Daele, M | 1 |
| Eggermont, E | 1 |
| Rao, GH | 1 |
| Malloy, CR | 1 |
| Goldberg, RK | 1 |
| Levine, S | 1 |
| Fenster, PE | 1 |
| Miller, KP | 2 |
| Hladovec, J | 1 |
| Weber, MA | 1 |
| Lorenz, RL | 1 |
| Schramm, W | 1 |
| Barnathan, ES | 1 |
| Schwartz, JS | 1 |
| Taylor, L | 1 |
| Laskey, WK | 2 |
| Kleaveland, JP | 1 |
| Kussmaul, WG | 1 |
| Douglas, JS | 1 |
| Bussmann, WD | 1 |
| Austin, GE | 1 |
| Lynn, M | 1 |
| Hollman, J | 1 |
| Zijlstra, FJ | 1 |
| Berk, L | 1 |
| Verdouw, PD | 1 |
| Aldridge, HE | 1 |
| Salvatori, VA | 1 |
| Henderson, M | 1 |
| Bonan, R | 1 |
| David, PR | 1 |
| Vahanian, A | 1 |
| Scheinberg, P | 1 |
| Tsang, V | 1 |
| Jeremy, JY | 1 |
| Walesby, RK | 1 |
| Wright, JC | 1 |
| Dandona, P | 1 |
| Kvantaliani, TG | 1 |
| Mamaladze, GT | 1 |
| Gaprindashvili, TG | 1 |
| Mullane, KM | 1 |
| Fornabaio, D | 1 |
| Sun, M | 1 |
| Steele, PM | 1 |
| Shimizu, Y | 1 |
| Takayama, Y | 1 |
| Hayashi, T | 1 |
| Ito, Y | 1 |
| Abe, M | 1 |
| Matsuda, M | 1 |
| Ida, T | 1 |
| Sakakibara, T | 1 |
| Obunai, Y | 1 |
| Tomaru, T | 1 |
| Sonoki, H | 1 |
| Sugimoto, T | 1 |
| Dubach, P | 1 |
| Savenkov, MP | 1 |
| Küpper, AJ | 1 |
| Galema, TW | 1 |
| Roos, JP | 1 |
| Goodman, DS | 1 |
| DiSciascio, G | 1 |
| Cowley, MJ | 1 |
| Muskett, A | 1 |
| Burton, NA | 1 |
| Eichwald, EJ | 1 |
| Shelby, J | 1 |
| Hendrickson, M | 1 |
| Sullivan, JJ | 1 |
| Xu, YS | 1 |
| Gao, SW | 1 |
| Chen, ZJ | 1 |
| Tao, SQ | 1 |
| Spławińska, B | 1 |
| Spławiński, J | 1 |
| Okuni, M | 2 |
| Harada, K | 2 |
| Yamaguchi, H | 1 |
| Yanagawa, H | 1 |
| Sonobe, T | 1 |
| Kawasaki, T | 1 |
| Ogino, H | 1 |
| Ogawa, M | 1 |
| Harima, Y | 1 |
| Kono, S | 1 |
| Ohkuni, H | 1 |
| Nishida, M | 1 |
| Yabuuchi, H | 1 |
| Klein, RC | 1 |
| Beckman, J | 1 |
| Peake, G | 1 |
| Iwasa, M | 1 |
| Sugiyama, K | 1 |
| Ando, T | 1 |
| Nomura, H | 1 |
| Katoh, T | 1 |
| Wada, Y | 1 |
| Usami, H | 1 |
| O'Konski, MS | 1 |
| White, FC | 1 |
| Longhurst, J | 1 |
| Roth, D | 1 |
| Bloor, CM | 1 |
| Louwerenburg, JW | 1 |
| Herie Kingma, J | 1 |
| Lewis, D | 1 |
| Ekeström, S | 1 |
| Henderson, AH | 1 |
| Jewitt, DE | 1 |
| Sleight, P | 1 |
| Levine, MN | 1 |
| Głab-Kordecka, E | 1 |
| Cerletti, C | 1 |
| Vermylen, J | 1 |
| Maekawa, T | 1 |
| Karwande, SV | 1 |
| Weksler, BB | 2 |
| Gay, WA | 2 |
| Subramanian, VA | 2 |
| Eigenberg, DA | 2 |
| Hignite, CE | 2 |
| Mickelson, JK | 1 |
| Winniford, M | 1 |
| Foster, JW | 1 |
| Stormorken, H | 2 |
| Cukingnan, RA | 1 |
| DeRouen, T | 1 |
| Goede, LV | 1 |
| Fee, HJ | 1 |
| Roth, JA | 1 |
| Carey, JS | 1 |
| Tack-Goldman, K | 1 |
| Gallus, AS | 1 |
| Hassanein, KM | 1 |
| Ogawa, K | 1 |
| Ito, T | 1 |
| Shekelle, RB | 1 |
| Gale, M | 1 |
| Norusis, M | 1 |
| Preston, FE | 1 |
| Greaves, M | 1 |
| Chesebro, JJ | 1 |
| Moffat, MP | 1 |
| Ferrier, GR | 1 |
| Forman, MB | 1 |
| Uderman, H | 1 |
| Jackson, EK | 1 |
| Roy, L | 1 |
| Bostick, D | 1 |
| Robertson, D | 1 |
| Robertson, RM | 1 |
| Jouve, R | 1 |
| Larrue, J | 1 |
| Untereker, WJ | 1 |
| Koren, G | 1 |
| Rose, V | 1 |
| Lavi, S | 1 |
| Rowe, R | 1 |
| Heusch, G | 1 |
| Deussen, A | 1 |
| Thämer, V | 1 |
| Mocchi, N | 1 |
| Sbalzarini, G | 1 |
| Cantaluppi, P | 1 |
| Machado, SG | 1 |
| Krol, WF | 1 |
| Barton, BA | 1 |
| Forbes, CD | 1 |
| Yang, BB | 1 |
| Wood, L | 1 |
| Weser, C | 1 |
| Scheidler, K | 1 |
| Lahiri, K | 2 |
| Lyons, M | 1 |
| Weisse, AB | 1 |
| Oldewurtel, HA | 1 |
| el-Dakhakhny, M | 1 |
| el-Sayed, M | 1 |
| Gormsen, J | 1 |
| Andersen, LA | 1 |
| Hynes, KM | 1 |
| Gau, GT | 1 |
| Rutherford, BD | 1 |
| Kazmier, FJ | 1 |
| McCormick, J | 1 |
| Weily, HS | 1 |
| Steele, PP | 1 |
| Schnetzer, GW | 1 |
| Penner, JA | 1 |
| Frank, MJ | 1 |
| Frank, N | 1 |
| Dziewolska, M | 1 |
| Krug, H | 1 |
| Harkavy, J | 1 |
| Peter, A | 1 |
| Jesrani, MU | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aspirin in Reducing Events in the Elderly[NCT01038583] | 19,114 participants (Actual) | Observational | 2010-01-31 | Active, not recruiting | |||
| Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study[NCT03794336] | Phase 4 | 1,293 participants (Actual) | Interventional | 2019-06-29 | Completed | ||
| Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)[NCT02642419] | Phase 4 | 2,200 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Ischemic And Bleeding Risk Assessment After TAVR (FOCUS ONE Registry)[NCT06000943] | 2,500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-01 | Recruiting | |||
| Research on Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin Based on the Metabolic Enzyme and PK-PD Model[NCT03306550] | 18 participants (Anticipated) | Interventional | 2017-10-10 | Not yet recruiting | |||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| The Impact of Meal Timing on Neurovascular Control in Adults[NCT04133701] | 34 participants (Actual) | Interventional | 2022-02-02 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.[NCT02084615] | 300 participants (Anticipated) | Interventional | 2014-08-31 | Enrolling by invitation | |||
| TAXUS Libertē Post Approval Study: A U.S. Post-Approval Study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System[NCT00997503] | 4,199 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris: Randomised, Double Blind, Placebo Controlled Trial[NCT04270071] | Phase 4 | 80 participants (Anticipated) | Interventional | 2020-12-31 | Not yet recruiting | ||
| Association Between Perioperative Bleeding and Aspirin Use in Spine Surgery: A Randomized, Controlled Trial[NCT02807441] | Phase 3 | 0 participants (Actual) | Interventional | 2016-07-31 | Withdrawn | ||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery in Patients at a High Risk of Cardiac Events[NCT05733208] | 766 participants (Anticipated) | Interventional | 2023-05-06 | Recruiting | |||
| CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation[NCT00007657] | Phase 3 | 3,260 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.[NCT00825604] | Phase 2 | 0 participants (Actual) | Interventional | 2009-01-31 | Withdrawn (stopped due to Because of poor inclusion difficulties to find patient) | ||
| Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status[NCT04475094] | 75 participants (Anticipated) | Observational | 2019-12-23 | Recruiting | |||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566] | Phase 4 | 624 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant[NCT02988115] | Phase 3 | 345 participants (Actual) | Interventional | 2016-11-16 | Completed | ||
| A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea[NCT00528411] | Phase 2 | 123 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study[NCT02597205] | Early Phase 1 | 190 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT00947843] | Phase 4 | 306 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
| Platelet Aggregometry to Drive the Surgical Timing in Elderlies With Hip Fracture and Receiving Clopidogrel.[NCT04642209] | 9 participants (Anticipated) | Observational | 2020-12-01 | Not yet recruiting | |||
| Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease[NCT01014624] | Phase 4 | 56 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Prospective, Multicenter, Blinded, Randomized, Noninferiority Clinical Trial of Coronary Angiography Fractional Flow Reserve (caFFR) Versus Fractional Flow Reserve (FFR) to Guide Percutaneous Coronary Intervention（Flash FFR Ⅱ ）[NCT04575207] | 2,132 participants (Anticipated) | Interventional | 2021-01-12 | Recruiting | |||
| The Impact of Coronary Revascularization on Absolute Myocardial Blood Flow as Assessed by Stress Myocardial Positron Tomography[NCT02931331] | 50 participants (Anticipated) | Observational [Patient Registry] | 2016-03-31 | Enrolling by invitation | |||
| FLOW 3 - The Association Between Catheter-based Absolute Coronary Flow and Resistance and 15O-H2O Positron Emission Tomography Scan-based Absolute Myocardial Blood Flow in the Coronary Artery Territory.[NCT04973410] | 40 participants (Anticipated) | Interventional | 2019-12-01 | Recruiting | |||
| Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI (REFINE PCI)[NCT05491668] | 107 participants (Anticipated) | Observational | 2022-10-11 | Recruiting | |||
| Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal Medical Treatment Versus Optimal Medical Treatment Alone in Patients With Stable Coronary Artery Disease[NCT01132495] | 1,170 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.[NCT02892903] | 1,100 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | |||
| RELATionship bEtween Lesion-level Invasive Fractional Flow Reserve AND Endothelial Wall Shear Stress the RELATE FFR and WSS Study[NCT04048005] | 200 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease (The FAVOR III China Study)[NCT03656848] | 3,847 participants (Actual) | Interventional | 2018-12-25 | Active, not recruiting | |||
| Assessment of NOn-culprit Lesions With dobutamiNe Stress eChocardiography, compUted Tomography and Fractional fLow Reserve in Patients With Acute[NCT03988881] | 100 participants (Anticipated) | Observational | 2017-03-30 | Recruiting | |||
| Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802] | 120 participants (Anticipated) | Interventional | 2014-08-31 | Not yet recruiting | |||
| Prognostic Impact of Fractional Flow Reserve in Chronic Coronary Syndrome: Quasi-Experimental Findings Using a Regression Discontinuity Design[NCT05592535] | 5,000 participants (Actual) | Observational | 2015-06-01 | Completed | |||
| Evaluation of Diagnostic Accuracy, Safety, and Cost-Effectiveness of the Non-Invasive Cardiolens FFR-CT Pro Method to Measure the Fractional Flow Reserve in Diagnostics of Chronic Coronary Syndromes Versus the Standard Diagnostic Modalities. A Multicentre[NCT04777513] | 450 participants (Anticipated) | Observational [Patient Registry] | 2020-08-06 | Recruiting | |||
| Comparison of Dobutamine Stress Echocardiography and Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease: Stable and Non-culprit Lesions Investigation[NCT03383718] | 200 participants (Actual) | Observational | 2014-12-01 | Completed | |||
| A Developmental Clinical Study of Management Guided by Coronary Angiography Combined With Fractional Flow Reserve (FFR) Measurement Versus Management Guided by Coronary Angiography Alone(Standard Care) in Patients With Non-ST Elevation MI.[NCT01764334] | Phase 4 | 350 participants (Actual) | Interventional | 2011-10-31 | Active, not recruiting | ||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131] | Phase 4 | 1,856 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147] | 400 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771] | Phase 4 | 44 participants (Anticipated) | Interventional | 2007-11-30 | Not yet recruiting | ||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| The Nueva Ecija Cardiovascular Risk Experiment: An Evaluation of the Impact of Risk Information and Screening on Primary Prevention of Cardiovascular Disease[NCT03512691] | 5,019 participants (Anticipated) | Interventional | 2018-01-20 | Recruiting | |||
| [NCT00006295] | 370 participants (Anticipated) | Observational | 2000-08-31 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary S[NCT01572129] | Phase 4 | 240 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576] | Phase 3 | 4,497 participants (Actual) | Interventional | 1999-11-01 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease[NCT02359643] | 300 participants (Anticipated) | Interventional | 2013-05-31 | Enrolling by invitation | |||
| The Effect of Serum LDL Lowering on Aspirin Resistance[NCT00466154] | 40 participants | Interventional | 2005-07-31 | Completed | |||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2[NCT03333590] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2017-11-06 | Active, not recruiting | ||
| Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171] | Phase 2/Phase 3 | 150 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Phase III Clinical Trial of the Effectiveness of Adherence Data and Motivational Interviewing to Improve Medication Adherence and Both Glycated Hemoglobin and Cholesterol Control[NCT00754741] | Phase 3 | 1,692 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| [NCT00000482] | Phase 3 | 0 participants | Interventional | 1965-04-30 | Completed | ||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves[NCT02963181] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-03-01 | Terminated (stopped due to PI leaving) | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| [NCT00005442] | 0 participants | Observational | 1994-06-30 | Completed | |||
| [NCT00005216] | 0 participants | Observational | 1988-04-30 | Completed | |||
| French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022] | 300 participants (Anticipated) | Observational [Patient Registry] | 2022-06-15 | Recruiting | |||
| Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809] | Phase 4 | 240 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401] | Phase 3 | 2,399 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615] | 50 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | |||
| Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) An Evaluation of the Metricath Gemini System, a Percutaneous Interventional Device Intended to Make Arterial Lumen Measurements and Perform Percutaneous Transluminal Angioplasty Dilations.[NCT00399646] | Phase 2 | 145 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome[NCT03007524] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003] | Phase 4 | 2,022 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250] | Phase 4 | 800 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [NCT00005182] | 50,000 participants (Actual) | Observational | 1985-12-31 | Completed | |||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293] | 1,505 participants (Actual) | Observational | 2021-07-20 | Completed | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771] | Phase 4 | 64 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Do Innovative Strategies Complement Medical Management to Reduce Cardiovascular Risk Factors Following Coronary Artery Bypass Graft Surgery?[NCT00462436] | Phase 2 | 35 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment[NCT02246101] | 406 participants (Actual) | Observational | 2014-07-31 | Completed | |||
| French Registry of Acute Coronary Syndrome With or Without ST Elevation[NCT00673036] | 3,750 participants (Actual) | Observational | 2005-10-31 | Active, not recruiting | |||
| French Cohort of Myocardial Infarction Evaluation[NCT04050956] | 15,000 participants (Anticipated) | Observational | 2019-03-11 | Recruiting | |||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [NCT00000520] | Phase 2 | 0 participants | Interventional | 1985-07-31 | Completed | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| [NCT00000491] | Phase 3 | 0 participants | Interventional | 1974-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
Cardiac death or myocardial infarction in the TAXUS Liberte Post-Approval Study enrolled population. For pooled data from the TAXUS Liberté and TAXUS Express patient populations, please see the citations. (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Libertē Post-Approval Study Enrolled Population | 2.1 |
"Stent Thrombosis (protocol definition):~The occurrence of any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:~Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion~Acute MI in the distribution of the treated vessel.~Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available." (NCT00997503)
Timeframe: 1-2 years
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Libertē: Overall Enrolled Population | 1.3 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.4 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.7 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.9 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.4 |
- Binary Rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 2.1 |
- Binary Rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.4 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.1 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.1 |
MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke. (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.1 |
"MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 7.8 |
"MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.7 |
"MACCE defined as the composite of cardiac death, myocardial infarction, target vessel revascularization and stroke.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.9 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 7.3 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.3 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.9 |
"MACE defined as the composite of cardiac death, myocardial infarction and target vessel revascularization.~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.1 |
"Major Bleeding defined as the composite of severe or moderate bleeding complication (based upon GUSTO classification).~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.6 |
"Major Bleeding defined as the composite of severe or moderate bleeding complication (based upon GUSTO classification).~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 2.3 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.4 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.0 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 1.0 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.9 |
"ARC - Academic Research Consortium~Binary Rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.8 |
"ARC - Academic Research Consortium~Binary rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.6 |
"-Binary rate~The occurrence of any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:~Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion~Acute MI in the distribution of the treated vessel.~Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available." (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.9 |
"-Binary rate~The occurrence of any of the following:~Clinical presentation of acute coronary syndrome with angiographic evidence of stent thrombosis:~Angiographic documentation of acute complete occlusion (TIMI flow 0 or 1) of a previously successfully treated artery (TIMI flow 2 to 3 immediately after stent placement and diameter stenosis less than or equal to 30%) and/or Angiographic documentation of a flow limiting thrombus within or adjacent to a previously successfully treated lesion~Acute MI in the distribution of the treated vessel.~Death within the first 30 days post index procedure (without other obvious cause) is considered a surrogate for stent thrombosis when angiography is not available." (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.6 |
-Binary Rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.5 |
-Binary Rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 0.4 |
"Target vessel failure is defined as any revascularization of the target vessel, MI (Q- and non-Q wave) related to the target vessel, or death related to the target vessel.~Binary rate" (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 6.4 |
"Target vessel failure is defined as any revascularization of the target vessel, MI (Q- and non-Q wave) related to the target vessel, or death related to the target vessel.~Binary Rate" (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.9 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 5.8 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 3.3 |
-Binary rate (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 4.3 |
-Binary rate (NCT00997503)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| TAXUS Liberté: Overall Enrolled Population | 2.5 |
Target vessel failure (TVF) for TAXUS Libertē Post-Approval Study medically-treated diabetic population. For pooled data from the TAXUS Liberté population, please see the citations (NCT00997503)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Medically Treated Diabetic Population | 6.1 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
PCFB was calculated as the ([post-Baseline (BL) value minus the BL value] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. PCFB in LDL-C was analyzed using analysis of covariance (ANCOVA), with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value. (NCT02988115)
Timeframe: Baseline; Week 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Bempedoic Acid | -22.58 |
| Placebo | -1.17 |
Percent change from Baseline was calculated as the ([post-Baseline value minus the Baseline value] divided by the Baseline value) x 100. Baseline for hsCRP is defined as the last non-missing value on or prior to Day 1. Percent change from Baseline in hsCRP, non-parametric (Wilcoxon rank-sum test) analysis with Hodges-Lehmann estimates and confidence interval was performed. (NCT02988115)
Timeframe: Baseline; Week 12
| Intervention | percent change (Median) |
|---|---|
| Bempedoic Acid | -25.37 |
| Placebo | 2.67 |
PCFB was calculated as the ([post-BL value minus the BL value] divided by the BL value ) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available then that single value was used as BL. PCFB in LDL-C was analyzed using ANCOVA, with treatment group and stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing lipid data at Week 12 who were no longer taking study treatment, missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking study treatment, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value. (NCT02988115)
Timeframe: Baseline; Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Bempedoic Acid | -21.17 |
| Placebo | -2.26 |
Change from Baseline is calculated as the ([post-Baseline value minus the Baseline value] divided by the Baseline value ) x 100. Baseline is defined as the mean of the last two non-missing values on or prior to Day 1. (NCT02988115)
Timeframe: Baseline; Week 12; Week 24
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Week 12 | Week 24 | |
| Bempedoic Acid | -39.3 | -37.0 |
| Placebo | -3.1 | -5.1 |
PCFB was calculated as: ([post-BL value minus the BL value] divided by the BL value) x 100. BL was defined as the mean of the last two non-missing values on or prior to Day 1. If only one value was available, that single value was used as BL. apoB and TC BL were defined as the last non-missing value on/prior to Day 1. PCFB was analyzed using ANCOVA, with treatment and group stratification factor (primary prevention; secondary prevention) as fixed effects and BL as a covariate. For participants with missing data at Week 12 who were no longer taking study treatment (ST), missing values were imputed using multiple imputation via a regression-based model including stratification and BL data from placebo participants only. In this imputation model, treatment group was not included. For participants with missing lipid data at Week 12 who were still taking ST, missing values were imputed using multiple imputation via a regression-based model including treatment, stratification and BL value. (NCT02988115)
Timeframe: Baseline; Week 12
| Intervention | percent change (Least Squares Mean) | ||
|---|---|---|---|
| non-HDL-C | TC | apoB | |
| Bempedoic Acid | -18.08 | -15.37 | -14.65 |
| Placebo | -0.14 | -0.61 | 0.32 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 96.59 |
| Clopidogrel | 96.78 |
| Placebo | 97.58 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 57.96 |
| Clopidogrel | 61.91 |
| Placebo | 59.92 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.71 |
| Placebo | 2.94 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.72 |
| Clopidogrel | 3.73 |
| Placebo | 4.03 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.89 |
| Placebo | 2.91 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.88 |
| Clopidogrel | 2.70 |
| Placebo | 2.50 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 12.92 |
| Clopidogrel | 12.17 |
| Placebo | 12.06 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: Baseline
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 163.34 |
| Clopidogrel | 185.98 |
| Placebo | 145.41 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: Baseline
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 75.01 |
| Clopidogrel | 73.04 |
| Placebo | 73.13 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.94 |
| Clopidogrel | 2.01 |
| Placebo | 1.91 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 14.79 |
| Clopidogrel | 14.15 |
| Placebo | 15.5 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 17.00 |
| Clopidogrel | 17.29 |
| Placebo | 15.83 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.96 |
| Clopidogrel | 0.89 |
| Placebo | 0.89 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.78 |
| Clopidogrel | 5.83 |
| Placebo | 6.10 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.74 |
| Placebo | 2.95 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 74.71 |
| Clopidogrel | 72.84 |
| Placebo | 74.27 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.70 |
| Clopidogrel | 3.78 |
| Placebo | 3.98 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 16.38 |
| Clopidogrel | 16.53 |
| Placebo | 16.09 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 60.70 |
| Clopidogrel | 62.38 |
| Placebo | 60.73 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.67 |
| Placebo | 2.91 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.73 |
| Clopidogrel | 2.79 |
| Placebo | 2.75 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 139.88 |
| Clopidogrel | 214.43 |
| Placebo | 140.68 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 15.21 |
| Clopidogrel | 15.10 |
| Placebo | 14.91 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.88 |
| Clopidogrel | 1.97 |
| Placebo | 1.90 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percentage (Mean) |
|---|---|
| Ticagrelor | 97.73 |
| Clopidogrel | 97.35 |
| Placebo | 98.56 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.70 |
| Clopidogrel | 5.85 |
| Placebo | 5.96 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 13.69 |
| Clopidogrel | 13.14 |
| Placebo | 11.45 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.92 |
| Clopidogrel | 0.93 |
| Placebo | 0.83 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: At 2 hours after first dose of study drug
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 93.15 |
| Clopidogrel | 31.05 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0 hour before last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 74.53 |
| Clopidogrel | 51.75 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0.5 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 45.39 |
| Clopidogrel | 4.71 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 1 hour after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 86.71 |
| Clopidogrel | 15.83 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 120 hours - Day 5 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 21.15 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 168 hours - Day 7 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 6.32 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 2 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 91.49 |
| Clopidogrel | 62.96 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 87.29 |
| Clopidogrel | 49.64 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 55.18 |
| Clopidogrel | 53.91 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 240 hours - Day 10 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 1.64 |
| Clopidogrel | 0.98 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 98.39 |
| Clopidogrel | 40.87 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.10 |
| Clopidogrel | 61.80 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 48 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 30.94 |
| Clopidogrel | 45.79 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 72 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 11.76 |
| Clopidogrel | 21.09 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.99 |
| Clopidogrel | 46.90 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 88.31 |
| Clopidogrel | 61.31 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour. (NCT00528411)
Timeframe: 4 to 72 Hours after last dose of study drug
| Intervention | Percentage/Hour (Least Squares Mean) |
|---|---|
| Ticagrelor | -1.037 |
| Clopidogrel | -0.482 |
Inhibition of platelet aggregation was assessed by Accumetrics VerifyNow® P2Y12 reaction units (PRU). On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. (NCT01014624)
Timeframe: Washout Day 1
| Intervention | percentage (Mean) |
|---|---|
| Prasugrel | 72.3 |
| Clopidogrel | 35.4 |
Time to return to baseline PRU (<= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to return to baseline PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to return to baseline PRU derived from: Number days to return to baseline PRU=-3.350+0.079*PI(1)+0.014*baseline PRU. The predicted number of days to return to baseline based on device-derived platelet percentage inhibition is reported for each treatment group. (NCT01014624)
Timeframe: up to 12 days after the last dose
| Intervention | days (Number) |
|---|---|
| Prasugrel | 6.2 |
| Clopidogrel | 3.7 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participants met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 3 | 5 | 6 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 3 | 5 | 7 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 5 | 5 | 6 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (<=) 20%. (NCT01014624)
Timeframe: up to 12 days after the last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 5 | 6 | 7 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of participants. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | cumulative percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| return to baseline PRU by washout day 1 | return to baseline PRU by washout day 3 | return to baseline PRU by washout day 5 | return to baseline PRU by washout day 6 | return to baseline PRU by washout day 7 | return to baseline PRU by washout day 9 | |
| Clopidogrel | 30.8 | 53.9 | 84.6 | 96.2 | 96.2 | 100.0 |
| Prasugrel | 0 | 3.6 | 37.0 | 62.9 | 77.8 | 100.0 |
On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | cumulative percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| returned to baseline PRU by washout day 1 | returned to baseline PRU by washout day 3 | returned to baseline PRU by washout day 5 | returned to baseline PRU by washout day 6 | returned to baseline PRU by washout day 7 | returned to baseline PRU by washout day 9 | |
| Clopidogrel | 30.8 | 53.9 | 80.8 | 88.5 | 96.2 | 100.0 |
| Prasugrel | 0.0 | 0.0 | 37.0 | 55.6 | 77.8 | 100.0 |
MACE: A composite of all cause death, documented MI, unplanned hospitalization leading to urgent revascularization. (NCT01132495)
Timeframe: 24 Month
| Intervention | percentage of subjects with SAEs (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Non Urgent Revascularization | Death or Myocardial Infarction | Myocardial Infarction | Unplanned Hospitalizations with urgent revasc | Death | Cerebrovascular Event | Other Serious Adverse Event (SAE) | |
| Cohort A - OMT Alone | 32.7 | 12.2 | 9.3 | 13.4 | 3.9 | 1.4 | 0.7 |
| Cohort A - PCI Plus OMT | 6.7 | 9.4 | 6.7 | 1.8 | 3.6 | 2.2 | 0.2 |
Individual components of the primary end point, cardiac death, and nonurgent revascularization (NCT01132495)
Timeframe: 3 years
| Intervention | percentage of subjects (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Overall MACE | Death from any cause | Myocardial infarction | Urgent revascularization | Any revascularization | Nonurgent revascularization | Cardiac death | |
| Cohort A: OMT Alone | 22 | 3.6 | 7.7 | 17.2 | 44.2 | 30.2 | 1.1 |
| Cohort A: PCI Plus OMT | 10.1 | 2.7 | 6.3 | 4.3 | 10.3 | 6.3 | 1.1 |
| Cohort B: Registry Cohort | 12.7 | 3.0 | 6.6 | 6.6 | 14.5 | 9.0 | 1.8 |
Percentage of fibers expressing GALGT2 in each biopsy sample. (NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | Percentage of Positive Fibers (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 1.95 |
| Cohort 2 | 1.72 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | ng/mg total protein (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 12 |
| Cohort 2 | 14.6 |
(NCT03333590)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 0 |
| Cohort 2 | 0 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1) and Day 180 for both cohorts
| Intervention | meters (Number) | |
|---|---|---|
| Day 90 (Cohort 2) /Day 120 (Cohort 1) | Day 180 | |
| Cohort 1 (Minimal Efficacious Dose) | 320 | 324 |
| Cohort 2 (Minimal Efficacious Dose) | 405 | 416 |
The NSAA provides a score between 0 and 34 where higher numbers represent greater muscle function. (NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | score on a scale (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 1 (Minimal Efficacious Dose) | 16 | 14 | 10 | 6 | 2 |
| Cohort 2 | 21 | 23 | 23 | 23 | 23 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | kg (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 90/Day 120-Right Knee Extension | Day 90/Day 120-Right Knee Flexion | Day 90/Day 120- Left Knee Extension | Day 90/Day 120-Left Knee Flexion | Day 180-Right Knee Extension | Day 180-Right Knee Flexion | Day 180-Left Knee Extension | Day 180-Left Knee Flexion | Month 12-Right Knee Extension | Month 12-Right Knee Flexion | Month 12-Left Knee Extension | Month 12-Left Knee Flexion | Month 18-Right Knee Extension | Month 18-Right Knee Flexion | Month 18-Left Knee Extension | Month 18-Left Knee Flexion | Month 24-Right Knee Extension | Month 24-Right Knee Flexion | Month 24-Left Knee Extension | Month 24-Left Knee Flexion | |
| Cohort 1 (Minimal Efficacious Dose) | 7.42 | 6.06 | 8.78 | 6.12 | 7.13 | 6.1 | 8.66 | 6.69 | 7.49 | 5.67 | 7.5 | 5.32 | 4.55 | 6.11 | 4.96 | 6.26 | 5.06 | 4.41 | 6.93 | 4.17 |
| Cohort 2 | 7.04 | 8.12 | 5.9 | 8.4 | 9.73 | 4.24 | 8.19 | 5.25 | 9.85 | 5.85 | 8.02 | 5.12 | 7.67 | 6.89 | 7.34 | 6.08 | 9.81 | 5.04 | 5.21 | 4.87 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | |||
|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | |
| Cohort 1 (Minimal Efficacious Dose) | 98.2 | 110.9 | 144.5 | 167.8 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 2 | 56.1 | 44.9 | 44.7 | 65.6 | 48.4 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 12 months post randomization represented use beginning at 9 months post-randomization and ending at 12 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.70 |
| Adherence Information | 0.69 |
| Adherence Information Plus Motivational Interviewing | 0.69 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 18 months post randomization represented use beginning at 15 months post-randomization and ending at 18 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.70 |
| Adherence Information | 0.70 |
| Adherence Information Plus Motivational Interviewing | 0.70 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 6 months post randomization represented use beginning at 3 months post-randomization and ending at 6 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.70 |
| Adherence Information | 0.69 |
| Adherence Information Plus Motivational Interviewing | 0.69 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 12 months post randomization represented use beginning at 9 months post-randomization and ending at 12 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.75 |
| Adherence Information | 0.74 |
| Adherence Information Plus Motivational Interviewing | 0.74 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 18 months post randomization represented use beginning at 15 months post-randomization and ending at 18 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.75 |
| Adherence Information | 0.73 |
| Adherence Information Plus Motivational Interviewing | 0.73 |
"Adherence is the estimated proportion of the prescribed dose taken over a 3-month period. Therefore, each estimate of medication adherence represented a 3-month window of use prior to and including the endpoint time (e.g., the adherence estimate at 6 months post randomization represented use beginning at 3 months post-randomization and ending at 6 months post-randomization). Pharmacy claims data (i.e., days supply and refill frequency) were used to estimate adherence at each endpoint date." (NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | Adherence - proportion (Mean) |
|---|---|
| Usual Care | 0.75 |
| Adherence Information | 0.74 |
| Adherence Information Plus Motivational Interviewing | 0.74 |
(NCT00754741)
Timeframe: at 24 months post randomization
| Intervention | participants (Number) |
|---|---|
| Usual Care | 63 |
| Adherence Information | 80 |
| Adherence Information Plus Motivational Interviewing | 58 |
(NCT00754741)
Timeframe: at 36 months post randomization
| Intervention | participants (Number) |
|---|---|
| Usual Care | 101 |
| Adherence Information | 112 |
| Adherence Information Plus Motivational Interviewing | 99 |
(NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | Percent (Mean) |
|---|---|
| Usual Care | 7.94 |
| Adherence Information | 7.96 |
| Adherence Information Plus Motivational Interviewing | 7.84 |
(NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | Percent (Mean) |
|---|---|
| Usual Care | 7.88 |
| Adherence Information | 7.91 |
| Adherence Information Plus Motivational Interviewing | 7.79 |
(NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | Percent (Mean) |
|---|---|
| Usual Care | 7.81 |
| Adherence Information | 7.90 |
| Adherence Information Plus Motivational Interviewing | 7.81 |
(NCT00754741)
Timeframe: at 12 months post randomization
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 90.63 |
| Adherence Information | 90.70 |
| Adherence Information Plus Motivational Interviewing | 87.43 |
(NCT00754741)
Timeframe: at 6 months post randomization
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 92.92 |
| Adherence Information | 92.07 |
| Adherence Information Plus Motivational Interviewing | 91.23 |
(NCT00754741)
Timeframe: at 18 months post randomization
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 89.02 |
| Adherence Information | 87.27 |
| Adherence Information Plus Motivational Interviewing | 85.56 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
350 reviews available for aspirin and Coronary Disease
| Article | Year |
|---|---|
Clinical efficacy of aspirin combination treatment in the treatment of coronary heart disease and its effect on inflammatory factors: a systematic review and meta-analysis.
Topics: Aspirin; C-Reactive Protein; Coronary Disease; Humans; Randomized Controlled Trials as Topic; Treatm | 2021 |
Aspirin Use and Risk of Alzheimer's Disease: A 2-Sample Mendelian Randomization Study.
Topics: Alzheimer Disease; Aspirin; Coronary Disease; Genome-Wide Association Study; Humans; Mendelian Rando | 2023 |
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
[Choosing Antithrombotic Therapy in Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus: How to Reduce the Risk of Death].
Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Humans | 2020 |
Delineating phenotypes of Kawasaki disease and SARS-CoV-2-related inflammatory multisystem syndrome: a French study and literature review.
Topics: Adolescent; Aspirin; C-Reactive Protein; Case-Control Studies; Child; Child, Preschool; Coronary Dis | 2021 |
The Effects of Aspirin With Combined Compound Danshen Dropping Pills on Hemorheology and Blood Lipids in Middle-Aged and Elderly Patients With CHD: A Systematic Review and Meta-Analysis.
Topics: Aged; Aspirin; Coronary Disease; Hemorheology; Humans; Lipids; Middle Aged; Salvia miltiorrhiza | 2021 |
Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents: A Meta-Analysis of Randomized Trials.
Topics: Aged; Aspirin; Bayes Theorem; Chi-Square Distribution; Coronary Disease; Coronary Thrombosis; Drug A | 2017 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
Dual antiplatelet therapy after percutaneous coronary intervention for stable CAD or ACS : Redefining the optimal duration of treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; D | 2018 |
Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibit | 2018 |
Antithrombotic Agents.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a | 2019 |
Antithrombotic dose: Some observations from published clinical trials.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Dose-Response Relations | 2019 |
Polypills for primary prevention of cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug Combinations; Huma | 2019 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions | 2013 |
Open and robot-assisted radical retropubic prostatectomy in men receiving ongoing low-dose aspirin medication: revisiting an old paradigm?
Topics: Aged; Anticoagulants; Aspirin; Blood Transfusion; Coronary Disease; Heparin, Low-Molecular-Weight; H | 2014 |
Role of platelet inhibition in microvascular surgery.
Topics: Angina, Unstable; Aspirin; Coronary Disease; Endothelium, Vascular; Free Tissue Flaps; Humans; Plate | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary D | 2014 |
Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Factor VIIa; Humans; Intracranial | 2015 |
Extended Dual Antiplatelet for Diabetic Elderly Patients After Drug-eluting Stent Implantation: an Evidence-based Clinical Review.
Topics: Aged; Aspirin; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Drug-Eluting Ste | 2015 |
Perioperative Management to Reduce Cardiovascular Events.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2016 |
Current antiplatelet therapies: benefits and limitations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Dru | 2008 |
Clinical profile of prasugrel, a novel thienopyridine.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary | 2008 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
Cardiovascular disease prevention tailored for women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste | 2008 |
[Acquired platelet function disorders: pathogenesis, classification, frequency, diagnosis, clinical management].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelet Disorders; Blood Platelets; Coronar | 2008 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
[Bleeding and thromboembolic risk. Perioperative strategy in aspirin/clopidogrel].
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Risk A | 2009 |
The present state of aspirin and clopidogrel resistance.
Topics: Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Disease; Drug Monitoring; Humans; Platelet | 2009 |
[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes].
Topics: Aspirin; Atherosclerosis; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Red | 2007 |
[Perioperative antiplatelet therapy of patients with coronary stents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort S | 2009 |
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
Topics: Aspirin; Attitude to Health; Coronary Disease; Delayed-Action Preparations; Dose-Response Relationsh | 2010 |
Aspirin for primary prevention of cardiovascular events in people with diabetes.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiop | 2010 |
Risk assessment and aspirin use in Asian and Western populations.
Topics: Asia; Aspirin; Coronary Disease; Drug Therapy, Combination; Europe; Female; Humans; Male; Platelet A | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti | 2010 |
Updated recommendations on daily aspirin use in patients with diabetes.
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Diabetes Mellitus; Dose-Response Relationship, | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2011 |
Cigarette smoking inhibits the anti-platelet activity of aspirin in patients with coronary heart disease.
Topics: Aspirin; Coronary Disease; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Smoking | 2011 |
[Antiplatelet therapy after coronary stenting and its importance in total joint arthroplasty].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2012 |
Seeking the optimal aspirin dose in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Endpoint Determination; | 2002 |
Interventional therapy for coronary artery disease.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; B | 2002 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Aspirin in the prophylaxis of coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi | 2002 |
Contemporary antithrombotic strategies in patients undergoing coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic A | 2002 |
[Anticoagulants and antiplatelets].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Heparin; Humans; | 1994 |
Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation.
Topics: Acute Disease; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Electrocardiography; Heparin, | 2002 |
Cardiology Grand Rounds from the University of North Carolina at Chapel Hill. The antioxidant vitamins and coronary heart disease: Part II. Randomized clinical trials.
Topics: Adult; Aged; alpha-Tocopherol; Antioxidants; Aspirin; beta Carotene; Cardiovascular Diseases; Corona | 2003 |
Utility of platelet adp receptor antagonism in the emergency department: a review.
Topics: Aspirin; California; Clopidogrel; Coronary Disease; Critical Care; Drug Utilization; Emergency Servi | 2003 |
[Treatment of coronary insufficiency in diabetics: Part 2: acute coronary insufficiency].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Angiot | 1999 |
[Management of aspirin discontinuation in stable coronary heart disease prior to elective surgery].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Drug | 1999 |
Contemporary view of the acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 2003 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography | 2002 |
[Role of low-molecular-weight heparin in acute coronary syndromes].
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Drug Administration Sche | 2002 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyrid | 2002 |
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2003 |
High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Topics: Arteriosclerosis; Aspirin; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Fi | 2003 |
Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks.
Topics: Angina, Unstable; Aspirin; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Ri | 2003 |
What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Coronary Diseas | 2003 |
Nurse-led interventions contribute to cutting the risks for heart disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Humans; Middle Aged; Outc | 2003 |
Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Di | 2003 |
Review of antithrombotic agents used for acute coronary syndromes in renal patients.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Fib | 2003 |
Antiplatelet treatment in stable coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Interactions; Humans; Platele | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C | 2003 |
Primary prevention of coronary heart disease in the elderly.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypercholestero | 2003 |
Modifiable risk factors for the primary prevention of heart disease in women.
Topics: Activities of Daily Living; Anger; Antioxidants; Anxiety; Aspirin; Attitude to Health; Coronary Dise | 2003 |
Indirect comparison meta-analysis of aspirin therapy after coronary surgery.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Coronary Disease; Graft Occlusion, Vascular; Humans; | 2003 |
Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Comorbidity; Co | 2004 |
Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Therap | 2004 |
[Acute coronary syndrome in patients using acetylsalicylic acid or warfarin].
Topics: Acute Disease; Anticoagulants; Aspirin; Contraindications; Coronary Disease; Fibrinolytic Agents; Hu | 2004 |
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc | 2004 |
[Acute coronary syndromes without ST segment elevation].
Topics: Acute Disease; Adrenergic beta-Antagonists; Analgesics, Opioid; Angina Pectoris; Angiotensin-Convert | 2004 |
Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin.
Topics: Acute Disease; Anticoagulants; Aspirin; Blood Coagulation Disorders; Coronary Disease; Heparin, Low- | 2004 |
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspir | 2004 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; | 2004 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel | 2004 |
Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combinat | 2004 |
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie | 2004 |
Lessons learned from a clinical trial.
Topics: Aspirin; Biomedical Research; Coronary Disease; Drug Therapy, Combination; Drugs, Investigational; H | 2004 |
Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Synergi | 2004 |
Variability in response to aspirin: do we understand the clinical relevance?
Topics: Acute Disease; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials a | 2005 |
Secondary prevention of coronary heart disease in the elderly.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inh | 2005 |
[Antithrombotic therapy of acute coronary syndromes].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2005 |
Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2005 |
Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection.
Topics: Adenosine Diphosphate; Animals; Antigens, CD; Apyrase; Aspirin; Blood Vessels; Cardiotonic Agents; C | 2005 |
What every emergency nurse needs to know about aspirin.
Topics: Aspirin; Colorectal Neoplasms; Coronary Disease; Delayed-Action Preparations; Drug Administration Sc | 2005 |
Long-term benefits of an early invasive management in acute coronary syndromes depend on intracoronary stenting and aggressive antiplatelet treatment: a metaregression.
Topics: Acute Disease; Aged; Aspirin; Chemotherapy, Adjuvant; Coronary Disease; Female; Humans; Male; Meta-A | 2005 |
Aspirin under fire: aspirin use in the primary prevention of coronary heart disease.
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Female; Humans; Male; Meta-Analysis as Topic; | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
Resistance to antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug Tolera | 2005 |
Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2005 |
[Primary prevention of coronary heart disease with aspirin].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Comorbidity; Coronary Di | 2005 |
[Cardiovascular protection and prevention in patients with cardiac conditions and diabetes].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Cardi | 2005 |
Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance.
Topics: Animals; Aspirin; Coronary Disease; Drug Resistance; Heart Failure; Humans; Ischemia; Platelet Aggre | 2006 |
Exercise rehabilitation in heart disease: the real "polypill" for primary and secondary prevention.
Topics: Aspirin; Chronic Disease; Coronary Disease; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; | 2005 |
Is clopidogrel cardiovascular medicine's double-edged sword?
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combination; | 2006 |
Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analys | 2006 |
Surgical, medical, and percutaneous therapies for patients with multivessel coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifi | 2005 |
The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2006 |
[Coronary heart disease in patients with diabetes mellitus].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarke | 2006 |
Clinical applications of antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; D | 2006 |
Prasugrel.
Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase I | 2006 |
Just a spoonful of sugar.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Depression; Drug Monitoring; Electronics; | 2006 |
Coronary artery disease screening, treatment, and follow-up.
Topics: Adult; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Coronary Artery Bypass; Coronary Dise | 2006 |
[Screening and management of coronary artery disease in diabetic patients].
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2006 |
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary Disease; Diabetes | 2007 |
Oral antiplatelet therapy for percutaneous coronary revascularization.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therap | 2007 |
Antiplatelet therapy for primary prevention in diabetes.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diab | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Internati | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinica | 2007 |
The role of aspirin resistance in the treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; | 2008 |
Pharmacogenomics of platelet responsiveness to aspirin.
Topics: Adult; Aspirin; Blood Platelets; Coronary Disease; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Huma | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The | 2008 |
Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Drug Resistance; Humans; Platel | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Antiplatelet drug nonresponsiveness.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Humans; Platelet A | 2008 |
[Conservative treatment of coronary heart disease--current options].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Body Mass Index; Cho | 2005 |
Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical da
Topics: American Heart Association; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Co | 2008 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
Drug therapy of hypertension and ischaemic heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Antihypertensive Agents; Aspirin; Clofibrate; C | 1981 |
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam | 1983 |
Antiplatelet agents: rationale and results.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Aspirin; Blood Plate | 1983 |
[Perspectives of the preventive treatment of patients after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Death, Sudden; Exercise Therapy; Humans; Myo | 1984 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
Chemistry, measurement, and clinical significance of platelet specific proteins.
Topics: Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Coagulation; Blood Coagulation Factors; Blood P | 1982 |
Increased platelet destruction.
Topics: Aspirin; beta-Thromboglobulin; Blood Platelets; Bone Marrow; Cell Membrane; Cell Survival; Chromium | 1982 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Percutaneous transluminal coronary angioplasty.
Topics: Angina, Unstable; Angioplasty, Balloon; Animals; Aspirin; Calcium Channel Blockers; Coronary Artery | 1984 |
Platelets, prostaglandins and thrombotic disorders.
Topics: Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Coronary Disease; Cyclic AMP | 1981 |
Cardiovascular diseases in the elderly.
Topics: Aged; Aging; Amyloidosis; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Car | 1983 |
The biologic background to some therapeutic uses of aspirin.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Carotid Artery Diseases; Coronary Disease; Humans; In | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
Kawasaki disease in Nebraska: a review of the literature.
Topics: Adrenal Cortex Hormones; Aneurysm; Anticoagulants; Aspirin; Blood Sedimentation; Child; Child, Presc | 1983 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
The 'tomato effect' in clinical nutrition. New treatments languishing on the vine?
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Attitude to Health; Cardiovascular Diseases; Child; Colchicin | 1984 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
Efficacy of antiplatelet drugs in the maintenance of aortocoronary vein bypass graft patency.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Diseas | 1983 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
[Critical evaluation of the usefulness of drugs inhibiting platelet function in the prevention of postoperative deep venous thrombosis and in ischemic cardiopathy].
Topics: Anticoagulants; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Flurbiprof | 1980 |
Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Dipyridamole; Sulfinpyrazone; T | 1980 |
Antithrombotic drugs in relation to prostaglandin metabolism.
Topics: Aspirin; Coronary Disease; Dipyridamole; Extracorporeal Circulation; Fibrinolytic Agents; Heparin; H | 1980 |
New strategies in the development of anti-atherosclerotic drugs.
Topics: 4-Aminobenzoic Acid; Animals; Arteriosclerosis; Aspirin; Coronary Disease; Fatty Acids, Nonesterifie | 1980 |
Prostaglandin inhibition and myocardial infarct size.
Topics: Acute Disease; Animals; Aspirin; Coronary Disease; Humans; Ibuprofen; Indomethacin; Models, Biologic | 1981 |
The coronary collateral circulation: determinants and functional significance in ischemic heart disease.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Col | 1981 |
[Platelet antiaggregants and arteriopathies].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyr | 1981 |
Antiplatelet therapy.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dipyridamole; Hea | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Antiplatelet therapy in coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disor | 1982 |
[Platelets and prostaglandins in ischemic cardiopathy. Theoretical and practical aspects and research prospects].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Platelet Aggrega | 1982 |
Current status of platelet inhibitor therapy in coronary artery disease.
Topics: Aspirin; Coronary Disease; Female; Humans; Ischemic Attack, Transient; Male; Myocardial Infarction; | 1982 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
[Blood thinning in heart patients].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Aspirin; Atrial Fibrillation; Clini | 1995 |
Is aspirin safe for patients with heart failure?
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Drug Interactions; Heart | 1995 |
Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Disease; Diagnos | 1995 |
The primary prevention of coronary heart disease in women.
Topics: Antioxidants; Aspirin; Coronary Disease; Estrogen Replacement Therapy; Female; Humans; Risk Factors | 1995 |
Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association.
Topics: Aspirin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Combined Modality Th | 1995 |
Novel antithrombotic approaches to coronary artery disease.
Topics: Antithrombins; Aspirin; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Plasminogen Activato | 1995 |
[Optimal dosage of acetylsalicylic acid in therapy of coronary heart disease].
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans | 1994 |
Principles of platelet inhibitor therapy--where we stood in 1993.
Topics: Animals; Arachidonic Acid; Aspirin; Blood Platelets; Coronary Circulation; Coronary Disease; Endothe | 1994 |
Primary prevention of coronary heart disease in women. Should asymptomatic women 50 years of age take aspirin regularly?
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Disease; Female; Humans; Middle Aged; Women's Health | 1994 |
[Coronary disease: benefits of aspirin. What dose for which disease?].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; | 1994 |
The role of serotonin 5HT2 receptor antagonism in the control of coronary artery disease.
Topics: Aspirin; Coronary Disease; Drug Synergism; Humans; Platelet Aggregation; Serotonin Antagonists; Thro | 1994 |
Cardiac manifestations of the antiphospholipid syndrome.
Topics: Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Disease; H | 1993 |
[Acetylsalicylic acid in arterial circulatory disorders. Which dosage in which indication?].
Topics: Arterial Occlusive Diseases; Aspirin; Blood Circulation; Cerebrovascular Disorders; Coronary Disease | 1994 |
[Complications of coronary angioplasty].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Contrast Media; Coronary Artery Bypass; Coro | 1993 |
[Blood platelet aggregation inhibitors in the treatment of heart diseases].
Topics: Angina, Unstable; Aspirin; Coronary Artery Disease; Coronary Disease; Dipyridamole; Humans; Platelet | 1993 |
How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
Topics: Adult; Aspirin; Blood Pressure; Coronary Disease; Diabetes Mellitus; England; Humans; Hypercholester | 1993 |
Aspirin for primary prevention of coronary disease.
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Risk Assessment | 1995 |
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Coronary Circulatio | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
Pharmacologic prevention of coronary artery disease. What do clinical trials show?
Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Estrogen Replacement Ther | 1996 |
Lowering risk without lowering cholesterol: implications for national cholesterol policy.
Topics: Adult; Antihypertensive Agents; Aspirin; Coronary Disease; Drug Costs; Estrogen Replacement Therapy; | 1996 |
Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Disease | 1996 |
Aspirin and heart disease.
Topics: Aged; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; | 1996 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyp | 1996 |
Stent thrombosis. Closing in on the best preventive treatment.
Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents; | 1997 |
Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Female; Humans; Immunoglobulins, Intravenous; In | 1997 |
[Antiplatelet agents (inhibitors of platelet function) orally administered. Bases for their practical use in coronary artery disease].
Topics: Administration, Oral; Aspirin; Coronary Disease; Dipyridamole; Dose-Response Relationship, Drug; Dru | 1996 |
[Antiplatelet therapy during coronary endoprosthesis placement].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin | 1996 |
The case of low-dose aspirin for the prevention of myocardial infarction: but how low is low?
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Epoprostenol | 1997 |
Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States.
Topics: Aspirin; Cardiology; Coronary Angiography; Coronary Disease; Disease Progression; Humans; Lipids; My | 1997 |
Ticlopidine and aspirin therapy following implantation of coronary artery stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thromb | 1997 |
Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Platel | 1997 |
Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Aspirin; Catheterization; Coronary Disease; Humans; Immuno | 1997 |
Reactivation of the coagulation system: rationale for long-term antithrombotic treatment.
Topics: Anticoagulants; Aspirin; Blood Coagulation Factors; Coronary Disease; Coronary Thrombosis; Drug Ther | 1997 |
Coronary heart disease: an older woman's major health risk.
Topics: Aged; Angina Pectoris; Aspirin; Cholesterol; Coronary Disease; Estrogen Replacement Therapy; Female; | 1997 |
Pharmacologic prevention of acute ischemic complications of coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Constriction, Pathologic | 1997 |
Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical benefits of aspirin?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, C | 1997 |
Risk factors for coronary heart disease in women.
Topics: Aged; Antioxidants; Aspirin; Cholesterol; Contraceptives, Oral; Coronary Disease; Diabetes Mellitus; | 1998 |
Current knowledge and significance of coronary artery ectasia: a chronologic review of the literature, recommendations for treatment, possible etiologies, and future considerations.
Topics: Anticoagulants; Aspirin; Calcium Channel Blockers; Coronary Disease; Coronary Vessels; Dilatation, P | 1998 |
Controversies in Kawasaki syndrome.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Corona | 1997 |
Risk reduction therapies for patients with coronary artery disease: a call for increased implementation.
Topics: Adrenergic beta-Antagonists; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; A | 1998 |
Antiplatelet agents prevent cardiac events in patients with coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Europe; Humans; Japan; Myocardial Infarction; P | 1998 |
[Consensus antithrombotic prophylaxis of vascular incidents in patients with manifest atherosclerotic vascular diseases. Central Guidance Organization for Peer Review].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Coronary | 1998 |
[Thrombosis and coronary disease: neutrophils, nitric oxide and aspirin].
Topics: Aspirin; Coronary Disease; Humans; Neutrophils; Nitric Oxide; Platelet Aggregation Inhibitors; Throm | 1998 |
Acute coronary syndromes: 2. Antiplatelet agents.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
Rationale for the management of coronary syndromes with low-molecular-weight heparins.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-We | 1998 |
[Primary prevention of coronary disease with drugs].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Coronary Disease; Fibrinolytic Agents; H | 1998 |
Antiplatelet therapy in coronary artery disease: review and update of efficacy studies.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Dipyridamole; Humans; Imm | 1998 |
[PTCA for acute coronary syndrome].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Fibrinolytic Agents; Hepar | 1998 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Fibrinolytic Agent | 1998 |
Antithrombotic therapy in patients undergoing coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary | 1998 |
Infectious agents in coronary artery disease: viral infection, aspirin, and gene expression in human coronary smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arteriosclerosis; Aspirin; Coronary Disea | 1998 |
Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Human | 1998 |
Coronary artery disease in women.
Topics: Adult; Age Factors; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Angiotensin-Converting En | 1998 |
Carotid endarterectomy.
Topics: Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Pressure; Car | 1998 |
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials.
Topics: Animals; Aspirin; Clinical Trials as Topic; Coronary Disease; Disease Models, Animal; Dogs; Fibrinol | 1999 |
How to improve the cardiac prognosis for diabetes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1999 |
Current concepts of thrombosis.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Female; Hemostasis; Humans; Platelet Function Tests; | 1994 |
Dosing and administration of ReoPro (c7E3 Fab).
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary | 1994 |
Long-term arterial patency after coronary reperfusion.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Humans; Myocardial Reperf | 1999 |
Definition of high blood pressure, epidemiology and goals of hypertension treatment.
Topics: Antihypertensive Agents; Aspirin; Blood Pressure Determination; Coronary Disease; Europe; Humans; Hy | 1998 |
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Co | 1999 |
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; H | 1999 |
Royal College of Physicians of Edinburgh Consensus Conference on lipid lowering to prevent vascular events 17 & 18 March 1999.
Topics: Adult; Aged; Aspirin; Cholesterol; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis | 1999 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombo | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Di | 1999 |
Anticoagulants in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
Preventing heart disease and cancer. What randomized, primary-prevention studies show.
Topics: Aged; Antineoplastic Agents; Aspirin; Breast Neoplasms; Coronary Disease; Female; Heart Diseases; Hu | 1999 |
Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; | 1999 |
Antiplatelet therapy in interventional cardiology: I. Newer oral antiplatelet agents.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2000 |
Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Aspirin; Bone Marrow Cells; Coronary Disease; Female; Gas | 2000 |
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Enoxaparin; F | 2000 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr | 2000 |
Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Care Facilit | 2000 |
Antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Coronary Disease; Humans; Immunoglobulin Fab Fragments; | 2000 |
Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug | 2000 |
Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; He | 2000 |
Anticoagulation therapy for atrial fibrillation and coronary disease.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Coronary Disease; Drug Thera | 2000 |
Antiplatelet agents in cardiology: the choice of therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; | 2000 |
The role of C-reactive protein in cardiovascular disease risk.
Topics: Arteriosclerosis; Aspirin; Biomarkers; C-Reactive Protein; Coronary Disease; Female; Humans; Male; P | 1999 |
The thienopyridines in coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; | 1999 |
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bezafibrate; Cholesterol; Cholestero | 2000 |
Hormone replacement therapy should not be used as secondary prevention of coronary heart disease.
Topics: Age Factors; Aged; Aspirin; Breast Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrog | 2000 |
Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
Topics: Administration, Oral; Aspirin; Clinical Trials, Phase III as Topic; Coronary Disease; Humans; Oximes | 2000 |
Optimization of platelet therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; C | 2000 |
[Acetylsalicylic acid and acute coronary syndromes: the difficult art of clinical medicine].
Topics: Acute Disease; Aspirin; Coronary Disease; Fibrinolytic Agents; Humans; Syndrome | 2000 |
[Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
Topics: Abciximab; Acute Disease; Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; | 2000 |
Long-term cardiac sequelae of Kawasaki disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Catheterization; Child; Child, Pres | 2000 |
Antithrombotic therapy in cardiac stent patients.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Di | 2001 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal | 2000 |
Antithrombotic agents in coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Embolism; Fibrinolytic Agents; Humans; Platelet | 2001 |
Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Hemorrhage; Humans; Male; Mortality; Myo | 2001 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary | 2001 |
Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease.
Topics: Acute Disease; Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as T | 2000 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifi | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
The use of antiplatelet agents in acute cardiac care.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitor | 2001 |
Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Coronary Disease; Female; Humans | 2001 |
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cilostazol; Coronary Disease; Coronary Restenosis; | 2001 |
[Diabetes and ischemic cardiopathy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Diabetic Angiopathies; Hu | 2001 |
Controversies in heart failure. Are beneficial effects of angiotensin-converting enzyme inhibitors attenuated by aspirin in patients with heart failure?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Comorbidity; Coronary Disease; Cyclooxygenase Inh | 2001 |
[Should coronary patients chronically taking a low-dose of aspirin receive gastroprotective agents?].
Topics: Aspirin; Coronary Disease; Gastrointestinal Diseases; Humans | 2001 |
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Odds | 2002 |
Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.
Topics: Adult; Aged; Aspirin; Chemoprevention; Coronary Disease; Evidence-Based Medicine; Female; Fibrinolyt | 2002 |
Glycemic control and beyond: the ABCs of standards of care for type 2 diabetes and cardiovascular disease.
Topics: Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Exercise; H | 2002 |
[Meta-analysis of the scientific evidence on the usefulness of sporadic intake of acetylsalicylic acid in the prevention of coronary heart disease].
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors | 2002 |
Management of intermittent claudication: the importance of secondary prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Blood Pressure; Coronary Disease; | 2002 |
[Aspirin-ACE inhibitors interaction: myth or reality?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Drug Interactions; Humans; Hype | 2001 |
Clinical practice. Aspirin for primary prevention of coronary events.
Topics: Algorithms; Aspirin; Cholesterol; Contraindications; Coronary Disease; Evidence-Based Medicine; Huma | 2002 |
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events.
Topics: Administration, Oral; Aspirin; Coronary Disease; Death, Sudden, Cardiac; Humans; Myocardial Infarcti | 2002 |
[Oral anticoagulants combined with aspirin in the prolonged treatment after acute coronary syndrome].
Topics: Acute Disease; Administration, Oral; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combin | 2002 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
Acetylsalicylic acid, hemostasis and human thromboembolism.
Topics: Adenosine Monophosphate; Aspirin; Blood Coagulation Tests; Blood Platelets; Cardiac Catheterization; | 1978 |
Hyperuricemia and gout. Classification, complications and management.
Topics: Acute Disease; Allopurinol; Arthritis; Aspirin; Colchicine; Coronary Disease; Diuretics; Gout; Human | 1979 |
Actions and clinical status of platelet-suppressive agents.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Heart Valve Dis | 1978 |
Platelet function inhibitors: their clinical use.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease | 1978 |
Platelet suppressive therapy.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clofibrate; Coro | 1978 |
Cardiac thromboembolism: evidence for role of platelets and value of platelet suppressant therapy.
Topics: Aspirin; Blood Platelets; Cell Survival; Clofibrate; Coronary Disease; Heart Diseases; Heart Valve D | 1978 |
[Pharmacological inhibition of platelet aggregation in primary and secondary prevention of ischemic heart disease].
Topics: Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Platelet Aggregation | 1979 |
Physiopathology and pharmacotherapy of occlusive arterial disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Platelets; Blood Viscosity; Cerebrovas | 1979 |
Antiplatelet drugs in thromboembolism.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Drug Therapy, Combination; | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
[Treatment with antiplatelet drugs. Current status of knowledge].
Topics: Aspirin; Blood Platelet Disorders; Cerebrovascular Disorders; Clofibrate; Coronary Disease; Dextrans | 1979 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
Antiplatelet agents: a review.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clofi | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
The use of aspirin in ischemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Myocardial Revascularizat | 1992 |
[Prevention of complications and the methods of increasing the safety of percutaneous transluminal coronary angioplasty (PTCA)].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Disease; Extracorporeal Circulati | 1992 |
[Therapeutic possibilities, respective implications in silent ischemia].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Coronary Artery Byp | 1992 |
Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins.
Topics: Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Lipid Metabolism; | 1992 |
Percutaneous coronary intervention in the 1990s. Results in patients with single or multivessel disease.
Topics: Angioplasty, Balloon, Coronary; Angioplasty, Laser; Aspirin; Clinical Trials as Topic; Coronary Dise | 1992 |
Prophylactic aspirin and the elderly population.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Male; Middle Aged; Myoca | 1992 |
The current role of platelet-active drugs in ischaemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1991 |
Kawasaki syndrome.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Drug Therapy, Combination; Female; gamma-Globuli | 1991 |
Risk factors, interventions and therapeutic agents in the prevention of atherosclerosis-related ischaemic diseases.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Humans; Male; Myocardial Infarction; Platelet Ag | 1991 |
Coronary artery disease. The latest on prevention.
Topics: Animals; Antioxidants; Aspirin; Body Weight; Coronary Disease; Estrogens; Exercise; Fish Oils; Human | 1992 |
Kawasaki disease. Epidemiology, late prognosis, and therapy.
Topics: Aspirin; Coronary Disease; Humans; Immunization, Passive; Mucocutaneous Lymph Node Syndrome; Prognos | 1991 |
[Platelet antiaggregants in the treatment of arterial thrombosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cerebrovascular Disorders; Coronary Artery | 1991 |
The porcine model for the understanding of thrombogenesis and atherogenesis.
Topics: Angioplasty, Balloon, Coronary; Animals; Aorta; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary | 1991 |
An apple a day or an aspirin a day?
Topics: Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Administration Schedule; Female; Hum | 1991 |
Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin.
Topics: Angina, Unstable; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Thrombosis; Humans; | 1990 |
[Pharmacological correction of disorders of the prostacyclin- thromboxane balance in ischemic heart disease: problems and prospects].
Topics: Aspirin; Coronary Disease; Epoprostenol; Humans; Thrombosis; Thromboxane A2; Thromboxane-A Synthase | 1990 |
Aspirin and exercise as a prophylaxis for heart disease. Is it safe?
Topics: Aspirin; Coronary Disease; Exercise Therapy; Humans | 1990 |
Aspirin and dipyridamole and their limitations in the therapy of coronary artery disease.
Topics: Animals; Aspirin; Coronary Disease; Coronary Thrombosis; Dipyridamole; Dogs; Drug Therapy, Combinati | 1990 |
Antithrombotic therapy in the primary and secondary prevention of coronary-related death and infarction: focus on gender differences.
Topics: Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Humans; Male; Myocardial Inf | 1990 |
[Aspirin in ischemic heart disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Po | 1990 |
Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Incidence; Randomized Controlled Trial | 1990 |
Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Cyclooxygenase Inhibitors | 1988 |
The Jeremiah Metzger lecture. Participation of eicosanoids in the syndromes of myocardial ischemia.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoids; Humans; Myocardial Infar | 1990 |
Coronary thrombolysis and the new biology.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Mutation; Platelet | 1989 |
Aspirin in the prevention of catastrophes of the coronary circulation.
Topics: Aspirin; Coronary Circulation; Coronary Disease; Death, Sudden; Humans | 1989 |
Antithrombotic agents in coronary artery disease.
Topics: Angina Pectoris; Anticoagulants; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet | 1989 |
[Aspirin in coronary heart disease].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Aspirin in myocardial ischemia: why, when, and how much?
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
Platelet inhibitor agents in cardiovascular disease: an update.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Graf | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
[Platelet antiaggregants and coronary pathology].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Coronar | 1989 |
Prevention of restenosis after coronary angioplasty: a pharmacological approach.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical | 1989 |
Clinical and immunologic aspects of Kawasaki disease.
Topics: Aspirin; Child, Preschool; Coronary Disease; Endothelium, Vascular; Humans; Immune System; Immunizat | 1989 |
Large vessel coronary vasospasm: diagnosis, natural history and treatment.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aspirin; Coronary Artery Bypass; Coronary | 1985 |
Secondary prevention of coronary events after myocardial infarction. Beta-blockers and/or anti-platelets: to whom, when and for how long. A review.
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myoca | 1985 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: the basis of their use, data from animal studies, clinical trial data, and current recommendations.
Topics: Angioplasty, Balloon; Animals; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Coronar | 1986 |
Influence of the methodology of percutaneous transluminal coronary angioplasty on restenosis.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Coronary Thrombosis; Huma | 1987 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
Controversies in the management of cerebral vascular disease.
Topics: Aspirin; Atrial Fibrillation; Carotid Arteries; Carotid Artery Diseases; Cerebrovascular Disorders; | 1988 |
A contemporary overview of ischaemic heart disease and anti-platelet therapy.
Topics: Aspirin; Coronary Disease; Dipyridamole; Female; Humans; Male; Platelet Aggregation Inhibitors | 1988 |
Antiplatelet therapy for ischemic heart disease in the elderly.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Disease; Humans; Myocardial Infarction; Platelet Agg | 1988 |
[Acetylsalicylic acid therapy in vascular diseases].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary | 1988 |
The role of arachidonic acid metabolites in cardiovascular homeostasis. Biochemical, histological and clinical cardiovascular effects of non-steroidal anti-inflammatory drugs and their interactions with cardiovascular drugs.
Topics: Arteriosclerosis; Aspirin; Coronary Disease; Eicosanoic Acids; Heart Valve Prosthesis; Homeostasis; | 1987 |
Thrombosis in unstable angina: angiographic aspects.
Topics: Angina Pectoris; Angina, Unstable; Angiography; Arteries; Aspirin; Coronary Circulation; Coronary Di | 1987 |
[Platelet and coronary disease].
Topics: Animals; Aspirin; Blood Platelet Disorders; Coronary Artery Disease; Coronary Disease; Humans | 1987 |
[Pharmacological prevention of coronary thrombosis].
Topics: Aspirin; Blood Coagulation; Coronary Disease; Coronary Thrombosis; Humans; Recurrence | 1987 |
[Primary prevention of intermittent claudication and frequently associated arteriopathies].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Coronary Disease; Diet; Humans; Hypercholesterolemia; Hyp | 1987 |
Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregati | 1987 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Current issues in thrombosis prevention with antiplatelet drugs.
Topics: Aspirin; Cell Division; Coronary Artery Bypass; Coronary Disease; Endothelium; Epoprostenol; Fibrin; | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
[Antiplatelet therapy of thrombosis].
Topics: Animals; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Postoperative Complications; | 1986 |
Aspirin and other platelet-aggregation inhibiting drugs.
Topics: Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Female; Heart Valv | 1985 |
[Analogs of prostaglandin-related substances and inhibitors of their synthesis and metabolism. Clinical application: cardiovascular diseases].
Topics: Angina Pectoris; Aspirin; Coronary Disease; Epoprostenol; Humans; Hypertension; Methacrylates; Myoca | 1985 |
Platelet suppressive therapy in clinical medicine.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Female; Heart Valve Prosthesi | 1985 |
Aortocoronary artery vein-graft disease: experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors.
Topics: Animals; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dogs; Gra | 1985 |
Management of thrombotic diseases.
Topics: Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Cerebrovascular Disorders; Coronary Dis | 1971 |
Platelets, thrombosis and coronary artery disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Blood Protein Disorders; Cell Survival; Coronary Disease | 1973 |
Cardiac manifestations due to hypersensitivity.
Topics: Adams-Stokes Syndrome; Anaphylaxis; Angina Pectoris; Antigen-Antibody Complex; Arrhythmias, Cardiac; | 1970 |
376 trials available for aspirin and Coronary Disease
| Article | Year |
|---|---|
Prognostic Value of a Polygenic Risk Score for Coronary Heart Disease in Individuals Aged 70 Years and Older.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Female; Humans; Male; Prognosis; Prospect | 2022 |
Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomi
Topics: Acarbose; Adult; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated | 2022 |
The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypertension; Lipids; Platel | 2022 |
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease.
Topics: Aged; Aspirin; Atrial Fibrillation; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combinat | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
Ticagrelor with or without Aspirin in High-Risk Patients after PCI.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; | 2019 |
The impact of acetylsalicylic acid dosed at bedtime on circadian rhythms of blood pressure in the high-risk group of cardiovascular patients-a randomized, controlled trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Circadian Rhythm; Coronary Disease; Drug Adm | 2021 |
Drug-drug interactions between salvianolate injection and aspirin based on their metabolic enzymes.
Topics: Aged; Aspirin; Beijing; Biotransformation; Catechol O-Methyltransferase; Coronary Disease; Drug Inte | 2021 |
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
Topics: Aged; Aspirin; Coronary Disease; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Dura | 2021 |
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and
Topics: Aged; Antineoplastic Agents; Apolipoprotein A-I; Aspirin; Cardiovascular Diseases; Cholesterol, HDL; | 2017 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fe | 2018 |
Comparison of Outcomes and Costs Associated With Aspirin ± Clopidogrel After Coronary Artery Bypass Grafting.
Topics: Aged; Aspirin; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Disease; Costs and Cost An | 2018 |
Research on the mechanism of drug-drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK-PD model: study protocol for a PK-PD trial.
Topics: Administration, Oral; Adult; Aged; Aspirin; Carboxylic Ester Hydrolases; Catechol O-Methyltransferas | 2018 |
Aspirin increases nitric oxide formation in chronic stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Aspirin; Biomarkers; Car | 2013 |
[Potential utility of optic aggregometry for identification of patients with coronary heart disease resistant to acetylsalicylic acid].
Topics: Acute Disease; Adult; Angina Pectoris; Aspirin; Coronary Disease; Drug Resistance; Female; Humans; M | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
[Effect of aspirin plus clopidogrel therapy on aspirin resistance after off-pump coronary artery bypass surgery].
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combin | 2013 |
Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications.
Topics: Age Factors; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation; Chi | 2014 |
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.
Topics: Aged; Anticholesteremic Agents; Aspirin; Azetidines; Cell-Derived Microparticles; Cholesterol, LDL; | 2014 |
Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2015 |
Decreased vascular endothelial growth factor expression is associated with cell apoptosis in low-dose aspirin-induced gastric mucosal injury.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Coronary Disea | 2015 |
Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling.
Topics: Aged; Aspirin; Biomarkers; Coronary Disease; Docosahexaenoic Acids; Drug Combinations; Eicosapentaen | 2016 |
[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
Topics: Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; | 2016 |
[Bleeding control of periodontal mechanical therapy for patients taking aspirin].
Topics: Aspirin; Chronic Periodontitis; Contraindications; Coronary Disease; Dental Scaling; Hemorrhage; Hem | 2017 |
Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Cross-O | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Serum urate predicts long-term risk of acute coronary events in women after a transient ischaemic attack and stroke.
Topics: Acute Disease; Aged; Aspirin; Biomarkers; Coronary Disease; Female; Humans; Ischemic Attack, Transie | 2008 |
[Intervening effect of naoxintong on anti-platelet treatment with aspirin].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Coronary Disease; Drug Therapy, Combinatio | 2008 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Double-B | 2009 |
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Dru | 2009 |
Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; Cross-Over Studies; Female; Fibr | 2009 |
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Factors responsible for "aspirin resistance" - can we identify them?
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Ag | 2010 |
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart | 2010 |
Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
Topics: Aspirin; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Humans; Middle Aged; Placebo | 2010 |
[Effect of tongxinluo capsule on platelet aggregation function in patients with aspirin resistance].
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Aspirin; Collagen; Coronary Disease; Drug Res | 2010 |
[Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Angioplasty, Balloon; Aspirin; Clopidogrel; Co | 2010 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Can resistance to aspirin be reversed after an additional dose?
Topics: Administration, Oral; Aged; Aspirin; Blood Platelets; Coronary Disease; Dose-Response Relationship, | 2011 |
Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Biomarkers; Blood Platelets; Chi-Square Distribution; Co | 2011 |
Bleeding evaluation during single tooth extraction in patients with coronary artery disease and acetylsalicylic acid therapy suspension: a prospective, double-blinded, and randomized study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Chi-Square Distribution; Coronary Dis | 2011 |
Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; | 2011 |
Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Computer Simulation; Coronary Disease; Cost-Benefit Analysi | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; | 2012 |
Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia.
Topics: Aged; Amino Acid Sequence; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Cytoskeletal Pro | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
The in vitro effects of verbascoside on human platelet aggregation.
Topics: Adenosine Diphosphate; Adult; Aged; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-St | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Disease-Free Survival; D | 2002 |
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy | 2002 |
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Th | 2002 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combin | 2002 |
Seeking the optimal aspirin dose in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Endpoint Determination; | 2002 |
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Comb | 2002 |
Aspirin and mortality from coronary bypass surgery.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Disease; Female; Humans; Is | 2002 |
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.
Topics: Antigens; Aspirin; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Clopidogrel; Cohort Stu | 2002 |
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal | 2003 |
PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Coronary Disease; Female; Flow Cytometry; | 2002 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysi
Topics: Aged; Alanine; Aspirin; Cerebrovascular Disorders; Coronary Disease; Double-Blind Method; Drug Thera | 2003 |
A paclitaxel-eluting stent for the prevention of coronary restenosis.
Topics: Angiogenesis Inhibitors; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2003 |
Durability of platelet inhibition by clopidogrel.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Pl | 2003 |
Thrombosis prevention trial: compliance with warfarin treatment and investigation of a retained effect.
Topics: Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Follow-Up Studies; Humans; Male; Mid | 2003 |
Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Topics: Amidines; Aspirin; Coronary Disease; Coronary Thrombosis; Double-Blind Method; Female; Flow Cytometr | 2003 |
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Benzodiazepines; Cerebrovascular Diso | 2003 |
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
Topics: Acute Disease; Aspirin; Causality; Coronary Disease; Coronary Thrombosis; Female; Humans; Incidence; | 2003 |
Coronary intervention with a heparin-coated stent and aspirin only.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Asia; Aspirin; Blood Vessel Prosthesis Implantation; Co | 2003 |
[Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Antithrombins; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinati | 2003 |
[Clopidogrel as adjunctive medication in patients with acute coronary syndrome].
Topics: Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2002 |
Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Epi | 2003 |
A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Admini | 2003 |
Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug The | 2003 |
Effects of high ticlopidine doses on platelet function in acute coronary syndrome patients.
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ma | 2004 |
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Female; Hemorrhage; Humans; Kidney Function Tests; M | 2003 |
Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Weight; Cholesterol; | 2004 |
Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2004 |
Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin.
Topics: Acute Disease; Anticoagulants; Aspirin; Blood Coagulation Disorders; Coronary Disease; Heparin, Low- | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiova | 2004 |
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Hepar | 2004 |
[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome].
Topics: Acute Disease; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Electrocardiography; Female; | 2004 |
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas | 2005 |
Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Case-Control Studies; Coronary Disease; Drug Synergi | 2005 |
Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment.
Topics: Adult; Aged; Aspirin; C-Reactive Protein; Coronary Disease; Double-Blind Method; Female; Humans; Mac | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Dalteparin; Electrocardiography; Female; | 2005 |
[Study on the relationship between aspirin resistance and incidence of myonecrosis after non-emergent percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Creatine Kinase, MB Form; Drug Resi | 2005 |
A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Co | 2005 |
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.
Topics: Adult; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Epi | 2005 |
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Coronary Disease; C | 2005 |
[Effects of aggressive therapy with simvastatin in patients with acute coronary syndrome and initially normal level of LDLP cholesterol on cardiovascular outcomes (LAOKOON). Pilot randomized trial].
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Aspirin; C-Reactive Protein; Cholesterol, LDL; Corona | 2005 |
Aspirin, warfarin and a thienopyridine for acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hematologic Agents; Human | 2006 |
[Effects of cilostazol on long-term clinical outcomes after coronary stenting].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Drug Therapy, Co | 2005 |
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Chemistry, Pharmaceutical; Coronary Disease; Female; | 2005 |
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Th | 2006 |
[Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Thera | 2006 |
Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assis | 2006 |
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
Topics: Aged; Arachidonic Acid; Aspirin; Blood Platelets; Calcimycin; Coronary Disease; Cyclooxygenase 1; Cy | 2006 |
[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Drug Therapy, Combinati | 2006 |
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease.
Topics: Aspirin; Biomarkers; Chemokine CCL2; Clopidogrel; Coronary Disease; Humans; Inflammation; Ticlopidin | 2006 |
Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole; Disease Progression; Drug Therapy, Co | 2007 |
Normalization of platelet reactivity in clopidogrel-treated subjects.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Collagen; Cor | 2007 |
The effect of high-dose aspirin pre-treatment on the incidence of myonecrosis following elective coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Creatine | 2008 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Ascorbic Acid; Aspirin; Biomarkers; Coronary Disease | 2007 |
Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Blood Platelets; Collagen; Coronary Disease | 2007 |
Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Asp | 2007 |
The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
Topics: Aged; Aspirin; Blood Platelets; Coronary Disease; Cross-Over Studies; Diabetic Angiopathies; Double- | 2007 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Colla | 2009 |
No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Angiography; Coronary Disease; Cyclooxygenase 1; C | 2008 |
Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Vessels; Dr | 2007 |
Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.
Topics: Adult; Aged; Antidepressive Agents; Aspirin; beta-Thromboglobulin; Biomarkers; Blood Platelets; Cita | 2009 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
A perspective on platelet-suppressant drug treatment in coronary artery and cerebrovascular disease.
Topics: Adrenergic beta-Antagonists; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascula | 1980 |
Mechanisms contributing to precipitation of unstable angina and acute myocardial infarction: implications regarding therapy.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon; Animals; Antic | 1984 |
High-dose intravenous gammaglobulin for Kawasaki disease.
Topics: Acute Disease; Administration, Oral; Aspirin; Child, Preschool; Clinical Trials as Topic; Coronary D | 1984 |
Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Artery Bypas | 1982 |
Platelet tests and antiplatelet drugs in coronary artery disease.
Topics: Adult; Aspirin; beta-Thromboglobulin; Blood Platelets; Cell Survival; Coronary Disease; Dipyridamole | 1983 |
Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dip | 1983 |
Pharmacological trials: primary and secondary prevention of coronary heart disease.
Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D | 1983 |
Aspirin in coronary heart disease. Comparison of six clinical trials.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle | 1983 |
The effect of antiplatelet therapy on saphenous vein coronary artery bypass graft patency.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Di | 1983 |
Role of platelet-active drugs in coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Co | 1983 |
[Low-dose acetylsalicylic acid (100 mg/day) following aortocoronary bypass operation].
Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Circulatio | 1984 |
[Results of ambulatory follow-up of patients after myocardial infarction treated with platelet aggregation inhibitors and antithrombotic drugs].
Topics: Acenocoumarol; Adult; Ambulatory Care; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyrida | 1983 |
Anticoagulant and platelet-antiaggregating therapy in stroke and threatened stroke.
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1983 |
[The antithrombotic action of oral anticoagulants, acetylsalicylic acid (Aspirin) and dipyridamole (Persantin)].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Fibrinolytic Agen | 1984 |
[Long-term antithrombotic treatment in coronary disease].
Topics: 4-Hydroxycoumarins; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Fibrinolyti | 1983 |
Efficacy of antiplatelet drugs in the maintenance of aortocoronary vein bypass graft patency.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Diseas | 1983 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
Present status of antiaggregating agents in coronary and cerebrovascular disease prevention.
Topics: Animals; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Dise | 1980 |
[Persantin and aspirin in coronary heart disease. The persantin-aspirin reinfarction study group (PARIS)].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Combin | 1980 |
Controversies in cardiology. Proposed: low-dose aspirin should be taken daily after age 40 if total serum cholesterol is greater than 160.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Epoprostenol; Humans; H | 1982 |
The Canadian trial of aspirin and sulfinpyrazone in threatened stroke.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Canada; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Summary of ongoing clinical trials of platelet-active drugs in cardiovascular disease.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials a | 1980 |
Clinical trials of platelet-active drugs in coronary heart disease: summary of design features.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Electroca | 1980 |
Aspirin in coronary heart disease. The Coronary Drug Project Research Group.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Hematuria; Humans; Hyperte | 1980 |
The Persantine-aspirin reinfarction study. The Persantine-aspirin Reinfarction Study (PARIS) research group.
Topics: Aspirin; Blood Pressure; Blood Urea Nitrogen; Cerebrovascular Disorders; Clinical Trials as Topic; C | 1980 |
Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts).
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1981 |
Are clinical trials in coronary heart disease oversold or undersold?
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction; Random Allocatio | 1981 |
[Platelets and coronary artery disease (CAD) (author's transl)].
Topics: Animals; Aspirin; Autopsy; Blood Platelets; Cardiomyopathies; Cell Wall; Clinical Trials as Topic; C | 1980 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
Antiplatelet agents: their role in the prevention of sudden death.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Clinical Trials as Topic; Coronary Circulation; Co | 1982 |
Antithrombotic effects of drugs which suppress platelet function: their potential in prevention growth of tumour cells.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cell Division; Clinical Trials as Topic; Coronary | 1982 |
[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid].
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Coronary Disease; Diabetic Angiopathies | 1982 |
Effect of platelet suppressant treatment with dipyridamole and aspirin on exercise performance and platelet survival time in coronary disease.
Topics: Aspirin; Blood Platelets; Blood Pressure; Cell Survival; Coronary Circulation; Coronary Disease; Dip | 1981 |
Persantine and aspirin in coronary heart disease. The Persantine-Aspirin Reinfarction Study Research Group.
Topics: Actuarial Analysis; Adult; Aged; Aspirin; Blood Pressure; Coronary Disease; Dipyridamole; Double-Bli | 1980 |
Persantine-aspirin reinfarction study. Design, methods and baseline results. By the persantine-aspirin reinfarction study research group.
Topics: Adult; Aged; Animals; Aspirin; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Electrocar | 1980 |
Aspirin and secondary mortality after myocardial infarction.
Topics: Adult; Aged; Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Female; Hemoglobins; Humans; Ma | 1980 |
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Angina, Unstable; Aspirin; Coronary Disease; Dos | 1995 |
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Double-Blind Method; Eptifibatide; | 1995 |
Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Glutathione; Heparin; Human | 1994 |
Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion.
Topics: Acute-Phase Proteins; Aged; Aspirin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery B | 1994 |
Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method | 1995 |
Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin.
Topics: Adult; Aged; Animals; Aorta; Aspirin; Coronary Disease; Coronary Thrombosis; Female; Humans; Male; M | 1995 |
Intracoronary stenting without coumadin: one month results of a French multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Ther | 1995 |
Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation: an alternative therapeutic strategy after bailout stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; | 1995 |
Histopathologic and coronary angiographic assessment of effectiveness of aspirin or aspirin-and-gammaglobulin in Kawasaki disease.
Topics: Acute Disease; Aspirin; Biopsy; Cardiomyopathies; Child; Child, Preschool; Coronary Aneurysm; Corona | 1993 |
Effect of treatment with low-dose warfarin-aspirin on activated factor VII.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Factor VIIa; Female; Humans; Male; Middl | 1995 |
Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease.
Topics: Aged; Antithrombin III; Arteriosclerosis; Aspirin; Bleeding Time; Coronary Artery Bypass; Coronary D | 1995 |
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Dipyridamole; Double-Blind Method | 1995 |
Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilazapril; Coronary Angiography; Coronary Disease; Double- | 1995 |
Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Hemato | 1995 |
Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Female | 1995 |
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Angiography; Coronar | 1995 |
Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.
Topics: Adult; Aged; Aspirin; Bleeding Time; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Doub | 1995 |
Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. Coumadin Aspirin Reinfarction (CARS) Pilot Study Group.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation; Coronary Disease; Drug Administ | 1994 |
Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding.
Topics: Aspirin; Bleeding Time; Blood Loss, Surgical; Blood Transfusion; Chest Pain; Cohort Studies; Coronar | 1994 |
Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Aneurysm; Coronary Disease; Drug Therapy, Combination; Fe | 1994 |
Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina.
Topics: Aspirin; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; C | 1994 |
Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting.
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Circulation; C | 1994 |
Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole; | 1994 |
Cardiac prognosis of patients with carotid stenosis and no history of coronary artery disease. Veterans Affairs Cooperative Study Group 167.
Topics: Aged; Aspirin; Carotid Stenosis; Coronary Disease; Endarterectomy, Carotid; Humans; Male; Middle Age | 1994 |
Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method | 1994 |
Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography; Exercise Test; Hemodynamics; | 1993 |
Height and incidence of cardiovascular disease in male physicians.
Topics: Adjuvants, Immunologic; Aspirin; beta Carotene; Body Height; Carotenoids; Cohort Studies; Coronary D | 1993 |
Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.
Topics: Amino Acid Sequence; Aspirin; Blood Coagulation; Blood Coagulation Tests; Cardiac Catheterization; C | 1993 |
Influence on early outcome and restenosis of urokinase before elective coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary | 1993 |
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Aspirin; Coronary Angiography; | 1996 |
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Disease-Free Survival; Equipment | 1996 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationshi | 1996 |
Patterns of aspirin use in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study.
Topics: Age Factors; Aged; Arteriosclerosis; Aspirin; Black or African American; Coronary Disease; Dose-Resp | 1996 |
[Coronary artery stenting without antivitamin K. Results after a month].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Di | 1996 |
Changes in membrane glycoproteins of circulating platelets after coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Blo | 1996 |
Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Aspirin; Coronary Artery Bypass; Coronary Diseas | 1996 |
Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutriments.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Diet; Humans; Mediterranean Sea; Nutritional Phy | 1996 |
[Elective coronary implantation of a newly developed stent without conventional anticoagulation].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; H | 1996 |
Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group.
Topics: Aged; Aspirin; Chi-Square Distribution; Cohort Studies; Coronary Disease; Digitalis Glycosides; Fema | 1996 |
Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.
Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Aspirin; Atherectomy, Coronary; Coronary Di | 1997 |
High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; Coronary Disease; Coronary Thro | 1997 |
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; | 1997 |
Control of bias in dietary trial to prevent coronary recurrences: The Lyon Diet Heart Study.
Topics: Adrenergic beta-Antagonists; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy.
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Eq | 1997 |
Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCA
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 1997 |
Coronary stenting (Cordis) without anticoagulation.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Evaluation Stu | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
[Secondary prevention in chronic coronary heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angiotensin-Convertin | 1997 |
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherectomy, Coronary; Coronary Disease; Eptifibatide | 1997 |
Antiplatelet effect of ticlopidine after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Constriction, Pathologic; Cor | 1997 |
A randomised controlled trial of feedback to general practitioners of their prophylactic aspirin prescribing.
Topics: Adult; Aged; Aspirin; Coronary Disease; Drug Administration Schedule; Drug Utilization Review; Estro | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Benzamidines; Coronary Disea | 1997 |
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro | 1997 |
[A prospective study on the timing of discontinuation of aspirin before coronary artery bypass grafting].
Topics: Aged; Aspirin; Blood Loss, Surgical; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Diseas | 1997 |
Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biphenyl Compounds; B | 1997 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coro | 1997 |
[Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
Topics: Abciximab; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Angina, Unstable | 1997 |
Impact of cilostazol on intimal proliferation after directional coronary atherectomy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherectomy, Coronary; Cell Division; Cilostazol; Cor | 1998 |
Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinogen; Hu | 1998 |
[Ascolong: a new buccal dosage form of acetylsalicylic acid to be used and antiaggregant].
Topics: Administration, Buccal; Aspirin; Cerebrovascular Disorders; Chromatography, High Pressure Liquid; Co | 1998 |
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy; Blood Coagu | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation.
Topics: Aged; Animals; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Dogs; Female; Follow-Up | 1998 |
Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients.
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; | 1998 |
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Topics: Administration, Oral; Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Coronary Disease; | 1998 |
The HOT Study. Hypertension Optimal Therapy.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Cerebrovascular | 1998 |
Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Calcium Channel Blocker | 1998 |
PTCA of degenerated vein grafts: experience of two periods (1992-93 and 1996-97) in 780 patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Coronary Artery Bypass; Coro | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
[Long term effects of 50 mg acetylsalicylic acid alone and in combination with dipyridamole on platelet function after coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dr | 1998 |
Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care.
Topics: Aged; Ambulatory Care Facilities; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease | 1998 |
Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent--a pilot study in the setting of coronary angioplasty.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Dis | 1999 |
The trapidil restenosis trial (STARC study): background, methods and clinical characteristics of the patient population.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Cohort Studies; Coronary D | 1994 |
Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary | 1994 |
Advances in post stenting medication protocol.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1995 |
Selective high dose gamma-globulin treatment in Kawasaki disease: assessment of clinical aspects and cost effectiveness.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Coronary Disease; Cost-Benefit | 1999 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method; Female; Humans; Male; Mi | 1999 |
Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Captopril; Coronary Disease; Cross-Over Studies; | 1999 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti | 1999 |
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium; Cell Division; Cilostazol; Combined Modality | 1999 |
[Beneficial effect of aspirin in diabetic coronary disease: facts to prove it].
Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Retrospective S | 1999 |
Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction.
Topics: Acetylcholine; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Bradykinin; Coronary Angiog | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Comparison of the efficacy and safety of aspirin alone with coumadin plus aspirin after provisional coronary stenting: final and follow-up results of a randomized study.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Cor | 1999 |
beta-Particle-emitting radioactive stent implantation. A safety and feasibility study.
Topics: Adult; Aged; Aspirin; Beta Particles; Brachytherapy; Coronary Angiography; Coronary Disease; Feasibi | 1999 |
Inhibition of platelet aggregation after intake of acetylsalicylic acid detected by a platelet function analyzer (PFA-100).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; Platel | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chest Pain; Corona | 1999 |
Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Coronary Disease; Dise | 1999 |
The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
Topics: Abciximab; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; B | 1999 |
Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting.
Topics: Adult; Antifibrinolytic Agents; Antithrombin III; Aprotinin; Aspirin; Blood Loss, Surgical; Coronary | 2000 |
Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Arterial Occlusive Diseases; Aspirin; C | 2000 |
Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting.
Topics: Acenocoumarol; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coron | 2000 |
Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.
Topics: Administration, Oral; Alanine; Anticoagulants; Aspirin; Coronary Disease; Double-Blind Method; Femal | 2000 |
Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Coumarins; Female; | 2000 |
Alcohol consumption and risk of coronary heart disease by diabetes status.
Topics: Alcohol Drinking; Aspirin; beta Carotene; Cardiovascular Diseases; Coronary Disease; Diabetes Mellit | 2000 |
Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Coumarins; Female; Fibrinolytic A | 2000 |
Plasma levels of C-reactive protein after coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Coronary An | 2000 |
A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary D | 2000 |
Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Automation; Beta Particles; Combined Modality Therapy; Coro | 2000 |
Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Aspirin; Biomarkers; Brachial Artery; C-Reactive Protein | 2000 |
Minimum effective intensity of oral anticoagulant therapy in primary prevention of coronary heart disease.
Topics: Aged; Anticoagulants; Aspirin; Coronary Disease; Humans; International Normalized Ratio; Male; Middl | 2000 |
Effects of cilostazol on angiographic restenosis after coronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease | 2000 |
A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adju | 2000 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Blood donations and risk of coronary heart disease in men.
Topics: Adult; Aged; Aspirin; Blood Donors; Coronary Disease; Electrocardiography; Ferritins; Follow-Up Stud | 2001 |
Low-grade exercise enhances platelet aggregability in patients with obstructive coronary disease independently of myocardial ischemia.
Topics: Aged; Aspirin; Combined Modality Therapy; Coronary Disease; Exercise Therapy; Female; Hematocrit; He | 2001 |
Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cell Adhesion; Cholesterol, HDL; Cholesterol | 2000 |
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, | 2001 |
Periodontal disease and risk of subsequent cardiovascular disease in U.S. male physicians.
Topics: Adult; Aged; Aspirin; Bacterial Infections; beta Carotene; Cause of Death; Coronary Disease; Double- | 2001 |
Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels.
Topics: Adult; Aged; Aspirin; Cholesterol; Coronary Disease; Drug Therapy, Combination; Hemostatics; Humans; | 2001 |
Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Com | 2001 |
Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Monophosphate; Adult; Aged; Angina, Unstable; Aspirin; Blood Coagulation Te | 2001 |
Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; | 2001 |
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relati | 2001 |
Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery.
Topics: Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Drug T | 2001 |
Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.
Topics: Administration, Oral; Adult; Aged; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Doub | 2001 |
Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
Topics: Adenine Nucleotides; Adult; Aged; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administratio | 2001 |
Abciximab readministration: results of the ReoPro Readministration Registry.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies; Antibodies, Monoclonal; Aspirin; Coronary Dis | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Does a fixed physician reminder system improve the care of patients with coronary artery disease? A randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; California; Cholesterol, LDL; Cohort Studies; Cor | 2001 |
Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Aprotinin; Aspirin; Blood Component Transfusion; Combined Modality Therapy; Coronary Artery By | 2001 |
Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Restenosis; Drug Therapy, Combin | 2001 |
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Double-B | 2001 |
Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Carbon; Coa | 2002 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Disease; Drug Synergism; Drug Therapy, C | 2002 |
Clopidogrel and the CURE results.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2001 |
Antithrombotic treatment and the incidence of angina pectoris.
Topics: Aged; Angina Pectoris; Anticoagulants; Aspirin; Cohort Studies; Coronary Disease; Double-Blind Metho | 2002 |
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin | 2002 |
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Topics: Aged; Aspirin; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; | 2002 |
Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coro | 2002 |
Role of blood platelets in coronary artery disease.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Clofibrate; Co | 1979 |
[Secondary prevention of coronary disease with platelet aggregation inhibiting drugs. Preliminary report].
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Female; Humans; Male; Middle Aged | 1979 |
'Persantin'-aspirin reinfarction study.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Combinations; D | 1976 |
[Pharmacological action on the thrombocyte link in hemostasis in the treatment of ischemic heart disease].
Topics: Aspirin; Blood Platelet Disorders; Blood Platelets; Clinical Trials as Topic; Clofibrate; Coronary D | 1978 |
Drug therapy: antiplatelet therapy (second of two parts).
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical T | 1978 |
The coronary drug project aspirin study. Implications for clinical care. Coronary Drug Project Research Group.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Follow-Up Studies; Humans; Male; Middle Aged; P | 1978 |
Preliminary study of effect of aspirin and dipyridamole on platelet adhesiveness and fibrinolytic activity in acute myocardial infarction.
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Evaluation; F | 1978 |
The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease.
Topics: Adult; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Interactions; Epinephrine; Fibrinog | 1979 |
Recruitment in the Coronary Drug Project and the Aspirin Myocardial Infarction Study.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; Human Experimentation; Humans; | 1979 |
Platelet inhibitors in the treatment of thrombosis.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Clinical Trials as Topic; Clof | 1978 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Aspirin, platelets and myocardial infarction--proposal for a trial.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Humans; Male; Myocardial Infar | 1975 |
Aspirin therapy in angina pectoris: effects on platelet aggregation, exercise tolerance, and electrocardiographic manifestations of ischemia.
Topics: Adult; Angina Pectoris; Aspirin; Clinical Trials as Topic; Coronary Disease; Female; Heart Function | 1976 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Proceedings: A clinical trial of antiplatelet therapy in patients with coronary arterial disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Humans; Sulfinpyrazone | 1975 |
[Acetylsalicylic acid in the prevention and therapy of thromboembolic diseases. Principles of practical use].
Topics: Animals; Aspirin; Coronary Disease; Dogs; Humans; Platelet Aggregation; Thromboembolism | 1975 |
Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Electrocardiography; Humans; Male; Middle Aged | 1992 |
Coronary revascularisation in insulin-dependent diabetic patients with chronic renal failure.
Topics: Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary | 1992 |
Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion.
Topics: Aspirin; Cardiac Catheterization; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Drug Thera | 1992 |
Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure.
Topics: Adult; Aged; Aspirin; Chi-Square Distribution; Chronic Disease; Coronary Disease; Double-Blind Metho | 1992 |
Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation.
Topics: Administration, Oral; Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combinatio | 1992 |
The current role of platelet-active drugs in ischaemic heart disease.
Topics: Angina Pectoris; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1991 |
Increased occurrence of exercise-induced silent ischemia after treatment with aspirin in patients admitted for suspected acute myocardial infarction.
Topics: Aged; Aspirin; Coronary Disease; Double-Blind Method; Electrocardiography; Exercise Test; Humans; Ma | 1991 |
[Modification of thrombocyte function in diagnostic and therapeutic interventions in cardiology].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double- | 1991 |
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARP
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Constriction, Pathologic; Coronary Dise | 1991 |
Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method | 1991 |
Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Double-Blind Method; Female | 1991 |
Effects of low-dose aspirin on restenosis after coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; Coronary Angiography; Coron | 1991 |
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Equipment Design; Female; F | 1991 |
Effects of diltiazem on complications and restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; Coronary Angiography; Coronary Di | 1991 |
[Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty].
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; | 1991 |
Rationale for a primary prevention study using low-dose aspirin to prevent coronary and cerebrovascular disease in the elderly.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Humans; | 1991 |
Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease.
Topics: Adult; Aged; Aspirin; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Epoproste | 1991 |
[Drug modulation of thromboxane A2/prostacyclin balance and lipid peroxidation in patients with coronary artery disease].
Topics: Aged; Aspirin; Coronary Disease; Diltiazem; Epoprostenol; Female; Humans; Lipid Peroxidation; Male; | 1990 |
Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1990 |
Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial.
Topics: Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Follow-Up Studies; Human | 1990 |
Coronary thrombolysis and aging.
Topics: Aged; Aging; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Fibrinolysis | 1990 |
The effect of ibustrin on early aortocoronary bypass patency.
Topics: Angiography, Digital Subtraction; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Di | 1990 |
Conjunctive antithrombotic and thrombolytic therapy for coronary-artery occlusion.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Thrombol | 1990 |
The effects of long-term antithrombotic treatment on left ventricular thrombi in patients after an acute myocardial infarction.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Echocardiography; Embol | 1990 |
The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Double-Blind Method; | 1990 |
Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Incidence; Randomized Controlled Trial | 1990 |
The treatment of Kawasaki syndrome with intravenous gamma globulin.
Topics: Aneurysm; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Echocardio | 1986 |
High-dose gammaglobulin therapy for Kawasaki disease.
Topics: Aspirin; Child, Preschool; Clinical Trials as Topic; Coronary Disease; Female; gamma-Globulins; Huma | 1987 |
Kawasaki disease: management guidelines.
Topics: Aspirin; Child; Clinical Trials as Topic; Coronary Disease; Drug Evaluation; gamma-Globulins; Humans | 1988 |
Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Preliminary report.
Topics: Acute Disease; Adolescent; Aspirin; Child; Child, Preschool; Clinical Trials as Topic; Coronary Dise | 1989 |
Coronary thrombolysis and the new biology.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Mutation; Platelet | 1989 |
A trial of dipyridamole and aspirin in the prevention of smoking-induced changes in platelets and endothelium in men with coronary artery disease.
Topics: Aged; Aspirin; beta-Thromboglobulin; Carboxyhemoglobin; Coronary Disease; Dipyridamole; Double-Blind | 1989 |
Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion.
Topics: 4-Hydroxycoumarins; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary | 1989 |
Aspirin in myocardial ischemia: why, when, and how much?
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans | 1989 |
Current perspectives in the antiplatelet therapy of thrombotic disorders.
Topics: Angina, Unstable; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; | 1989 |
[Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies].
Topics: Aspirin; Canada; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Dipyridamole; Drug | 1989 |
Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Coronar | 1989 |
Prevention of restenosis after coronary angioplasty: a pharmacological approach.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical | 1989 |
Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids.
Topics: Angioplasty, Balloon; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Angiography; Coro | 1988 |
Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Blood Platelets; Cholesterol; C | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: the basis of their use, data from animal studies, clinical trial data, and current recommendations.
Topics: Angioplasty, Balloon; Animals; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Coronar | 1986 |
Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Coronary Angiography; | 1988 |
[Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heparin; Hu | 1988 |
Usefulness of aspirin for coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Graft Occ | 1988 |
Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Double-Blind | 1988 |
[Acetylsalicylic acid therapy in vascular diseases].
Topics: Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary | 1988 |
Japanese gamma globulin trials for Kawasaki disease.
Topics: Aspirin; Child, Preschool; Clinical Trials as Topic; Coronary Disease; Echocardiography; Female; Hum | 1987 |
Intravenous gamma globulin therapy in Kawasaki disease--trial of low dose gamma globulin.
Topics: Aspirin; Child, Preschool; Clinical Trials as Topic; Coronary Disease; Female; Humans; Immunization, | 1987 |
U.S. gamma globulin trial.
Topics: Aspirin; Child; Child, Preschool; Clinical Trials as Topic; Coronary Disease; Humans; Immunization, | 1987 |
Clinical evaluation of gammaglobulin preparations for the treatment of Kawasaki disease.
Topics: Aspirin; Child; Clinical Trials as Topic; Coronary Disease; Humans; Immunization, Passive; Japan; Mu | 1987 |
Absence of differential inhibition of thromboxane A2 and prostacyclin by low and high dose aspirin in coronary artery disease.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Coronary Disease; Electrocardiography; Epoprostenol; Hu | 1987 |
Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregati | 1987 |
Antithrombotic agents in coronary artery disease.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disea | 1986 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary A | 1986 |
Effectiveness of anticoagulants.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Angina, Unstable; Anticoagulants; Aspirin; Blood | 1986 |
Hemorrhagic complications of anticoagulant therapy.
Topics: Administration, Oral; Animals; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorde | 1986 |
[Secondary prevention of ischemic heart disease. Evaluation of platelet function in patients treated with anticoagulants and cod liver oil].
Topics: Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Cod Liver Oil; Coronary Disease; Dip | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
Aspirin and ischaemic heart disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction | 1986 |
A critical appraisal of the clinical efficiency of anti-platelet drugs.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1986 |
Effect of preoperative antiplatelet drugs on vascular prostacyclin synthesis.
Topics: Aspirin; Blood Platelets; Blood Vessels; Coronary Disease; Dipyridamole; Drug Evaluation; Drug Thera | 1987 |
Lack of effect of aspirin on cigarette smoke-induced increase in circulating endothelial cells.
Topics: Adult; Aged; Aspirin; Blood Cells; Cell Count; Coronary Disease; Endothelium; Humans; Male; Middle A | 1987 |
Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Di | 1985 |
Cigarette smoking--induced enhancement of platelet function: lack of prevention by aspirin in men with coronary artery disease.
Topics: Adult; Aged; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Human | 1985 |
Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1985 |
Effects of indomethacin on systemic and coronary hemodynamics in patients with coronary artery disease.
Topics: Adult; Aspirin; Blood Pressure; Coronary Circulation; Coronary Disease; Cyclooxygenase Inhibitors; F | 1985 |
[Eicosanoids, myocardial ischemia and sudden death].
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Clinical Trials as Topic; Coronary Disease; Cyclooxygenase I | 1985 |
Effect of aspirin on brachial artery occlusion following brachial arteriotomy for coronary arteriography.
Topics: Administration, Oral; Angiography; Arterial Occlusive Diseases; Aspirin; Blood Pressure; Brachial Ar | 1973 |
Aspirin in prophylaxis of ischemic heart disease.
Topics: Arteriosclerosis; Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Platelet Adhesiveness | 1973 |
807 other studies available for aspirin and Coronary Disease
| Article | Year |
|---|---|
Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2022 |
Evaluation of efficacy and safety of aspirin combination treatment in treating patients with coronary heart disease: A protocol for systematic review and meta-analysis.
Topics: Aged; Aspirin; Coronary Disease; Drugs, Chinese Herbal; Humans; Meta-Analysis as Topic; Middle Aged; | 2022 |
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Topics: Aged; Aspirin; Cerebral Infarction; China; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; | 2022 |
Preventive effect of Helicobacter pylori eradication on the coronary heart diseases depending on age and sex with a median follow-up of 51 months.
Topics: Anti-Bacterial Agents; Aspirin; Coronary Disease; Female; Follow-Up Studies; Helicobacter Infections | 2023 |
Prevalence and management of aspirin hypersensitivity in a cardiology practice.
Topics: Adult; Aged; Aged, 80 and over; Allergens; Aspirin; Coronary Disease; Diagnostic Errors; Drug Hypers | 2020 |
[Clinical characteristics and combined medication of Suxiao Jiuxin Pills in 16 856 elderly patients in real world study].
Topics: Aged; Aspirin; Coronary Disease; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Salvi | 2020 |
Clinical efficacy of ticagrelor combined with aspirin in patients with coronary heart disease angina pectoris and its effects on NT-ProBNP and CK-MB levels.
Topics: Adult; Aspirin; Coronary Disease; Creatine Kinase, MB Form; Drug Therapy, Combination; Female; Human | 2020 |
Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
Topics: Adult; Aspirin; Atherosclerosis; Cohort Studies; Coronary Artery Disease; Coronary Disease; Eye Hemo | 2021 |
Early stopping of a randomised trial for efficacy: a medical, ethical and regulatory challenge.
Topics: Aspirin; Continuity of Patient Care; Coronary Disease; Early Termination of Clinical Trials; Fibrino | 2021 |
Recommendations on the Clinical Use of Compound Danshen Dripping Pills.
Topics: Angina Pectoris; Aspirin; Camphanes; Clopidogrel; Coronary Disease; Diabetes Mellitus; Diabetic Neph | 2017 |
Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease.
Topics: Aspirin; Child, Preschool; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2017 |
Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregatio | 2017 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human | 2017 |
The Effect of Monthly Medication on Mortality After a Coronary Event.
Topics: Aged; Aspirin; Cardiovascular Agents; Coronary Disease; Female; Follow-Up Studies; Humans; Hydroxyme | 2018 |
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018.
Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure Monitoring, Ambulatory; Coronary Disease; Di | 2018 |
Kawasaki Disease - A Review of Treatment and Outcomes in an Irish Paediatric Cohort 2010-14.
Topics: Adrenal Cortex Hormones; Aspirin; Child; Cohort Studies; Coronary Disease; Humans; Immunoglobulins, | 2018 |
Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report.
Topics: Adolescent; Anticholesteremic Agents; Aspirin; Coronary Disease; Ezetimibe; Female; Heart Failure; H | 2018 |
Association between TNF-α polymorphisms and the risk of upper gastrointestinal bleeding induced by aspirin in patients with coronary heart disease.
Topics: Aged; Alleles; Aspirin; Coronary Disease; Female; Gastrointestinal Hemorrhage; Genotype; Haplotypes; | 2019 |
Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid.
Topics: Aged; Aspirin; Blood Loss, Surgical; Blood Transfusion; Cardiovascular Diseases; Case-Control Studie | 2019 |
Influence of drugs on the prospective diagnostic method for coronary heart disease with urine.
Topics: Aspirin; Becaplermin; Clopidogrel; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2019 |
BMS consensus statement for primary prevention of coronary heart disease in women.
Topics: Age Factors; Antihypertensive Agents; Aspirin; Coronary Disease; Diet; Estrogen Replacement Therapy; | 2019 |
[Rational pharmacotherapy of patients with coronory heart disease combined with anxiety disorders].
Topics: Adrenergic beta-Antagonists; Affect; Angiotensin-Converting Enzyme Inhibitors; Anti-Anxiety Agents; | 2012 |
Polypill. Faulty logic justifies aspirin use for primary prevention of cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Female; Humans; Male; Platelet Aggregation Inhib | 2013 |
Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2014 |
Coronary mortality in China: fence, ambulance, or hospital treatments?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Hu | 2014 |
[Outcome study on parenterally administered shenfu in treatment of coronary heart disease].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Drug Therapy, Combination; Drugs, Chinese | 2013 |
[Real-world study in analysis of effects on concomitant medications with parenterally administered shenmai for coronary heart disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Combination | 2013 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona | 2014 |
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Topics: Aged; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP- | 2014 |
Million Hearts Delaware: Primum Non Nocere.
Topics: Aged; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Ri | 2013 |
Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Calcium; Coronary Disease; Coronary Vessels; Ethn | 2014 |
[The specific features of gout in the elderly].
Topics: Adult; Age of Onset; Aged; Arthritis, Gouty; Aspirin; Comorbidity; Coronary Disease; Cyclooxygenase | 2014 |
Perioperative aspirin: to give or not to give?
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Female; Fibrinolytic Agents; H | 2014 |
Bleeding complication with dual antiplatelet therapy: spontaneous uvula hematoma.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Hematoma; Humans; Lary | 2014 |
Evaluation of resistance to anti-platelet therapy in patients with coronary heart disease in a developing country.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Developing Countries; Drug Resistance; Hosp | 2014 |
Long-term secondary prevention after high-risk stenting: a good drug for a bad stent.
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Prasu | 2015 |
[Analysis of traditional Chinese medicine syndrome, traditional Chinese medicine and western medicine in 84 697 patients with coronary heart disease based on big data].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drugs, Chinese Herbal; Femal | 2014 |
[Preliminary study on integration of traditional Chinese medicine and western medicine in patients with coronary heart disease in real world].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Aspirin; Combined Modality The | 2014 |
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery By | 2015 |
Non-instrumented extradural lumbar spine surgery under low-dose acetylsalicylic acid: a comparative risk analysis study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Blood Transfusion; Case-Control Studies; Cor | 2016 |
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Cytochrome P | 2015 |
Effectiveness of and risk associated with aspirin therapy in hemodialysis patients with a background of antiplatelet factor 4/heparin complex antibody detection.
Topics: Adult; Aged; Antibodies; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Heparin; Humans; Ma | 2015 |
Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Comorbidity; Coronary Disease; Coronary Restenosis; Drug Sub | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-4 | 2015 |
[Anticoagulants to more people can prevent many cases of stroke].
Topics: Age Factors; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Humans; Medication Adhe | 2015 |
Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Int | 2016 |
Letter by Shah and Buch regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purin | 2015 |
Letter by Jeger and Pfisterer regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purin | 2015 |
Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
Topics: Aspirin; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Paclitaxel; Piperazines; Purin | 2015 |
[Long term aspirin in stable coronary disease with an indication for anticoagulation: is it reasonable?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Drug Therapy, Combination; Hemorrhag | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
[Polypill for secondary coronary heart disease prevention].
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Medicatio | 2015 |
Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Blood Platelets; China; Clopidogrel; Coronary Disease; Female; Haplotyp | 2016 |
[Combination drug improves adherence].
Topics: Aspirin; Atorvastatin; Capsules; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; | 2016 |
Effects of low-dose aspirin in subjects with dyslipidemia.
Topics: Adult; Aspirin; C-Reactive Protein; Cholesterol, LDL; Convalescence; Coronary Angiography; Coronary | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trial | 2016 |
[Antiplatelet medicine].
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Pyridines | 2016 |
Non-coronary chest pain does not affect long-term mortality: a prospective, observational study using a matched population control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Case-Control Studies; Cause of Death; Chest Pain; | 2016 |
Nonsteroidal anti-inflammatory drugs-induced small bowel enteropathy and obscure gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Capsule Endoscopy; Case-Control Studies | 2018 |
[Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Case-Control Studies; China; Consensus; Coronary | 2017 |
Aspirin desensitization in patients with coronary artery disease: Cost savings.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost Savings; Desensitization, Immunologic; Drug Hypersensit | 2017 |
Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; | 2008 |
Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)?
Topics: Aged; Aged, 80 and over; Aspirin; Black or African American; Coronary Disease; Cross-Sectional Studi | 2008 |
Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relat | 2008 |
CHARISMA revisited: is the glass half full or just empty?
Topics: Aspirin; Clopidogrel; Coronary Disease; Disease Progression; Humans; Platelet Aggregation Inhibitors | 2008 |
[Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Resistan | 2008 |
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma | 2008 |
Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Female; Gastr | 2008 |
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspir | 2008 |
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ma | 2008 |
Drug-coated coronary stents offer life-saving benefits. A 74-year-old Ohio judge is still presiding in court three years after receiving the implants to reopen a blocked artery.
Topics: Aged; Aspirin; Clopidogrel; Contraindications; Coronary Disease; Drug-Eluting Stents; Humans; Male; | 2008 |
Aspirin following PCI: too much of a good thing?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Humans; Platel | 2009 |
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibito | 2009 |
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio | 2009 |
Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.
Topics: Aspirin; Blood Platelets; CD40 Ligand; Coronary Disease; Dose-Response Relationship, Drug; Eptifibat | 2010 |
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; D | 2009 |
Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study.
Topics: Aged; Alleles; Apolipoproteins A; Aspirin; Coronary Disease; Humans; Incidence; Middle Aged; Platele | 2009 |
Diabetes mellitus is associated with increased ex vivo-platelet aggregation and decreased response to aspirin - antithrombotic potential of ACE-inhibitors and AT1-antagonists.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2 | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Co | 2009 |
Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronar | 2009 |
[The present status of the use of aspirin for secondary prevention of coronary artery disease].
Topics: Aged; Aspirin; China; Coronary Disease; Female; Humans; Male; Middle Aged; Secondary Prevention | 2009 |
The prevalence of aspirin resistance in patients with metabolic syndrome.
Topics: Aged; Aspirin; Biomarkers, Pharmacological; Blood Glucose; Blood Pressure; Body Mass Index; Coronary | 2009 |
Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: a primary care physician survey.
Topics: Adult; Anticholesteremic Agents; Aspirin; Cardiology; Coronary Disease; Decision Support Techniques; | 2010 |
Trial watch. DAPT study.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-El | 2010 |
Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Dis | 2010 |
Early and intermediate outcomes of left main coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
Approach to the patient who is intolerant of statin therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Corona | 2010 |
Late and very late stent thrombosis after polymer-based sirolimus- or paclitaxel-eluting stent implantation in real-world clinical practice.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Humans; Paclitaxel | 2010 |
Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Huma | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma.
Topics: Aged; Aged, 80 and over; Aspirin; Behavioral Risk Factor Surveillance System; Coronary Disease; Fema | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Clopidogrel; C | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronary Disease; Drug Administr | 2010 |
I've read that some people are aspirin resistant and do not benefit from the daily use of aspirin to prevent a heart attack or stroke. Should I be tested for aspirin resistance?
Topics: Aged; Aspirin; Coronary Disease; Drug Resistance; Female; Health Knowledge, Attitudes, Practice; Hum | 2010 |
Prior aspirin use and outcomes in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Angiography; Coronary Disease; Female; Humans; Kaplan-Mei | 2010 |
Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease.
Topics: Aged; Aspirin; Blood Platelets; Coronary Disease; Dose-Response Relationship, Drug; Enzyme-Linked Im | 2010 |
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco | 2010 |
Aspirin and your heart: many questions, some answers.
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Health Knowledge, Attitudes, Practice; | 2010 |
Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coated Materials, Biocom | 2011 |
Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Topics: Aged; Aspirin; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Gastr | 2011 |
Clinical data extraction and feedback in general practice: a case study from Australian primary care.
Topics: Aspirin; Australia; Coronary Disease; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hydroxymethylg | 2010 |
Significance of cardiocoronary pathology in acute stroke.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin | 2011 |
Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Disease; Drug-Eluting | 2011 |
[Prevention and treatment of low-dose aspirin induced gastric ulcer in coronary artery disease after coronary intervention].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Humans; Stomach Ulcer | 2011 |
Ask the doctor. My doctor recently advised me to start taking an 81-mg aspirin once a day. I am physically active 62-year-old and have been a vegetarian-mostly vegan-for 35 years. My BMI is less than 24, my HDL is over 70, and my Framingham risk score
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Health Status; Humans; Male; Middle Age | 2011 |
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cor | 2011 |
Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity.
Topics: Adenosine Diphosphate; Aspirin; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Dise | 2011 |
Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care.
Topics: Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Coronary Disease; Humans; Medication Adheren | 2011 |
Preoperative aspirin resistance does not increase myocardial injury during off-pump coronary artery bypass surgery.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Resistance; | 2011 |
Genetic variants in the apolipoprotein(a) gene and coronary heart disease.
Topics: Alleles; Apolipoproteins A; Aspirin; Coronary Disease; Genetic Variation; Genotype; Heterozygote; Ho | 2011 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar | 2012 |
Aspirin 50 versus 100 mg: a case of wrong dosing.
Topics: Aspirin; Blood Platelets; Coronary Disease; Female; Humans; Male; Platelet Aggregation Inhibitors | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru | 2012 |
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Coronary Artery Disease; Co | 2012 |
Risk models and patient-centered evidence: should physicians expect one right answer?
Topics: Aspirin; Coronary Disease; Decision Making; Evidence-Based Medicine; Female; Humans; Male; Models, T | 2012 |
[Aspirin].
Topics: Angina Pectoris; Aspirin; Coronary Disease; Female; Humans; Male; Myocardial Infarction | 2011 |
[Prevalence of laboratory aspirin resistance in 431 old patients].
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Drug Resistance; Female; Humans; Male; P | 2012 |
Dual antiplatelet therapy after stenting. More than 12 months of treatment might not be necessary.
Topics: Aspirin; Coronary Disease; Coronary Restenosis; Drug Administration Schedule; Drug Therapy, Combinat | 2012 |
Should acetylsalicylic acid (ASA) therapy for prevention of thromboembolic events be stopped prior to surgical extractions?
Topics: Aspirin; Blood Loss, Surgical; Coronary Disease; Female; Humans; Male; Platelet Aggregation Inhibito | 2012 |
Erythrocyte stearidonic acid and other n-3 fatty acids and CHD in the Physicians' Health Study.
Topics: Aged; Aging; Aspirin; beta Carotene; Case-Control Studies; Coronary Disease; Double-Blind Method; Er | 2013 |
Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2012 |
[Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori].
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Clopid | 2012 |
Utilization of statins and aspirin among patients with diabetes and hyperlipidemia: Taiwan, 1998-2006.
Topics: Adult; Aged; Aspirin; Coronary Disease; Diabetes Mellitus; Drug Utilization; Female; Humans; Hydroxy | 2012 |
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Confounding Factors, Epidem | 2002 |
Assessment of platelet activation after exercise using a standardized whole blood flow cytometry assay.
Topics: Aged; Antibodies, Monoclonal; Aspirin; Coronary Disease; Exercise Test; Female; Flow Cytometry; Huma | 2002 |
Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
Topics: Arteriosclerosis; Aspirin; Cerebral Infarction; Coronary Disease; Female; Humans; Hypolipidemic Agen | 2002 |
Aspirin for the primary prevention of coronary events.
Topics: Aspirin; Coronary Disease; Diabetes Complications; Humans; Platelet Aggregation Inhibitors; Risk Fac | 2002 |
Aspirin for the primary prevention of coronary events.
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Fact | 2002 |
CURE works patients with acute coronary syndromes at all risk levels.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2002 |
[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiology; C | 2002 |
Aspirin with bypass surgery--from taboo to new standard of care.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedule; Humans; Inflammatio | 2002 |
Coronary and cardiovascular risk estimation in uncomplicated mild hypertension. A comparison of risk assessment methods.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Health Status Ind | 2002 |
Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Data Collection; Fe | 2002 |
Cardiovascular medications taken by patients aged >or=70 years hospitalized for acute coronary syndromes before hospitalization and at hospital discharge.
Topics: Acute Disease; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium C | 2002 |
A partial CURE for acute coronary syndromes--but how did it happen?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platele | 2002 |
Aspirin therapy now recommended for people at risk for heart disease.
Topics: Aspirin; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Male; Practice Guidelines as Topic | 2002 |
Acute coronary occlusion during radiofrequency catheter ablation of typical atrial flutter.
Topics: Acute Disease; Aged; Aspirin; Atrial Flutter; Catheter Ablation; Coronary Disease; Electrocardiograp | 2002 |
Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia.
Topics: Aspirin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Resistance; Female; Humans; Hype | 2003 |
Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trial | 2003 |
Summaries for patients. Risk factors and treatment in women with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Clinical Trial | 2003 |
Warfarin, aspirin, or both after myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 2003 |
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control S | 2002 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Industry; Fees, Phar | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Industry; Fees, Phar | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Medically Uninsured; Platelet | 2003 |
[Which interactions are there for equal doses of acetylsalicylic acid and ACE inhibitors?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Coronary Disease; Drug I | 2003 |
Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; C-Reacti | 2003 |
Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
Topics: Adenosine Diphosphate; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspiri | 2003 |
Hormones for coronary disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Estrogens; Female; Humans | 2003 |
[When the cardiac patient with arthritis needs aspirin and NSAID: how to protect the stomach?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxi | 2003 |
[In high risk patients cyclooxygenase inhibitor plus proton pump inhibitor].
Topics: Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Coronary Disease; Cyclooxygenase 2; Cyclooxygenas | 2003 |
Differential effect of aspirin on platelet aggregation in patients with coronary artery disease in relation with associated risk factors.
Topics: Adult; Aged; Aspirin; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Humans; Hyperlip | 2003 |
A technique for type 4a coronary bifurcation lesions: initial results and 6-month clinical evaluation.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiography; Coronary Disease; | 2003 |
[Aspirin and inflammatory markers in patients with coronary disease].
Topics: Aspirin; Biomarkers; C-Reactive Protein; Coronary Disease; Fibrinogen; Humans; Platelet Aggregation | 2003 |
[Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prevenir 1, Prevenir 2 and Usic 2000 surveys].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angiotensin-Converting Enzyme In | 2003 |
Long-term prognosis of patients with acute coronary syndrome and moderate coronary artery stenosis.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Coronary Angiography; C | 2003 |
Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents | 2003 |
Long waiting list for by-pass surgery.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Coronary Ar | 2003 |
Information from your family doctor. Coronary artery disease: reducing your risk.
Topics: Aspirin; Coronary Disease; Diet, Atherogenic; Exercise; Humans; Vitamins | 2003 |
High oxidative stress in patients with stable coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Case- | 2003 |
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Hemorrhage; Heparin; Humans; Male; | 2003 |
Study identifies risk factors for women's coronary heart disease.
Topics: Aspirin; Blood Pressure; Coronary Disease; Diabetes Complications; Ethnicity; Exercise; Female; Huma | 2003 |
Effect of preoperative aspirin use in off-pump coronary artery bypass operations.
Topics: Aged; Aspirin; Blood Transfusion; Case-Control Studies; Coronary Artery Bypass; Coronary Disease; Fe | 2003 |
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Transfusion; Coronary Angiograp | 2003 |
Elevated erythrocyte aggregation as a predisposing factor to aspirin resistance.
Topics: Adult; Aspirin; Behcet Syndrome; Coronary Disease; Disease Susceptibility; Drug Resistance; Erythroc | 2003 |
Clopidogrel before urgent coronary artery bypass graft.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Art | 2003 |
Aspirin for cardiovascular disease prevention.
Topics: Aspirin; Atrial Fibrillation; Coronary Disease; Heart Valve Prosthesis; Humans; Myocardial Infarctio | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper | 2003 |
Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H | 2003 |
Clopidogrel in acute coronary syndromes: can the cost effectiveness improve?
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combinat | 2003 |
[Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; E | 2003 |
Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Thrombosis | 1953 |
The effect of salicylate on the serum lipids and lipoproteins in coronary artery disease.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Humans; Lipids; Lipoproteins; Salicylates | 1959 |
Statin use is associated with enhanced collateralization of severely diseased coronary arteries.
Topics: Aged; Aspirin; Atorvastatin; Calcium Channels; Collateral Circulation; Coronary Angiography; Coronar | 2003 |
The polypill.
Topics: Antihypertensive Agents; Aspirin; Coronary Disease; Drug Combinations; Folic Acid; Humans; Hydroxyme | 2003 |
Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Azetidines; Ben | 2003 |
Red vs white thrombi: treating the right clot is crucial.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2003 |
Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Collateral Circulation; | 2003 |
Aspirin withdrawal increases risk of heart problems.
Topics: Aspirin; Coronary Disease; Heart Diseases; Humans; Substance Withdrawal Syndrome | 2003 |
Who should be taking aspirin to prevent coronary events?
Topics: Aged; Algorithms; Aspirin; Contraindications; Coronary Disease; Dose-Response Relationship, Drug; Fe | 2003 |
Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disea | 2003 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2004 |
[Controversial effects of aspirin on coronary artery disease and chronic heart failure].
Topics: Aspirin; Coronary Disease; Drug Interactions; Heart Failure; Humans | 2003 |
GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention.
Topics: Abciximab; Aged; Analysis of Variance; Antibodies, Monoclonal; Aspirin; CD40 Ligand; Chemokine CCL5; | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbid | 2004 |
Coronary risk scores.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypertension; | 2004 |
When guidelines collide...
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications.
Topics: Adult; Aged; Aspirin; Coronary Disease; Cross-Sectional Studies; Diabetic Angiopathies; Female; Huma | 2004 |
Heart to Heart: a computerized decision aid for assessment of coronary heart disease risk and the impact of risk-reduction interventions for primary prevention.
Topics: Adult; Antihypertensive Agents; Aspirin; Coronary Disease; Diagnosis, Computer-Assisted; Female; Hum | 2004 |
[Primary prevention of coronary heart disease with aspirin].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Female; Germa | 2004 |
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disea | 2004 |
Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Body Mass Inde | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Case- | 2004 |
A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Europe; Female; Humans; Male; Neoplasms; Platelet A | 2004 |
Late incidence and determinants of stroke after aortic and mitral valve replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aortic Valve; Aspirin; Atrial Fibrillation; Cerebral | 2004 |
Clopidogrel resistance: a new chapter in a fast-moving story.
Topics: Angioplasty; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; | 2004 |
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Americas; Angiotensin-Convertin | 2004 |
Preventive therapy in patients with insignificantly narrowed coronary arteries: evaluation of physician attitude and practice.
Topics: Adult; Aspirin; Attitude of Health Personnel; Coronary Disease; Coronary Vessels; Disease Progressio | 2004 |
Practising what is preached: the MINAP study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coron | 2004 |
Today's guidance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Guide | 2004 |
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Agents; China; Coronary Disease; Devel | 2004 |
[Aspirin in the primary prevention of coronary disease. Is it good for everybody?].
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors | 2004 |
Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Depression, Chemical; Endothelium, Vascular; H | 2004 |
[Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need abciximab infusion? Results of ISAR-REACT study].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2004 |
Aspirin. A look at an old drug's new uses.
Topics: Aspirin; Coronary Disease; Humans; Neoplasms; Stroke | 2004 |
Clopidogrel and postoperative bleeding.
Topics: Aprotinin; Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; | 2004 |
Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Inflammatory Agents; Aspirin; C-Reactive Protein; Clinical Trials as Topic; Coro | 2005 |
Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary D | 2004 |
A mainstay drug underperforms. But a bedside test makes it easier to spot "aspirin resistance".
Topics: Angioplasty, Balloon, Coronary; Aspirin; Contraindications; Coronary Disease; Drug Interactions; Dru | 2004 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat | 2005 |
Postmenopausal hormone use in women with acute coronary syndromes.
Topics: Aged; Aspirin; Attitude to Health; Coronary Disease; Estrogen Replacement Therapy; Female; Global He | 2004 |
Aspirin use for prevention of CHD: an FP's story.
Topics: Advisory Committees; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Drug Labeling; Hum | 2005 |
The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin.
Topics: Aspirin; Case-Control Studies; Coronary Disease; Humans; Platelet Aggregation; Platelet Aggregation | 2004 |
Aspirin resistance and a single gene.
Topics: Alleles; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Coronary Disease; DNA Mutational | 2005 |
[Characteristic features of the pathogenesis and treatment of coronary heart diseases, heart failure and arterial hypertension in patients with diabetes mellitus].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Glucose; Calcium Channel Blockers; Clinical Trial | 2005 |
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Computer Simulation; | 2005 |
Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women.
Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Diabetic Angi | 2005 |
P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Disease; Female; Genotype; Haplotypes; H | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Cardiovascular risk in patients with type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Aspirin; Ca | 2005 |
[Revascularization of multiple coronary vascular disease in diabetes mellitus--a case report].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Male; | 2005 |
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary D | 2005 |
A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Cholangio | 2005 |
Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Catheterizat | 2006 |
Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; | 2005 |
Patients undergoing coronary revascularisation: a missed opportunity for secondary prevention?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Angiote | 2005 |
An editorial update: should she take aspirin?
Topics: Aspirin; Coronary Disease; Evidence-Based Medicine; Female; Fibrinolytic Agents; Humans; Middle Aged | 2005 |
Aspirin in the prevention of cardiovascular disease in women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Humans; Myocardial Infar | 2005 |
Low-dose aspirin increases aspirin resistance in patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Drug Resistance; Female; Hemoglob | 2005 |
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
Topics: Abciximab; Adult; Aged; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; C-Reactiv | 2005 |
[A new risk score for patients with a normal or non-diagnostic ECG admitted to a chest pain unit].
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain; Coronary Disease; D | 2005 |
Combined pharmacologic treatment with clopidogrel and statin for patients with acute coronary syndrome: is there a survival advantage?
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reducta | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Inflammation, atherosclerosis, and coronary artery disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Coronary Disease; Humans; Infl | 2005 |
Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; D | 2005 |
Should aspirin be discontinued before coronary artery bypass surgery?
Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox | 2005 |
Should aspirin be discontinued before coronary artery bypass surgery?
Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox | 2005 |
Should aspirin be discontinued before coronary artery bypass surgery?
Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox | 2005 |
Should aspirin be discontinued before coronary artery bypass surgery?
Topics: Aged; Angina Pectoris; Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Cycloox | 2005 |
Summaries for patients. Benefits and harms of warfarin plus aspirin after acute coronary events.
Topics: Acute Disease; Anticoagulants; Aspirin; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; H | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation.
Topics: Adult; Aspirin; Blood Platelets; Coronary Disease; Drug Resistance; Exercise; Female; Humans; Male; | 2005 |
Borderline coronary lesions may lead to serious coronary events--long-term outcome in 65 conservatively treated patients.
Topics: Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Coronary | 2005 |
Physicians' attitudes toward preventive therapy for coronary artery disease: is there a gender bias?
Topics: Adult; Aspirin; Attitude of Health Personnel; Coronary Disease; Female; Fibrinolytic Agents; Humans; | 2005 |
Preoperative aspirin therapy is associated with improved postoperative outcomes in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Drug Administration Schedul | 2005 |
Adherence to medications by patients after acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; | 2005 |
Use of evidence-based management for acute coronary syndrome.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoag | 2005 |
Racial differences in the use of aspirin: an important tool for preventing heart disease and stroke.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Coronary Disease; Femal | 2005 |
Prior clopidogrel use and outcome of acute coronary syndrome.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Odds Ratio; Platelet Aggregation Inhibitors; Ticlopi | 2006 |
Aspirin use for the primary prevention of coronary heart disease in older adults.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Coronary Disease; Diabetes Complications; Drug Uti | 2005 |
Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Coronary Angiography; Coronary Care Units; Corona | 2005 |
Images in cardiovascular medicine. Detection of active coronary arterial vasculitis using magnetic resonance imaging in Kawasaki disease.
Topics: Aspirin; Coronary Disease; Humans; Immunoglobulins, Intravenous; Infant; Magnetic Resonance Imaging; | 2005 |
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; | 2005 |
[Intra-individual variability of the platelet anti-aggregation effect of aspirin in coronary patients].
Topics: Acute Disease; Adult; Aged; Aspirin; Coronary Disease; Drug Resistance; Humans; Middle Aged; Observe | 2005 |
Use of ankle brachial index screening for selecting patients for antiplatelet drug therapy.
Topics: Ankle; Aspirin; Blood Gas Monitoring, Transcutaneous; Brachial Artery; Coronary Disease; Humans; Per | 2005 |
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France].
Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene | 2005 |
Secondary prevention in coronary heart disease: goal achievement and drug prescribing.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2005 |
Is aspirin effective in diabetic patients? Yes.
Topics: Aspirin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Treatment Outcome | 2005 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2006 |
[Delayed coronary heart disease diagnosis, incomplete therapy. Misunderstood women's hearts].
Topics: Aspirin; Cholesterol, LDL; Coronary Disease; Diagnosis, Differential; Female; Humans; Hypercholester | 2005 |
[Inhibition of platelet aggregation for the secondary prevention after ACS: when clopidogrel instead of ASA, when clopidogrel and ASA?].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Synd | 2006 |
Predictors of rehospitalization after acute coronary syndromes.
Topics: Acute Disease; Aspirin; Calcium Channel Blockers; Coronary Disease; Female; Humans; Male; Middle Age | 2006 |
Comments in response to "low-dose aspirin increases aspirin resistance in patients with coronary artery disease".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Coronary Disease; Dose-Response R | 2006 |
What is the answer you got?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Drug Resistance; Humans; Publish | 2006 |
Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Female; Humans; Male; Middle Aged; Mult | 2006 |
Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
Topics: Aspirin; Computer Simulation; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Com | 2006 |
Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Topics: Aspirin; Computer Simulation; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Com | 2006 |
[The effect of paclitaxel-eluting stents on restenosis].
Topics: Animals; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Coronary | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Nationwide survey of pregnancy and delivery in patients with coronary arterial lesions caused by Kawasaki disease in Japan.
Topics: Adolescent; Adult; Aspirin; Cesarean Section; Coronary Artery Bypass; Coronary Disease; Coronary Ves | 2006 |
A cross-sectional study of secondary cardiac care in general practice: impact of personal and practice characteristics.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aortography; Aspirin; Coronary Angiogra | 2006 |
Statins are associated with lower risk of gastrointestinal bleeding in patients with unstable coronary syndromes: analysis of the Orbofiban in Patients with Unstable coronary Syndromes-Thrombolysis In Myocardial Infarction 16 (OPUS-TIMI 16) trial.
Topics: Acute Disease; Administration, Oral; Aged; Alanine; Anticoagulants; Aspirin; Coronary Disease; Femal | 2006 |
Coronary-artery stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors; | 2006 |
Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ste | 2006 |
Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Ang | 2006 |
Aspirin resistance.
Topics: Aspirin; Coronary Disease; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Humans; Thr | 2006 |
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS1 Protein; Aged; Apoptosis; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; C | 2006 |
Unveiling the inflammatory face of antiplatelet drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Di | 2006 |
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug | 2006 |
Secondary prevention of coronary heart disease in primary health care.
Topics: Adult; Aged; Aspirin; Body Mass Index; Coronary Disease; Female; Humans; Hypercholesterolemia; Hyper | 2006 |
Cost-effectiveness of statins added to aspirin therapy.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hydroxymethylglut | 2006 |
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.
Topics: Aged; Angioplasty; Aryl Hydrocarbon Hydroxylases; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cor | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic | 2006 |
Platelet activation and cardiovascular outcomes in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Humans; Platelet Activation; Platelet Aggregation Inhibito | 2006 |
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2006 |
Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Arteries; Aspirin; beta-Thromboglobulin; Blood Pla | 2006 |
A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Costs and Cost Analysis; Female; Hong Kong; Humans; Ma | 2006 |
An appraisal of aspirin therapy in diabetes.
Topics: Adult; Aspirin; Coronary Disease; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Aggregati | 2006 |
Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease ("hybrid approach").
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Coronary Disease | 2006 |
Regression of coronary artery outward remodeling in patients with non-ST-segment acute coronary syndromes: a longitudinal study using noninvasive magnetic resonance imaging.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoag | 2006 |
Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cohort Studies; Coronary Disease; D | 2006 |
Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Female; Hem | 2007 |
Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage.
Topics: Aged; Aspirin; Coronary Disease; Electrocardiography; Female; Gastrointestinal Hemorrhage; Hospital | 2007 |
Letter by Kronish et al regarding article, "Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance".
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Coronary Disease; Cyclooxygenase 1; Cyclooxygenase | 2007 |
Platelet non-responsiveness to dual antiplatelet therapy and relation to coronary disease among diabetes patients.
Topics: Adult; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Disease; Diabetes Melli | 2007 |
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2007 |
Gender differences in aspirin use among adults with coronary heart disease in the United States.
Topics: Age Factors; Aged; Aspirin; Coronary Disease; Female; Health Behavior; Health Care Surveys; Humans; | 2007 |
Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy.
Topics: Aged; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Blood Platelets; Cardiovascular Disea | 2007 |
Clinical use of evidence-based medicine--clinical questions. Is low-dose aspirin a better choice in patients with coronary artery disease and bleeding risks?
Topics: Aspirin; Coronary Disease; Evidence-Based Medicine; Gastrointestinal Hemorrhage; Humans; Platelet Ag | 2007 |
Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Arte | 2007 |
Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1.
Topics: Adult; Arachidonic Acid; Aspirin; beta-Thromboglobulin; Black or African American; Blood Platelets; | 2007 |
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions,
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Education, Professiona | 2007 |
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study.
Topics: Aspirin; Atherosclerosis; Biomarkers; Black or African American; Case-Control Studies; Coronary Dise | 2008 |
TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Cytokines; Diabetes Mellitus, Type 2; Di | 2007 |
Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: a drug-drug interaction?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Cor | 2007 |
Study suggests limiting use of aspirin plus warfarin.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Disease; Drug Therapy, Combination; Humans; W | 2007 |
Exploring the treatment-risk paradox in coronary disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Coronary Angiography; Coron | 2007 |
Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study.
Topics: Aged; Aspirin; Blood Proteins; Coronary Disease; Drug Resistance; Electrophoresis, Gel, Two-Dimensio | 2007 |
Gastroduodenal lesions in coronary artery disease patients. Frequency, endoscopic characteristics and risk factors.
Topics: Aspirin; Coronary Disease; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middl | 2007 |
PCI for stable coronary disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; D | 2007 |
[After coronary intervention. Which platelet inhibitor for whom?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Dise | 2007 |
[Coronary heart disease patient does not tolerate acetylsalicylic acid. Can clopidogrel be prescribed?].
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Disease; Drug Therapy, Combination; Humans; Peptic | 2007 |
Adherence to clinical guidelines in the prevention of coronary heart disease in type II diabetes mellitus.
Topics: Adult; Aged; Aspirin; Clinical Protocols; Coronary Disease; Diabetes Mellitus, Type 2; Female; Guide | 2008 |
Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland.
Topics: Adult; Aged; Aspirin; Coronary Disease; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; | 2008 |
Clinical decisions. Management of stable coronary disease.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; Diabetes Me | 2007 |
Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic.
Topics: Aspirin; Coronary Disease; Drug Resistance; Humans; Platelet Activation; Platelet Aggregation Inhibi | 2008 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Diabetes Complications | 2008 |
Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy.
Topics: Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Endoscop | 2008 |
Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combi | 2008 |
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Topics: Aged; Antihypertensive Agents; Aspirin; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Drug | 2008 |
Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Coated Materials, Biocompatible; C | 2008 |
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female; | 2008 |
Comment on: DiChiara et al. (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study: Diabetes 56:3014-3019, 2007.
Topics: Aged; Aspirin; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Female; Humans; Male; Middl | 2008 |
Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albuminuria; Aspirin; Blood Pressure; Chol | 2008 |
Experimental basis of platelet aggregation inhibition by acetylsalicylic acid.
Topics: Adenosine Diphosphate; Aspirin; Carotid Artery Thrombosis; Cerebral Infarction; Coronary Circulation | 1984 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
[Role of medical treatment in the rehabilitation of the coronary patient].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Heart Diseases; Humans; Myoc | 1981 |
Aspirin and emboli.
Topics: Aspirin; Coronary Disease; Heart Aneurysm; Humans; Thrombosis | 1981 |
[Inhibitors of thrombocytic function for prophylaxis of coronary heart disease (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Coronary Diseas | 1982 |
Clinical trials and ischaemic heart disease: can drugs reduce coronary mortality?
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Femal | 1982 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
Effects of an electrical field and its polarity on an abnormal part of the body or organ representation point associated with a diseased internal organ, and its influence on the Bi-Digital O-Ring Test (simple, non-invasive dysfunction localization method)
Topics: Acupuncture Therapy; Adult; Aspirin; Brain Ischemia; Child; Coronary Disease; Electric Stimulation T | 1982 |
Secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B | 1984 |
[Effects of medical therapy on long-term survival in ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Anticoagulants; Aspirin; Calcium Channel Blocker | 1984 |
Antiplatelet drugs.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Dextrans; Dipyridamole; Epopr | 1983 |
Efficacy of adjunctive dextran during percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Coronary Disease; Dextrans; Dipyridamole; Female; Humans; Male; Middl | 1984 |
Serial angiographic evidence of rapid resolution of coronary artery stenosis.
Topics: Angina Pectoris; Angiography; Angioplasty, Balloon; Aspirin; Coronary Disease; Dipyridamole; Humans; | 1983 |
[Incidence of recurrence after successful transluminal coronary angioplasty].
Topics: Angioplasty, Balloon; Aspirin; Coronary Disease; Exercise Test; Humans; Isosorbide Dinitrate; Premed | 1983 |
Platelet function in blood from the coronary sinus in patients with arteriosclerotic heart disease.
Topics: Adenosine Diphosphate; Aspirin; beta-Thromboglobulin; Blood Platelets; Collagen; Coronary Disease; C | 1983 |
Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy.
Topics: Adult; Angina Pectoris, Variant; Angiography; Angioplasty, Balloon; Aspirin; Constriction, Pathologi | 1984 |
Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Topics: Acrylates; Animals; Aspirin; Blood Platelets; Coronary Disease; Cyclic AMP; Cyclooxygenase Inhibitor | 1981 |
Unstable angina in a patient with mucocutaneous lymph node syndrome.
Topics: Aneurysm; Angina Pectoris; Angina, Unstable; Aspirin; Child; Coronary Angiography; Coronary Artery B | 1984 |
[Blood thromboxane A2 and prostaglandin I2 levels and platelet phospholipid fatty acid composition ratios in ischemic heart disease and cerebral infarction--with special reference to the effect of antiplatelet agents].
Topics: Aged; Aspirin; Blood Platelets; Cerebral Infarction; Coronary Disease; Dipyridamole; Epoprostenol; F | 1983 |
MI: recent insights--and new treatments?
Topics: Animals; Aspirin; Coronary Disease; Diet; Dogs; Epoprostenol; Humans; Male; Platelet Aggregation; Ri | 1984 |
Brief description of the Coronary Drug Project and other studies.
Topics: Adult; Aspirin; Bibliographies as Topic; Clinical Trials as Topic; Coronary Disease; Double-Blind Me | 1983 |
Conversion from chronic to acute coronary artery disease: speculation regarding mechanisms.
Topics: Adult; Aged; Angina Pectoris; Angina Pectoris, Variant; Angina, Unstable; Aorta; Aspirin; Blood Pres | 1984 |
Role of thromboxanes in vasotonic versus vaso-occlusive angina.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Ca | 1983 |
Mechanism of nitroglycerin-induced coronary dilatation: lack of relation to intracoronary thromboxane concentrations.
Topics: Adult; Aged; Aspirin; Coronary Circulation; Coronary Disease; Coronary Vessels; Female; Humans; Male | 1984 |
[Effect of various doses of aspirin after a single and long-term administration on platelet aggregation in patients with ischemic heart disease].
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fo | 1984 |
Kawasaki disease or mucocutaneous lymph node syndrome. Has it a microbial aetiology?
Topics: Adrenal Cortex Hormones; Aneurysm; Animals; Aspirin; Child, Preschool; Coronary Disease; Humans; Imm | 1984 |
Kawasaki disease: a report of 26 patients.
Topics: Adrenal Cortex Hormones; Aspirin; Child, Preschool; Coronary Disease; Erythema; Female; Humans; Infa | 1984 |
[Acetosal and the heart].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence | 1984 |
Cardiovascular complications of mucocutaneous lymph node syndrome.
Topics: Aneurysm; Aspirin; Child, Preschool; Coronary Disease; Echocardiography; Female; Heart Diseases; Hea | 1984 |
The role of the platelets.
Topics: Adenosine Diphosphate; Angina Pectoris; Animals; Aspirin; Blood Platelets; Coronary Disease; Hemodyn | 1984 |
Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease.
Topics: Aspirin; Cardiac Pacing, Artificial; Coronary Disease; Humans; Imidazoles; Lactates; Male; Middle Ag | 1984 |
Reduction of enzyme release from reperfused ischemic hearts by steroidal and non-steroidal prostaglandin synthesis inhibitors.
Topics: Animals; Aspirin; Coronary Disease; Creatine Kinase; Dexamethasone; Heart; Hydrocortisone; Indometha | 1983 |
Drugs in the treatment of thrombo-embolic disease--part I.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Carotid Artery Diseases; Cerebrovasc | 1983 |
Use of common antiplatelet drugs for vascular diseases.
Topics: Aspirin; Blood Platelets; Cerebrovascular Disorders; Coronary Artery Bypass; Coronary Disease; Couma | 1983 |
[Optimizing therapeutic success in aortocoronary bypass operations].
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Humans; Myocardial Contraction; Postoperative Com | 1983 |
[Therapy of Kawasaki disease in the acute phase: steroid and aspirin therapy].
Topics: Acute Disease; Age Factors; Aneurysm; Aspirin; Child, Preschool; Coronary Disease; Humans; Infant; M | 1983 |
[Prevention and treatment of coronary lesions in Kawasaki disease. Treatment with anti-platelet agents and aspirin: optimum dosages and their evaluation].
Topics: Aneurysm; Aspirin; Coronary Disease; Drug Evaluation; Fibrinolytic Agents; Humans; Mucocutaneous Lym | 1983 |
Evolution and funding of the Coronary Drug Project.
Topics: Anticholesteremic Agents; Aspirin; Budgets; Clinical Trials as Topic; Coronary Disease; Costs and Co | 1983 |
[Kawasaki disease: new and important problems in cardiology].
Topics: Aortic Aneurysm; Aspirin; Coronary Angiography; Coronary Disease; Echocardiography; Humans; Infant; | 1983 |
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans | 1982 |
Randomized surgical clinical trials for treatment of coronary artery disease.
Topics: Angina Pectoris; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Europe | 1982 |
Elevated lipid peroxide levels in platelets of chronic ischemic heart disease patients.
Topics: Anticoagulants; Aspirin; Blood Platelets; Chronic Disease; Citrates; Citric Acid; Coronary Disease; | 1982 |
Etiologic factors for recurrent carotid artery stenosis.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Constriction, Pathologic; Coronary D | 1983 |
Mucocutaneous lymph node syndrome in North Louisiana: review of 15 cases.
Topics: Arteritis; Aspirin; Blood Sedimentation; C-Reactive Protein; Child; Child, Preschool; Coronary Disea | 1983 |
Clinical trials and statistical verdicts: probable grounds for appeal.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Humans; Jurisprudence; Lung | 1983 |
[Blood platelet function in patients with coronary disease after administration of acetylsalicylic acid and dipyridamole].
Topics: Adult; Aged; Aspirin; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Female; Humans; Mal | 1983 |
Non-steroidal anti-inflammatory agents and coronary heart disease.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Caroti | 1980 |
Significance of platelet function and thromboxane B2 levels across the human myocardial vascular bed.
Topics: Arteriosclerosis; Aspirin; Coronary Circulation; Coronary Disease; Coronary Vessels; Dipyridamole; H | 1981 |
Platelet factor 4 levels in patients with coronary artery disease.
Topics: Acute Disease; Adult; Aged; Aspirin; Blood Coagulation Factors; Coronary Artery Bypass; Coronary Dis | 1981 |
Recent concepts on platelet function and dietary lipids in coronary thrombosis, vasospasm and angina.
Topics: Angina Pectoris; Arachidonic Acids; Aspirin; Constriction, Pathologic; Coronary Disease; Dietary Fat | 1980 |
Antiplatelet therapy.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprost | 1981 |
Prostaglandins show marked differences when tested against early ischemic dysrhythmias in rat.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Coronary Disease; Di | 1981 |
Platelets and coronary heart disease: therapy update.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Hemostasis | 1982 |
Mediation of cardiac ischemia by thromboxanes released from human platelets.
Topics: Aspirin; Blood Platelets; Coronary Circulation; Coronary Disease; Epoprostenol; Fluorescence; Humans | 1982 |
Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?
Topics: Animals; Aspirin; Constriction, Pathologic; Coronary Angiography; Coronary Circulation; Coronary Dis | 1982 |
[Electron microscopic, histochemical and functional assessment of the effect of aspirin on the thrombocytes of healthy persons and ischemic heart disease patients].
Topics: Adult; Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Histocytochemistry; Humans; Micr | 1982 |
Factor VIII. Aspirin and ischaemic heart disease: some comments.
Topics: Adult; Aged; Aspirin; Coronary Disease; Factor XIII; Humans; Middle Aged; Research Design | 1982 |
Failure of thromboxane A2 blockade to prevent attacks of vasospastic angina.
Topics: Adult; Aspirin; Coronary Disease; Coronary Vasospasm; Electrocardiography; Humans; Male; Middle Aged | 1982 |
[A contribution to the study of blood platelet aggregation].
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation; Sulfinpyrazone | 1982 |
Effect of aspirin on plasma fibrinolytic activity in patients of coronary heart disease.
Topics: Adult; Aged; Aspirin; Coronary Disease; Female; Fibrinolysis; Humans; Male; Middle Aged | 1982 |
[Interactions of digoxin and the nonsteroidal anti-inflammatory drugs, acetylsalicylic acid and nifedipine].
Topics: Adult; Arthritis; Aspirin; Coronary Disease; Digoxin; Drug Interactions; Humans; Indomethacin; Male; | 1982 |
[Blood serum salicylate concentration and platelet aggregation after administration of acetylsalicylic acid].
Topics: Adult; Aged; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Half-Life; Humans; Male; M | 1980 |
[The treatment of chronic ischemic heart disease with acidum acetylsalicylicum in older patients (author's transl)].
Topics: Aged; Angina Pectoris; Aspirin; Cholesterol; Coronary Disease; Double-Blind Method; Humans; Male; Ri | 1980 |
[The mucocutaneous lymph node syndrome (Kawasaki syndrome). A case with gallbladder hydrops and coronary artery aneurysm].
Topics: Aneurysm; Aspirin; Child, Preschool; Coronary Disease; Edema; Erythromycin; Exanthema; Gallbladder D | 1981 |
Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Coronary Disease; Dogs; Myocardium; Thromboxane B2; Thrombox | 1981 |
[Aspirin sensitivity of healthy persons and patients].
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Coronary Disease; Drug Resistance; Female; Humans; Male; Mid | 1981 |
Effect of inhibition of platelet function with carbenicillin or aspirin on experimental canine sudden death.
Topics: Animals; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Carbenicillin; Coronary Disease; Dea | 1981 |
Production of circulating platelet aggregates by exercise in coronary patients.
Topics: Adult; Aged; Aspirin; Blood Circulation; Coronary Disease; Electrocardiography; Exercise Test; Heart | 1980 |
Platelet activation during exercise-induced myocardial ischemia.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Aspirin; Blood Coagulation Factors; Blood Platelets; Child | 1980 |
Platelets and ischemic heart disease.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Death, Sudden; Exercise Test; Humans; M | 1980 |
Scanning electron microscopy after coronary transluminal angioplasty of normal canine coronary arteries.
Topics: Animals; Aspirin; Catheterization; Coronary Disease; Coronary Vessels; Dextrans; Dilatation; Dogs; E | 1980 |
Relationship of plasma anti-heparin activity and platelet survival time in coronary disease.
Topics: Aspirin; Blood Coagulation Factors; Blood Platelets; Cell Survival; Coronary Disease; Dipyridamole; | 1980 |
Platelet function studies in coronary artery disease. VII. Effect of aspirin and tachycardia stress on aortic and coronary venous blood.
Topics: Adult; Angina Pectoris; Aorta; Aspirin; Coronary Disease; Coronary Vessels; Humans; Middle Aged; Pla | 1980 |
Kawasaki disease, or mucocutaneous lymph node syndrome: report of seven cases in North America.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Diagnosis, Differential; Edema; Female; Gallblad | 1980 |
Platelet trapping in myocardial infarct in baboons: therapeutic effect of aspirin.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Electrocardiography; Endocardium; Ligation; Myo | 1980 |
Antithrombotic therapy in coronary artery disease.
Topics: Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Fibrinolytic Agents; Humans; Myocardial | 1980 |
Chronic use of aspirin versus indomethacin during non-thrombotic myocardial ischemia: effects on survival.
Topics: Animals; Aspirin; Coronary Disease; Dogs; Electrocardiography; Hemodynamics; Indomethacin; Male; Pot | 1980 |
Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy.
Topics: Adult; Aspirin; Blood Platelets; Cell Survival; Coronary Disease; Dipyridamole; Female; Humans; Male | 1981 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
Lack of effect of aspirin on myocardial infarct size in the dog.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Coronary Vessels; Dogs; Dose-Response Relations | 1981 |
[Stent after-care: new approaches to coagulation inhibiting therapy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; | 1995 |
[Use of aspirin in coronary disease].
Topics: Angina Pectoris; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Humans | 1995 |
[Antiaggregants, aspirin, myocardial infarction and coronary deaths in the Haute-Garonne area].
Topics: Aspirin; Coronary Disease; Drug Utilization; Female; France; Hospitalization; Humans; Male; Myocardi | 1995 |
Use of low-dose aspirin as a preventive measure.
Topics: Aspirin; Colonic Neoplasms; Coronary Disease; Humans | 1995 |
Use of low-dose aspirin as a preventive measure.
Topics: American Cancer Society; American Heart Association; Aspirin; Cerebral Hemorrhage; Coronary Disease; | 1995 |
Non-invasive management of coronary artery disease. Report of a meeting at the University of Texas Medical School at Houston.
Topics: Aged; Anticholesteremic Agents; Aspirin; beta Carotene; Carotenoids; Cholesterol, Dietary; Coronary | 1995 |
Kawasaki disease and its cardiac sequelae.
Topics: Aspirin; Blood Sedimentation; Child, Preschool; Coronary Disease; Diagnosis, Differential; gamma-Glo | 1993 |
Major depression and medication adherence in elderly patients with coronary artery disease.
Topics: Aged; Aspirin; Coronary Disease; Depressive Disorder; Dose-Response Relationship, Drug; Female; Huma | 1995 |
Coronary stenting without anticoagulation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Coronary An | 1995 |
[Primary prevention of coronary heart disease with drugs: wishful thinking or reality?].
Topics: Antioxidants; Aspirin; Calcium Channel Blockers; Coronary Disease; Diet; Estrogen Replacement Therap | 1994 |
[Characteristics of patients with coronary disease and aspirin prescription in Haute-Garonne].
Topics: Adult; Analysis of Variance; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fi | 1994 |
Is coronary artery disease associated with radiotherapy preventable by salicylates?
Topics: Animals; Aspirin; Coronary Disease; Epoprostenol; Humans; Radiotherapy; Thromboxane A2 | 1995 |
Sudden chest pain with sertraline.
Topics: 1-Naphthylamine; Antidepressive Agents; Aspirin; Chest Pain; Coronary Disease; Depression; Humans; M | 1994 |
Management of myocardial infarction patients with an occluded infarct-related artery.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Aspirin; Calcium | 1994 |
[Sliding indications for balloon angioplasty].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspi | 1994 |
Effect of coronary artery bypass graft surgery on survival.
Topics: Aspirin; Confounding Factors, Epidemiologic; Coronary Artery Bypass; Coronary Disease; Humans; Risk | 1994 |
Anticoagulation after intracoronary stent insertion.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clinical Protocols; Coronary Disease; Drug Adminis | 1994 |
Antiplatelet therapy in the treatment of coronary heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase I | 1994 |
[Diagnosis of iatrogenic vascular injuries with color-coded duplex ultrasound].
Topics: Aneurysm, False; Arteriovenous Fistula; Aspirin; Cardiac Catheterization; Coronary Angiography; Coro | 1994 |
In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin therapy.
Topics: Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Collagen; Coronary Disease; Humans; Middl | 1993 |
[20,000 kg aspirin and 45 pages British Medical Journal].
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Coronary Disease; Hu | 1994 |
Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs.
Topics: Animals; Aspirin; Blood Pressure; Coronary Circulation; Coronary Disease; Disease Models, Animal; Do | 1993 |
Management of Kawasaki disease in the British Isles.
Topics: Adolescent; Aspirin; Child; Child, Preschool; Coronary Disease; Electrocardiography; Female; Humans; | 1993 |
Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease.
Topics: Adult; Aspirin; Blood Coagulation; Blood Platelets; Coronary Disease; Fibrin; Humans; Platelet Activ | 1994 |
Aspirin and coronary artery diseases.
Topics: Aspirin; Coronary Disease; Gastrointestinal Diseases; Humans; Platelet Aggregation | 1993 |
Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease.
Topics: Aged; Analysis of Variance; Aspirin; Body Weight; Coronary Disease; Female; Heparin; Humans; Infusio | 1993 |
Platelet adhesion/aggregation in an in vitro model of coronary artery stenosis.
Topics: Aspirin; Contrast Media; Coronary Disease; Coronary Thrombosis; Diatrizoate; Diatrizoate Meglumine; | 1993 |
Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
Topics: Amino Acid Sequence; Animals; Aspirin; Bleeding Time; Coronary Disease; Coronary Vessels; Dogs; Fema | 1993 |
Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome.
Topics: Aspirin; Child; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Economics; Humans; | 1993 |
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Dogs; Drug Therapy, Combination; Hirudin Therap | 1993 |
Labeled WBC cardiac imaging and two-dimensional echocardiography to evaluate high-dose gamma globulin treatment in Kawasaki disease.
Topics: Aspirin; Coronary Disease; Echocardiography; Female; Heart; Humans; Immunoglobulins, Intravenous; In | 1995 |
Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Aspirin; Blood Platelets; Coro | 1996 |
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Topics: Animals; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiazem; Disea | 1995 |
Use of aspirin in secondary prevention of coronary heart disease is rising.
Topics: Adult; Aged; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged | 1996 |
Low-molecular-weight heparin during instability in coronary artery disease.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-We | 1996 |
Intracoronary stenting without intravascular ultrasound guidance followed by antiplatelet therapy with aspirin alone in selected patients.
Topics: Aspirin; Combined Modality Therapy; Constriction, Pathologic; Coronary Angiography; Coronary Disease | 1996 |
Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries.
Topics: Animals; Aspirin; Coronary Disease; Dogs; Female; Fibrinolytic Agents; Male; Platelet Aggregation In | 1996 |
[What dose of aspirin should be prescribed in patients with coronary disease?].
Topics: Aspirin; Blood Platelets; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, D | 1995 |
Follow up after spontaneous coronary artery dissection: a report of five cases.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aged; Aortic Dissection; Aspirin; Coronary Angiog | 1996 |
Ticlopidine and renal function.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Creatinine; Drug Therapy, Combination; Hu | 1996 |
A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cardiac Care Facilities; Cardiology; Cholesterol; | 1996 |
Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Cor | 1996 |
Primary stent implantation without coumadin in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; | 1996 |
Platelets are degranulated by some, but not all, contrast media.
Topics: Aspirin; Cells, Cultured; Contrast Media; Coronary Angiography; Coronary Disease; Diatrizoate; Flow | 1996 |
Marked reduction in long-term cardiac deaths with aspirin after a coronary event. Multicenter Myocardial Ischemia Research Group.
Topics: Aspirin; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pla | 1996 |
Aspirin and coronary disease.
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors | 1996 |
Changing from intensive anticoagulation to treatment with aspirin alone for coronary stents: the experience of one centre in the United Kingdom.
Topics: Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Female; Humans; Length of Stay; Male | 1996 |
Platelet function and platelet-leukocyte adhesion in symptomatic coronary heart disease. Effects of intravenous magnesium.
Topics: Adenosine Diphosphate; Adult; Aged; Angina Pectoris; Aspirin; Cell Adhesion; Coronary Disease; Dose- | 1996 |
A prospective study of anger and coronary heart disease. The Normative Aging Study.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Anger; Angina Pecto | 1996 |
Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Plate | 1996 |
If I woke with central chest pain....
Topics: Aspirin; Attitude to Health; Cardiology; Chest Pain; Coronary Disease; Hospitalization; Humans; Pati | 1996 |
Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Benzamidines; Cell Movement; Cells, Cultured; Coro | 1996 |
Intracoronary stenting using slotted tubular stents with intravascular ultrasound and anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Mo | 1996 |
Intravascular ultrasound-guided emergency coronary Palmaz-Schatz stent placement without post-procedural systemic anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Follow-Up Studies; Humans; Male; | 1996 |
Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Causality; Coronary Angiography; Coronary Disease; Co | 1997 |
[Medical treatment of acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Aspirin; Coronary Disease; Fibrinolytic Agents; Heparin; Humans; Pl | 1995 |
Ticlopidine and aspirin interactions.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, C | 1997 |
Neutropenia with ticlopidine plus aspirin.
Topics: Agranulocytosis; Aspirin; Coronary Disease; Humans; Monitoring, Physiologic; Neutropenia; Platelet A | 1997 |
[Single-center experience with the Palmaz-Schatz intracoronary stent: the immediate results and medium- and long-term follow-up].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary | 1996 |
Unstable coronary artery disease--need for long-term antithrombotic treatment. Aspirin alone is not sufficient, I would associate an anticoagulant.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Plat | 1997 |
Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Humans; Myocardial Infarction; | 1997 |
Ticlopidine in the prevention of thrombus formation after percutaneous transluminal coronary angioplasty (PTCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis | 1997 |
Outcome of unstable angina in patients with diabetes mellitus.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty; Aspirin; Calcium Channel Blockers; | 1997 |
Myocardial infarction caused by coronary artery myocardial bridge.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Atenolol; Cardiac Catheterization; Coronary Angio | 1997 |
Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Ar | 1997 |
Combination of aspirin and metoclopramide produces a synergistic antithrombotic effect in a canine model of coronary artery thrombosis.
Topics: Animals; Aspirin; Blood Pressure; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Disea | 1997 |
Predictors of hospital readmission two years after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Aspirin; Coronary Artery | 1997 |
Acetylsalicylic acid is unlikely to beneficially interfere with radiation-induced vasculopathy.
Topics: Aspirin; Coronary Disease; Epoprostenol; Humans; Platelet Aggregation Inhibitors; Radiotherapy; Sali | 1997 |
Antioxidants and ischaemic heart disease.
Topics: Antioxidants; Aspirin; beta Carotene; Coronary Disease; Humans; Vitamin E | 1997 |
Prevention of subsequent coronary events.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1997 |
Can aspirin be replaced in the treatment of coronary artery disease?
Topics: Aspirin; Coronary Disease; Humans; Platelet Aggregation Inhibitors | 1997 |
The role of nitric oxide in blood cell interaction.
Topics: Animals; Aspirin; Blood Cells; Blood Platelets; Cell Communication; Coronary Disease; Humans; Neutro | 1997 |
New stent delivery balloon: a technical note.
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Hu | 1997 |
Antithrombotic therapy with intracoronary stenting.
Topics: Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary D | 1997 |
Antiplatelet therapy following stent deployment.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary Disease; Humans; | 1997 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
Use of statins. Other, cheaper and simpler, measures should be tried first.
Topics: Adrenergic beta-Agonists; Aspirin; Coronary Disease; Humans; Hypolipidemic Agents; Risk Assessment; | 1997 |
XIX congress of the European Society of Cardiology August 24-28, 1997, Stockholm, Sweden.
Topics: Amiodarone; Angioplasty, Balloon, Coronary; Anti-Arrhythmia Agents; Anticoagulants; Arteriosclerosis | 1997 |
Coronary artery disease and diabetes.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Diabetic Angiopathies; Female; Humans; Hypolipidemi | 1997 |
Early and intermediate term clinical outcome after multiple coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Coron | 1998 |
Activation of coagulation and fibrinolysis after rehabilitative exercise in patients with coronary artery disease.
Topics: Adult; Aged; Aspirin; Blood Coagulation; Coronary Disease; Exercise Therapy; Fibrin; Fibrinolysin; F | 1998 |
Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Confounding Factors, Epidemiologic; Coronary Disease; Coron | 1998 |
[Coronary stents].
Topics: Aspirin; Belgium; Coronary Disease; Humans; Myocardial Revascularization; Platelet Aggregation Inhib | 1998 |
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood P | 1998 |
Clinical and angiographic outcome of Micro Stent II implantation in native coronary arteries.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Vessel Prosthesis Implantation; Coro | 1998 |
Weight watching in cardiology: low molecular weight heparin for acute coronary syndromes.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Coronary Disease; H | 1998 |
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female; | 1998 |
Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage.
Topics: Aspirin; Blood Coagulation; Coronary Disease; Dose-Response Relationship, Drug; Humans; Myocardial I | 1998 |
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Topics: Adult; Aged; Arteriosclerosis; Aspirin; Coronary Disease; Cross-Sectional Studies; Female; Humans; H | 1998 |
Coronary stenting in unstable angina: early and late clinical outcomes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
Association between coronary heart disease and cancers of the breast, prostate, and colon.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Case-Control Studies; Colo | 1998 |
Coronary-artery stents--gauging, gorging, and gouging.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1998 |
Secondary prevention in coronary heart disease. Cost effectiveness of treatment must be borne in mind.
Topics: Aspirin; Coronary Disease; Cost-Benefit Analysis; Humans; Hypolipidemic Agents; Simvastatin | 1998 |
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channe | 1998 |
[Acetylsalicylic acid in renal failure].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Dose-Response Relationship, Drug | 1998 |
Diabetes and coronary heart disease.
Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Platelet Aggregation Inhibitors | 1998 |
A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; Cost-Benef | 1998 |
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Confounding Factors, Epidemiologic; Coronary Disease; Diab | 1998 |
[Reduction of in-hospital complications after elective percutaneous transluminal coronary angioplasty using a combined pretreatment with ticlopidine and aspirin].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coron | 1998 |
[Heart magnyl or statins?].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Humans; Hypercholesterolemia; Risk Factors | 1998 |
Systemic and translesional activation of coagulation, fibrinolytic, and inhibitory systems in candidates for coronary angioplasty: basal state and effect of successful dilation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation; Blood Coagulation Factors; Coronary Dise | 1999 |
Intracoronary Multi-link stents: experience in 218 patients using aspirin alone.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Vesse | 1998 |
Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Hormone Replacement Ther | 1999 |
Drug therapy before coronary artery surgery: nitrates are independent predictors of mortality and beta-adrenergic blockers predict survival.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 1999 |
Effects of antiaggregant and antiinflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Bradykinin; Coronary Disease; Coronary Vessels; Cycl | 1999 |
Hormone replacement therapy for secondary prevention of coronary heart disease.
Topics: Aspirin; Coronary Disease; Female; Hormone Replacement Therapy; Humans; Risk | 1999 |
ST-T alternans and myocardial ischemia.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chi-Square Distribution; Coron | 1999 |
Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Cohort Studies; Coronary | 1999 |
On the evidence. Cholesterol and coronary heart disease screening & treatment.
Topics: Antihypertensive Agents; Aspirin; Cholesterol; Cholesterol, Dietary; Coronary Disease; Cost-Benefit | 1998 |
Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Cor | 1999 |
Pravastatin and coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analy | 1999 |
Antithrombotic therapy after coronary-artery stenting.
Topics: Anemia, Aplastic; Aspirin; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination | 1999 |
Secondary prevention in coronary heart disease. Effects of statins have been in addition to those of aspirin and beta blockers.
Topics: Adrenergic beta-Agonists; Aspirin; Coronary Disease; Fibrinolytic Agents; Humans; Hypolipidemic Agen | 1999 |
Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Coronary Disease; Humans; Plat | 1999 |
Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Ca | 1999 |
Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications.
Topics: Aspirin; Blood Platelets; Coronary Disease; Fibrinogen; Humans; P-Selectin; Platelet Activation; Pla | 1999 |
Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent.
Topics: Aspirin; Coronary Disease; Hemothorax; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; R | 1999 |
Safer non-cardiac surgery for patients with coronary artery disease. Preoperative aspirin does increase risk of perioperative bleeding.
Topics: Aspirin; Blood Loss, Surgical; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Risk Facto | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia.
Topics: Adult; Age Distribution; Aged; Aspirin; Blood Pressure; Coronary Disease; Female; Hospitalization; H | 1999 |
British Hypertension Society guidelines for hypertension management 1999: summary.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Blood Pressure Determination; Card | 1999 |
Trends in the post-hospitalization medical treatment of unstable angina pectoris: 1990 to 1995.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cohort Studi | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
Intravenous aspirin at reperfusion does not reduce infarct size in the dog with a residual critical stenosis.
Topics: 6-Ketoprostaglandin F1 alpha; Anesthesia; Animals; Aspirin; Blood Cell Count; Cell Movement; Coronar | 1999 |
Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, C | 1999 |
[The rate of acetylsalicylic acid non-respondents among patients hospitalized for acute coronary disease, previously undergoing secondary salicylic acid prophylaxis].
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Coronary Disease; Drug Resistance; Female; Hospitali | 1999 |
Lateral rectus palsy in Kawasaki disease.
Topics: Abducens Nerve Diseases; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Coronary Disease; | 1999 |
Taming platelets in coronary stenting: ticlopidine out, clopidogrel in?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Cor | 1999 |
Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Gastrointestinal Diseases; Human | 1999 |
Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Coronary Disease; Female; Humans; Hyperlipidemias; M | 1999 |
Dialogue with a patient with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Exercise Test; Humans; | 1999 |
Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.
Topics: Aspirin; Coronary Disease; Disease Management; Drug Therapy, Combination; Fibrinolytic Agents; Hepar | 2000 |
Secondary prevention of coronary heart disease in primary care: a healthy heart initiative.
Topics: Antihypertensive Agents; Aspirin; Coronary Disease; Female; Health Education; Humans; Life Style; Ma | 1999 |
Aspirin use is low among United States outpatients with coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Drug Utilization; Female; Humans; Male; M | 2000 |
Is the lower mortality in patients treated with aspirin and angiotensin-converting enzyme inhibitors due to decreased norepinephrine release?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; Coronary Disease; Drug Interactions; | 2000 |
Should elderly individuals who frequently nap take beta-blockers and/or aspirin?
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aspirin; Coronary Disease; Humans; Platelet Aggregat | 2000 |
Successful non-operative management of right coronary artery perforation during percutaneous coronary intervention in a patient receiving abciximab and aspirin.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Antibodies | 2000 |
[Clopidogrel--an expensive thrombocyte inhibitor with a small marginal benefit].
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Myocardial Ischemia; Platelet | 2000 |
Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angioedema; Aspirin; Coronary Disease; Desensi | 2000 |
Does gastroscopy induce myocardial ischemia in patients with coronary heart disease?
Topics: Adult; Aged; Aspirin; Coronary Disease; Electrocardiography, Ambulatory; Esophageal Diseases; Exerci | 2000 |
[Acute myocardial infarction: time delay from onset of pain to hospital presentation and thrombolysis].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Chest Pain; Coronary Disease; Female; Hospital | 2000 |
Heparins in management of acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aspirin; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Fibrinolyt | 2000 |
Combination therapy with clopidogrel and aspirin after coronary stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2000 |
Postoperative drug therapy to extend survival after coronary artery bypass grafting.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Combined Modality Th | 2000 |
Diaspirin-crosslinked hemoglobin reduces mortality of severe hemorrhagic shock in pigs with critical coronary stenosis.
Topics: Animals; Aspirin; Blood Substitutes; Coronary Disease; Female; Hemoglobins; Male; Random Allocation; | 2000 |
[Acetylsalicylic acid long-term therapy for the ailing heart. More damage than good?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Heart Failure; Humans; Long-Term | 1999 |
The action of diaspirin cross-linked haemoglobin blood substitute on human arterial bypass conduits.
Topics: Aged; Aspirin; Blood Substitutes; Carbachol; Cholinergic Agents; Coronary Artery Bypass; Coronary Di | 2000 |
Increased soluble platelet/endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy.
Topics: Aged; Aspirin; Biomarkers; Cardiomyopathy, Dilated; Coronary Disease; Enzyme-Linked Immunosorbent As | 1999 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; | 2000 |
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coron | 2000 |
Increased rate of formation of small-sized platelet aggregates in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Cohort Studies; Coronary D | 2000 |
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disease; Cyclooxygenase Inhibitors | 2000 |
National service framework for coronary heart disease. Ambiguities need to be clarified.
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Protocols; Coronary Disease; Humans; Hypolipidemic Ag | 2000 |
Platelet glycoprotein IIb/IIIa receptor inhibitor preserves coronary flow reserve during progressive coronary arteriostenosis in swine.
Topics: Animals; Aspirin; Azepines; Coronary Circulation; Coronary Disease; Hemodynamics; Heparin; Models, A | 2000 |
Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus (SLE)?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Humans; Hypertension; Lupus Eryt | 2000 |
Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa).
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Adult; Ar | 2000 |
[Vasodilator effects of bradykinin on the resistive circulation of the forearm of coronary patients].
Topics: Acetylcholine; Adult; Aged; Aspirin; Bradykinin; Coronary Disease; Forearm; Humans; Infusions, Intra | 2000 |
[Undertreatment in secondary prevention of patients with coronary heart disease after revascularization].
Topics: Adrenergic beta-Antagonists; Aftercare; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; | 2000 |
How hot is inflammation in acute coronary syndrome?
Topics: Angina, Unstable; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Corona | 2000 |
Nonplatelet effects of aspirin during acute coronary occlusion: electrophysiologic and cation alterations in ischemic myocardium.
Topics: Action Potentials; Animals; Aspirin; Coronary Disease; Dogs; Epinephrine; Male; Myocardial Ischemia; | 2000 |
Authors' reply on aspirin for primary prevention.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Gastrointestinal Hemorrhage; Hum | 2001 |
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
Topics: Amidines; Animals; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Blood Coagul | 2001 |
High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biomarkers; C-Reactive P | 2000 |
Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.
Topics: Abciximab; Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2001 |
Who should take aspirin for primary prophylaxis of coronary heart disease?
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibit | 2001 |
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Femal | 2001 |
Secondary prevention may help intermittent claudication.
Topics: Aged; Aspirin; Cholesterol; Coronary Disease; Fibrinolytic Agents; Follow-Up Studies; Humans; Interm | 2001 |
Aspirin and the treatment of heart failure in the elderly.
Topics: Age Factors; Aged; Aspirin; Cohort Studies; Connecticut; Coronary Disease; Female; Heart Failure; Hu | 2001 |
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C | 2001 |
Effects of cyclo-oxygenase and thromboxane synthetase inhibitors on right atrial prostaglandins.
Topics: Aspirin; Benzofurans; Coronary Artery Bypass; Coronary Disease; Culture Techniques; Cyclooxygenase I | 2000 |
ABCs of secondary prevention of CHD: easier said than done.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Aspirin; Coronary Disease; Diet; Exercise; Hu | 2001 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Status of secondary prevention in patients undergoing coronary revascularization.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2001 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |
Ticlopidine monotherapy following coronary stent deployment: "penny wise and pound foolish".
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stent | 2001 |
[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery].
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Compl | 2001 |
[Acetylsalicylic acid and acute coronary syndrome].
Topics: Acute Disease; Aspirin; Coronary Disease; Drug Utilization; Fibrinolytic Agents; Humans | 2001 |
[Decreased platelet aggregation during angiotensin-converting enzyme inhibitor therapy. Results of a pilot study].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Case-Control Studies; Coronary Disease; Dru | 2001 |
Implementation of evidence based cardiovascular risk treatments by general practitioners.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Coronary Disease; Evidence-Based Medicine; Family Practi | 2001 |
Guidelines for acute coronary syndromes: translating the evidence to best practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Disease; Evidence-Based Medicine; Guideli | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
Clopidogrel in invasive management of non-ST-elevation ACS.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Humans; My | 2001 |
Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis.
Topics: Aspirin; Cause of Death; Coronary Disease; Echocardiography; Exercise Test; Female; Humans; Male; Mi | 2001 |
Uniform platelet activation exists before coronary stent implantation despite aspirin therapy.
Topics: Adult; Aspirin; Coronary Disease; Coronary Vessels; Female; Humans; Male; Middle Aged; Platelet Acti | 2001 |
Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests.
Topics: Aged; American Heart Association; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; | 2001 |
The antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Cholesterol, LDL; Confounding | 2001 |
Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure | 2001 |
Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Angina Pectoris; Aspirin; Case-Control Stud | 2001 |
Intracoronary stent implantation under intracoronary ultrasound guidance with aspirin and ticlopidine therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Female; | 2001 |
Gathering intelligence on antiplatelet drugs: the view from 30 000 feet. When combined with other information overviews lead to conviction.
Topics: Aspirin; Coronary Disease; Humans; Meta-Analysis as Topic; Platelet Aggregation Inhibitors; Stroke | 2002 |
Aspirin for the primary prevention of cardiovascular events: recommendation and rationale.
Topics: Adult; Aged; Aspirin; Chemoprevention; Coronary Disease; Evidence-Based Medicine; Female; Fibrinolyt | 2002 |
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study.
Topics: Age Distribution; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; C | 2002 |
[Cardiovascular diseases in diabetes].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Clinical Trials as Topic; Coronary Disea | 2001 |
Aspirin gets a tentative nod.
Topics: Aspirin; Coronary Disease; Gastrointestinal Hemorrhage; Humans; Risk Assessment; Risk Factors; Strok | 2002 |
Neutrophil free oxygen radical production and blood total antioxidant capacity in patients with coronary heart disease using various medications.
Topics: Adrenergic beta-Antagonists; Aged; Antioxidants; Aspirin; Calcium Channel Blockers; Coronary Disease | 2001 |
Natural history of small and medium-sized side branches after coronary stent implantation.
Topics: Acute Disease; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary An | 2002 |
Clinical practice guidelines. USPSTF recommendations.
Topics: Aspirin; Chlamydia Infections; Coronary Disease; Evidence-Based Medicine; Humans; Mass Screening; Pl | 2002 |
Summaries for patients. Aspirin for the prevention of heart attacks in people without previous cardiovascular events: recommendations from the United States Preventive Services Task Force.
Topics: Adult; Aged; Aspirin; Chemoprevention; Coronary Disease; Evidence-Based Medicine; Female; Fibrinolyt | 2002 |
Optimising drug utilisation in long term care.
Topics: Aspirin; Coronary Disease; Drug Prescriptions; Drug Utilization; Humans; Long-Term Care; Platelet Ag | 2002 |
Antiplatelet therapy and atherosclerotic events. Commentary is inaccurate.
Topics: Aspirin; Coronary Disease; Data Interpretation, Statistical; Humans; Meta-Analysis as Topic; Platele | 2002 |
Cardiovascular disease. Does inflammation cut to the heart of the matter?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Biological Evol | 2002 |
Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease.
Topics: Aspirin; Coronary Disease; Humans; Patient Selection; Platelet Aggregation Inhibitors; Risk Factors | 2002 |
NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspirin; Coronary Disease; E | 2002 |
Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients undergoing coronary artery bypass grafting.
Topics: Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Cyclooxygenase 1; Cyclooxygenase | 2002 |
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Computer Simulation; Coronary Disease; Cost-Be | 2002 |
When increased therapeutic benefit comes at increased cost.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Platelet Aggregation Inhi | 2002 |
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh | 2002 |
[Clinical aspects of control in therapy with platelet inhibitors].
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Tests; Blood Platelets; Coronary Disease; Fibrin; | 1979 |
The effect of heparin and acetysal on blood platelet functions in coronary sclerosis.
Topics: Adult; Angina Pectoris; Aspirin; Blood Platelets; Coronary Disease; Heparin; Humans; Myocardial Infa | 1978 |
Aspirin inhibits development of coronary atherosclerosis in cynomolgus monkeys (Macaca fascicularis) fed an atherogenic diet.
Topics: Animals; Aortic Diseases; Arteriosclerosis; Aspirin; Coronary Disease; Diet, Atherogenic; Haplorhini | 1979 |
Studies on the progression and regression of coronary and peripheral atherosclerosis in the cynomolgus monkey. I. Effects of dipyridamole and aspirin.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Aspirin; Calcium; Cholesterol; Cholesterol, Dietary; Col | 1979 |
[Evaluation of antithrombin III activity in ischemic cardiopathy: changes due to treatment with platelet anti-aggregants].
Topics: Anticoagulants; Antithrombin III; Aspirin; Coronary Disease; Female; Humans; Male; Platelet Aggregat | 1979 |
Does aspirin have a prophylactic vascular effect?
Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Hum | 1979 |
Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin.
Topics: Animals; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dogs | 1979 |
[Action mechanism and clinical indications for thrombocyte aggregation inhibitors].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Humans; Ischemic Attack, Transient; Myocard | 1979 |
Status of antiplatelet drugs in coronary heart disease.
Topics: Aspirin; Blood Platelets; Clofibrate; Coronary Disease; Dipyridamole; Humans; Male; Models, Biologic | 1979 |
Kawasaki disease: effect of treatment on coronary artery involvement.
Topics: Aspirin; Cephalexin; Child, Preschool; Coronary Angiography; Coronary Circulation; Coronary Disease; | 1979 |
[Preliminary experience with the catheter dilatation of coronary artery stenoses (author's transl)].
Topics: Adult; Angiocardiography; Arteries; Aspirin; Cardiac Catheterization; Coronary Disease; Coronary Ves | 1979 |
Platelet aggregability, thromboxane A2 and malonaldehyde formation following administration of aspirin to man.
Topics: Adult; Arachidonic Acids; Aspirin; Blood Platelets; Coronary Disease; Dose-Response Relationship, Dr | 1979 |
Aspirin and transient ischaemic attacks.
Topics: Aspirin; Coronary Disease; Humans | 1979 |
[Treatment of ischemic heart disease with mikristin].
Topics: Adult; Aged; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged | 1979 |
Changes in coronary vascular resistance associated with prolonged hypoxia in isolated rat hearts: a possible role of prostaglandins.
Topics: Aging; Animals; Aspirin; Chloroquine; Coronary Circulation; Coronary Disease; In Vitro Techniques; I | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
[Acetylsalicylic acid in coronary disease and cerebral ischemia (proceedings)].
Topics: Aspirin; Coronary Disease; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; | 1977 |
[In vivo platelet aggregation in coronary disease and following administration of various drugs].
Topics: Aspirin; Coronary Disease; Humans; Hyperlipidemias; Platelet Aggregation | 1977 |
Effect of sodium salicylate and acetylsalicylic acid on epicardial ST-segment elevation during coronary artery occlusion in dogs.
Topics: Animals; Aspirin; Coronary Disease; Dogs; Fatty Acids, Nonesterified; Female; Isoproterenol; Male; M | 1977 |
[Platelet anti-aggregant and anticoagulant therapy in the secondary prevention of coronary disease. Preliminary note].
Topics: Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Myocardial Infarct | 1977 |
Antiarrhythmic effects of aspirin during nonthrombotic coronary occlusion.
Topics: Animals; Anti-Arrhythmia Agents; Aspirin; Blood Pressure; Coronary Disease; Dogs; Fatty Acids, Nones | 1978 |
A case-control study of regular aspirin use and coronary deaths.
Topics: Adult; Aged; Aspirin; Coronary Disease; Humans; Male; Middle Aged; Research Design; Retrospective St | 1978 |
Aspirin and coronary deaths.
Topics: Aspirin; Coronary Disease; Humans; Male; Research Design | 1978 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
[Platelet aggregation in atherosclerotic disease after administration of lysine acetylsalicylate].
Topics: Adult; Aged; Angina Pectoris; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Coronary Disea | 1978 |
Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study.
Topics: Adult; Aged; Angina Pectoris; Arthritis, Rheumatoid; Aspirin; Cerebrovascular Disorders; Coronary Di | 1978 |
Acetylsalicylic acid and the cardiovascular effects of ADP in the rat.
Topics: Adenosine Diphosphate; Animals; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Coronary Disease; Mal | 1978 |
Platelet aggregation studies in coronary artery disease. Past 4. Effect of aspirin.
Topics: Adult; Aspirin; Blood Platelets; Cell Count; Coronary Disease; Humans; Middle Aged; Platelet Aggrega | 1978 |
The frequency of coronary heart disease and myocardial infarction in rheumatoid arthritis patients.
Topics: Adult; Arthritis, Rheumatoid; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; Myocardi | 1978 |
[Influence of acute exertion and physical training on platelet function of the coronary patient].
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Disease; Fibrinogen; Humans; Lipids; Male; | 1976 |
Platelet and fibrinogen survival in coronary atherosclerosis. Response to medical and surgical therapy.
Topics: Adult; Aged; Aspirin; Blood Platelets; Cell Survival; Coronary Disease; Dipyridamole; Fibrinogen; Hu | 1977 |
Effects of acute myocardial ischaemia on platelet aggregation in the coronary sinus and aorta in dogs.
Topics: Acute Disease; Animals; Aorta; Aspirin; Blood Cell Count; Coronary Disease; Coronary Vessels; Dogs; | 1977 |
Effect of drugs of platelets and complications of vascular disease.
Topics: Animals; Anticoagulants; Aspirin; Blood Coagulation; Blood Platelets; Clofibrate; Coronary Disease; | 1977 |
Thromboembolic complications in coronary angiography. Prevention with acetyl-salicylic acid.
Topics: Angiography; Aspirin; Coronary Angiography; Coronary Disease; Humans; Intracranial Embolism and Thro | 1977 |
Influence of nonsteroidal anti-inflammatory agents on myocardial ischemia in the cat.
Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Aspirin; Blood Pressure; Cats; Coronary Disease; | 1976 |
Mortality among arthritics.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Cardiovascular Diseases; Central Nervous System Diseases; Coro | 1976 |
Platelet aggregation in partially obstructed vessels and its elimination with aspirin.
Topics: Animals; Aspirin; Blood Flow Velocity; Blood Pressure; Coronary Circulation; Coronary Disease; Coron | 1976 |
Primary and secondary prevention trials in coronary heart disease.
Topics: Adult; Aspirin; Coronary Disease; Diet; Diet, Atherogenic; Evaluation Studies as Topic; Humans; Male | 1976 |
Editorial: Much hope but little proof.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Coronary Disease; Humans; Physical Exertion; Platel | 1976 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Dis | 1976 |
Are agents affecting platelet function clinically useful in patients with coronary artery disease?
Topics: Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clofibrate; Coro | 1976 |
Acute idiopathic pericarditis in the aged.
Topics: Acute Disease; Age Factors; Aged; Aspirin; Coronary Disease; Diagnosis, Differential; Female; Humans | 1975 |
[A case of consumption coagulopathy due to atrial giant thrombus. Detection of thrombus by scintillation camera using fibrinogen labelled with 125I, 131I and warfarin-aspirin combination therapy (author's transl)].
Topics: Aspirin; Coronary Disease; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Female | 1975 |
Editorial: Platelet aggregation.
Topics: Adenosine Diphosphate; Aspirin; Cerebrovascular Disorders; Coronary Disease; Glucose; Humans; Hyperl | 1975 |
Proceedings: Effect of aspirin and methysergide during acute intracoronary thrombosis in the dog.
Topics: Animals; Aspirin; Coronary Disease; Dogs; Hemodynamics; Methysergide | 1975 |
The filtragometer: a new device for measuring platelet aggregation in venous blood of man.
Topics: Aspirin; Citrates; Coronary Disease; Female; Heparin; Hirudins; Humans; Male; Methods; Micropore Fil | 1975 |
Treatment of Kawasaki disease using the intravenous aspirin anti-inflammatory effect of salicylate.
Topics: Acute Disease; Aspirin; Child; Child, Preschool; Coronary Disease; Female; Humans; Infant; Inflammat | 1992 |
[Therapy of coronary disease].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Clinical Trials as | 1992 |
Influence of mild to moderate treated hypertension on 9-11 year mortality in patients with pre-existing coronary heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Cohort Studies; Coronary Disease; Female; Humans; Hyper | 1992 |
Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Cyclic AMP; Female; Humans; Male; Platele | 1992 |
Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids.
Topics: Animals; Aspirin; Coronary Disease; Disease Models, Animal; Female; Heart; Myocardial Infarction; My | 1992 |
The effects of preoperative aspirin therapy on platelet function in cardiac surgery.
Topics: Adult; Aged; Aortic Valve Stenosis; Aspirin; Blood Coagulation Tests; Blood Loss, Surgical; Coronary | 1992 |
Gastric changes in coronary-operated patients with low-dose aspirin.
Topics: Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Fe | 1992 |
Aspirin and dipyridamole in the prevention of coronary disease and coronary artery bypass graft occlusion.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Graft Occlusion, Vascular; Humans | 1992 |
[A heart remedy daily--and the risk of cerebral hemorrhage].
Topics: Aspirin; Cerebral Hemorrhage; Coronary Disease; Humans; Risk Factors | 1992 |
Primary thrombocytosis and myocardial ischemic syndrome in a young woman.
Topics: Adult; Aspirin; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Humans; Hydroxy | 1992 |
Heparin-releasable platelet factor 4 in patients with coronary artery disease.
Topics: Aspirin; Coronary Disease; Female; Heparin; Humans; Male; Platelet Factor 4 | 1992 |
Starting aspirin therapy after operation.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Graft Occlusion, Vascular; Humans; Postoperative | 1992 |
[Cardiovascular risk factors and restenosis after PTCA].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1992 |
[Unexpected complication of anticoagulation after implantation of a coronary stent].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Arm Injuries; Aspirin; Blood Pressure Monitors; Coro | 1992 |
Complications after intracoronary stent implantation: three cases.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Di | 1992 |
Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Vessels; Eicosanoid | 1992 |
Myocardial infarction in patients with previous bypass surgery.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Diltiazem; Electrocard | 1991 |
[Ulcer prevention in therapy with low-dose acetylsalicylic acid?].
Topics: Aspirin; Brain Ischemia; Coronary Disease; Drug Therapy, Combination; Histamine H2 Antagonists; Huma | 1991 |
Alcohol and mortality.
Topics: Alcohol Drinking; Aspirin; Cause of Death; Coronary Disease; Humans; Male | 1991 |
[Heparin therapy in coronary disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial | 1992 |
[Alcohol consumption and coronary sclerosis].
Topics: Adult; Aged; Alcohol Drinking; Aspirin; Coronary Disease; Humans; Male; Middle Aged; Prospective Stu | 1992 |
Aspirin and coronary artery disease.
Topics: Aspirin; Coronary Disease; Humans | 1991 |
[The level of vasoactive prostanoids in patients with ischemic heart disease in the early period following aortocoronary bypass].
Topics: Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Drug The | 1991 |
[Treatment of acute manifestation of hemichorea with aspirin. A case report].
Topics: Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Brain Ischemia; Carotid Stenosis; Chorea; Cor | 1991 |
[Thrombophilia in patients with arterial occlusive diseases and its therapeutic modification].
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Blood Coagulation Tests; Coronary Disease; Cor | 1991 |
[Clinical interventions for prevention and therapy of restenosis of coronary heart disease].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Follow-Up Stud | 1991 |
Platelet adhesion/aggregation and endothelial cell function in flowing blood: effects of contrast media.
Topics: Adult; Animals; Aspirin; Cattle; Contrast Media; Coronary Circulation; Coronary Disease; Endothelium | 1991 |
Thrombocythemia and coronary artery disease.
Topics: Adult; Aged; Aspirin; Busulfan; Coronary Disease; Female; Humans; Male; Middle Aged; Polycythemia Ve | 1991 |
Clinical aspects of 100 patients with Kawasaki disease.
Topics: Aspirin; Blood Sedimentation; Child; Child, Preschool; Coronary Aneurysm; Coronary Disease; Dipyrida | 1991 |
A possible acute MI: what location and type?
Topics: Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Eme | 1991 |
Coronary bypasses 10 years on.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; | 1991 |
Aspirin and cataract.
Topics: Aspirin; Case-Control Studies; Cataract; Coronary Disease; Humans; Male; Patient Compliance; Randomi | 1991 |
Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cholesterol; Cholesterol, HDL; Cholesterol, LD | 1991 |
Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Coronary Circulation; Coronary Disease; Coronary Thr | 1991 |
Drug effects on myocardial ischemia- and reperfusion-induced arrhythmias in anesthetized rats.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Coronary Disease; Male; Mannitol; Myocardial Reperfusion Inj | 1991 |
Aspirin-induced decline in prostacyclin production in patients with coronary artery disease is due to decreased endoperoxide shift. Analysis of the effects of a combination of aspirin and n-3 fatty acids on the eicosanoid profile.
Topics: Aged; Arachidonic Acid; Aspirin; Coronary Disease; Eicosanoids; Eicosapentaenoic Acid; Epoprostenol; | 1991 |
Heart disease, aspirin, and fish oil.
Topics: Aspirin; Coronary Disease; Epoprostenol; Fatty Acids; Fish Oils; Humans; Thromboxanes | 1991 |
Circadian rhythms in cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Cardiovascular Diseases; Circadian R | 1990 |
Low-dose aspirin and heparin in unstable coronary artery disease.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Random | 1990 |
Therapeutic interventions which may improve survival in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Aspirin; Coronary Artery Bypass; Cor | 1990 |
[Secondary prevention of ischemic heart disease].
Topics: Adult; Aged; Aspirin; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Female; Hemodynamic | 1991 |
Aspirin use and chronic diseases.
Topics: Aspirin; Chronic Disease; Cohort Studies; Coronary Disease; Humans; Kidney Neoplasms | 1990 |
[Ischemic heart disease and prostanoids: pathogenesis and its implications for treatment].
Topics: Arachidonic Acids; Aspirin; Coronary Artery Disease; Coronary Disease; Coronary Vasospasm; Cyclooxyg | 1990 |
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
Topics: Animals; Antibodies, Monoclonal; Antithrombins; Arginine; Aspirin; Coronary Circulation; Coronary Di | 1990 |
Detection of silent myocardial ischemia in asymptomatic selected population and in unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Electrocardiography, Ambulatory; Exercise | 1990 |
Case 4--1990. A 66-year-old woman who is taking aspirin continues to bleed after routine care.
Topics: Aged; Algorithms; Antifibrinolytic Agents; Aspirin; Blood Coagulation Tests; Blood Platelet Disorder | 1990 |
Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
Topics: Animals; Aspirin; Bridged Bicyclo Compounds, Heterocyclic; Coronary Circulation; Coronary Disease; D | 1990 |
Pharmacological therapy after coronary angioplasty. Early experience with low molecular weight heparin for prophylaxis of reocclusion.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Heparin, Low-M | 1990 |
[Aspirin against aging? For whom and how much?].
Topics: Arachidonic Acids; Aspirin; Cerebrovascular Disorders; Coronary Disease; Dose-Response Relationship, | 1990 |
Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; C | 1990 |
[Aspirin in the prevention and management of coronary artery disease].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction | 1990 |
[Rotation angioplasty of chronic coronary artery stenosis].
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Coronary Angiography; Coronary Dise | 1990 |
[Coronary endoprostheses (stents)].
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Angiography; Coronary Dis | 1990 |
Some acute effects of smoking on endothelial cells and platelets.
Topics: Aspirin; Blood Platelets; Blood Proteins; Carboxyhemoglobin; Coronary Disease; Dipyridamole; Endothe | 1990 |
Pathogenetic components of acute ischemic syndromes. Focus on acute ischemic stimuli.
Topics: Aspirin; Coronary Artery Disease; Coronary Disease; Coronary Thrombosis; Humans; Thromboxane A2 | 1990 |
Aspirin and coronary heart disease. Clinical applications.
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Endothelium, Vascular; Female; Humans; Male; P | 1990 |
Acute infarction during triple-vessel coronary angioplasty due to acute occlusion of a nonattempted vessel.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Combined Modality Therapy; | 1990 |
Combined inhibitory effects of aspirin and ethanol on adrenaline exacerbation of acute platelet thrombus formation in stenosed canine coronary arteries.
Topics: Animals; Aspirin; Blood Flow Velocity; Blood Pressure; Coronary Circulation; Coronary Disease; Coron | 1990 |
[The patient following PTCA].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary Disease; Exercise Test; | 1990 |
Low-dose preoperative aspirin therapy, postoperative blood loss, and transfusion requirements.
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Erythrocyte Transfusion; Femal | 1990 |
[Use of acetylsalicylic acid and dextran preparations in the treatment of ischemic heart disease].
Topics: Adult; Aged; Aspirin; Coronary Disease; Dextrans; Drug Therapy, Combination; Female; Humans; Male; M | 1985 |
Treatment of Kawasaki syndrome.
Topics: Aneurysm; Aspirin; Child; Coronary Disease; Drug Therapy, Combination; Female; gamma-Globulins; Huma | 1986 |
[Effects of low-dose acetylsalicylic acid on thrombocytes in health subjects and in patients with coronary heart disease].
Topics: Adenosine Diphosphate; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Collagen; Coro | 1989 |
Thromboxane is produced in response to intracoronary infusions of complement C5a in pigs. Cyclooxygenase blockade does not reduce the myocardial ischemia and leukocyte accumulation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aspirin; Complement C5a | 1989 |
Aspirin use and chronic diseases: a cohort study of the elderly.
Topics: Aged; Aged, 80 and over; Aspirin; California; Cataract; Chronic Disease; Cohort Studies; Coronary Di | 1989 |
Effect of aspirin on myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disea | 1989 |
Platelet release in coronary heart disease: effect of antiplatelet drugs and coronary artery bypass graft.
Topics: Adult; Aged; Aspirin; Beta-Globulins; beta-Thromboglobulin; Blood Platelets; Coronary Artery Bypass; | 1985 |
Physicians' health study: aspirin and primary prevention of coronary heart disease.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Humans; Male; Middle Aged; Physicians | 1989 |
[Unstable stenocardia: various problems of pathogenesis and treatment].
Topics: Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic | 1989 |
[Effects of arginine aspirin on changes in effective refractory period and ventricular fibrillation threshold of ischemic myocardium in rabbit].
Topics: Animals; Aspirin; Coronary Disease; Female; Male; Neural Conduction; Platelet Aggregation; Platelet | 1989 |
Inhibition of accelerated cardiac allograft arteriosclerosis by fish oil.
Topics: Animals; Aspirin; Coronary Disease; Dipyridamole; Fish Oils; Heart Transplantation; Postoperative Co | 1989 |
Individually controlled aspirin in the long-term treatment of patients with chronic arterial diseases.
Topics: Adenosine Diphosphate; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; | 1989 |
Cardiovascular disease.
Topics: Adult; Aspirin; Cardiovascular Diseases; Coronary Disease; Electrophysiology; Humans | 1989 |
Aspirin in the prevention of coronary disease.
Topics: Aspirin; Coronary Disease; Humans | 1989 |
Analysis of risk factors for myocardial infarction following carotid endarterectomy.
Topics: Arteriosclerosis; Aspirin; Carotid Artery Diseases; Coronary Disease; Endarterectomy; Female; Humans | 1989 |
Blood lipid peroxides in TIA: relation to platelet function and metabolic profile.
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Glucose; Blood Platelets; Coronary Dise | 1989 |
Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs.
Topics: Animals; Antibodies, Monoclonal; Aspirin; Coronary Disease; Coronary Thrombosis; Dipyridamole; Dogs; | 1988 |
[Thrombocytic hemostasis in the complex treatment of patients with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Ma | 1985 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
[Antiaggregants of thrombocytes in ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Dipyridamole; Fibrinolytic Agents; Humans; M | 1985 |
Aspirin: what dose?
Topics: Aspirin; Coronary Disease; Cyclooxygenase Inhibitors; Fibrinolysis; Humans; Thrombophlebitis | 1986 |
Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Atrial Fibrillatio | 1986 |
Carotid and coronary artery involvement in infantile periarteritis nodosa possibly induced by Coxsackie B4 infection. Favourable course under corticosteroid treatment.
Topics: Aspirin; Carotid Artery Diseases; Coronary Disease; Coxsackievirus Infections; Dexamethasone; Dipyri | 1987 |
Problem with aspirin as antithrombotic agent in coronary artery disease.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Epinephrine; Humans; Platelet Aggregation | 1988 |
Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology.
Topics: Aged; Angina Pectoris; Angiography; Aorta; Aspirin; Blood Specimen Collection; Coronary Circulation; | 1989 |
Management of patients after thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Circulati | 1985 |
Protective effect of oxygen-derived free radical scavengers on the endothelium in vivo.
Topics: alpha-Tocopherol; Animals; Anticoagulants; Ascorbic Acid; Aspirin; Coronary Disease; Endothelium; Fe | 1986 |
[Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Circulation; Coro | 1986 |
Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty.
Topics: Acute Disease; Angioplasty, Balloon; Aspirin; Coronary Disease; Coronary Thrombosis; Dipyridamole; H | 1987 |
Reocclusions after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Animals; Aspirin; Constriction, Pathologic; Coronary Disease; Dipyridamole; Hu | 1987 |
The Frankfurt experience in restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Follow-Up Studies; German | 1987 |
Laboratory test results as predictors of recurrent coronary artery stenosis following angioplasty.
Topics: Aged; Angioplasty, Balloon; Aspirin; Cholesterol; Clinical Laboratory Techniques; Coronary Disease; | 1987 |
The effect of the thromboxane receptor antagonist BM 13.177 on experimentally induced coronary artery thrombosis in the pig.
Topics: Animals; Anti-Arrhythmia Agents; Aspirin; Coronary Disease; Coronary Thrombosis; Electric Stimulatio | 1988 |
Release of prostacyclin from the human aorta.
Topics: Adult; Aged; Aorta; Aortic Valve Insufficiency; Aortic Valve Stenosis; Aspirin; Coronary Disease; Ep | 1988 |
Contribution of prostaglandins to reperfusion-induced ventricular failure in isolated rat hearts.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Coronary Circulation; Coronary Disease; Cyclooxygena | 1986 |
[Detection of latent disorders of coronary circulation and heart rhythm in ischemic heart disease patients by using psychoemotional loading].
Topics: Adult; Arrhythmias, Cardiac; Aspirin; Coronary Disease; Diagnosis, Computer-Assisted; Electrocardiog | 1987 |
Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Topics: Acrylates; Animals; Aspirin; Biomechanical Phenomena; Blood Platelets; Coronary Disease; Cyclooxygen | 1988 |
The coming competition among clot-busting drugs.
Topics: Anistreplase; Aspirin; Coronary Disease; Drug Industry; Fibrinolytic Agents; Humans; Plasminogen; St | 1988 |
Platelet-inhibitor therapy in cardiovascular disease. Effective defense against thromboembolism.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Bioprosthesis; Blood Platelets; Coronary Disease; Dip | 1985 |
Recurrence rate after successful coronary angioplasty.
Topics: Angiography; Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Combined Modality Therapy; Con | 1985 |
Clinical experience of percutaneous transluminal coronary angioplasty--technique and results.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; | 1985 |
Preventive effects of batroxobin on experimental canine coronary thrombosis.
Topics: Animals; Aspirin; Batroxobin; Coronary Disease; Coronary Thrombosis; Disease Models, Animal; Dogs; E | 1988 |
[Aspirin and coronary heart disease].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Coronary Disease; Humans; Male; | 1988 |
[Anti-aggregation therapy of patients with ischemic heart disease].
Topics: Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Platelet Aggregation; Platelet Agg | 1988 |
Aspirin and vascular disease--an update.
Topics: Aspirin; Cardiovascular Diseases; Coronary Disease; Humans | 1988 |
The effect of antiplatelet drugs on graft atherosclerosis in rat heterotopic cardiac allografts.
Topics: Animals; Aspirin; Coronary Disease; Cyclosporins; Dipyridamole; Graft Rejection; Heart Transplantati | 1987 |
[Effects of low-dose aspirin on platelet aggregation and the biosynthesis of PGI2 and TXA2 in patients with coronary heart disease].
Topics: Aspirin; Coronary Disease; Epoprostenol; Female; Humans; Male; Middle Aged; Platelet Aggregation; Th | 1987 |
Position statement. Physicians' Health Study report on aspirin. American Heart Association.
Topics: American Heart Association; Aspirin; Coronary Disease; Drug Evaluation; Humans; Male; United States | 1988 |
Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries.
Topics: Animals; Aspirin; Blood Flow Velocity; Blood Pressure; Coronary Disease; Coronary Thrombosis; Dogs; | 1988 |
Can consensus be reached in cardiac management of Kawasaki syndrome? Review of a survey among Japanese and U.S. pediatric cardiologists.
Topics: Aspirin; Cardiac Catheterization; Child; Coronary Disease; Data Collection; Echocardiography; Humans | 1987 |
Selection of high-risk children for immunoglobulin therapy in Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Humans; Immunization, Passive; Mucocutaneous Lym | 1987 |
Can early treatment provide better prognosis in Kawasaki disease? A retrospective study on 616 children.
Topics: Aspirin; Child; Child, Preschool; Coronary Disease; Female; Flurbiprofen; Humans; Immunization, Pass | 1987 |
Ameroid constriction of the proximal left circumflex coronary artery in swine. A model of limited coronary collateral circulation.
Topics: Animals; Aspirin; Collateral Circulation; Constriction; Coronary Circulation; Coronary Disease; Coro | 1987 |
Aspirin withdrawal in a patient with essential thrombocythemia: possible cause of myocardial infarction.
Topics: Aspirin; Coronary Disease; Coronary Thrombosis; Humans; Male; Middle Aged; Myocardial Infarction; Su | 1987 |
Dissolution of angiographically detected intracoronary thrombus for unstable angina pectoris after aspirin therapy.
Topics: Aged; Angina Pectoris; Angina, Unstable; Angiography; Aspirin; Coronary Disease; Coronary Thrombosis | 1987 |
Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes.
Topics: Angina, Unstable; Animals; Aspirin; Coronary Circulation; Coronary Disease; Coronary Vasospasm; Dogs | 1986 |
Antithrombotic therapy for cerebrovascular disease. Prevention and treatment of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Endarterectomy; Heparin; Humans; Middle Aged | 1986 |
[Acetylsalicylic acid. The dosage question].
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Humans; Thrombosis | 1987 |
Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Blood Platelets; Blood Vessels; Coronary Disease; Epoprosteno | 1985 |
Prostaglandin involvement in hypersensitivity of ischemic hearts to arrhythmogenic influence of ouabain.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arachidonic Acid; Arachidonic Acids; Arrhythmias, Cardiac; As | 1985 |
Effect of high dose aspirin on coronary hemodynamics during pacing-induced myocardial ischemia.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Aspirin; Cardiac Pacing, Artificial; Coronary Ci | 1985 |
Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease.
Topics: Aneurysm; Aspirin; Child, Preschool; Coronary Disease; Drug Administration Schedule; Echocardiograph | 1985 |
Cardiac sympathetic nerve activity and progressive vasoconstriction distal to coronary stenoses: feed-back aggravation of myocardial ischemia.
Topics: Animals; Aspirin; Coronary Circulation; Coronary Disease; Dogs; Feedback; Heart; Hemodynamics; Lacta | 1985 |
[Anti-platelet aggregation action and paradoxical effects of acetylsalicylic acid].
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Cerebrovascular Disorders; Coronary Disease; Extr | 1985 |
Does dipyridamole have antithrombotic potential?
Topics: Aspirin; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; P | 1985 |
White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction.
Topics: Adult; Aged; Aspirin; Cholesterol; Coronary Disease; Dipyridamole; Diuretics; Female; Hematocrit; Hu | 1985 |
Effects of vagotomy and drugs on the ventricular fibrillation threshold of normal and ischemic hearts in the anesthetized rat.
Topics: Adenosine; Anesthesia; Animals; Aspirin; Blood Pressure; Bretylium Compounds; Coronary Disease; Hear | 1985 |
Treatment of atherosclerosis and thrombosis with aspirin.
Topics: Adult; Age Factors; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Diabetes | 1972 |
[Differential treatment of coronary heart disease].
Topics: Angina Pectoris; Aspirin; Cardiac Glycosides; Coronary Disease; Dipyridamole; Furosemide; Heparin; H | 1974 |
Relation of microcirculatory thrombosis to thrombus in the proximal coronary artery: effect of aspirin, dipyridamole, and thrombolysis.
Topics: Animals; Aspirin; Blood Platelets; Chromium Isotopes; Coronary Circulation; Coronary Disease; Dipyri | 1973 |
The effect of some drugs on oxalic acid excretion in urine.
Topics: Ascorbic Acid; Aspirin; Asthma; Calcium; Citrates; Coronary Disease; Depression, Chemical; Diabetes | 1970 |
[Incidence of thrombosis and the status of coagulation in ischaemic heart disease].
Topics: Acute Disease; Aspirin; Blood Coagulation; Chronic Disease; Coronary Disease; Depression, Chemical; | 1974 |
Chronic intravascular coagulation syndrome associated with atherosclerotic aortic aneurysm.
Topics: Aged; Aortic Aneurysm; Arteriosclerosis; Aspirin; Blood Cell Count; Blood Platelets; Chronic Disease | 1973 |
Prophylactic aspirin?
Topics: Aspirin; Coronary Disease; Humans; Thrombosis | 1973 |
[Role of thrombotic agent in coronary insufficiency--therapeutic implications (author's transl)].
Topics: Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Coronary Disease; | 1974 |
Effect of aspirin upon experimental coronary and non-coronary thrombosis and arrhythmia.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Blood Platelets; Coronary Disease; Dogs; Femoral Artery; Thr | 1972 |
[Anti-adhesion and anti-coagulant substances in thrombosis therapy. Acetylsalicylic acid and Persantin in the spotlight].
Topics: Animals; Aspirin; Coronary Disease; Dipyridamole; Humans; Thrombophlebitis; Thrombosis | 1971 |